0001628280-22-029627.txt : 20221114 0001628280-22-029627.hdr.sgml : 20221114 20221114082327 ACCESSION NUMBER: 0001628280-22-029627 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 84 CONFORMED PERIOD OF REPORT: 20220930 FILED AS OF DATE: 20221114 DATE AS OF CHANGE: 20221114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ROCKWELL MEDICAL, INC. CENTRAL INDEX KEY: 0001041024 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 383317208 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-23661 FILM NUMBER: 221380562 BUSINESS ADDRESS: STREET 1: 30142 WIXOM ROAD CITY: WIXOM STATE: MI ZIP: 48393 BUSINESS PHONE: 8004493353 MAIL ADDRESS: STREET 1: 30142 WIXOM ROAD CITY: WIXOM STATE: MI ZIP: 48393 FORMER COMPANY: FORMER CONFORMED NAME: ROCKWELL MEDICAL TECHNOLOGIES INC DATE OF NAME CHANGE: 20120530 FORMER COMPANY: FORMER CONFORMED NAME: ROCKWELL MEDICAL, INC. DATE OF NAME CHANGE: 20120525 FORMER COMPANY: FORMER CONFORMED NAME: ROCKWELL MEDICAL TECHNOLOGIES INC DATE OF NAME CHANGE: 19970722 10-Q 1 rmti-20220930.htm 10-Q rmti-20220930
0001041024false12-312022Q30.090.0900010410242022-01-012022-09-3000010410242022-11-11xbrli:shares00010410242022-09-30iso4217:USD00010410242021-12-31iso4217:USDxbrli:shares00010410242022-07-012022-09-3000010410242021-07-012021-09-3000010410242021-01-012021-09-300001041024us-gaap:PreferredStockMember2021-12-310001041024us-gaap:CommonStockMember2021-12-310001041024us-gaap:AdditionalPaidInCapitalMember2021-12-310001041024us-gaap:RetainedEarningsMember2021-12-310001041024us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001041024us-gaap:RetainedEarningsMember2022-01-012022-03-3100010410242022-01-012022-03-310001041024us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001041024us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001041024us-gaap:PreferredStockMember2022-03-310001041024us-gaap:CommonStockMember2022-03-310001041024us-gaap:AdditionalPaidInCapitalMember2022-03-310001041024us-gaap:RetainedEarningsMember2022-03-310001041024us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-3100010410242022-03-310001041024us-gaap:RetainedEarningsMember2022-04-012022-06-3000010410242022-04-012022-06-300001041024us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300001041024rmti:PublicOfferingMemberus-gaap:CommonStockMember2022-04-012022-06-300001041024rmti:PublicOfferingMemberus-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300001041024rmti:PublicOfferingMember2022-04-012022-06-300001041024us-gaap:CommonStockMemberrmti:AtTheMarketOfferingMember2022-04-012022-06-300001041024us-gaap:AdditionalPaidInCapitalMemberrmti:AtTheMarketOfferingMember2022-04-012022-06-300001041024rmti:AtTheMarketOfferingMember2022-04-012022-06-300001041024us-gaap:PreferredStockMember2022-04-012022-06-300001041024us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300001041024us-gaap:CommonStockMember2022-04-012022-06-300001041024us-gaap:PreferredStockMember2022-06-300001041024us-gaap:CommonStockMember2022-06-300001041024us-gaap:AdditionalPaidInCapitalMember2022-06-300001041024us-gaap:RetainedEarningsMember2022-06-300001041024us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-3000010410242022-06-300001041024us-gaap:RetainedEarningsMember2022-07-012022-09-300001041024us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300001041024us-gaap:CommonStockMember2022-07-012022-09-300001041024us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300001041024us-gaap:PreferredStockMember2022-09-300001041024us-gaap:CommonStockMember2022-09-300001041024us-gaap:AdditionalPaidInCapitalMember2022-09-300001041024us-gaap:RetainedEarningsMember2022-09-300001041024us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-300001041024us-gaap:CommonStockMember2020-12-310001041024us-gaap:AdditionalPaidInCapitalMember2020-12-310001041024us-gaap:RetainedEarningsMember2020-12-310001041024us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-3100010410242020-12-310001041024us-gaap:RetainedEarningsMember2021-01-012021-03-3100010410242021-01-012021-03-310001041024us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310001041024us-gaap:CommonStockMember2021-01-012021-03-310001041024us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310001041024us-gaap:CommonStockMember2021-03-310001041024us-gaap:AdditionalPaidInCapitalMember2021-03-310001041024us-gaap:RetainedEarningsMember2021-03-310001041024us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-3100010410242021-03-310001041024us-gaap:RetainedEarningsMember2021-04-012021-06-3000010410242021-04-012021-06-300001041024us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-04-012021-06-300001041024us-gaap:CommonStockMember2021-04-012021-06-300001041024us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-300001041024us-gaap:CommonStockMember2021-06-300001041024us-gaap:AdditionalPaidInCapitalMember2021-06-300001041024us-gaap:RetainedEarningsMember2021-06-300001041024us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-3000010410242021-06-300001041024us-gaap:RetainedEarningsMember2021-07-012021-09-300001041024us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-07-012021-09-300001041024us-gaap:CommonStockMemberrmti:AtTheMarketOfferingMember2021-07-012021-09-300001041024us-gaap:AdditionalPaidInCapitalMemberrmti:AtTheMarketOfferingMember2021-07-012021-09-300001041024rmti:AtTheMarketOfferingMember2021-07-012021-09-300001041024us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-300001041024us-gaap:CommonStockMember2021-09-300001041024us-gaap:AdditionalPaidInCapitalMember2021-09-300001041024us-gaap:RetainedEarningsMember2021-09-300001041024us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-09-3000010410242021-09-30rmti:facilityutr:sqft0001041024rmti:DaVitaHealthcarePartnersIncMemberus-gaap:PrivatePlacementMemberrmti:SeriesXConvertiblePreferredStockMember2022-04-060001041024rmti:DaVitaHealthcarePartnersIncMemberrmti:ShareIssuanceTrancheOneMemberus-gaap:PrivatePlacementMemberrmti:SeriesXConvertiblePreferredStockMember2022-04-062022-04-060001041024rmti:DaVitaHealthcarePartnersIncMemberrmti:ShareIssuanceTrancheOneMember2022-04-062022-04-060001041024rmti:DaVitaHealthcarePartnersIncMemberus-gaap:PrivatePlacementMemberrmti:ShareIssuanceTrancheTwoMemberrmti:SeriesXConvertiblePreferredStockMember2022-06-152022-06-150001041024rmti:DaVitaHealthcarePartnersIncMemberrmti:ShareIssuanceTrancheTwoMember2022-06-152022-06-150001041024rmti:DaVitaHealthcarePartnersIncMemberus-gaap:PrivatePlacementMemberrmti:SeriesXConvertiblePreferredStockMember2022-06-152022-06-150001041024rmti:CantorFitzgeraldCoMemberrmti:ControlledEquityOfferingMember2022-04-080001041024rmti:CantorFitzgeraldCoMemberrmti:ControlledEquityOfferingMember2022-09-300001041024rmti:RegisteredDirectOfferingMember2022-05-302022-05-300001041024rmti:RegisteredDirectOfferingMember2022-05-300001041024rmti:RegisteredDirectOfferingWarrantsMember2022-05-300001041024rmti:RegisteredDirectOfferingWarrantsMemberrmti:RegisteredDirectOfferingMember2022-05-300001041024rmti:PIPEPurchaseAgreementWarrantMember2022-05-300001041024rmti:PIPEPurchaseAgreementPreFundedWarrantMember2022-05-3000010410242022-05-302022-06-020001041024us-gaap:EmployeeStockOptionMember2022-01-012022-09-300001041024us-gaap:EmployeeStockOptionMember2021-01-012021-09-300001041024us-gaap:RestrictedStockMember2022-01-012022-09-300001041024us-gaap:RestrictedStockMember2021-01-012021-09-300001041024us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-09-300001041024us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-09-300001041024us-gaap:ConvertiblePreferredStockMember2022-01-012022-09-300001041024us-gaap:ConvertiblePreferredStockMember2021-01-012021-09-300001041024us-gaap:WarrantMember2022-01-012022-09-300001041024us-gaap:WarrantMember2021-01-012021-09-3000010410242022-05-092022-05-09xbrli:purermti:agreement0001041024us-gaap:TransferredAtPointInTimeMemberrmti:DrugProductSalesMember2022-07-012022-09-300001041024country:USus-gaap:TransferredAtPointInTimeMemberrmti:DrugProductSalesMember2022-07-012022-09-300001041024us-gaap:TransferredAtPointInTimeMemberus-gaap:NonUsMemberrmti:DrugProductSalesMember2022-07-012022-09-300001041024us-gaap:TransferredAtPointInTimeMemberrmti:DrugProductSalesMember2022-01-012022-09-300001041024country:USus-gaap:TransferredAtPointInTimeMemberrmti:DrugProductSalesMember2022-01-012022-09-300001041024us-gaap:TransferredAtPointInTimeMemberus-gaap:NonUsMemberrmti:DrugProductSalesMember2022-01-012022-09-300001041024rmti:DrugLicenseFeeMemberus-gaap:TransferredOverTimeMember2022-07-012022-09-300001041024country:USrmti:DrugLicenseFeeMemberus-gaap:TransferredOverTimeMember2022-07-012022-09-300001041024rmti:DrugLicenseFeeMemberus-gaap:TransferredOverTimeMemberus-gaap:NonUsMember2022-07-012022-09-300001041024rmti:DrugLicenseFeeMemberus-gaap:TransferredOverTimeMember2022-01-012022-09-300001041024country:USrmti:DrugLicenseFeeMemberus-gaap:TransferredOverTimeMember2022-01-012022-09-300001041024rmti:DrugLicenseFeeMemberus-gaap:TransferredOverTimeMemberus-gaap:NonUsMember2022-01-012022-09-300001041024rmti:DrugRevenueMember2022-07-012022-09-300001041024country:USrmti:DrugRevenueMember2022-07-012022-09-300001041024rmti:DrugRevenueMemberus-gaap:NonUsMember2022-07-012022-09-300001041024rmti:DrugRevenueMember2022-01-012022-09-300001041024country:USrmti:DrugRevenueMember2022-01-012022-09-300001041024rmti:DrugRevenueMemberus-gaap:NonUsMember2022-01-012022-09-300001041024us-gaap:TransferredAtPointInTimeMemberrmti:ConcentrateProductSalesMember2022-07-012022-09-300001041024country:USus-gaap:TransferredAtPointInTimeMemberrmti:ConcentrateProductSalesMember2022-07-012022-09-300001041024us-gaap:TransferredAtPointInTimeMemberrmti:ConcentrateProductSalesMemberus-gaap:NonUsMember2022-07-012022-09-300001041024us-gaap:TransferredAtPointInTimeMemberrmti:ConcentrateProductSalesMember2022-01-012022-09-300001041024country:USus-gaap:TransferredAtPointInTimeMemberrmti:ConcentrateProductSalesMember2022-01-012022-09-300001041024us-gaap:TransferredAtPointInTimeMemberrmti:ConcentrateProductSalesMemberus-gaap:NonUsMember2022-01-012022-09-300001041024us-gaap:TransferredOverTimeMemberrmti:ConcentrateProductLicenseFeeMember2022-07-012022-09-300001041024country:USus-gaap:TransferredOverTimeMemberrmti:ConcentrateProductLicenseFeeMember2022-07-012022-09-300001041024us-gaap:TransferredOverTimeMemberrmti:ConcentrateProductLicenseFeeMemberus-gaap:NonUsMember2022-07-012022-09-300001041024us-gaap:TransferredOverTimeMemberrmti:ConcentrateProductLicenseFeeMember2022-01-012022-09-300001041024country:USus-gaap:TransferredOverTimeMemberrmti:ConcentrateProductLicenseFeeMember2022-01-012022-09-300001041024us-gaap:TransferredOverTimeMemberrmti:ConcentrateProductLicenseFeeMemberus-gaap:NonUsMember2022-01-012022-09-300001041024rmti:ConcentrateProductsMember2022-07-012022-09-300001041024country:USrmti:ConcentrateProductsMember2022-07-012022-09-300001041024rmti:ConcentrateProductsMemberus-gaap:NonUsMember2022-07-012022-09-300001041024rmti:ConcentrateProductsMember2022-01-012022-09-300001041024country:USrmti:ConcentrateProductsMember2022-01-012022-09-300001041024rmti:ConcentrateProductsMemberus-gaap:NonUsMember2022-01-012022-09-300001041024country:US2022-07-012022-09-300001041024us-gaap:NonUsMember2022-07-012022-09-300001041024country:US2022-01-012022-09-300001041024us-gaap:NonUsMember2022-01-012022-09-300001041024us-gaap:TransferredAtPointInTimeMemberrmti:DrugProductSalesMember2021-07-012021-09-300001041024country:USus-gaap:TransferredAtPointInTimeMemberrmti:DrugProductSalesMember2021-07-012021-09-300001041024us-gaap:TransferredAtPointInTimeMemberus-gaap:NonUsMemberrmti:DrugProductSalesMember2021-07-012021-09-300001041024us-gaap:TransferredAtPointInTimeMemberrmti:DrugProductSalesMember2021-01-012021-09-300001041024country:USus-gaap:TransferredAtPointInTimeMemberrmti:DrugProductSalesMember2021-01-012021-09-300001041024us-gaap:TransferredAtPointInTimeMemberus-gaap:NonUsMemberrmti:DrugProductSalesMember2021-01-012021-09-300001041024rmti:DrugLicenseFeeMemberus-gaap:TransferredOverTimeMember2021-07-012021-09-300001041024country:USrmti:DrugLicenseFeeMemberus-gaap:TransferredOverTimeMember2021-07-012021-09-300001041024rmti:DrugLicenseFeeMemberus-gaap:TransferredOverTimeMemberus-gaap:NonUsMember2021-07-012021-09-300001041024rmti:DrugLicenseFeeMemberus-gaap:TransferredOverTimeMember2021-01-012021-09-300001041024country:USrmti:DrugLicenseFeeMemberus-gaap:TransferredOverTimeMember2021-01-012021-09-300001041024rmti:DrugLicenseFeeMemberus-gaap:TransferredOverTimeMemberus-gaap:NonUsMember2021-01-012021-09-300001041024rmti:DrugRevenueMember2021-07-012021-09-300001041024country:USrmti:DrugRevenueMember2021-07-012021-09-300001041024rmti:DrugRevenueMemberus-gaap:NonUsMember2021-07-012021-09-300001041024rmti:DrugRevenueMember2021-01-012021-09-300001041024country:USrmti:DrugRevenueMember2021-01-012021-09-300001041024rmti:DrugRevenueMemberus-gaap:NonUsMember2021-01-012021-09-300001041024us-gaap:TransferredAtPointInTimeMemberrmti:ConcentrateProductSalesMember2021-07-012021-09-300001041024country:USus-gaap:TransferredAtPointInTimeMemberrmti:ConcentrateProductSalesMember2021-07-012021-09-300001041024us-gaap:TransferredAtPointInTimeMemberrmti:ConcentrateProductSalesMemberus-gaap:NonUsMember2021-07-012021-09-300001041024us-gaap:TransferredAtPointInTimeMemberrmti:ConcentrateProductSalesMember2021-01-012021-09-300001041024country:USus-gaap:TransferredAtPointInTimeMemberrmti:ConcentrateProductSalesMember2021-01-012021-09-300001041024us-gaap:TransferredAtPointInTimeMemberrmti:ConcentrateProductSalesMemberus-gaap:NonUsMember2021-01-012021-09-300001041024us-gaap:TransferredOverTimeMemberrmti:ConcentrateProductLicenseFeeMember2021-07-012021-09-300001041024country:USus-gaap:TransferredOverTimeMemberrmti:ConcentrateProductLicenseFeeMember2021-07-012021-09-300001041024us-gaap:TransferredOverTimeMemberrmti:ConcentrateProductLicenseFeeMemberus-gaap:NonUsMember2021-07-012021-09-300001041024us-gaap:TransferredOverTimeMemberrmti:ConcentrateProductLicenseFeeMember2021-01-012021-09-300001041024country:USus-gaap:TransferredOverTimeMemberrmti:ConcentrateProductLicenseFeeMember2021-01-012021-09-300001041024us-gaap:TransferredOverTimeMemberrmti:ConcentrateProductLicenseFeeMemberus-gaap:NonUsMember2021-01-012021-09-300001041024rmti:ConcentrateProductsMember2021-07-012021-09-300001041024country:USrmti:ConcentrateProductsMember2021-07-012021-09-300001041024rmti:ConcentrateProductsMemberus-gaap:NonUsMember2021-07-012021-09-300001041024rmti:ConcentrateProductsMember2021-01-012021-09-300001041024country:USrmti:ConcentrateProductsMember2021-01-012021-09-300001041024rmti:ConcentrateProductsMemberus-gaap:NonUsMember2021-01-012021-09-300001041024country:US2021-07-012021-09-300001041024us-gaap:NonUsMember2021-07-012021-09-300001041024country:US2021-01-012021-09-300001041024us-gaap:NonUsMember2021-01-012021-09-300001041024rmti:ConcentrateProductsMember2021-12-310001041024rmti:ConcentrateProductsMember2022-09-300001041024rmti:BaxterHealthcareOrganizationMember2022-09-300001041024rmti:TrifericInventoryMember2022-09-300001041024rmti:TrifericAPIMember2022-09-300001041024rmti:TrifericInventoryMember2022-01-012022-09-300001041024us-gaap:LeaseholdImprovementsMember2022-09-300001041024us-gaap:LeaseholdImprovementsMember2021-12-310001041024us-gaap:MachineryAndEquipmentMember2022-09-300001041024us-gaap:MachineryAndEquipmentMember2021-12-310001041024us-gaap:OfficeEquipmentMember2022-09-300001041024us-gaap:OfficeEquipmentMember2021-12-310001041024us-gaap:OtherMachineryAndEquipmentMember2022-09-300001041024us-gaap:OtherMachineryAndEquipmentMember2021-12-310001041024rmti:BaxterHealthcareOrganizationMember2014-10-012014-10-310001041024rmti:BaxterHealthcareOrganizationMember2022-07-012022-09-300001041024rmti:BaxterHealthcareOrganizationMember2022-01-012022-09-300001041024rmti:BaxterHealthcareOrganizationMember2021-07-012021-09-300001041024rmti:BaxterHealthcareOrganizationMember2021-01-012021-09-300001041024rmti:BaxterHealthcareOrganizationMember2021-12-310001041024rmti:WanbangBiopharmaceuticalMember2016-01-012016-12-310001041024rmti:WanbangBiopharmaceuticalMember2021-07-012021-09-300001041024rmti:WanbangBiopharmaceuticalMember2022-07-012022-09-300001041024rmti:WanbangBiopharmaceuticalMember2021-01-012021-09-300001041024rmti:WanbangBiopharmaceuticalMember2022-01-012022-09-300001041024rmti:WanbangBiopharmaceuticalMember2022-09-300001041024rmti:WanbangBiopharmaceuticalMember2021-12-310001041024rmti:SunPharmaAgreementsMember2020-01-012020-01-310001041024rmti:SunPharmaAgreementsMember2021-07-012021-09-300001041024rmti:SunPharmaAgreementsMember2022-07-012022-09-300001041024rmti:SunPharmaAgreementsMember2022-01-012022-09-300001041024rmti:SunPharmaAgreementsMember2021-01-012021-09-300001041024rmti:SunPharmaAgreementsMember2022-09-300001041024rmti:SunPharmaAgreementsMember2021-12-310001041024rmti:JeilPharmaAgreementsMember2020-09-012020-09-300001041024rmti:JeilPharmaAgreementsMember2022-05-012022-05-310001041024rmti:JeilPharmaAgreementsMember2022-07-012022-09-300001041024rmti:JeilPharmaAgreementsMember2022-01-012022-09-300001041024rmti:JeilPharmaAgreementsMember2021-07-012021-09-300001041024rmti:JeilPharmaAgreementsMember2021-01-012021-09-300001041024rmti:JeilPharmaAgreementsMember2022-09-300001041024rmti:JeilPharmaAgreementsMember2021-12-310001041024rmti:DrogsanAgreementsMember2021-06-012021-06-300001041024rmti:DrogsanAgreementsMember2021-07-012021-09-300001041024rmti:DrogsanAgreementsMember2022-07-012022-09-300001041024rmti:DrogsanAgreementsMember2022-01-012022-09-300001041024rmti:DrogsanAgreementsMember2021-01-012021-09-300001041024rmti:DrogsanAgreementsMember2022-09-300001041024rmti:DrogsanAgreementsMember2021-12-310001041024rmti:DaVitaHealthcarePartnersIncMemberus-gaap:PrivatePlacementMemberrmti:ShareIssuanceTrancheTwoMemberrmti:SeriesXConvertiblePreferredStockMember2022-06-162022-06-160001041024rmti:DaVitaHealthcarePartnersIncMemberrmti:ShareIssuanceTrancheTwoMember2022-06-162022-06-160001041024rmti:SeriesXConvertiblePreferredStockMember2022-04-062022-04-060001041024rmti:SeriesXConvertiblePreferredStockMember2022-04-060001041024rmti:CantorFitzgeraldCoMemberrmti:ControlledEquityOfferingMember2022-06-302022-06-300001041024rmti:CantorFitzgeraldCoMemberrmti:ControlledEquityOfferingMember2022-06-300001041024rmti:RegisteredDirectOfferingWarrantsMember2022-09-300001041024rmti:PIPEPurchaseAgreementWarrantMember2022-09-300001041024rmti:PIPEPurchaseAgreementPreFundedWarrantMember2022-09-300001041024rmti:ServiceBasedRestrictedStockUnitsMember2022-07-012022-09-300001041024rmti:ServiceBasedRestrictedStockUnitsMember2021-07-012021-09-300001041024rmti:ServiceBasedRestrictedStockUnitsMember2022-01-012022-09-300001041024rmti:ServiceBasedRestrictedStockUnitsMember2021-01-012021-09-300001041024rmti:ServiceBasedStockOptionAwardsMember2022-07-012022-09-300001041024rmti:ServiceBasedStockOptionAwardsMember2021-07-012021-09-300001041024rmti:ServiceBasedStockOptionAwardsMember2022-01-012022-09-300001041024rmti:ServiceBasedStockOptionAwardsMember2021-01-012021-09-300001041024rmti:ServiceBasedAwardsMember2022-07-012022-09-300001041024rmti:ServiceBasedAwardsMember2021-07-012021-09-300001041024rmti:ServiceBasedAwardsMember2022-01-012022-09-300001041024rmti:ServiceBasedAwardsMember2021-01-012021-09-300001041024rmti:PerformanceBasedRestrictedStockAwardsMember2022-07-012022-09-300001041024rmti:PerformanceBasedRestrictedStockAwardsMember2021-07-012021-09-300001041024rmti:PerformanceBasedRestrictedStockAwardsMember2022-01-012022-09-300001041024rmti:PerformanceBasedRestrictedStockAwardsMember2021-01-012021-09-300001041024rmti:PerformanceBasedStockOptionAwardsMember2022-07-012022-09-300001041024rmti:PerformanceBasedStockOptionAwardsMember2021-07-012021-09-300001041024rmti:PerformanceBasedStockOptionAwardsMember2022-01-012022-09-300001041024rmti:PerformanceBasedStockOptionAwardsMember2021-01-012021-09-300001041024rmti:PerformanceBasedAwardsMember2022-07-012022-09-300001041024rmti:PerformanceBasedAwardsMember2021-07-012021-09-300001041024rmti:PerformanceBasedAwardsMember2022-01-012022-09-300001041024rmti:PerformanceBasedAwardsMember2021-01-012021-09-300001041024us-gaap:RestrictedStockMember2022-01-012022-09-300001041024rmti:PerformanceBasedRestrictedStockAwardsMember2021-12-310001041024rmti:PerformanceBasedRestrictedStockAwardsMember2022-09-300001041024rmti:PerformanceBasedRestrictedStockAwardsMember2020-12-310001041024rmti:PerformanceBasedRestrictedStockAwardsMember2021-09-300001041024rmti:ServiceBasedRestrictedStockUnitsMember2021-12-310001041024rmti:ServiceBasedRestrictedStockUnitsMember2022-09-300001041024rmti:ServiceBasedRestrictedStockUnitsMember2020-12-310001041024rmti:ServiceBasedRestrictedStockUnitsMember2021-09-300001041024rmti:ServiceBasedRestrictedStockUnitsMembersrt:MinimumMember2022-01-012022-09-300001041024rmti:ServiceBasedRestrictedStockUnitsMembersrt:MaximumMember2022-01-012022-09-300001041024rmti:ServiceBasedStockOptionAwardsMembersrt:MinimumMember2022-09-300001041024srt:MaximumMemberrmti:ServiceBasedStockOptionAwardsMember2022-09-300001041024rmti:ServiceBasedStockOptionAwardsMembersrt:MinimumMember2022-01-012022-09-300001041024srt:MaximumMemberrmti:ServiceBasedStockOptionAwardsMember2022-01-012022-09-300001041024rmti:ServiceBasedStockOptionAwardsMember2021-12-310001041024rmti:ServiceBasedStockOptionAwardsMember2021-01-012021-12-310001041024rmti:ServiceBasedStockOptionAwardsMember2022-09-300001041024rmti:ServiceBasedStockOptionAwardsMember2020-12-310001041024rmti:ServiceBasedStockOptionAwardsMember2020-01-012020-12-310001041024rmti:ServiceBasedStockOptionAwardsMember2021-09-3000010410242018-10-072018-10-070001041024rmti:MasterServicesAndIpAgreementMember2022-09-300001041024srt:MaximumMember2022-09-300001041024stpr:MIrmti:WixomMichiganPropertyOneMember2022-09-300001041024rmti:WixomMichiganPropertyTwoMemberstpr:MI2022-09-300001041024stpr:TX2022-09-300001041024stpr:SC2022-09-300001041024stpr:NJ2022-09-300001041024rmti:TermLoanMemberus-gaap:MediumTermNotesMember2020-03-160001041024us-gaap:MediumTermNotesMemberrmti:TermLoanTrancheOneMember2020-03-160001041024us-gaap:MediumTermNotesMemberrmti:TermLoanTrancheTwoMember2020-03-160001041024rmti:TermLoanTrancheThreeMemberus-gaap:MediumTermNotesMember2020-03-160001041024us-gaap:MediumTermNotesMemberrmti:TermLoanTrancheOneMember2020-03-162020-03-160001041024rmti:TermLoanMemberus-gaap:MediumTermNotesMember2020-03-162020-03-160001041024srt:MaximumMemberrmti:TermLoanTrancheTwoAndTrancheThreeMemberus-gaap:MediumTermNotesMember2020-03-160001041024rmti:TermLoanTrancheTwoAndTrancheThreeMemberus-gaap:MediumTermNotesMember2020-03-162020-03-160001041024rmti:TermLoanMembersrt:MinimumMemberus-gaap:MediumTermNotesMember2020-03-162020-03-160001041024srt:MaximumMemberrmti:TermLoanMemberus-gaap:MediumTermNotesMember2020-03-162020-03-160001041024rmti:TermLoanMemberus-gaap:MediumTermNotesMember2022-07-012022-09-300001041024rmti:TermLoanMemberus-gaap:MediumTermNotesMember2021-07-012021-09-300001041024rmti:TermLoanMemberus-gaap:MediumTermNotesMember2022-01-012022-09-300001041024rmti:TermLoanMemberus-gaap:MediumTermNotesMember2021-01-012021-09-300001041024rmti:TermLoanMemberus-gaap:MediumTermNotesMember2021-09-300001041024rmti:TermLoanMemberus-gaap:MediumTermNotesMember2021-09-012021-09-30rmti:installment0001041024rmti:TermLoanMemberus-gaap:MediumTermNotesMember2022-09-300001041024us-gaap:NotesPayableToBanksMemberrmti:A540NotePayableMember2022-06-020001041024us-gaap:NotesPayableToBanksMemberrmti:A540NotePayableMember2022-06-022022-06-020001041024us-gaap:NotesPayableToBanksMemberrmti:A540NotePayableMember2022-09-300001041024us-gaap:SubsequentEventMemberrmti:PIPEPurchaseAgreementPreFundedWarrantMember2022-10-280001041024us-gaap:SubsequentEventMember2022-10-282022-10-280001041024rmti:TermLoanMemberus-gaap:SubsequentEventMemberus-gaap:MediumTermNotesMember2022-11-10

United States
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q
__________________________________________________
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2022
or
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                              to                              
Commission File Number: 000-23661
ROCKWELL MEDICAL, INC.
(Exact name of registrant as specified in its charter)
Delaware38-3317208
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)
30142 S. Wixom Road, Wixom, Michigan
48393
(Address of principal executive offices)(Zip Code)
(248) 960-9009
(Registrant’s telephone number, including area code)


(Former name, former address and former fiscal year,
if changed since last report)
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   Yes      No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes      No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filerAccelerated filer
Non-accelerated filerSmaller reporting company
 Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes 
  No
Securities registered pursuant to Section 12(b) of the Act:
Title of each class:Trading SymbolName of each exchange on which registered:
Common Stock, par value $0.0001RMTI
Nasdaq Capital Market
The number of shares of common stock outstanding as of November 11, 2022 was 11,632,673.



Rockwell Medical, Inc. and Subsidiaries
Index to Form 10-Q
Page
2


PART I – FINANCIAL INFORMATION
Item 1.  Financial Statements
ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(Dollars In Thousands)
September 30,
2022
December 31,
2021
(Unaudited)
ASSETS
Cash and Cash Equivalents$12,980 $13,280 
Investments Available-for-Sale14,584 9,158 
Accounts Receivable, net7,367 5,913 
Inventory, net5,020 4,076 
Prepaid and Other Current Assets2,407 2,861 
Total Current Assets42,358 35,288 
Property and Equipment, net2,264 2,486 
Inventory, Non-Current1,193 1,523 
Right of Use Assets, net6,928 7,737 
Goodwill921 921 
Other Non-Current Assets522 619 
Total Assets$54,186 $48,574 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Accounts Payable$3,051 $3,739 
Accrued Liabilities5,887 5,090 
Lease Liability - Current1,992 2,004 
Deferred License Revenue - Current2,164 2,171 
Term Loan - Net of Issuance Costs5,131 7,381 
Insurance Financing Note Payable1,006 437 
Customer Deposits107 144 
Total Current Liabilities19,338 20,966 
Lease Liability - Long-Term5,171 5,887 
Term Loan, Net of Issuance Costs8,962 13,186 
Deferred License Revenue - Long-Term4,565 5,986 
Long Term Liability - Other14 14 
Total Liabilities38,050 46,039 
Stockholders’ Equity:
Preferred Stock, $0.0001 par value, 2,000,000 shares authorized; 15,000 and nil shares issued and outstanding at September 30, 2022 and December 31, 2021
  
Common Stock, $0.0001 par value; 170,000,000 shares authorized; 11,152,673 and 8,544,225 shares issued and outstanding at September 30, 2022 and December 31, 2021
1 1 
Additional Paid-in Capital402,480 372,562 
Accumulated Deficit(386,399)(370,080)
Accumulated Other Comprehensive Income54 52 
Total Stockholders’ Equity16,136 2,535 
Total Liabilities and Stockholders’ Equity$54,186 $48,574 
The accompanying notes are an integral part of the condensed consolidated financial statements.
3


ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In Thousands, Except Shares and Per Share Amounts)
Three Months Ended September 30, 2022Three Months Ended September 30, 2021Nine Months Ended September 30, 2022Nine Months Ended September 30, 2021
Net Sales$18,691 $15,988 $53,497 $46,599 
Cost of Sales17,914 16,317 51,760 46,788 
Gross Profit (Loss)777 (329)1,737 (189)
Research and Product Development469 1,221 2,963 5,445 
Selling and Marketing762 1,541 1,743 4,860 
General and Administrative3,254 3,881 11,845 11,483 
Operating Loss(3,708)(6,972)(14,814)(21,977)
Other (Expense) Income
Realized Gain on Investments  4 (1)
Interest Expense(476)(609)(1,497)(1,772)
Interest Income(6) (10)17 
Total Other Expense(482)(609)(1,503)(1,756)
Net Loss$(4,190)$(7,581)$(16,317)$(23,733)
Basic and Diluted Net Loss per Share$(0.40)$(0.89)$(1.75)$(2.79)
Basic and Diluted Weighted Average Shares Outstanding10,528,148 8,534,740 9,299,788 8,520,603 
The accompanying notes are an integral part of the condensed consolidated financial statements.
4


ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(In Thousands)
Three Months Ended September 30, 2022Three Months Ended September 30, 2021Nine Months Ended September 30, 2022Nine Months Ended September 30, 2021
Net Loss$(4,190)$(7,581)$(16,317)$(23,733)
Unrealized Gain (Loss) on Available-for-Sale Debt Instrument Investments5 4 5 (4)
Foreign Currency Translation Adjustments  (3)3 
Comprehensive Loss$(4,185)$(7,577)$(16,315)$(23,734)
The accompanying notes are an integral part of the condensed consolidated financial statements.
5


ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY
(Dollars in Thousands)
PREFERRED STOCKCOMMON STOCKADDITIONAL PAID-IN CAPITALACCUMULATED
DEFICIT
ACCUMULATED
OTHER
COMPREHENSIVE
INCOME
TOTAL
STOCKHOLDERS'
 (DEFICIT)
SHARESAMOUNTSHARESAMOUNT
Balance as of January 1, 2022 $ 8,544,225 $1 $372,562 $(370,080)$52 $2,535 
Net Loss— — — — — (7,162)— (7,162)
Foreign Currency Translation Adjustments— — — — — — (1)(1)
Stock-based Compensation— — — — (179)— — (179)
Balance as of March 31, 2022 $ 8,544,225 $1 $372,383 $(377,242)$51 $(4,807)
Net Loss— — — — — (4,967)— (4,967)
Foreign Currency Translation Adjustments— — — — — — (2)(2)
Issuance of common stock, net of offering costs/Public Offering— — 844,613 — 14,893 — — 14,893 
Issuance of common stock, net of offering costs/At-the-Market Offering— — 7,500 — 15 — — 15 
Issuance of preferred stock, net of offering costs15,000 — — — 14,916 — — 14,916 
Vesting of Restricted Stock Units Issued, net of taxes withheld— — 10,958 — — — — — 
Stock-based Compensation and modification expense— — — — 97 — — 97 
Balance as of June 30, 202215,000 $ 9,407,296 $1 $402,304 $(382,209)$49 $20,145 
Net Loss— — — — — (4,190)— (4,190)
Unrealized Gain on Available-for-Sale Investments— — — — — — 5 5 
Issuance of common stock, net of offering costs/Public Offering— 1,745,377 — — — — — 
Stock-based Compensation expense— — — — 176 — — 176 
Balance as of September 30, 202215,000 $ 11,152,673 $1 $402,480 $(386,399)$54 $16,136 

    The accompanying notes are an integral part of the condensed consolidated financial statements.

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY
(Dollars in Thousands)
PREFERRED STOCKCOMMON STOCKADDITIONAL PAID-IN CAPITALACCUMULATED
DEFICIT
ACCUMULATED
OTHER
COMPREHENSIVE
INCOME
TOTAL
STOCKHOLDERS'
EQUITY
SHARESAMOUNTSHARESAMOUNT
Balance as of January 1, 2021 $ 8,506,651 $1 $371,518 $(337,406)$57 $34,170 
Net Loss— — — — — (7,752)— (7,752)
Unrealized Loss on Available-for-Sale Investments— — — — — — (7)(7)
Foreign Currency Translation Adjustments— — — — — — 3 3 
Stock-based Compensation— — 2,396 — (236)— — (236)
Balance as of March 31, 2021 $ 8,509,047 $1 $371,282 $(345,158)$53 $26,178 
Net Loss— — — — — (8,400)— (8,400)
Unrealized Loss on Available-for-Sale Investments— — — — — — (1)(1)
Vesting of Restricted Stock Units Issued, net of taxes withheld— — 19,260 — (7)— — (7)
Stock-based Compensation— — — — 433 — — 433 
Balance as of June 30, 2021 $ 8,528,307 $1 $371,708 $(353,558)$52 $18,203 
Net Loss— — — — — (7,581)— (7,581)
Unrealized Gain on Available-for-Sale Investments— — — — — — 4 4 
Issued shares for services— — 14,090 — 107 — — 107 
Stock-based Compensation— — — — 361 — — 361 
Balance as of September 30, 2021 $ 8,542,397 $1 $372,176 $(361,139)$56 $11,094 
The accompanying notes are an integral part of the condensed consolidated financial statements.

6


ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Dollars in Thousands)
For the nine months ended September 30, 2022 and 2021
Nine Months Ended
September 30, 2022
Nine Months Ended
September 30, 2021
Cash Flows From Operating Activities:
Net Loss$(16,317)$(23,733)
Adjustments To Reconcile Net Loss To Net Cash Used In Operating Activities:
Depreciation and Amortization422 535 
Stock-based Compensation95 558 
Increase in Inventory Reserves307 89 
Amortization of Right of Use Asset1,518 1,312 
Amortization of Debt Financing Costs and Accretion of Debt Discount276 276 
(Gain) Loss on Disposal of Assets(3)7 
Realized (Gain) Loss on Sale of Investments Available-for-Sale(4)1 
Foreign Currency Translation Adjustment(3)3 
Changes in Assets and Liabilities:
Increase in Accounts Receivable, net(1,454)(1,865)
Increase in Inventory(921)(554)
Decrease in Prepaid and Other Assets2,058 1,760 
(Decrease) Increase in Accounts Payable(688)679 
Decrease in Lease Liability(1,435)(1,266)
Increase (Decrease) in Other Liabilities756 (825)
Decrease in Deferred License Revenue(1,427)(1,485)
Changes in Assets and Liabilities(3,111)(3,556)
Cash Used In Operating Activities(16,820)(24,508)
Cash Flows From Investing Activities:
Purchase of Investments Available-for-Sale(17,389)(19,107)
Sale of Investments Available-for-Sale11,972 19,286 
Purchase of Equipment(197)(408)
Cash Used In Investing Activities(5,614)(229)
Cash Flows From Financing Activities:
Payments on Debt(6,750) 
Payments on Short Term Note Payable(941)(656)
Proceeds from the Issuance of Common Stock15,016  
Offering Costs from the Issuance of Common Stock(106) 
Proceeds from the Issuance of Preferred Stock15,000  
Offering Costs from the Issuance of Preferred Stock(85) 
Proceeds from the Issuance of Common Stock for payment related to services provided 107 
Repurchase of Common Stock to Pay Employee Withholding Taxes (6)
Cash Provided by (Used In) Financing Activities22,134 (555)
Decrease in Cash and Cash Equivalents(300)(25,292)
Cash and Cash Equivalents at Beginning of Period13,280 48,682 
Cash and Cash Equivalents at End of Period$12,980 $23,390 
Supplemental Disclosure of Cash Flow Information:
Cash Paid for Interest$1,261 $1,318 
Supplemental Disclosure of Noncash Investing and Financing Activities:
Change in Unrealized Loss on Marketable Securities Available-for-Sale$5 $(4)
The accompanying notes are an integral part of the condensed consolidated financial statements.

7


ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
1.  Description of Business
Rockwell Medical, Inc. (“Rockwell Medical,” “Rockwell,” or the “Company”) is a commercial healthcare company focused on providing life-sustaining products for patients suffering from blood disorders and diseases associated with the kidney. Rockwell is a revenue-generating business and the second largest supplier of acid and bicarbonate concentrates for dialysis patients in the United States. Hemodialysis is the most common form of end-stage kidney disease treatment and is usually performed at a freestanding outpatient dialysis center, at a hospital-based outpatient center, or in a patient’s home. This represents a large market opportunity for which Rockwell's products are well-positioned to meet the needs of patients.
Rockwell manufactures hemodialysis concentrates under cGMP regulations at its three facilities in Michigan, Texas, and South Carolina totaling approximately 175,000 square feet, and manufactures mixers in its Iowa facility. Rockwell delivers the majority of its hemodialysis concentrates products and mixers to dialysis clinics throughout the United States and internationally utilizing its own delivery trucks and third-party carriers. Rockwell has developed a core expertise in manufacturing and delivering hemodialysis concentrates, and has built a longstanding reputation for reliability, quality, and excellent customer service.
Rockwell has a proprietary parenteral iron product, TRIFERIC® (ferric pyrophosphate citrate, "FPC"), which is indicated to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease. The Company has established several international partnerships with companies seeking to develop and commercialize TRIFERIC® outside the United States and is working closely with these international partners to develop and commercialize TRIFERIC® in their respective regions.
Rockwell continues to evaluate the viability of its FPC platform and FPC's potential to treat iron deficiency and iron deficiency anemia and for acute heart failure.
Rockwell’s strategy is focused on growing the Company's revenue-generating business, which currently includes hemodialysis concentrates and international partnerships for TRIFERIC® and achieving profitability in 2024 to put the Company in a stronger and more stable financial position.
8


ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
2.  Liquidity and Capital Resources
As of September 30, 2022, Rockwell had approximately $27.6 million of cash, cash equivalents and investments available-for-sale, and working capital of $23.0 million. Net cash used in operating activities for the nine months ended September 30, 2022 was approximately $16.8 million. Based on the currently available working capital and capital raises described below, management believes the Company currently has sufficient funds to meet its operating requirements for at least the next twelve months from the date of the filing of this report.
On April 6, 2022, the Company and DaVita, Inc. ("DaVita") entered into an amendment (the "Amendment") to the Products Purchase Agreement, dated July 1, 2019, under which the Company supplies DaVita with certain dialysis concentrates. Under the Amendment, the Company and DaVita agreed to certain price increases, effective May 1, 2022, as well as the pass-through of certain inflationary costs, determined on a quarterly basis. Certain costs are subject to a cap. The Amendment also requires the Company to implement certain cost containment and cost-cutting measures. The Amendment contains certain covenants with respect to the Company’s ongoing operations, including a minimum cash covenant of $10 million, or the Company will be in default under the Products Purchase Agreement. An event of default could result in termination of that agreement.
On April 6, 2022, the Company and DaVita entered into a Securities Purchase Agreement (the “SPA”), pursuant to which the Company issued $15 million of preferred stock to DaVita in two separate tranches. The Company initially issued 7,500 shares of a newly designated series of preferred stock, which is designated “Series X Convertible Preferred Stock” (the “Series X Preferred Stock”) for gross proceeds of $7.5 million. On June 15, 2022, the Company issued to DaVita an additional 7,500 shares of Series X Preferred Stock in a second closing (the “Second Tranche”) for an additional $7.5 million. The Second Tranche was conditioned upon the Company raising an additional $15 million in capital within a certain timeline, which took place on June 2, 2022.
On April 8, 2022, the Company entered into a sales agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), pursuant to which the Company may offer and sell from time to time up to $12,200,000 of shares of Company’s common stock through the Agent. The offering and sale of such shares has been registered under the Securities Act of 1933, as amended (the “Securities Act”), pursuant to the Company’s Registration Statement on Form S-3 (File No. 333-259923) (the “Registration Statement”), which was originally filed with the Securities and Exchange Commission (“SEC”) on September 30, 2021 and declared effective by the SEC on October 8, 2021, the base prospectus contained within the Registration Statement, and a prospectus supplement that was filed with the SEC on April 8, 2022. During the three months ended September 30, 2022, the Company did not make any sales pursuant to the Sales Agreement. Approximately $12.2 million remains available for sale under the ATM facility.
On May 30, 2022, the Company entered into a Securities Purchase Agreement (the “RD Purchase Agreement”) with the purchaser named therein (the “Purchaser”), pursuant to which the Company agreed to issue and sell, in a registered direct offering (the “Offering”), 844,613 shares of its common stock at price of $1.39 per share, and prefunded warrants to purchase up to an aggregate of 7,788,480 shares of common stock (the “Pre-Funded Warrants” and the shares of common stock underlying the Pre-Funded Warrants, the “Warrant Shares”). The purchase price of each Pre-Funded Warrant was equal to the price at which a share of common stock was sold to the public in the Offering, minus $0.0001, and the exercise price of each Pre-Funded Warrant is $0.0001 per share.
Also on May 30, 2022, concurrently with the Offering, the Company entered into a Securities Purchase Agreement with the Purchaser (the “PIPE Purchase Agreement”) relating to the offering and sale (the “Private Placement”) of warrants to purchase up to a total of 9,900,990 shares of common stock and pre-funded warrants to purchase up to a total of 1,267,897 shares of common stock (the “PIPE Warrants”). Each warrant was sold at a price of $0.125 per underlying warrant share and is exercisable at an exercise price of $1.39 per share. The purchase price of each Pre-Funded Warrant was equal to the price at which a share of common stock was sold to the public in the Offering, minus $0.0001, and the exercise price of each prefunded warrant is $0.0001 per share. The Offering and the Private Placement closed on June 2, 2022. The net proceeds to the Company from the Offering and the Private Placement were approximately $14.9 million, after deducting fees and expenses.
The Company may require additional capital to sustain its operations and make the investments it needs to execute its strategic plan. If the Company attempts to obtain additional debt or equity financing, the Company cannot assume such financing will be available on favorable terms, if at all.
Currently, because the Company's public float is less than $75 million, it is subject to the baby shelf limitations under its current registration statement on Form S-3, which limit the amount the Company may offer under the Form S-3. This could limit its ability to raise capital under this registration statement.

In addition, the Company is subject to certain covenants and cure provisions under its Loan Agreement with Innovatus. As of the date of this report, the Company is in compliance with all covenants (See Note 14 for further detail).

The COVID-19 pandemic and resulting domestic and global disruptions, particularly in the supply chain and labor market, among other areas, have adversely affected the Company's business and operations, including, but not limited to, its sales and marketing efforts and its research and development activities, its plant and transportation operations and the operations of third parties upon whom the Company relies. The Company's international business development activities may also continue to be negatively impacted by COVID-19.

The COVID-19 pandemic and the resulting global disruptions and recent inflationary pressures have caused significant volatility in financial and credit markets. Rockwell has utilized a range of financing methods to fund its operations in the past; however, current conditions in the financial and credit markets may limit the availability of funding, refinancing or increase the cost of funding. Due to the rapidly evolving nature of the global situation, it is not possible to predict the extent to which these conditions could adversely affect the Company's liquidity and capital resources in the future.
9


ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
3.  Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements

The accompanying condensed consolidated financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the instructions to Form 10-Q and Rule 10-01 of Regulation S-X of the U. S. Securities and Exchange Commission (“SEC”) and on the same basis as the Company prepares its annual audited consolidated financial statements.

The condensed consolidated balance sheet at September 30, 2022, condensed consolidated statements of operations for the three and nine months ended September 30, 2022 and 2021, condensed consolidated statements of comprehensive loss for the three and nine months ended September 30, 2022 and 2021, condensed consolidated statement of changes in stockholders' equity for the three and nine months ended September 30, 2022 and 2021, and condensed consolidated statements of cash flows for the nine months ended September 30, 2022 and 2021 are unaudited, but include all adjustments, consisting of normal recurring adjustments, the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The results for the three and nine months ended September 30, 2022 are not necessarily indicative of results to be expected for the year ending December 31, 2022 or for any future interim period. The condensed consolidated balance sheet at December 31, 2021 has been derived from audited financial statements, however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying condensed consolidated financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2021 and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 as filed with the SEC on April 8, 2022. The Company’s consolidated subsidiaries consisted of its wholly-owned subsidiaries, Rockwell Transportation, Inc. and Rockwell Medical India Private Limited.

The accompanying condensed consolidated interim financial statements include the accounts of the Company and its subsidiaries. All material intercompany balances and transactions have been eliminated in consolidation.
Reverse Stock Split
On May 9, 2022, the stockholders of the Company authorized the Board of Directors to effect a reverse stock split of all outstanding shares of common stock. The Board of Directors subsequently approved the implementation of a reverse stock split as a ratio of one-for-eleven shares, which became effective on May 13, 2022. The Company’s outstanding stock options were also adjusted to reflect the one-for-eleven reverse stock split of the Company’s common stock. Outstanding stock options were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased. The reverse stock split resulted in an adjustment to the Series X convertible preferred stock conversion prices to reflect a proportional decrease in the number of shares of common stock to be issued upon conversion. All share and per share data in these condensed consolidated financial statements and related notes hereto have been retroactively adjusted to account for the effect of the reverse stock split for the three and nine month periods ended September 30, 2022 and 2021, respectively, and the balance sheet at September 30, 2022 and December 31, 2021.
Use of Estimates
The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates.
Leases
The Company accounts for its leases under Accounting Standards Codification (“ASC”) 842, Leases. Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the consolidated balance sheet as both a right-of-use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term. Variable lease expenses, if any, are recorded when incurred.
In calculating the right-of-use asset and lease liability, the Company elects to combine lease and non-lease components. The Company excludes short-term leases having initial terms of 12 months or less from the new guidance as an accounting policy election and recognizes rent expense on a straight-line basis over the lease term.
Loss Per Share
ASC 260, Earnings Per Share, requires dual presentation of basic and diluted earnings per share (“EPS”), with a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS computation. Basic EPS excludes dilution. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that are then sharing in the earnings of the entity.
Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding plus the effect of dilutive potential common shares outstanding during the period determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss per share calculation, common stock warrants, unvested restricted stock units and stock options are considered to be potentially dilutive securities but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive, and therefore, basic and diluted net loss per share were the same for all periods presented.
The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share for the nine months ended September 30, 2022 and 2021, respectively, because to do so would be anti-dilutive (in common equivalent shares):
As of September 30,
20222021
Options to purchase common stock1,311,691 533,784 
Unvested restricted stock awards891 7,118 
Unvested restricted stock units125,000 31,116 
Preferred stock conversion to common stock1,363,636  
Warrants to purchase common stock17,507,268 2,402,442 
Total20,308,486 2,974,460 
Adoption of Recent Accounting Pronouncements
The Company continually assesses new accounting pronouncements to determine their applicability. When it is determined a new accounting pronouncement affects the Company’s financial reporting, the Company undertakes a review to determine the consequences of the change to its consolidated financial statements and assures there are sufficient controls in place to ascertain the Company’s consolidated financial statements properly reflect the change.
In August 2020, the FASB issued ASU No. 2020-06, “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity”, which simplifies the accounting for convertible instruments by eliminating the requirement to separate embedded conversion features from the host contract when the conversion features are not required to be accounted for as derivatives under Topic 815, Derivatives and Hedging, or do not result in substantial premiums accounted for as paid-in capital. By removing the separation model, a convertible debt instrument will be reported as a single liability instrument with no separate accounting for embedded conversion features. This new standard also removes certain settlement conditions required for contracts to qualify for equity classification and simplifies the diluted earnings per share calculations by requiring an entity use the if-converted method and the effect of potential share settlement be included in diluted earnings per share calculations. This new standard will be effective for the Company for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently assessing the impact of adopting this standard on the consolidated financial statements.
10


ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
4.  Revenue Recognition

The Company recognizes revenue under ASC 606, Revenue from Contracts with Customers. The core principle of the new revenue standard is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The following five steps are applied to achieve that core principle:

Step 1: Identify the contract with the customer
Step 2: Identify the performance obligations in the contract
Step 3: Determine the transaction price
Step 4: Allocate the transaction price to the performance obligations in the contract
Step 5: Recognize revenue when the company satisfies a performance obligation
Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by us from a customer, are excluded from revenue.
Shipping and handling costs associated with outbound freight related to contracts with customers are accounted for as a fulfillment cost and are included in cost of sales when control of the goods transfers to the customer.
Nature of goods and services
The following is a description of principal activities from which the Company generates its revenue.
Product sales –The Company accounts for individual products and services separately if they are distinct (i.e., if a product or service is separately identifiable from other items and if a customer can benefit from it on its own or with other resources that are readily available to the customer). The consideration, including any discounts, is allocated between separate products and services based on their stand-alone selling prices. The stand-alone selling prices are determined based on the cost plus margin approach.
Drug and dialysis concentrates products are sold directly to dialysis clinics and to wholesale distributors in both domestic and international markets. Distribution and license agreements for which upfront fees are received are evaluated upon execution or modification of the agreement to determine if the agreement creates a separate performance obligation from the underlying product sales.  For all existing distribution and license agreements, the distribution and license agreement is not a distinct performance obligation from the product sales.  In instances where regulatory approval of the product has not been established and the Company does not have sufficient experience with the foreign regulatory body to conclude regulatory approval is probable, the revenue for the performance obligation is recognized over the term of the license agreement (over time recognition). Conversely, when regulatory approval already exists or is probable, revenue is recognized at the point in time control of the product transfers to the customer.
The Company received upfront fees under five distribution and license agreements that have been deferred as a contract liability.  The amounts received from Wanbang Biopharmaceuticals Co., Ltd. (“Wanbang”), Sun Pharmaceutical Industries Ltd. ("Sun Pharma"), Jeil Pharmaceutical Co., Ltd. ("Jeil Pharma") and Drogsan Pharmaceuticals ("Drogsan Pharma") are recognized as revenue over the estimated term of the applicable distribution and license agreement as regulatory approval was not received and the Company did not have sufficient experience in China, India, South Korea and Turkey, respectively, to determine regulatory approval was probable as of the execution of the agreement.  The amounts received from Baxter Healthcare Corporation (“Baxter”) are recognized as revenue at the point in time the estimated product sales under the agreement occur. 
For the business under the Company’s Distribution Agreement with Baxter (the “Baxter Agreement”) and for the majority of the Company’s international customers, the Company recognizes revenue at the shipping point, which is generally the Company’s plant or warehouse. For other business, the Company recognizes revenue based on when the customer takes control of the product. The amount of revenue recognized is based on the purchase order less returns and adjusted for any rebates, discounts, chargebacks or other amounts paid to customers. There were no such adjustments for the periods reported. Customers typically pay for the product based on customary business practices with payment terms averaging 30 days, while distributor payment terms average 45 days.
Disaggregation of revenue
Revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition.
In thousands of U.S. dollars ($) Three Months Ended September 30, 2022Nine Months Ended September 30, 2022
Products By Geographic AreaTotalU.S.Rest of WorldTotalU.S.Rest of World
Drug Revenues
Product Sales – Point-in-time$193 $193 $ $834 $561 $273 
License Fee – Over time65  65 192  192 
Total Drug Products258 193 65 1,026 561 465 
Concentrates Products
Product Sales – Point-in-time17,953 16,619 1,334 51,035 46,334 4,701 
License Fee – Over time480 480  1,436 1,436  
Total Concentrate Products18,433 17,099 1,334 52,471 47,770 4,701 
Net Revenue$18,691 $17,292 $1,399 $53,497 $48,331 $5,166 
In thousands of U.S. dollars ($)Three Months Ended September 30, 2021Nine Months Ended September 30, 2021
Products By Geographic AreaTotalU.S.Rest of WorldTotalU.S.Rest of World
Drug Revenues
Product Sales – Point-in-time$217 $217 $ $656 $656 $ 
License Fee – Over time62  62 179  179 
Total Drug Products279 217 62 835 656 179 
Concentrates Products
Product Sales – Point-in-time15,224 13,541 1,683 44,308 39,768 4,540 
License Fee – Over time485 485  1,456 1,456  
Total Concentrate Products15,709 14,026 1,683 45,764 41,224 4,540 
Net Revenue$15,988 $14,243 $1,745 $46,599 $41,880 $4,719 
Contract balances
The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers.
In thousands of U.S. dollars ($)September 30, 2022December 31, 2021
Receivables, which are included in "Trade and other receivables"$7,367 $5,913 
Contract liabilities$6,729 $8,157 
There were no impairment losses recognized related to any receivables arising from the Company’s contracts with customers for the three and nine months ended September 30, 2022 and 2021.
For the three and nine months ended September 30, 2022 and September 30, 2021, the Company did not recognize any material bad-debt expense. There were no material contract assets recorded on the condensed consolidated balance sheet as of September 30, 2022 and December 31, 2021.  The Company does not generally accept returns of its concentrates products and no material reserve for returns of concentrates products was established as of September 30, 2022 or December 31, 2021. 
The contract liabilities primarily relate to upfront payments and consideration received from customers that are received in advance of the customer assuming control of the related products
Transaction price allocated to remaining performance obligations
For the three and nine months ended September 30, 2022, revenue recognized from performance obligations related to prior periods was not material.
Revenue expected to be recognized in any future year related to remaining performance obligations, excluding revenue pertaining to contracts that have an original expected duration of one year or less, contracts where revenue is recognized as invoiced, and contracts with variable consideration related to undelivered performance obligations, totaled $6.7 million as of September 30, 2022. The amount relates primarily to upfront payments and consideration received from customers in advance of the customer assuming control of the related products. The Company applies the practical expedient in paragraph 606-10-50-14 and does not disclose information about remaining performance obligations having original expected durations of one year or less. The Baxter Agreement includes minimum commitments of product sales over the duration of the agreement. Unfulfilled minimum commitments related to the Baxter Agreement are product sales of $3.8 million as of September 30, 2022, which is amortized ratably through expiration of the Baxter Agreement on October 2, 2024.
11


ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
5.  Investments - Available-for-Sale
Investments available-for-sale consisted of the following as of September 30, 2022 and December 31, 2021 (table in thousands):
September 30, 2022
Amortized CostUnrealized GainUnrealized LossAccrued InterestFair Value
Available-for-Sale Securities
Bonds$14,578 $6 $(1)$1 $14,584 

December 31, 2021
Amortized CostUnrealized GainUnrealized LossAccrued InterestFair Value
Available-for-Sale Securities
Bonds$9,143 $1 $ $14 $9,158 
The fair value of investments available-for-sale are determined using quoted market prices from daily exchange-traded markets based on the closing price as of the balance sheet date and are classified as a Level 1 measurement under ASC 820 Fair Value Measurements.
As of September 30, 2022 and December 31, 2021, the amortized cost and estimated fair value of our available-for-sale securities were due within one year.
6.  Inventory
Components of inventory, net of reserves, as of September 30, 2022 and December 31, 2021 are as follows (table in thousands):
September 30,
2022
December 31,
2021
Raw Materials$4,074 $3,434 
Work in Process336 201 
Finished Goods1,803 1,964 
Total$6,213 $5,599 
As of September 30, 2022, the Company classified $1.2 million of inventory as non-current, all of which was related to the active pharmaceutical ingredient and raw materials for TRIFERIC®. As of September 30, 2022, the total TRIFERIC® inventory net of reserve was $1.2 million.
The $1.2 million net value of TRIFERIC® inventory consisted of $0.3 million of TRIFERIC® API with an estimated useful life extending through 2023, and $0.9 million of raw materials for TRIFERIC® with an estimated useful life of 25 years.
12


ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
7.  Property and Equipment
As of September 30, 2022 and December 31, 2021, the Company’s property and equipment consisted of the following (table in thousands):
September 30,
2022
December 31,
2021
Leasehold Improvements$1,257 $1,204 
Machinery and Equipment5,985 5,864 
Information Technology & Office Equipment1,845 1,845 
Laboratory Equipment660 676 
9,747 9,589 
Accumulated Depreciation(7,483)(7,103)
Property and Equipment, net$2,264 $2,486 
Depreciation expense for both the three months ended September 30, 2022 and 2021 was $0.1 million. Depreciation expense for nine months end September 30, 2022 and 2021 was $0.4 million and $0.5 million, respectively.
13


ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
8.  Accrued Liabilities
Accrued liabilities as of September 30, 2022 and December 31, 2021 consisted of the following (table in thousands):
September 30,
2022
December 31,
2021
Accrued Research & Development Expense$65 $366 
Accrued Compensation and Benefits3,006 1,791 
Accrued Unvouchered Receipts581 796 
Accrued Workers Compensation294 382 
Other Accrued Liabilities1,941 1,755 
Total Accrued Liabilities$5,887 $5,090 
9.  Deferred Revenue
In October 2014, the Company entered into the Baxter Agreement, which has a term of 10 years and received an upfront fee of $20 million. The upfront fee was recorded as deferred revenue and is being recognized based on the proportion of product shipments to Baxter in each period, compared with total expected sales volume over the term of the Distribution Agreement. The Company recognized revenue of approximately $0.5 million and $1.4 million for the three and nine months ended September 30, 2022, respectively. The Company recognized revenue of approximately $0.5 million and $1.5 million for the three and nine month ended September 30, 2021, respectively. Deferred revenue related to the Baxter Agreement totaled $3.8 million as of September 30, 2022 and $5.2 million as of December 31, 2021.
In 2016, the Company entered into a distribution agreement with Wanbang (the "Wanbang Agreement") and received an upfront fee of $4.0 million. The upfront fee was recorded as deferred revenue and is being recognized as revenue based on the agreement term. The Company recognized revenue of approximately $0.1 million and $0.2 million during each of the three and nine months ended September 30, 2022 and 2021, respectively. Deferred revenue related to the Wanbang Agreement totaled $2.3 million as of September 30, 2022 and $2.5 million as of December 31, 2021.

In January 2020, the Company entered into license and supply agreements with Sun Pharma (the "Sun Pharma Agreements"), for the rights to commercialize TRIFERIC® (dialysate) (ferric pyrophosphate citrate) in India. In consideration for the license, the Company received an upfront fee of $0.1 million. The upfront fee was recorded as deferred revenue and is being recognized as revenue based on the agreement term. The Company recognized revenue of approximately $2,500 and $7,500 for each of the three and nine months ended September 30, 2022 and 2021, respectively. Deferred revenue related to the Sun Pharma Agreement totaled $72,500 and $80,000 as of September 30, 2022 and December 31, 2021, respectively.

In September 2020, the Company entered into a license and supply agreements with Jeil Pharma (the "Jeil Pharma Agreements"), for the rights to commercialize TRIFERIC® (dialysate) (ferric pyrophosphate citrate) in South Korea. In consideration for the license, the Company received an upfront fee of $0.2 million. In May 2022, Jeil Pharma obtained regulatory approval in South Korea and paid the Company $0.2 million in consideration of reaching the milestone. The upfront fee and milestone payments were recorded as deferred revenue and are being recognized as revenue based on the agreement term. The Company recognized revenue of $5,200 and $13,000 for the three and nine months ended September 30, 2022, respectively, and $2,500 and $7,500 for the three and nine months ended September 30, 2021, respectively. Deferred revenue related to the Jeil Pharma Agreement totaled approximately $0.4 million and $0.2 million as of September 30, 2022 and December 31, 2021 respectively.

In June 2021, the Company entered into license and supply agreements with Drogsan Pharma (the "Drogsan Agreements"), for the rights to commercialize TRIFERIC® (dialysate) and TRIFERIC® AVNU in Turkey. In consideration for the license, the Company received an upfront fee of $0.15 million. The upfront fee was recorded as deferred revenue and will be recognized as revenue based on the agreement term. The Company recognized revenue of $3,750 and $11,250 for each of the three and nine months ended September 30, 2022 and 2021, respectively. Deferred revenue related to the Drogsan Agreements totaled approximately $0.13 million and $0.15 million as of September 30, 2022 and December 31, 2021, respectively.
14


ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
10.  Stockholders’ Equity

Reverse Stock Split
On May 9, 2022, the stockholders of the Company authorized the Board of Directors to effect a reverse stock split of all outstanding shares of common stock. The Board of Directors subsequently approved the implementation of a reverse stock split as a ratio of one-for-eleven shares, which became effective on May 13, 2022. The Company’s outstanding stock options were also adjusted to reflect the one-for-eleven reverse stock split of the Company’s common stock. Outstanding stock options were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased.
Preferred Stock
On April 6, 2022, the Company and DaVita entered into the SPA, which provided for the issuance by the Company of up to $15 million of preferred stock to DaVita. On April 6, 2022, the Company issued 7,500 shares of Series X Preferred Stock for gross proceeds of $7.5 million. On June 2, 2022, the Company met the conditions for the Second Tranche through a Registered Direct and Private Placement Offering by raising $15 million in additional capital. As a result, on June 16, 2022 the Company issued an additional 7,500 shares of the Series X Preferred Stock to DaVita for gross proceeds of $7.5 million.

The Series X Preferred Stock was issued for a price of $1,000 per share (the "Face Amount"), subject to accretion at a rate of 1% per annum, compounded annually. If the Company’s common stock trades above $22.00 for a period of 30 calendar days, the accretion will thereafter cease.

The Series X Convertible Preferred Stock is convertible to common stock at rate equal to the Face Amount, divided by a conversion price of $11.00 per share (subject to adjustment for future stock splits, reverse stock splits and similar recapitalization events). As a result, each share of Series X Preferred Stock will initially convert into approximately 91 shares of common stock. DaVita’s right to convert to common stock is subject to a beneficial ownership limitation, which is initially set at 9.9% of the outstanding common stock, which limitation may be reset (not to exceed 19.9%) at DaVita’s option and upon providing prior written notice to the Company. In addition, any debt financing is limited by the terms of our Securities Purchase Agreement with DaVita. Specifically, until DaVita owns less than 50% of its investment, the Company may only incur additional debt in the form of a purchase money loan, a working capital line of up to $5 million or to refinance existing debt, unless DaVita consents.
Additionally, the Series X Preferred Stock has a deemed liquidation event and redemption clause which could be triggered if the sale of all or substantially all of the Company's assets relating to the Company's dialysis concentrates business line. Since the Series X Preferred Stock may be redeemed if certain assets are sold at the option of the holder, but is not mandatorily redeemable, the preferred stock has been classified as permanent equity and initially recognized at fair value of $15 million (the proceeds on the date of issuance) less issuance costs of $0.1 million, resulting in an initial value of $14.9 million. The Company will assess at each reporting period whether conditions have changed to now meet the mandatorily redemptive definition which could trigger liability classification.
As of September 30, 2022 and December 31, 2021, there were 2,000,000 shares of preferred stock, $0.0001 par value per share, authorized and 15,000 and nil shares of preferred stock issued and outstanding, respectively.
Common Stock
As of September 30, 2022 and December 31, 2021, there were 170,000,000 shares of common stock, $0.0001 par value per share, authorized and 11,152,673 and 8,544,225 shares issued and outstanding, respectively.
Controlled Equity Offering

On April 8, 2022, the Company entered into the Sales Agreement with Cantor Fitzgerald & Co. as Agent, pursuant to which the Company may offer and sell from time to time up to $12,200,000 of shares of Company’s common stock through the Agent. The offering and sale of such shares has been registered under the Securities Act of 1933, as amended, pursuant to the Company’s Registration Statement on Form S-3 (File No. 333-259923) (the “Registration Statement”), which was originally filed with the SEC on September 30, 2021 and declared effective by the SEC on October 8, 2021, the base prospectus contained within the Registration Statement, and a prospectus supplement that was filed with the SEC on April 8, 2022.

In May 2022, the Company sold 7,500 shares of its common stock pursuant to the Sales Agreement for gross proceeds of $15,135, at a weighted average selling price of approximately $2.02. The Company paid $378 in commissions and offering fees related to the sale of shares of common stock.

Under the RD Purchase Agreement and the PIPE Purchase Agreement discussed below, the Company has agreed not to make any sales under any at-the-market offering facility, including pursuant to the Sales Agreement, until at least January 1, 2023 (or until such later time when the Company is permitted to make additional sales under Instruction I.B.6 to Form S-3).
Registered Direct Offering

On May 30, 2022, the Company entered into the RD Purchase Agreement with the Purchaser named therein, pursuant to which the Company agreed to issue and sell, in a registered direct offering (the “Offering”), 844,613 shares of its common stock at price of $1.39 per share, and pre-funded warrants to purchase up to an aggregate of 7,788,480 shares of common stock (the “Pre-Funded Warrants” and the shares of common stock underlying the Pre-Funded Warrants, the “Warrant Shares”). The purchase price of each Pre-Funded Warrant is equal to the price at which a share of common stock was sold to the public in the Offering, minus $0.0001, and the exercise price of each Pre-Funded Warrant is $0.0001 per share.

A holder (together with its affiliates) may not exercise any portion of the Pre-Funded Warrants to the extent the holder would own more than 9.99% of the Company’s outstanding common stock immediately after exercise, as such percentage ownership is determined in accordance with the terms of the Pre-Funded Warrant. The RD Purchase Agreement contains customary representations and warranties and agreements of the Company and the Purchaser and customary indemnification rights and obligations of the parties.

A total of 7,311,000 Pre-Funded Warrants remained outstanding as of September 30, 2022.
Private Placement

Also on May 30, 2022, concurrently with the Offering, the Company entered into the PIPE Purchase Agreement relating to the offering and sale (the “Private Placement”) of warrants to purchase up to a total of 9,900,990 shares of common stock and pre-funded warrants to purchase up to a total of 1,267,897 shares of common stock (the “PIPE Warrants”). Each warrant was sold at a price of $0.125 per underlying warrant share and is exercisable at an exercise price of $1.39 per share. The purchase price of each Pre-Funded Warrant was equal to the price at which a share of common stock was sold to the public in the Offering, minus $0.0001, and the exercise price of each prefunded warrant is $0.0001 per share.

As of September 30, 2022 9,900,990 PIPE Warrants and no Pre-Funded PIPE Warrants remained outstanding.

In connection with the Private Placement, the Company entered into a Registration Rights Agreement with the Purchaser, dated as of June 2, 2022 (the “RRA”). Pursuant to the RRA, the Company was required to prepare and file a registration statement with the SEC no later than July 1, 2022, and to use its reasonable best efforts to have the registration statement declared effective as promptly as possible, subject to certain specified penalties if timely effectiveness is not achieved. The Company filed a registration statement on June 22, 2022 which became effective on July 5, 2022.

The Offering and the Private Placement closed on June 2, 2022. The net proceeds to the Company from the Offering and the Private Placement were approximately $14.9 million, after deducting fees and expenses. Subject to certain ownership limitations, the PIPE Warrants are exercisable upon issuance.

The Company has accounted for the common stock related to the Offering and Private Placement as equity on the accompanying consolidated balance sheets as of September 30, 2022. The amount allocated to common stock was $2.0 million. This allocation is equal to the total proceeds of $15.0 million less the amount allocated to Warrants of $12.9 million and is also net of the direct and incremental costs associated with the Offering and Private Placement of $0.1 million. The Black-Scholes pricing model was used to calculate the value of Warrants relating to the Offering and Private Placement.
15


ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
11.  Stock-Based Compensation
The Company recognized total stock-based compensation expense during the three and nine months ended September 30, 2022 and 2021 as follows (table in thousands):
Three Months Ended
September 30,
Nine Months Ended
September 30,
2022202120222021
Service-based awards:
Restricted stock units$46 $81 $84 $263 
Stock option awards130 315 401 1,050 
176 396 485 1,313 
Performance-based awards:
Restricted stock awards  (391)(391)
Stock option awards (35) (364)
 (35)(391)(755)
Total$176 $361 $94 $558 
Performance Based Restricted Stock
A summary of the Company’s restricted stock awards during the nine months ended September 30, 2022 is as follows:
Number of SharesWeighted Average
Grant-Date
Fair Value
Unvested at January 1, 20227,118 $62.70 
Forfeited(6,227)$62.70 
Unvested at September 30, 2022891 $62.70 
A summary of the Company’s restricted stock awards during the nine months ended September 30, 2021 is as follows:
Number of SharesWeighted Average
Grant-Date
Fair Value
Unvested at January 1, 202113,345 $62.70 
Forfeited(6,227)$62.70 
Unvested at September 30, 20217,118 $62.70 
The fair value of restricted stock awards are measured based on their fair value on the date of grant and amortized over the vesting period of 20 months. As of September 30, 2022, unvested restricted stock awards of 891 were related to performance-based awards. The forfeited performance-based restricted stock awards of 6,227 was due to the resignation of the Company's Chief Development Officer on March 25, 2022. These forfeited awards reduced stock-based compensation expense by $0.4 million. As of September 30, 2021, unvested restricted stock awards of 7,118 were related to performance-based awards. The forfeited performance-based restricted stock awards of 6,227 was due to the termination of the Company's former Chief Science Officer on January 19, 2021. These forfeited awards reduced stock-based compensation expense by $0.4 million.
16


ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Service-Based Restricted Stock Units
A summary of the Company’s service-based restricted stock units during the nine months ended September 30, 2022 is as follows:
Number of SharesWeighted Average
Grant-Date
Fair Value
Unvested at January 1, 202229,289 $12.87 
Granted125,000 1.47 
Vested(23,515)11.33 
Forfeited(5,774)19.00 
Unvested at September 30, 2022125,000 $1.47 

A summary of the Company’s service-based restricted stock units during the nine months ended September 30, 2021 is as follows:
Number of SharesWeighted Average
Grant-Date
Fair Value
Unvested at January 1, 202124,136 $28.60 
Granted28,186 9.90 
Vested(20,134)26.18 
Forfeited(1,073)52.91 
Unvested at September 30, 202131,115 $12.87 
The fair value of service based restricted stock units are measured based on their fair value on the date of grant and amortized over the vesting period. The vesting periods range from 1 to 3 years. Stock-based compensation expense of $46,193 and $83,607 was recognized for the three and nine months ended September 30, 2022, respectively. Stock-based compensation expense of $0.1 million and $0.3 million was recognized for the three and nine months ended September 30, 2021, respectively. As of September 30, 2022, the unrecognized stock-based compensation expense was $0.1 million, which is expected to be recognized over an estimated weighted average remaining term of less than 1 year.
Service-Based Stock Options
The fair value of the service-based stock options granted for the nine months ended September 30, 2022 were based on the following assumptions:
September 30,
2022
Exercise price
$1.28 - $1.66
Expected stock price volatility
76.2% - 78.5%
Risk-free interest rate
1.97% - 3.44%
Term (years)
5.5 - 6
17


ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
A summary of the Company’s service-based stock option activity for the nine months ended September 30, 2022 is as follows:
Shares
Underlying
Options
Weighted
Average Exercise
Price
Weighted
Average
Remaining
Contractual
Term
Aggregate
Intrinsic
Value
Outstanding at January 1, 2022528,591 $32.01 7.5$ 
Granted898,659 1.49 5.5— 
Forfeited(30,093)15.11 — — 
Expired(85,466)82.09 — — 
Outstanding at September 30, 20221,311,691 $8.23 9.1$ 
Exercisable at September 30, 2022243,973 $29.31 6.9$ 
A summary of the Company’s service-based stock option activity for the nine months ended September 30, 2021 is as follows:
Shares
Underlying
Options
Weighted
Average Exercise
Price
Weighted
Average
Remaining
Contractual
Term
Aggregate
Intrinsic
Value
Outstanding at January 1, 2021519,814 $50.05 6.6$ 
Granted170,197 9.79 6.0— 
Forfeited(35,025)25.30 — — 
Expired(121,202)78.76 — — 
Outstanding at September 30, 2021533,784 $32.45 7.7$ 
Exercisable at September 30, 2021230,858 $54.56 5.8$ 
The aggregate intrinsic value in the table above is calculated as the difference between the closing price of the Company's common stock and the exercise price of the stock options that had strike prices below the closing price.
During the nine months ended September 30, 2022, the Company granted stock options to purchase up to 898,659 shares of common stock to certain employees. During the nine months ended September 30, 2022, 30,093 shares were forfeited and 85,466 shares expired. Forfeitures are recorded in the period of occurrence; compensation expense is adjusted accordingly.
Stock-based compensation expense recognized for service-based stock options was $0.1 million and $0.4 million for the three and nine months ended September 30, 2022, respectively. Stock-based compensation expense recognized for service-based stock options was $0.3 million and $1.0 million for the three and nine months ended September 30, 2021, respectively. As of September 30, 2022, total stock-based compensation expense related to unvested options not yet recognized totaled approximately $1.4 million, which is expected to be recognized over an estimated weighted average remaining term of 3.6 years.
18


ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
12.  Licensing Agreements
Product License Agreements
The Company is a party to a Licensing Agreement between the Company and Charak, LLC ("Charak") dated January 7, 2002 (the "2002 Agreement") that grants the Company exclusive worldwide rights to certain patents and information related to our TRIFERIC® product. On October 7, 2018, the Company entered into a Master Services and IP Agreement (the “Charak MSA”) with Charak and Dr. Ajay Gupta, a former Officer of the Company. Pursuant to the MSA, the parties entered into three additional agreements described below related to the license of certain soluble ferric pyrophosphate (“SFP”) intellectual property owned by Charak. As of September 30, 2022, the Company has accrued $85,400 relating to certain IP reimbursement expenses and certain sublicense royalty fees and is included within accrued liabilities on the condensed consolidated balance sheet.
Pursuant to the Charak MSA, the aforementioned parties entered into an Amendment, dated as of October 7, 2018 (the “Charak Amendment”), to the 2002 Agreement, under which Charak granted the Company an exclusive, worldwide, non-transferable license to commercialize SFP for the treatment of patients with renal failure. The Charak Amendment amends the royalty payments due to Charak under the 2002 Agreement such that the Company is liable to pay Charak royalties on net sales by the Company of products developed under the license, which includes the Company’s TRIFERIC® product, at a specified rate until December 31, 2021 and thereafter at a reduced rate from January 1, 2022 until February 1, 2034. Additionally, the Company shall pay Charak a percentage of any sublicense income during the term of the agreement, which amount shall not be less than a minimum specified percentage of net sales of the licensed products by the sublicensee in jurisdictions where there exists a valid claim, on a country-by-country basis, and be no less than a lower rate of the net sales of the licensed products by the sublicensee in jurisdictions where there exists no valid claim, on a country-by-country basis.
Also pursuant to the Charak MSA, the Company and Charak entered into a Commercialization and Technology License Agreement I.V. TRIFERIC®, dated as of October 7, 2018 (the “IV Agreement”), under which Charak granted the Company an exclusive, sublicensable, royalty-bearing license to SFP for the purpose of commercializing certain intravenous-delivered products incorporating SFP for the treatment of iron disorders worldwide for a term that expires on the later of February 1, 2034 or upon the expiration or termination of a valid claim of a licensed patent. The Company is liable to pay Charak royalties on net sales by the Company of products developed under the license at a specified rate until December 31, 2021. From January 1, 2022 until February 1, 2034, the Company is liable to pay Charak a base royalty at a reduced rate on net sales and an additional royalty on net sales while there exists a valid claim of a licensed patent, on a country-by-country basis. The Company shall also pay to Charak a percentage of any sublicense income received during the term of the IV Agreement, which amount shall not be less than a minimum specified percentage of net sales of the licensed products by the sublicensee in jurisdictions where there exists a valid claim, on a country-by-country basis, and not be less than a lower rate of the net sales of the licensed products by the sublicensee in jurisdictions where there exists no valid claim, on a country-by-country basis.
Also pursuant to the Charak MSA, the Company and Charak entered into a Technology License Agreement TPN TRIFERIC®, dated as of October 7, 2018 (the “TPN Agreement”), pursuant to which Charak granted the Company an exclusive, sublicensable, royalty-bearing license to SFP for the purpose of commercializing worldwide certain TPN products incorporating SFP. The license grant under the TPN Agreement continues for a term that expires on the later of February 1, 2034 or upon the expiration or termination of a valid claim of a licensed patent. During the term of the TPN Agreement, the Company is liable to pay Charak a base royalty on net sales and an additional royalty on net sales while there exists a valid claim of a licensed patent, on a country-by-country basis. The Company shall also pay to Charak a percentage of any sublicense income received during the term of the TPN Agreement, which amount shall not be less than a minimum royalty on net sales of the licensed products by the sublicensee in jurisdictions where there exists a valid claim, on a country-by-country basis, and not be less than a lower rate of the net sales of the licensed products by the sublicensee in jurisdictions where there exists no valid claim, on a country-by-country basis.
The potential milestone payments are not yet considered probable, and no milestone payments have been accrued at September 30, 2022.
19


ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
13.  Leases
Rockwell leases its production facilities and administrative offices as well as certain equipment used in its operations including leases on transportation equipment used in the delivery of its products. The lease terms range from monthly to six years. Rockwell occupies a 51,000 square foot facility and a 17,500 square foot facility in Wixom, Michigan under a lease expiring in August 2024. Rockwell also occupies two other manufacturing facilities, a 51,000 square foot facility in Grapevine, Texas under a lease expiring in December 2025, and a 57,000 square foot facility in Greer, South Carolina under a lease expiring February 2026. In addition, Rockwell occupied 4,100 square feet of office space in Hackensack, New Jersey under a lease expiring on October 31, 2024. This lease was subleased on December 15, 2021 with an expiration date of October 31, 2024.
At September 30, 2022, the Company had operating and finance lease liabilities of $7.2 million and right-of-use assets of $6.9 million, which are included in the consolidated balance sheet.
At December 31, 2021, the Company had operating lease liabilities of $7.9 million and right-of-use assets of $7.7 million, which are included in the consolidated balance sheet.
The following summarizes quantitative information about the Company’s operating leases (table in thousands):
Three Months Ended September 30, 2022Three Months Ended September 30, 2021Nine Months Ended September 30, 2022Nine Months Ended September 30, 2021
Operating leases
Operating lease cost$410 $457 $1,289 $1,309 
Variable lease cost101 94 287 286 
Operating lease expense511 551 1,576 1,595 
Finance leases
Amortization of right-of-use assets141 73 424 184 
Interest on lease obligations44 22 136 55 
Finance lease expense185 95 560 239 
Short-term lease rent expense5 4 14 12 
Total rent expense$701 $650 $2,150 $1,846 
Other information
Operating cash flows from operating leases$427 $444 $1,338 $1,298 
Operating cash flows from finance leases$44 $22 $136 $56 
Financing cash flows from finance leases$121 $59 $359 $152 
Right of use assets exchanged for operating lease liabilities$768 $718 $768 $4,089 
Right of use assets exchanged for finance lease liabilities$ $588 $ $1,365 
Weighted-average remaining lease term – operating leases3.23.73.23.7
Weighted-average remaining lease term – finance leases4.75.54.75.5
Weighted-average discount rate – operating leases6.4 %6.3 %6.4 %6.3 %
Weighted-average discount rate – finance leases6.4 %5.9 %6.4 %5.9 %
Future minimum rental payments under operating lease agreements are as follows (in thousands):
OperatingFinance
Year ending December 31, 2022 (remaining)$434 $165 
Year ending December 31, 20231,692 669 
Year ending December 31, 20241,404 672 
Year ending December 31, 2025937 676 
Year ending December 31, 2026310 666 
Remaining future payments120 311 
Total$4,897 $3,159 
Less present value discount(467)(426)
Operating and finance lease liabilities$4,430 $2,733 
20


ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
14. Loan and Security Agreement

On March 16, 2020, the Company and Rockwell Transportation, Inc., as Borrowers, entered into a Loan and Security Agreement (the "Loan Agreement") with Innovatus Life Sciences Lending Fund I, LP ("Innovatus"), as collateral agent and the lenders party thereto, pursuant to which Innovatus, as a lender, agreed to make certain term loans to the Company in the aggregate principal amount of up to $35.0 million (the "Term Loans"). Funding of the first $22.5 million tranche was completed on March 16, 2020. The Company is no longer eligible to draw on a second tranche of $5.0 million or a third tranche of $7.5 million, which were tied to the achievement of certain milestones by a specific date. Net draw down proceeds were $21.2 million with closing costs of $1.3 million.
In connection with each funding of the Term Loans, the Company is required to issue to Innovatus a warrant (the “Warrants”) to purchase a number of shares of the Company’s common stock equal to 3.5% of the principal amount of the relevant Term Loan funded divided by the exercise price, which will be based on the lower of (i) the volume weighted average closing price of the Company’s stock for the 5-trading day period ending on the last trading day immediately preceding the execution of the Loan Agreement or (ii) the closing price on the last trading day immediately preceding the execution of the Loan Agreement (or for the second and third tranches only at the lower of (i) $18.15 per share or (ii) the volume weighted average closing price of the Company’s stock for the 5-trading day period ending on the last trading day immediately preceding the relevant Term Loan funding). The Warrants may be exercised on a cashless basis and are immediately exercisable through the seventh anniversary of the applicable funding date. The number of shares of common stock for which each Warrant is exercisable and the associated exercise price are subject to certain proportional adjustments as set forth in such Warrant. In connection with the first tranche of the Term Loans, the Company issued a Warrant to Innovatus, exercisable for an aggregate of 43,388 shares of the Company’s common stock at an exercise price of $18.15 per share. The Company evaluated the warrant under ASC 470, Debt, and recognized an additional debt discount of approximately $0.5 million based on the relative fair value of the base instruments and warrants. The Company calculated the fair value of the warrant using the Black-Scholes model.

The Company is entitled to make interest-only payments for thirty months, or up to thirty-six months if certain conditions are met. The Term Loans will mature on March 16, 2025, and will bear interest at the greater of (i) Prime Rate (as defined in the Loan Agreement) and (ii) 4.75%, plus 4.00% with an initial interest rate of 8.75% per annum and an effective interest rate of 10.9%. The Company has the option, under certain circumstances, to add 1.00% of such interest rate amount to the then outstanding principal balance in lieu of paying such amount in cash. For the three months ended September 30, 2022 and 2021, interest expense amounted to $0.4 million and $0.6 million, respectively. For the nine months ended September 30, 2022 and 2021, interest expense amounted to $1.2 million and $1.8 million, respectively.

The Loan Agreement is secured by all assets of the Company and Rockwell Transportation, Inc. Proceeds are used for working capital purposes. The Loan Agreement contains customary representations and warranties and covenants, subject to customary carve outs, and includes financial covenants related to liquidity and trailing twelve months sales of TRIFERIC®, with the latter beginning with the period ending December 31, 2020. The Company cannot assure you that we can maintain compliance with the covenants under our Loan Agreement, which may result in an event of default. The Company's ability to comply with these covenants may be adversely affected by events beyond its control. For example, the Loan Agreement contains certain financial covenants relating to sales and, as a result of the ongoing COVID-19 pandemic and its effect on the Company's sales activities, among other factors, the Company may not be able to satisfy such covenants in the future. If the Company is unable to comply with the covenants under the Loan Agreement, it would pursue all available cure options in order to regain compliance. However, the Company may not be able to mutually agree with Innovatus on appropriate remedies to cure a future breach of a covenant, which could give rise to an event of default. If the Company is unable to avoid an event of default, any required repayments could have an adverse effect on its liquidity.

In September 2021, the Company entered into an amendment to the Loan Agreement in which the Company, in exchange for Innovatus lowering the sales covenants, agreed to (i) prepay an aggregate principal amount of $7,500,000 in ten installments commencing on December 1, 2021; (ii) pay an additional prepayment premium of 5% on prepaid amounts if the Company elects to prepay all outstanding Term Loans on or before September 24, 2023 and (iii) maintain minimum liquidity of no less than $5,000,000 if the aggregate principal amount of Term Loans is greater than $15,000,000 pursuant to the liquidity covenant in the Loan Agreement.

On March 31, 2022, the Collateral Agent and Lenders consented to the delivery to Collateral Agent and Lenders of its annual audited financial statements for the fiscal year 2021 by April 15, 2022 as opposed to within 90 days of December 31, 2021, as required pursuant to Loan Agreement.

As of September 30, 2022, the Company was in compliance with all covenants under the Loan Agreement.

As of September 30, 2022, the outstanding balance of the Term Loan was $14.1 million, net of unamortized issuance costs and discount of $0.9 million.

The following table reflects the schedule of principal payments on the Term Loan as of September 30, 2022 (in thousands):
Principal Payments
2022$1,000 
20236,000 
20246,000 
20252,000 
$15,000 

21


ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
15. Insurance Financing Note Payable
On June 2, 2022, the Company entered into a short-term note payable for $1.5 million, bearing interest at 5.40% per annum to finance various insurance policies. Principal and interest payments related to this note began on July 3, 2022 and were paid on a straight-line amortization over 9 months with the final payment due on March 3, 2023. As of September 30, 2022, the Company's insurance note payable balance was $1.0 million.
16. Subsequent Events
On October 28, 2022, 480,000 Pre-Funded Warrants to purchase common stock pursuant the SPA entered into on May 30, 2022 were exercised. The exercise price of each Pre-Funded Warrant is $0.0001 per share and resulted in gross proceeds of $48.00 (See Note 10 for more detail on the SPA).
On November 9, 2022, Rockwell reacquired its distribution rights to its hemodialysis concentrates products from Baxter and has agreed to terminate the exclusive distribution agreement dated October 2, 2014. Exclusivity and other provisions associated with the distribution agreement terminated November 9, 2022 and the remaining operational elements of the agreement terminate December 31, 2022. Under the exclusive distribution agreement, Baxter distributed and commercialized Rockwell’s hemodialysis concentrates products and provided customer service and order delivery to nearly all United States customers. Following the reacquisition of these rights, Rockwell will now be able to sell its hemodialysis concentrates products to dialysis clinics throughout the United States and around the world.
Rockwell will pay Baxter a fee for the reacquisition of its distribution rights. This fee will be payable in two equal installments on January 1, 2023 and April 1, 2023. To ensure that customer needs continue to be met after January 1, 2023, Baxter and Rockwell are working closely together to transition customers’ purchases of Rockwell’s hemodialysis concentrates from Baxter to Rockwell.
On November 10, 2022, the Company entered into a Second Amendment to the Loan and Security Agreement (the “Second Amendment”) dated as of November 14, 2022 with Innovatus, which amended the Loan Agreement. Pursuant to the Second Amendment, the Company (i) shall prepay an aggregate principal amount of $5.0 million in Term Loans (as defined in the Loan Agreement) in one installment on November 14, 2022; (ii) shall pay interest only payments until September 2023 at which time will resume scheduled debt payments.
Separation of Chief Financial Officer
On November 10, 2022, the Board of Directors of Rockwell terminated the employment of Russell Skibsted as Chief Financial Officer of the Company, effective immediately. The termination of employment of Mr. Skibsted by the Company without cause entitles Mr. Skibsted to severance in accordance with the Employment Agreement, dated September 15, 2020, by and between the Company and Mr. Skibsted (the “Employment Agreement”). The severance benefits under the Employment Agreement are subject to the execution and non-revocation of a release of claims in favor of the Company. In connection with Mr. Skibsted’s termination, the Board of Directors appointed Mark Strobeck, the Company’s Chief Executive Officer, as interim principal financial officer.



22


Item 2.  Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion and analysis should be read in conjunction with our condensed consolidated financial statements and related notes in “Item 1. Condensed Consolidated Financial Statements”. References in this report to “Rockwell,” the “Company,” “we,” “our” and “us” are references to Rockwell Medical, Inc. and its subsidiaries.
Forward-Looking Statements
We make forward-looking statements in this report and may make such statements in future filings with the Securities and Exchange Commission, or SEC.  We may also make forward-looking statements in our press releases or other public or shareholder communications.  Our forward-looking statements are subject to risks and uncertainties and include information about our current expectations and possible or assumed future results of our operations. When we use words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “could,” “plan,” “potential,” “predict,” “forecast,” “project,” “intend,” or similar expressions, or make statements regarding our intent, belief, or current expectations, we are making forward-looking statements. Our forward looking statements also include, without limitation, statements about our liquidity and capital resources; our ability to continue as a going concern; our ability to develop Ferric Pyrophosphate Citrate (“FPC”) for other indications; our ability to successfully execute on our business strategy and development of new indications; our ability to raise additional capital; our ability to renegotiate certain terms of our supply contracts; our ability to successfully implement certain cost containment and cost-cutting measures; our ability to achieve profitability and statements regarding our anticipated future financial condition, operating results, cash flows and business plans.
While we believe our forward-looking statements are reasonable, you should not place undue reliance on any such forward-looking statements, which are based on information available to us on the date of this report or, if made elsewhere, as of the date made.  Because these forward-looking statements are based on estimates and assumptions that are subject to significant business, economic and competitive uncertainties, many of which are beyond our control or are subject to change, actual results could be materially different.  Factors that might cause such a difference include, without limitation, the risks and uncertainties discussed in this report, “Item 1A — Risk Factors” in our Form 10-K for the year ended December 31, 2021 and from time to time in our other reports filed with the SEC, including in this Form 10-Q.
Other factors not currently anticipated may also materially and adversely affect our results of operations, cash flow and financial position.  There can be no assurance future results will meet expectations.  Forward-looking statements speak only as of the date of this report and we expressly disclaim any intent to update or alter any statements whether as a result of new information, future events or otherwise, except as may be required by applicable law.
Overview
Rockwell Medical is a commercial healthcare company focused on providing life-sustaining products for patients suffering from blood disorders and diseases associated with the kidney.
Rockwell is a revenue-generating business and the second largest supplier of acid and bicarbonate concentrates for dialysis patients in the United States. Hemodialysis is the most common form of end-stage kidney disease treatment and is usually performed at a freestanding outpatient dialysis center, at a hospital-based outpatient center, or in a patient’s home. This represents a large market opportunity for which Rockwell's products are well-positioned to meet the needs of patients.
Rockwell manufactures hemodialysis concentrates under cGMP regulations at its three facilities in Michigan, Texas, and South Carolina totaling approximately 175,000 square feet, and manufactures mixers in its Iowa facility. Rockwell delivers the majority of its hemodialysis concentrates products and mixers to dialysis clinics throughout the United States and internationally utilizing its own delivery trucks and third-party carriers. Rockwell has developed a core expertise in manufacturing and delivering hemodialysis concentrates, and has built a longstanding reputation for reliability, quality, and excellent customer service.
Rockwell has a proprietary parenteral iron product, TRIFERIC® (ferric pyrophosphate citrate, "FPC"), which is indicated to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease. While Rockwell has discontinued commercialization of TRIFERIC® in the United States, the Company has established several international partnerships with companies seeking to develop and commercialize TRIFERIC® outside the United States and is working closely with these international partners to develop and commercialize TRIFERIC® in their respective regions.
Rockwell continues to evaluate the viability of its FPC platform and FPC's potential to treat iron deficiency and iron deficiency anemia and for acute heart failure.
Rockwell’s strategy is focused on growing the Company's revenue-generating business, which currently includes hemodialysis concentrates and international partnerships for TRIFERIC® and achieving profitability in 2024 to put the Company in a stronger and more stable financial position.
Hemodialysis Concentrates Business: Rockwell is the second largest supplier of life-sustaining hemodialysis concentrates products to dialysis clinics in the United States. Our hemodialysis concentrates products are used to sustain a patient's life by removing toxins and balancing electrolytes in a dialysis patient’s bloodstream. A key element of our dialysis business strategy going forward is to improve the strength of our concentrates business. We believe we can achieve this by growing our business through the addition of new customers, expanding our territory coverage, increasing the efficiency by which Rockwell produces its products, and pricing our products appropriately to drive profitability.
Prior to the second quarter of 2022, Rockwell's concentrates business operated at a loss. This loss was accelerated due to inflation, which has increased our manufacturing and operating costs. We undertook discussions with our largest customers to renegotiate our existing supply contracts to improve the profitability of this business line. On April 6, 2022, we amended our agreement with our long-time partner, DaVita, Inc. ("DaVita"), a leading provider of kidney care, to enable us to stabilize our concentrates business. The amended agreement provides a stronger financial arrangement which encompasses pricing, cost share, cost cutting, and joint efforts to improve supply chain, all of which is intended to drive Rockwell’s concentrates business to operate profitably in the future. In addition to the amended agreement, DaVita invested $15 million in preferred stock in two equal tranches. The first tranche of $7.5 million was funded on April 7, 2022. The second tranche of $7.5 million was funded on June 16, 2022. We continue to review our entire supply chain to identify opportunities for improvement, prioritizing initiatives that will have the largest impact on long-term efficiency, profitability, and growth.
On November 9, 2022, Rockwell reacquired its distribution rights to its hemodialysis concentrates products from Baxter and has agreed to terminate the exclusive distribution agreement dated October 2, 2014. Exclusivity and other provisions associated with the distribution agreement terminated November 9, 2022 and the remaining operational elements of the agreement terminate December 31, 2022. Under the exclusive distribution agreement, Baxter distributed and commercialized Rockwell’s hemodialysis concentrates products in the United States and certain other countries. Rockwell manufactured all hemodialysis concentrates products and provided customer service and order delivery to nearly all U.S. customers. Following the reacquisition of these rights, Rockwell will now be able to sell its hemodialysis concentrates products directly to dialysis clinics throughout the United States and around the world. Additionally, Rockwell will now be able to independently price its products, eliminate costs associated with manufacturing covenants, improve manufacturing efficiencies, realize the full benefits from those improvements, and develop, in-license, or acquire new products to develop a broader kidney care products portfolio. This is expected to improve Rockwell's overall profitability and set the Company on a positive growth trajectory. Collectively, this affords Rockwell the opportunity to expand its leadership position within a large market opportunity, which currently is valued at $380 million and is anticipated to grow to approximately $500 million by 2026 in the United States alone.
Rockwell will pay Baxter a fee for the reacquisition of its distribution rights. This fee will be payable in two equal installments on January 1, 2023 and April 1, 2023. To ensure that customer needs continue to be met after January 1, 2023, Baxter and Rockwell are working closely together to transition customers’ purchases of Rockwell’s hemodialysis concentrates from Baxter to Rockwell.
TRIFERIC®: Our first two branded products from our FPC platform, TRIFERIC® (dialysate) and TRIFERIC® AVNU (intravenous), are indicated to maintain hemoglobin in patients undergoing hemodialysis. We began commercializing TRIFERIC® and TRIFERIC® AVNU in the United States in the second half of 2019 and in early 2021, respectively. In addition, Rockwell established six international partnerships to develop and commercialize TRIFERIC® in China, India, Korea, Turkey, Peru and Chile.
Rockwell undertook a strategic review of TRIFERIC®'s viability in the United States. TRIFERIC® was launched into a very competitive marketplace with well-entrenched products and a lack of consensus regarding unmet medical needs for dialysis patients with anemia. Due to its limited market adoption, unfavorable reimbursement, and absence of interest from other companies to license or acquire TRIFERIC® despite Rockwell's significant effort to partner the program, the Company discontinued its New Drug Applications (“NDAs”) for TRIFERIC® and TRIFERIC® AVNU in the United States. Sustaining
TRIFERIC® commercially in the United States resulted in a loss to Rockwell of approximately $2 million to $3 million, annually. The decision to discontinue the NDAs was not made lightly as the Company realizes the direct impact this action has on patients currently using the products. TRIFERIC® and its approved presentations were not discontinued for safety reasons.
Rockwell will continue to support its partners outside the United States. Rockwell has six international partnerships in China, India, Korea, Turkey, Peru, and Chile with organizations who have exclusive license agreements to develop and commercialize TRIFERIC® outside the United States.  Partnering in these regions allows us to better leverage the development, regulatory, commercial presence and expertise of business partners to increase sales of our products throughout the world. We believe there is still significant opportunity for TRIFERIC® internationally and will work diligently to support our partners, which requires minimal financial commitment from Rockwell and provides us with potential for near- and long-term revenue. We continue to pursue international licensing opportunities in other countries and regions.
Research and Development Pipeline:
FPC for Home Infusion is Rockwell's follow-up to TRIFERIC® and utilizes the FPC platform in the home infusion setting.
In late 2021, Rockwell filed an Investigational New Drug (“IND”) application with the United States Food and Drug Administration (“FDA”) for the treatment of iron deficiency anemia in patients, who are receiving medications in the home infusion setting. During the second quarter 2022, Rockwell provided the FDA with supplemental data to be used in Rockwell’s clinical studies and to clinically support the Company’s IND application for home infusion. The FDA placed this program on Clinical Hold and requested that additional data related to the microbiology and short-term stability of this formulation be provided to support the application. During the third quarter of 2022, Rockwell conducted a microbiological and short-term stability study of FPC for Home Infusion, in accordance with FDA guidance, to support the Company’s IND application. Preliminary results from the microbiology and short-term stability study indicated that the program would likely not meet the FDA’s requirements to support the IND application and would require significant capital expenditure and resources to support additional re-formulation work and conduct a Phase 2 study. As a result, Rockwell has put development work associated with FPC for Home Infusion on hold.
Rockwell is also exploring FPC’s impact on the treatment of hospitalized acute heart failure patients, which affects more than one million people in the United States annually. We believe that FPC may deliver rapidly bioavailable iron to the heart and improve cardiac energetics during hospitalization. This effect could help patients recover faster potentially resulting in shorter hospital stays and fewer 30-day re-admissions. If realized, these outcomes could translate into a meaningful reduction in healthcare costs and human suffering. Rockwell submitted a pre-IND meeting request to the FDA and expects to meet with the FDA before the end of this year. Depending on the feedback from FDA, Rockwell will determine the path forward for this program.

Reverse Stock Split
On May 9, 2022, the Company's stockholders authorized the Company's Board of Directors to effect a reverse stock split of all outstanding shares of common stock, warrants and options. The Board of Directors subsequently approved the implementation of a reverse stock split as a ratio of one-for-eleven shares, which became effective on May 13, 2022. The Company’s outstanding stock options were also adjusted to reflect the one-for-eleven reverse stock split of the Company’s common stock. Outstanding stock options were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased. The reverse stock split resulted in an adjustment to the Series X convertible preferred stock conversion prices to reflect a proportional decrease in the number of shares of common stock to be issued upon conversion. All share and per share data in these condensed consolidated financial statements and related notes hereto have been retroactively adjusted to the account for the effect of the reverse stock split for the three- and nine-month periods ended September 30, 2022 and 2021, respectively, and the balance sheet at September 30, 2022 and December 31, 2021.
23


Results of Operations for the Three Months Ended September 30, 2022 and 2021
The following table summarizes our operating results for the periods presented below (dollars in thousands):
For the Three Months Ended September 30,
2022% of Revenue2021% of Revenue% Change
Net Sales$18,691 $15,988 16.9 %
Cost of Sales17,914 95.8 %16,317 102.1 %9.8 
Gross Profit (Loss)777 4.2 (329)(2.1)(336.2)
Research and Product Development469 2.5 1,221 7.6 (61.6)
Selling and Marketing762 4.1 1,541 9.6 (50.6)
General and Administrative3,254 17.4 3,881 24.3 (16.2)
Operating Loss$(3,708)(19.8)%$(6,972)(43.6)%(46.8)%
Net Sales
During the three months ended September 30, 2022, our net sales were $18.7 million compared to net sales of $16.0 million during the three months ended September 30, 2021. The increase of $2.7 million was primarily due to the restructuring of our supply contract with DaVita and increased pricing to other customers.
Gross Profit (Loss)
Cost of sales during the three months ended September 30, 2022 was $17.9 million, resulting in gross profit of $0.8 million during the three months ended September 30, 2022, compared to cost of sales of $16.3 million and a gross loss of $0.3 million during the three months ended September 30, 2021. Gross profit increased by $1.1 million primarily due to the restructuring of our supply contract with DaVita and increased pricing to other customers. As a result, the Company expects an improvement in margins for the remainder of 2022.
Research and Product Development Expense
Research and product development expenses were $0.5 million and $1.2 million for the three months ended September 30, 2022 and 2021, respectively. Research and product development expenses decreased by $0.7 million due to greater cash management over project costs, a reduction in headcount and shifting our project timelines as noted above in the "Overview and Recent Developments" section above.
Selling and Marketing Expense
Selling and marketing expenses were $0.8 million during the three months ended September 30, 2022, compared with $1.5 million during the three months ended September 30, 2021. The decrease of $0.7 million is due to reduced marketing spend for our TRIFERIC® products and previous headcount reduction. See "Overview and Recent Developments" for more detail.
General and Administrative Expense
General and administrative expenses were $3.3 million during the three months ended September 30, 2022, compared with $3.9 million during the three months ended September 30, 2021. The decrease is primarily due to greater cash management and the reduced usage of outside agencies.
Other Income (Expense)
Other income for the three months ended September 30, 2022 and 2021 was negligible. Other expense for the three months ended September 30, 2022 was $0.5 million of interest expense related to our debt facility (see Note 14 to the condensed consolidated financial statements included elsewhere in this Form 10-Q for more information on our debt facility). Other expense for the three months ended September 30, 2021 was $0.6 million of interest expense related to our debt facility.
24


Results of Operations for the Nine Months Ended September 30, 2022 and 2021
The following table summarizes our operating results for the periods presented below (dollars in thousands):
For the Nine Months Ended September 30,
2022% of Revenue2021% of Revenue% Change
Net Sales$53,497 $46,599 14.8 %
Cost of Sales51,760 96.8 %46,788 100.4 %10.6 
Gross Profit (Loss)1,737 3.2 (189)(0.4)(1,019.0)
Research and Product Development2,963 5.5 5,445 11.7 (45.6)
Selling and Marketing1,743 3.3 4,860 10.4 (64.1)
General and Administrative11,845 22.1 11,483 24.6 3.2 
Operating Loss$(14,814)(27.7)%$(21,977)(47.2)%(32.6)%
Net Sales
During the nine months ended September 30, 2022, our net sales were $53.5 million compared to net sales of $46.6 million during the nine months ended September 30, 2021. The increase of $6.9 million was primarily due to the restructuring of our supply contract with DaVita and increased pricing to other customers.
Gross Profit (Loss)
Cost of sales during the nine months ended September 30, 2022 was $51.8 million, resulting in gross profit of $1.7 million during the nine months ended September 30, 2022, compared to cost of sales of a $46.8 million and a gross loss of $0.2 million during the nine months ended September 30, 2021. Gross profit increased by $1.9 million primarily due to the restructuring of our supply contract with DaVita and increased pricing to other customers. As a result, the Company expects an improvement in margins for the remainder of 2022.
Research and Product Development Expense
Research and product development expenses were $3.0 million for the nine months ended September 30, 2022, compared with $5.4 million during the nine months ended September 30, 2021. This decrease of $2.4 million is primarily due to the resignation of our Chief Development Officer, headcount reductions, greater cash management over projects costs and shifting our project timelines as noted above in the "Overview and Recent Developments" section above.
Selling and Marketing Expense
Selling and marketing expenses were $1.7 million during the nine months ended September 30, 2022, compared with $4.9 million during the nine months ended September 30, 2021. The decrease of $3.2 million is primarily due to reduced marketing spend for our TRIFERIC® products and headcount reductions. See "Overview and Recent Developments" for more detail.
General and Administrative Expense
General and administrative expenses were $11.8 million during the nine months ended September 30, 2022, compared with $11.5 million during the nine months ended September 30, 2021. The increase of $0.3 million is due primarily to a one-time charge related to the severance agreement for our former Chief Executive Officer offset by reductions in the use of outside agencies.
Other Income (Expense)
Other income for the nine months ended September 30, 2022 and 2021 was $(10,000) and $17,000, respectively. Other expense for the nine months ended September 30, 2022 was $1.5 million of interest expense related to our debt facility (see Note 14 for more information on our debt facility). Other expense for the nine months ended September 30, 2021 was $1.8 million of interest expense related to our debt facility.
25


Liquidity and Capital Resources
As of September 30, 2022, we had approximately $27.6 million of cash, cash equivalents and investments available-for-sale, and working capital of $23.0 million. Net cash used in operating activities for the nine months ended September 30, 2022 was approximately $16.8 million.
On April 6, 2022, the Company and DaVita entered into an amendment (the "Amendment") to the Products Purchase Agreement, dated July 1, 2019, under which the Company supplies DaVita with certain dialysis concentrates. Under the Amendment, the Company and DaVita agreed to certain price increases, effective May 1, 2022, as well as the pass-through of certain inflationary costs, determined on a quarterly basis. The Amendment also requires the Company to implement certain cost containment and cost-cutting measures. The Amendment contains certain covenants with respect to the Company’s ongoing operations, including a minimum cash covenant of $10 million, or we will be in default under the Products Purchase Agreement. An event of default could result in termination of that agreement.
On April 6, 2022, the Company and DaVita entered into a Securities Purchase Agreement (the “SPA”), pursuant to which the Company issued $15 million of preferred stock to DaVita in two separate tranches. The Company initially issued 7,500 shares of a newly designated series of preferred stock, which is designated “Series X Convertible Preferred Stock” (the “Series X Preferred Stock”) for gross proceeds of $7.5 million. On June 15, 2022, the Company issued to DaVita an additional 7,500 shares of Series X Preferred Stock in a second closing (the “Second Tranche”) for an additional $7.5 million. The Second Tranche was conditioned upon the Company raising an additional $15.0 million in capital within a certain timeline, which took place on June 2, 2022.
On April 8, 2022, the Company entered into a sales agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), pursuant to which the Company may offer and sell from time to time up to $12,200,000 of shares of Company’s common stock through the Agent. The offering and sale of such shares has been registered under the Securities Act of 1933, as amended (the “Securities Act”), pursuant to the Company’s Registration Statement on Form S-3 (File No. 333-259923) (the “Registration Statement”), which was originally filed with the Securities and Exchange Commission (“SEC”) on September 30, 2021 and declared effective by the SEC on October 8, 2021, the base prospectus contained within the Registration Statement, and a prospectus supplement that was filed with the SEC on April 8, 2022. During the quarter ended September 30, 2022, no sales were made pursuant to the Sales Agreement. Approximately $12.2 million remains available for sale under the ATM facility. Under the RD Purchase Agreement and the PIPE Purchase Agreement discussed below, the Company has agreed not to make any sales under any at-the-market offering facility, including pursuant to the Sales Agreement, until at least January 1, 2023 (or until such later time when the Company is permitted to make additional sales under Instruction I.B.6 to Form S-3).
On May 30, 2022, the Company entered into a Securities Purchase Agreement (the “RD Purchase Agreement”) with the purchaser named therein (the “Purchaser”), pursuant to which the Company agreed to issue and sell, in a registered direct offering (the “Offering”), 844,613 shares of its common stock at price of $1.39 per share, and prefunded warrants to purchase up to an aggregate of 7,788,480 shares of common stock (the “Pre-Funded Warrants” and the shares of common stock underlying the Pre-Funded Warrants, the “Warrant Shares”). The purchase price of each Pre-Funded Warrant was equal to the price at which a share of common stock was sold to the public in the Offering, minus $0.0001, and the exercise price of each Pre-Funded Warrant is $0.0001 per share.
Also on May 30, 2022, concurrently with the Offering, the Company entered into a Securities Purchase Agreement with the Purchaser (the “PIPE Purchase Agreement”) relating to the offering and sale (the “Private Placement”) of warrants to purchase up to a total of 9,900,990 shares of common stock and pre-funded warrants to purchase up to a total of 1,267,897 shares of common stock (the “PIPE Warrants”). Each warrant was sold at a price of $0.125 per underlying warrant share and is exercisable at an exercise price of $1.39 per share. The purchase price of each Pre-Funded Warrant was equal to the price at which a share of common stock was sold to the public in the Offering, minus $0.0001, and the exercise price of each prefunded warrant is $0.0001 per share. The Offering and the Private Placement closed on June 2, 2022. The net proceeds to the Company from the Offering and the Private Placement were approximately $14.9 million, after deducting fees and expenses.
The Offering and the Private Placement closed on June 2, 2022. The net proceeds to the Company from the Offering and the Private Placement were approximately $14.9 million, after deducting fees and expenses.
Based on the currently available working capital, and capital raises described above, management believes the Company currently has sufficient funds to meet its operating requirements for at least the next twelve months from the date of the filing of this report.
The Company may require additional capital to sustain its operations and make the investments it needs to execute its strategic plan. If the Company attempts to obtain additional debt or equity financing, the Company cannot assume such financing will be available on favorable terms, if at all.
In addition, the Company is subject to certain covenants and cure provisions under its Loan Agreement with Innovatus. As of the date of this report, the Company is in compliance with all covenants (See Note 14 to the condensed consolidated financial statements included elsewhere in this Form 10-Q for more information on our debt facility).

The COVID-19 pandemic and resulting domestic and global disruptions, particularly in the supply chain and labor market, among other areas, have adversely affected Rockwell's business and operations, including, but not limited to, the Company's sales and marketing efforts and its research and development activities, the Company's plant and transportation operations, and the operations of third parties upon whom Rockwell relies. The Company's international business development activities may also continue to be negatively impacted by COVID-19.

The COVID-19 pandemic and the resulting global disruptions and recent inflationary pressures have caused significant volatility in financial and credit markets. Rockwell has utilized a range of financing methods to fund its operations in the past; however, current conditions in the financial and credit markets may limit the availability of funding, refinancing, or increase the cost of funding. Due to the rapidly evolving nature of the global situation, it is not possible to predict the extent to which these conditions could adversely affect the Company's liquidity and capital resources in the future.

General
The actual amount of cash we will need to execute our business strategy is subject to many factors, including, but not limited to, the expenses and revenue associated with the commercial operations in the United States and internationally (with partners); the timing and magnitude of cash received from product sales; the timing and expenditures associated with the development programs including our FPC technology; and the costs associated with our manufacturing and transportation operations related to our concentrate business.
We may elect to raise capital in the future through one or more of the following: (i) equity and debt raises through the equity and capital markets, though there can be no assurance we will be able to secure additional capital or funding on acceptable terms, or if at all; and (ii) strategic transactions, including potential alliances and collaborations focused on markets outside the United States, as well as potential combinations (including by merger or acquisition) or other corporate transactions.
We believe our ability to fund our activities in the long term will be highly dependent upon 1) our ability to execute on the growth strategy of our hemodialysis concentrates business, 2) our ability to achieve profitability, and 3) our ability to identify, develop, in-license, or acquire new products in developing our renal care product portfolio. All of these strategies are subject to significant risks and uncertainties such that there can be no assurance we will be successful in achieving them. If we are unsuccessful in executing our business plan and we are unable to raise the required capital, we may be forced to curtail all of our activities and, ultimately, cease operations. Even if we are able to raise sufficient capital, such financings may only be available on unattractive terms, or result in significant dilution of stockholders’ interests and, in such event, the market price of our common stock may decline.
Cash Used in Operating Activities
Net cash used in operating activities was $16.8 million for the nine months ended September 30, 2022 compared to net cash used in operating activities of $24.5 million for the nine months ended September 30, 2021. The decrease in cash used from operating activities during the current period was primarily due to an increase in net income, offset by changes in current balance sheet accounts in the ordinary course of business of approximately $3.1 million, including an increase in net account receivable of $1.5 million, decrease in other assets of $2.1 million, decrease in lease liability of $1.4 million and decrease in deferred revenue of $1.4 million.
Cash Provided by (Used in) Investing Activities
Net cash provided by investing activities was $5.6 million during the nine months ended September 30, 2022 compared to net cash used in investing activities of $0.2 million for the nine months ended September 30, 2021. The net cash provided by investing activities during the nine months ended September 30, 2022 was primarily due to sales and purchase of available-for-sale investments during the year.
Cash Provided by (Used in) Financing Activities
Net cash provided by financing activities was $22.1 million during the nine months ended September 30, 2022 compared to the net cash used in financing activities of $0.6 million for the nine months ended September 30, 2021. The net cash provided during the nine months ended September 30, 2022 was primarily due to multiple equity raises (See Note 10), offset by payments on the Company's debt and short term note payable.
Contractual Obligations and Other Commitments

See Note 12 to the condensed consolidated financial statements included elsewhere in this Form 10-Q for additional disclosures. There have been no other material changes from the Contractual Obligations and Other Commitments disclosed in Note 14 to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2021.
26


Critical Accounting Policies and Significant Judgments and Estimates
Our critical accounting policies and significant estimates are detailed in our Annual Report on Form 10-K for the year ended December 31, 2021. Our critical accounting policies and significant estimates have not changed from those previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2021.
Recently issued and adopted accounting pronouncements:
We have evaluated all recently issued accounting pronouncements and believe such pronouncements do not have a material effect our financial statements. See Note 3 to the condensed consolidated financial statements included elsewhere in this Form 10-Q.
Item 3.  Quantitative and Qualitative Disclosures about Market Risk

Per §229.305 of Regulation S-K, the Company, designated a Smaller Reporting Company as defined in §229.10(f)(1) of Regulation S-K, is not required to provide the disclosure required by this Item.
Item 4.  Controls and Procedures
Evaluation of Disclosure Controls and Procedures
We maintain disclosure controls and procedures designed to ensure material information required to be disclosed in our reports we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required financial disclosure. In designing and evaluating the disclosure controls and procedures, we recognized a control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected. Management was required to apply its judgment in evaluating the cost‑benefit relationship of possible controls and procedures.
Under the supervision of and with the participation of our management, including the Company’s Chief Executive Officer and Chief Financial Officer, we evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of September 30, 2022. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded our disclosure controls and procedures were effective as of September 30, 2022.
Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting in connection with the evaluation required by Rule 13a-15(d) of the Exchange Act that occurred during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
27


PART II – OTHER INFORMATION
Item 1.  Legal Proceedings
We may be involved in certain routine legal proceedings from time to time before various courts and governmental agencies. We cannot predict the final disposition of such proceedings. We regularly review legal matters and record provisions for claims considered probable of loss. The resolution of these pending proceedings is not expected to have a material effect on our operations or consolidated financial statements in the period in which they are resolved.
Item 1A. Risk Factors
Our business is subject to various risks, including those described in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2021. There have been no material changes to the risk factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2021 under "Item 1A - Risk Factors" except as noted below.
Our reacquisition of distribution rights for our concentrates products from Baxter through the termination of our Exclusive Distribution Agreement has many attendant risks and may not result in the financial outcome we expect.
We recently terminated our Exclusive Distribution Agreement with Baxter and reacquired the distribution rights related to our concentrates products for Baxter’s portfolio of clinics. Our Distribution Agreement with Baxter enabled us to charge Baxter an amount above cost for our concentrates products, while limiting us to a capped percentage of sales for the transportation costs associated with delivering those products. When we assume full responsibility for selling and delivering our concentrates products to Baxter customers and any other customers we may add, we will bear all financial and other risk associated with the business. We may lose former Baxter customers if we need to increase the prices of our concentrates products due to rising costs or for other reasons. In addition, since we agreed to charge these customers a fixed cost through the transition period which ends on December 31, 2022 (and for a certain portfolio of customers, through March 31, 2023), we may lose money if those fixed costs do not cover our actual costs. We also may be unable to renegotiate unprofitable contracts with certain customers. Each of these scenarios could result in the business we reacquired generating less revenue or less profit than we expect and could adversely impact our financial condition or results of operations.
Unfavorable weather, economic conditions or supply shortages could adversely affect our business, financial condition or results of operations.
Our results of operations could be adversely affected by general weather conditions, as well as conditions in the United States and global economy and in the global financial markets. A severe weather or other geological event in our locations or those of our suppliers, or prolonged economic downturn or persistent inflation have and could continue to result in a variety of risks to our business, including our ability to recover our costs or to raise additional capital when needed on acceptable terms, if at all. In addition, weather-related events may jeopardize our ability to deliver our products as required by our contracts. For example, after Hurricane Ian severely damaged parts of the Florida Gulf Coast, many roads and bridges were destroyed. While we were able to make our deliveries after the storm, that may not always be the case. A weak or declining United States or global economy could also strain our suppliers, possibly resulting in supply disruption. In addition, due to macro-economic conditions in the global economy, there have been shortages in raw materials, parts and fuel that we need to run our business. Recently, our suppliers have experienced shortages in bicarbonate and acid, which are components of our dialysis concentrates, and parts needed for our equipment to make certain of our products. Diesel fuel is also in short supply in the United States and our delivery trucks run on diesel. While we have been able to minimize the impact of these disruptions to date, there can be no assurance that will continue. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business.
We have been and may continue to be affected materially and adversely by increases in raw material and transportation costs and may be unable to recover certain costs due to provisions in our material contracts.
A significant portion of our costs relates to chemicals and other raw materials and transportation, which such costs are out of our control, and we may not be able to recover a portion of such costs due to provisions in our material contracts with
Baxter and DaVita. The costs of chemicals and other raw materials are subject to price volatility based on supply and demand and are highly influenced by the overall level of economic activity in the United States and abroad.
These costs have tended to rise from year to year and are likely to continue to rise in the future. In the past year, raw materials costs have increased significantly, due to short supply and excess demand. Transportation also comprises a significant portion of our costs. We have been adversely affected by a general shortage in commercial truckers in the United States and significant increases in labor and fuel costs. In addition, as mentioned above, there is now a nationwide shortage of diesel fuel in the United States, which we use to run our delivery trucks. If that shortage is not rectified, the cost of diesel fuel could rise or diesel fuel could be unavailable and we would need to find another way to deliver our products to clinics. If we are unable to do so, we could be in breach of our contracts.
Our Product Purchase Agreement (“Product Agreement”) with DaVita provides for a fixed price to DaVita, with limited increases from year to year, regardless of the increases in raw materials costs. As a result, we have in the past been unable to fully recover our costs for the products we sell to DaVita (including transportation costs). This has had and could in the future have a material and adverse impact on our financial position. On April 6, 2022, we entered into an amendment to the Products Purchase Agreement under which we agreed to a price increase, effective May 1, 2022, as well as the pass-through of certain costs, determined on a quarterly basis. Certain costs are subject to a cap. If our costs exceed those caps, we may be unable to fully recover our costs or if costs increase in excess of an overall cap, the Products Purchase Agreement may be subject to termination by DaVita.
We expect that if we continue to be subject to the limitations in the agreements with our customers, the increasing costs may continue to negatively impact our profit margins and materially and adversely affect our financial position.
We may become the target of litigation, which is costly and time-consuming to defend.
We have in the past been subject to litigation and it is possible that legal proceedings could be brought against us in the future based upon decisions we make regarding our strategy or otherwise. Litigation can be costly and time-consuming and the results of complex legal proceedings are difficult to predict. These lawsuits assert types of claims that, if resolved against us, could give rise to substantial damages, and an unfavorable outcome or settlement of these lawsuits, or any future lawsuits, could have a material adverse effect on our business, financial condition, results of operations and/or stock price. Even if any future lawsuits are not resolved against us, the costs of defending such lawsuits may be material to our business and our operations. Moreover, these lawsuits may divert our Board and our management’s attention from the operation of our business.
Current and future legislation may increase the difficulty and cost for us, and any collaborators, to obtain marketing approval of and commercialize our drug candidates and affect the prices we, or they, may obtain.
Heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products has resulted in several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. We expect that additional state and federal healthcare reform measures will be adopted in the future, particularly in light of the new presidential administration, any of which could limit the amounts that federal and state governments will pay for healthcare therapies, which could result in reduced demand for our product candidates or additional pricing pressures. Most recently, on August 16, 2022, President Biden signed into law the Inflation Reduction Act of 2022 (“IRA”), which, among other provisions, included several measures intended to lower the cost of prescription drugs and related healthcare reforms. We cannot be sure whether additional legislation or rule making related to the IRA will be issued or enacted, or what impact, if any, such changes will have on the profitability of any of our drug candidates, if approved for commercial use, in the future.
Our revenue growth and profitability projections are based on various assumptions that may not come to fruition.
Our revenue growth and profitability projections are subject to many assumptions regarding our future operations, including that we are successful in expanding to new territories, that we successfully develop and launch new product offerings, that we are able to increase our prices to keep up with inflation, and that we do not experience significant disruptions to the manufacturing or distribution of our products, among other assumptions. If we are unsuccessful in one or more of those efforts, we may not be able to achieve our projected growth and profitability.
28


Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
None.
Item 3. Defaults Upon Senior Securities.
None.
Item 4. Mine Safety Disclosures.
Not applicable.
Item 5. Other Information.
Amended Bylaws
On November 9, 2022, the Board of Directors of Rockwell adopted Amended and Restated Bylaws of the Company (the “Amended Bylaws”), effective immediately. The amendments effected through the Amended Bylaws address, among other things, (i) requirements and procedures for annual and special meetings of stockholders, (ii) advance notice requirements for stockholder submission of proposals and director nominations, and (iii) requirements regarding the information stockholders must submit and representations stockholders must make in connection with stockholder proposals and director nominations. The Amended Bylaws also effected certain other administrative, modernizing, clarifying, and conforming changes.
The foregoing general description of the Amended Bylaws does not purport to be complete and is qualified in its entirety by reference to the full text of the Amended Bylaws set forth in Exhibit 3.1 to this Quarterly Report on Form 10-Q and incorporated herein by reference.
Loan Agreement Amendment
On November 10, 2022, the Company entered into the Second Amendment to Loan and Security Agreement (the “Second Amendment”) dated as of November 14, 2022 with Innovatus, which further amended the Loan Agreement. Pursuant to the Second Amendment, the Company (i) shall prepay an aggregate principal amount of $5.0 million in Term Loans (as defined in the Loan Agreement) in one installment on November 14, 2022; (ii) shall pay interest only payments until September 2023 at which time will resume scheduled debt payments.
The foregoing general description of the Second Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Second Amendment set forth in Exhibit 10.3 to this Quarterly Report on Form 10-Q and incorporated herein by reference.
Baxter Termination
On November 9, 2022, Rockwell entered into a Distribution Termination and Acquisition Agreement with Baxter (the “Baxter Termination Agreement”) to reacquire full distribution rights to its hemodialysis concentrates products and has agreed to concurrently terminate the exclusive distribution agreement dated October 2, 2014. Rockwell will pay Baxter a nominal fee for the reacquisition of its distribution rights. This fee will be payable in two equal installments on January 1, 2023 and April 1, 2023. See Note 16 to the condensed consolidated financial statements included elsewhere in this Form 10-Q for more information on the agreement with Baxter.
The foregoing general description of the Baxter Termination Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Baxter Termination Agreement.
Separation of Chief Financial Officer
On November 10, 2022, the Board of Directors of Rockwell terminated the employment of Russell Skibsted as Chief Financial Officer of the Company, effective immediately. The termination of employment of Mr. Skibsted by the Company without cause entitles Mr. Skibsted to severance in accordance with the Employment Agreement, dated September 15, 2020, by
and between the Company and Mr. Skibsted (the “Employment Agreement”). The severance benefits under the Employment Agreement are subject to the execution and non-revocation of a release of claims in favor of the Company. In connection with Mr. Skibsted’s termination, the Board of Directors appointed Mark Strobeck, the Company’s Chief Executive Officer, as interim principal financial officer.
29


Item 6. Exhibits

The exhibits filed or furnished as part of this Quarterly Report on Form 10-Q are set forth on the Exhibit Index, which Exhibit Index is incorporated herein by reference.
EXHIBIT INDEX
Exhibit No.Description
3.1 *
10.1 +*
10.2 +*
10.3 *
31.1*
32.1**
101.INS*XBRL Instance Document
101.SCH*XBRL Taxonomy Extension Schema
101.CAL*XBRL Taxonomy Extension Calculation Linkbase
101.DEF*XBRL Taxonomy Extension Definition Database
101.LAB*XBRL Taxonomy Extension Label Linkbase
101.PRE*XBRL Taxonomy Extension Presentation Linkbase
104*The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, formatted in Inline XBRL (included as Exhibit 101)
*Filed herewith
**Furnished herewith and not deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act
+Indicates management contract or compensatory plan.

30


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
ROCKWELL MEDICAL, INC.
(Registrant)
Date: November 14, 2022/s/ Mark Strobeck
Mark Strobeck, Ph.D.
Chief Executive Officer (Principal Executive Officer and Interim Financial Officer)
31
EX-3.1 2 amendedandrestatedbylawsex.htm EX-3.1 Document

AMENDED AND RESTATED BYLAWS
OF
ROCKWELL MEDICAL, INC.
(a Delaware corporation)
ARTICLE I
CORPORATE OFFICES
Section 1.1 Registered Office. The registered office of the Corporation shall be fixed in the Certificate of Incorporation of the Corporation.
Section 1.2 Other Offices. The Corporation may also have an office or offices, and keep the books and records of the Corporation, except as otherwise required by law, at such other place or places, either within or without the State of Delaware, as the Corporation may from time to time determine or the business of the Corporation may require.
ARTICLE II
MEETINGS OF STOCKHOLDERS
Section 2.1 Annual Meeting. The annual meeting of stockholders, for the election of directors to succeed those whose terms expire and for the transaction of such other business as may properly come before the meeting, shall be held at such place, if any, either within or without the State of Delaware, on such date, and at such time as the Board of Directors of the Corporation (the “Board” or the “Board of Directors”) shall fix. The Board of Directors may postpone, reschedule or cancel any annual meeting of stockholders previously scheduled by the Board of Directors.
Section 2.2 Special Meeting.
(a) Except as otherwise required by law, and except as otherwise provided for or fixed pursuant to the Certificate of Incorporation, including any certificate of designations relating to any series of Preferred Stock (each hereinafter referred to as a “Preferred Stock Designation”), a special meeting of the stockholders of the Corporation: (i) may be called at any time by the Corporation’s chief executive officer or Board of Directors; and (ii) shall be called by the Chairperson of the Board of Directors or the Secretary of the Corporation upon the written request or requests of one or more persons that: (i) own (as defined below) shares representing at least a majority of the voting power of the stock entitled to vote on the matter or matters to be brought before the proposed special meeting (hereinafter, the “requisite percent”) at the time a request is delivered; and (ii) comply with the notice procedures set forth in this Section 2.2 with respect to any matter that is a proper subject for the meeting pursuant to Section 2.2(f); provided, that stockholders shall not be permitted, except as required by applicable law, to call a special meeting for the purpose of electing directors or amending, or adopting any provision inconsistent with, this Section 2.2. Except as otherwise required by law, and except as otherwise provided for or fixed pursuant to the Certificate of Incorporation (including any Preferred Stock Designation), special meetings of the stockholders of the Corporation may not be called by any other person or persons.
(b) For purposes of satisfying the requisite percent under this Section 2.2:
(i) A person is deemed to “own” only those outstanding shares of stock of the Corporation as to which such person possesses both: (A) the full voting and investment rights pertaining to the shares; and (B) the full economic interest in (including the opportunity for profit and risk of loss on) the shares, except that the number of shares calculated in accordance with the foregoing clauses (A) and (B) shall not include any shares: (1) sold by such person in any transaction that has not been settled or closed; (2) borrowed by the person for any purposes or purchased by the person pursuant to an agreement to resell; or (3) subject to any option, warrant, forward contract, swap, contract of sale, or other derivative or similar agreement entered into by the person, whether the instrument or agreement is to be settled with shares or with cash based on the notional amount or value of outstanding shares of stock of the Corporation, if the instrument or agreement has, or is intended to have, or if



exercised would have, the purpose or effect of: (x) reducing in any manner, to any extent or at any time in the future, the person’s full right to vote or direct the voting of the shares; and/or (y) hedging, offsetting or altering to any degree any gain or loss arising from the full economic ownership of the shares by the person. For purposes of the foregoing clauses (1)-(3), the term “person” includes its affiliates; and
(ii) A person “owns” shares held in the name of a nominee or other intermediary so long as such person retains both: (A) the full voting and investment rights pertaining to the shares; and (B) the full economic interest in the shares. The person’s ownership of shares is deemed to continue during any period in which the person has delegated any voting power by means of a proxy, power of attorney, or other instrument or arrangement that is revocable at any time by the person.
(c) Any stockholder seeking to request a special meeting shall first request that the Board of Directors fix a record date to determine the stockholders entitled to request a special meeting (the “ownership record date”) by delivering notice in writing to the Secretary of the Corporation at the principal executive offices of the Corporation (the “record date request notice”) by registered mail. A stockholder’s record date request notice shall contain information about the class or series and number of shares of stock of the Corporation which are owned of record and beneficially by the stockholder and state the business proposed to be acted on at the meeting. A record date request notice shall include all of the information that must be included in a written request for a special meeting, as set forth in Section 2.2(d) below, and the information required by Section 2.10(a) below. Upon receiving a record date request notice, the Board of Directors may set an ownership record date. Notwithstanding any other provision of these Bylaws, the ownership record date shall not precede the date upon which the resolution fixing the ownership record date is adopted by the Board of Directors, and shall not be more than 28 days after the close of business on the date upon which the resolution fixing the ownership record date is adopted by the Board of Directors. If the Board of Directors, within 28 days after the date upon which a valid record date request notice is received by the Secretary of the Corporation, does not adopt a resolution fixing the ownership record date, the ownership record date shall be the close of business on the 28th day after the date upon which a valid record date request notice is received by the Secretary (or, if such 28th day is not a business day, the first business day thereafter).
(d) In order for a special meeting requested by the stockholders to be called by the Secretary of the Corporation, one or more written requests for a special meeting signed by stockholders (or their duly authorized agents) who own or who are acting on behalf of persons who own, as of the ownership record date, at least the requisite percent (the “special meeting request”), shall be delivered to the Secretary. A special meeting request shall: (i) state the purpose of the meeting, which shall be limited to the business set forth in the record date request notice received by the Secretary, and the matters (including the identity of nominees for election as a director, if any) proposed to be acted on at the meeting, which shall be limited to the business set forth in the record date request notice received by the Secretary; (ii) bear the date of signature of each such stockholder (or duly authorized agent) submitting the special meeting request; (iii) set forth the name and address of each stockholder submitting the special meeting request, as they appear on the Corporation’s books; (iv) contain the information required by Section 2.10(a) below with respect to any director nominations or other business proposed to be presented at the special meeting, and as to each stockholder requesting the meeting and each other person (including any beneficial owner) on whose behalf the stockholder is acting, other than stockholders or beneficial owners who have provided such request solely in response to any form of public solicitation for such requests, and the additional information required by Section 2.9(a) below; (v) include documentary evidence that the requesting stockholders own the requisite percent as of the ownership record date; provided, however, that if the requesting stockholders are not the beneficial owners of the shares representing the requisite percent, then to be valid, the special meeting request must also include documentary evidence of the number of shares owned (as defined in Section 2.2(b) above) by the beneficial owners on whose behalf the special meeting request is made as of the ownership record date; (vi) be delivered to the Secretary of the Corporation at the principal executive offices of the Corporation, by hand or by certified or registered mail, return receipt requested, within 30 days after the ownership record date and (vii) state a time requested for the special meeting (which shall not be less than 35 nor more than 60 days after the receipt of the special meeting request (or in the case of written requests from more than one stockholder, not less than 35 nor more than 60 days after the receipt of the written request that results in the requisite percentage). The special meeting request shall be updated and supplemented within five business days after the record date for determining the



stockholders entitled to vote at the stockholder requested-special meeting (or by the opening of business on the date of the meeting, whichever is earlier, if the record date for determining the stockholders entitled to vote at the meeting is different from the record date for determining the stockholders entitled to notice of the meeting), and in either case such information when provided to the Corporation shall be current as of the record date for determining the stockholders entitled to vote at the meeting. In addition, the requesting stockholder and each other person (including any beneficial owner) on whose behalf the stockholder is acting, shall provide such other information as the Corporation may reasonably request within 10 business days of such a request.
(e) After receiving a special meeting request, the Board of Directors shall determine in good faith whether the stockholders requesting the special meeting have satisfied the requirements for calling a special meeting of stockholders, and the Corporation shall notify the requesting stockholder of the Board’s determination about whether the special meeting request is valid. The date, time and place of the special meeting shall be fixed by the Board of Directors, and the date of the special meeting shall not be more than 90 days after the date on which the Board of Directors fixes the date of the special meeting. The record date for the special meeting shall be fixed by the Board of Directors as set forth in Section 7.6(a) below. Any requesting stockholder may revoke a request for a special meeting by written revocation delivered to the Secretary of the Corporation at any time prior to the giving of notice of the special meeting.
(f) A special meeting request shall not be valid, and the Corporation shall not call a special meeting if: (i) the special meeting request relates to an item of business that is not a proper subject for stockholder action under, or that involves a violation of, applicable law or that may not be transacted pursuant to a restriction set forth in the Certificate of Incorporation; (ii) an item of business that is the same or substantially similar (as determined in good faith by the Board of Directors) was presented at a meeting of stockholders occurring within 90 days preceding the earliest date of signature on the special meeting request, provided that the removal of directors shall not be considered the same or substantially similar to the election of directors at the preceding annual meeting of stockholders; (iii) the special meeting request is delivered during the period commencing 90 days prior to the first anniversary of the preceding year’s annual meeting and ending on the date of the next annual meeting of stockholders; or (iv) the special meeting request does not comply with the requirements of this Section 2.2.
(g) Any stockholder who submitted a special meeting request may revoke its written request by written revocation delivered to the Secretary of the Corporation at the principal executive offices of the Corporation at any time prior to the stockholder-requested special meeting. A special meeting request shall be deemed revoked (and any meeting scheduled in response may be cancelled) if the stockholders submitting the special meeting request, and any beneficial owners on whose behalf they are acting (as applicable), do not continue to own (as defined in Section 2.2(b) above) at least the requisite percent at all times between the date the record date request notice is received by the Corporation and the date of the applicable stockholder-requested special meeting, and the requesting stockholder shall promptly notify the Secretary of the Corporation of any decrease in ownership of shares of stock of the Corporation that results in such a revocation. If, as a result of any revocations, there are no longer valid unrevoked written requests from the requisite percent, the Board of Directors shall have the discretion to determine whether or not to proceed with the special meeting.
(h) Business transacted at a stockholder-requested special meeting shall be limited to: (i) the business stated in the valid special meeting request received from the requisite percent; and (ii) any additional business that the Board of Directors determines to include in the Corporation’s notice of meeting. If none of the stockholders who submitted the special meeting request (or their qualified representatives, as defined in Section 2.10(c)(i)) appears at the special meeting to present the matter or matters to be brought before the special meeting that were specified in the special meeting request, the Corporation need not present the matter or matters for a vote at the meeting, notwithstanding that proxies in respect of such vote may have been received by the Corporation. The Board of Directors may postpone, reschedule or cancel any special meeting of stockholders previously scheduled pursuant to this Section 2.2.




Section 2.3 Notice of Stockholders’ Meetings.
(a) Whenever stockholders are required or permitted to take any action at a meeting, notice of the place, if any, date, and time of the meeting of stockholders, the record date for determining the stockholders entitled to vote at the meeting (if such date is different from the record date for determining the stockholders entitled to notice of the meeting) and the means of remote communications, if any, by which stockholders and proxyholders may be deemed to be present in person and vote at such meeting, shall be given. The notice shall be given not less than 10 nor more than 60 days before the date on which the meeting is to be held, to each stockholder entitled to vote at such meeting as of the record date for determining the stockholders entitled to notice of the meeting, except as otherwise provided by law, the Certificate of Incorporation (including any Preferred Stock Designation) or these Bylaws. In the case of a special meeting, the purpose or purposes for which the meeting is called also shall be set forth in the notice. Except as otherwise required by law, notice may be given personally or by mail, or by electronic transmission to the extent permitted by Section 232 of the General Corporation Law of the State of Delaware (as the same exists or may hereafter be amended from time to time, the “DGCL”). If mailed, such notice shall be deemed given when deposited in the United States mail, postage prepaid, directed to each stockholder at such stockholder’s address as it appears on the records of the Corporation. Notice by electronic transmission shall be deemed given as provided in Section 232 of the DGCL. An affidavit that notice has been given, executed by the Secretary of the Corporation, Assistant Secretary or any transfer agent or other agent of the Corporation, shall be prima facie evidence of the facts stated in the notice in the absence of fraud. Notice shall be deemed to have been given to all stockholders who share an address if notice is given in accordance with the “householding” rules set forth in Rule 14a-3(e) under the Securities Exchange Act of 1934 (the “Exchange Act”) and Section 233 of the DGCL.
(b) When a meeting is adjourned to another time or place (including an adjournment taken to address a technical failure to convene or continue a meeting using remote communication), notice need not be given of the adjourned meeting if the place, if any, date and time thereof, and the means of remote communications, if any, by which stockholders and proxyholders may be deemed to be present in person and vote at such adjourned meeting are (i) announced at the meeting at which the adjournment is taken; (ii) displayed, during the time scheduled for the meeting, on the same electronic network used to enable stockholders and proxyholders to participate in the meeting by means of remote communication; or (iii) set forth in the notice of meeting given in accordance with Section 2.3(a); provided, however, that if the adjournment is for more than 30 days, a notice of the adjourned meeting shall be given to each stockholder of record entitled to vote at the meeting. If after the adjournment a new record date for stockholders entitled to vote is fixed for the adjourned meeting, the Board of Directors shall fix a new ‘record date for notice of such adjourned meeting in accordance with Section 7.6(a), and shall give notice of the adjourned meeting to each stockholder of record entitled to vote at such adjourned meeting as of the record date fixed for notice of such adjourned meeting.
Section 2.4 Organization.
(a) Meetings of stockholders shall be presided over by the Chairperson of the Board of Directors, or in their absence, by the Chief Executive Officer or, in their absence, by another person designated by the Board of Directors. The Secretary of the Corporation, or in their absence, an Assistant Secretary, or in the absence of the Secretary and all Assistant Secretaries, a person whom the chairperson of the meeting shall appoint, shall act as secretary of the meeting and keep a record of the proceedings thereof.
(b) The date and time of the opening and the closing of the polls for each matter upon which the stockholders shall vote at a meeting of stockholders shall be announced at the meeting. The Board of Directors may adopt such rules and regulations for the conduct of any meeting of stockholders as it shall deem appropriate. Except to the extent inconsistent with such rules and regulations as adopted by the Board of Directors, the chairperson of the meeting shall have the authority to adopt and enforce such rules and regulations for the conduct of any meeting of stockholders and the safety of those in attendance as, in the judgment of the chairperson, are necessary, appropriate’ or convenient for the conduct of the meeting. Rules and regulations for the conduct of meetings of stockholders, whether adopted by the Board of Directors or by the chairperson of the meeting, may include without limitation, establishing: (i) an agenda or order of business for the meeting; (ii) rules and procedures for maintaining order at the meeting and the safety of those present; (iii) limitations on attendance at or participation in the meeting to



stockholders entitled to vote at the meeting, their duly authorized and constituted proxies, qualified representatives (including rules around who qualifies as such) and such other persons as the chairperson of the meeting shall permit; (iv) restrictions on entry to the meeting after the time fixed for the commencement thereof; (v) limitations on the time allotted for consideration of each agenda item and for questions and comments by participants; (vi) regulations for the opening and closing of the polls for balloting and matters which are to be voted on by ballot (if any); and (vii) procedures (if any) requiring attendees to provide the Corporation advance notice of their intent to attend the meeting. Subject to any rules and regulations adopted by the Board of Directors, the chairperson of the meeting may convene and, for any reason, from time to time, adjourn and/or recess any meeting of stockholders pursuant to Section 2.7. The chairperson of the meeting, in addition to making any other determinations that may be appropriate to the conduct of the meeting, shall have the power to declare that a nomination or other business was not properly brought before the meeting if the facts warrant (including if a determination is made, pursuant to Section 2.10(c)(i) of these Bylaws, that a nomination or other business was not made or proposed, as the case may be, in accordance with Section 2.10 of these Bylaws), and if such chairperson should so declare, such nomination shall be disregarded or such other business shall not be transacted.
Section 2.5 List of Stockholders. The Corporation shall prepare, no later than the tenth day before each meeting of stockholders, a complete list of the stockholders entitled to vote at the meeting; provided, however, that if the record date for determining the stockholders entitled to vote is less than 10 days before the date of the meeting, the list shall reflect the stockholders entitled to vote as of the 10th day before the meeting date. Such list shall be arranged in alphabetical order and shall show the address of each stockholder and the number of shares registered in the name of each stockholder. Nothing in this Section 2.5 shall require the Corporation to include electronic mail addresses or other electronic contact information on such list. Such list shall be open to the examination of any stockholder, for any purpose germane to the meeting for 10 days ending on the day before the meeting date: (a) on a reasonably accessible electronic network, provided that the information required to gain access to such list is provided with the notice of meeting; or (b) during ordinary business hours at the principal place of business of the Corporation. In the event that the Corporation determines to make the list available on an electronic network, the Corporation may take reasonable steps to ensure that such information is available only to stockholders of the Corporation. Except as otherwise required by law, the stock ledger shall be the only evidence as to who are the stockholders entitled to examine the list of stockholders required by this Section 2.5 or to vote in person or by proxy at any meeting of stockholders.
Section 2.6 Quorum. Except as otherwise required by law, the Certificate of Incorporation (including any Preferred Stock Designation) or these Bylaws, at any meeting of stockholders, a majority of the voting power of the stock outstanding and entitled to vote at the meeting, present in person or represented by proxy, shall constitute a quorum for the transaction of business; provided, however, that where a separate vote by a class or series or classes or series is required, a majority of the voting power of the stock of such class or series or classes or series outstanding and entitled to vote on that matter, present in person or represented by proxy, shall constitute a quorum entitled to take action with respect to such matter. If a quorum is not present or represented at any meeting of stockholders, then the chairperson of the meeting, or a majority of the voting power of the stock present in person or represented by proxy at the meeting and entitled to vote thereon, shall have power to adjourn or recess the meeting from time to time in accordance with Section 2.7, until a quorum is present or represented. Subject to applicable law, if a quorum initially is present at any meeting of stockholders, the stockholders may continue to transact business until adjournment or recess, notwithstanding the withdrawal of enough stockholders to leave less than a quorum, but if a quorum is not present at least initially, no business other than adjournment or recess may be transacted.
Section 2.7 Adjourned or Recessed Meeting. Any annual or special meeting of stockholders, whether or not a quorum is present, may be adjourned or recessed for any reason from time to time by the chairperson of the meeting, subject to any rules and regulations adopted by the Board of Directors pursuant to Section 2.4(b). Any such meeting may be adjourned for any reason (and may be recessed if a quorum is not present or represented) from time to time by a majority of the voting power of the stock present in person or represented by proxy at the meeting and entitled to vote thereon. At any such adjourned or recessed meeting at which a quorum may be present, any business may be transacted that might have been transacted at the meeting as originally called.




Section 2.8 Voting; Proxies.
(a) Except as otherwise required by law or the Certificate of Incorporation (including any Preferred Stock Designation), each holder of stock of the Corporation entitled to vote at any meeting of stockholders shall be entitled to one vote for each share of such stock held of record by such holder that has voting power upon the subject matter in question.
(b) Except as otherwise required by law, the Certificate of Incorporation (including any Preferred Stock Designation), these Bylaws or any law, rule or regulation applicable to the Corporation or its securities, at each meeting of stockholders at which a quorum is present, all corporate actions to be taken by vote of the stockholders shall be authorized by the affirmative vote of at least a majority of the votes cast, affirmatively or negatively, by the holders of shares entitled to vote on such action; provided, that abstentions shall not be considered votes cast on such action. Voting at meetings of stockholders need not be by written ballot.
(c) Every stockholder entitled to vote for directors, or on any other matter, shall have the right to do so either in person or by one or more persons authorized to act for such stockholder by proxy, but no such proxy shall be voted or acted upon after three years from its date, unless the proxy provides for a longer period. A proxy shall be irrevocable if it states that it is irrevocable and if, and only as long as, it is coupled with an interest sufficient in law to support an irrevocable power. A proxy may be made irrevocable regardless of whether the interest with which it is coupled is an interest in the stock itself or an interest in the Corporation generally. A stockholder may revoke any proxy which is not irrevocable by attending the meeting and voting in person or by delivering to the Secretary of the Corporation a revocation of the proxy or executed new proxy bearing a later date.
Section 2.9 Submission of Information by Director Nominees.
(a) To be eligible to be a nominee for election or re-election as a director of the Corporation, a person must deliver to the Secretary of the Corporation at the principal executive offices of the Corporation the following information:
(i) a written representation and agreement, which shall be signed by such person and pursuant to which such person shall represent and agree that such person: (A) consents to serving as a director if elected and to being named as a nominee in a proxy statement and form of proxy relating to the meeting at which directors are to be elected, and currently intends to serve as a director for the full term for which such person is standing for election; (B) is not and will not become a party to any agreement, arrangement or understanding with, and has not given any commitment or assurance to, any person or entity: (1) as to how the person, if elected as a director, will act or vote on any issue or question that has not been disclosed to the Corporation; or (2) that could limit or interfere with the person’s ability to comply, if elected as a director, with such person’s fiduciary duties under applicable law; (C) is not and will not become a party to any agreement, arrangement or understanding with any person or entity other than the Corporation with respect to any direct or indirect compensation, reimbursement or indemnification in connection with service or action as a director or nominee that has not been disclosed to the Corporation; and (D) if elected as a director, will comply with all of the Corporation’s policies and guidelines related to corporate governance, conflict of interest, confidentiality, stock ownership and trading policies and guidelines, and any other Corporation policies and guidelines applicable to directors (which will be provided to such person promptly following a request therefor); and
(ii) all fully completed and signed questionnaires prepared by the Corporation (including those questionnaires required of the Corporation’s directors and any other questionnaire the Corporation determines is necessary or advisable to assess whether a nominee will satisfy any qualifications or requirements imposed by the Certificate of Incorporation or these Bylaws, any law, rule, regulation or listing standard that may be applicable to the Corporation, and the Corporation’s corporate governance policies and guidelines) (all of the foregoing, “Questionnaires”). The Questionnaires will be promptly provided by the Corporation following a request therefor.
(b) A nominee for election or re-election as a director of the Corporation shall also provide to the Corporation such other information as it may reasonably request. The Corporation may request such additional



information as necessary to permit the Corporation to determine the eligibility of such person to serve as a director of the Corporation, including information relevant to a determination whether such person can be considered an independent director.
(c) If a stockholder has submitted notice of an intent to nominate a candidate for election or re-election as a director pursuant to Section 2.10, all written and signed representations and agreements and all fully completed and signed Questionnaires described in Section 2.9(a) above shall be provided to the Corporation at the same time as such notice and all information described in Section 2.9(b) above shall be provided to the Corporation promptly upon request by the Corporation, but in any event within five business days after such request. All information provided pursuant to this Section 2.9 shall be deemed part of the stockholder’s notice submitted pursuant to Section 2.10.
(d) Notwithstanding the foregoing, if any information or communication submitted pursuant to this Section 2.9 is inaccurate or incomplete in any material respect (as determined by the Board of Directors (or any authorized committee thereof)) such information shall be deemed not to have been provided in accordance with this Section 2.9. Any stockholder providing information pursuant to this Section 2.9 shall promptly notify the Secretary in writing at the principal executive office of the Corporation of any inaccuracy or change in any previously provided information within two business days after becoming aware of such inaccuracy or change. Upon written request of the Secretary, such stockholder shall provide, within seven business days after delivery of such request (or such longer period as may be specified in such request), (i) written verification, reasonably satisfactory to the Corporation, to demonstrate the accuracy of any information submitted and (ii) a written affirmation of any information submitted as of an earlier date. If the stockholder giving notice of an intent to nominate a candidate for election fails to provide such written verification or affirmation within such period, the information as to which written verification or affirmation was requested may be deemed not to have been provided in accordance with this Section 2.9.
Section 2.10 Notice of Stockholder Business and Nominations.
(a) Annual Meeting.
(i) Nominations of persons for election to the Board of Directors and the proposal of business other than nominations to be considered by the stockholders may be made at an annual meeting of stockholders only: (A) pursuant to the Corporation’s notice of meeting (or any supplement thereto); (B) by or at the direction of the Board of Directors (or any authorized committee thereof); or (C) by any stockholder of the Corporation who is a stockholder of record at the time the notice provided for in this Section 2.10(a) is delivered to the Secretary of the Corporation, who is entitled to vote at the meeting and who complies with the notice procedures set forth in this Section 2.10(a). For the avoidance of doubt, the foregoing clause (C) shall be the exclusive means for a stockholder to make nominations or propose other business at an annual meeting of stockholders (other than a proposal included in the Corporation’s proxy statement pursuant to and in compliance with Rule 14a-8 under the Exchange Act).
(ii) For nominations or other business to be properly brought before an annual meeting by a stockholder pursuant to clause (C) of the foregoing paragraph, the stockholder must have given timely notice thereof in writing to the Secretary of the Corporation and, in the case of business other than nominations, such business must be a proper subject for stockholder action. To be timely, a stockholder’s notice must be delivered to the Secretary at the principal executive offices of the Corporation not later than the close of business (as defined in Section 2.10(c)(ii) below) on the 120th day nor earlier than the close of business on the 150th day prior to the first anniversary of the date on which the Corporation first mailed its proxy materials for the preceding year’s annual meeting; provided, however, that in the event that the date of the annual meeting is more than 30 days before or more than 60 days after such anniversary date, or if no annual meeting was held in the preceding year, notice by the stockholder to be timely must be so delivered not earlier than the close of business on the 150th day prior to such annual meeting and not later than the close of business on the later of the 120th day prior to such annual meeting or the 10th day following the date on which public announcement (as defined in Section 2.10(c)(ii) below) of the date of such meeting is first made by the Corporation. In no event shall an adjournment or recess of an annual meeting, or



a postponement of an annual meeting for which notice of the meeting has already been given to stockholders or a public announcement of the meeting date has already been made, commence a new time period (or extend any time period) for the giving of a stockholder’s notice as described above. The number of nominees a stockholder may nominate for election at the annual meeting (or in the case of a stockholder giving the notice on behalf of a beneficial owner, the number of nominees a stockholder may nominate for election at the annual meeting on behalf of the beneficial owner) shall not exceed the number of directors to be elected at such annual meeting. Such stockholder’s notice shall set forth:
(A) as to each person whom the stockholder proposes to nominate for election or re-election as a director: (1) a written statement, not to exceed 500 words, in support of such person; (2) all information relating to such person that is required to be disclosed in solicitations of proxies for election of directors in an election contest, or is otherwise required, in each case pursuant to and in accordance with Regulation 14A under the Exchange Act; and (3) the information required to be submitted by nominees pursuant to Section 2.9(a) above;
(B) as to any other business that the stockholder proposes to bring before the meeting, a brief description of the business desired to be brought before the meeting, the text of the proposal or business (including the text of any resolutions proposed for consideration and in the event that such business includes a proposal to amend the Bylaws of the Corporation, the language of the proposed amendment), the reasons for conducting such business at the meeting and any substantial interest (within the meaning of Item 5 of Schedule 14A under the Exchange Act) in such business of such stockholder and the beneficial owner (within the meaning of Section 13(d) of the Exchange Act), if any, on whose behalf the proposal is made;
(C) as to the stockholder giving the notice and the beneficial owner, if any, on whose behalf the nomination is made or the other business is proposed:
(1) the name and address of such stockholder, as they appear on the Corporation’s books, and the name and address of such beneficial owner;
(2) the class or series and number of shares of stock of the Corporation which are owned of record by such stockholder and such beneficial owner as of the date of the notice, and a representation that the stockholder will notify the Corporation in writing within five business days after the record date for such meeting of the class or series and number of shares of stock of the Corporation owned of record by the stockholder and such beneficial owner as of the record date for the meeting; and
(3) a representation that the stockholder (or a qualified representative of the stockholder) intends to appear at the meeting to make such nomination or propose such business;
(D) as to each Proposing Person:
(1) the class or series and number of shares of stock of the Corporation which are, directly or indirectly, owned of record or beneficially owned (as defined in Section 2.10(c)(ii) below) by such Proposing Person as of the date of the notice;;
(2) any debt securities or other debt instruments of the Corporation or any of its subsidiaries (“Debt”) that are, directly or indirectly, owned of record or beneficially owned by each such Proposing Person;
(3) all information that would be required to be set forth in a Schedule 13D filed pursuant to Rule 13d-1(a) promulgated under the Exchange Act or an amendment pursuant to Rule 13d-2(a) promulgated under the Exchange Act as if such a statement were required to be filed under the Exchange Act by such Proposing Person (regardless of such Proposing Person is actually required to file a Schedule 13D); and



(4) a description (which descriptions shall include, in addition to all other information, information identifying all parties thereto) of any agreement, arrangement or understanding (including without limitation any option, warrant, forward contract, swap, contract of sale or other derivative or similar agreement or short positions, profit interests, options, hedging or pledging transactions, voting rights, dividend rights, and/or borrowed or loaned shares) whether the instrument or agreement is to be settled with shares or with cash based on the notional amount of value of outstanding shares of stock of the Corporation, that has been entered into as of the date of the stockholder’s notice by, or on behalf of any Proposing Person, the effect or intent of which is to mitigate loss, manage risk or benefit from changes in the share price of any class or series of the Corporation’s stock or Debt, or the share price of any class of the capital stock of any principal competitor of the Corporation (as defined for the purposes of Section 8 of the Clayton Antitrust Act of 1914) or maintain, increase or decrease the voting power of any Proposing Person with respect to securities of the Corporation;
(5) any proportionate interest in shares of the Corporation, Debt, or any other instruments described under clause (ii)(D)(4) of this Section 2.10(a), held, directly or indirectly, by a general or limited partnership, limited liability company, or similar entity in which any Proposing Person (x) is a general partner or, directly or indirectly, beneficially owns an interest in a general partner of such general or limited partnership or (y) is the manager, managing member, or, directly or indirectly, beneficially owns an interest in the manager or managing member of such limited liability company or similar entity;
(6) a description of any proxy (other than a revocable proxy given in response to a solicitation made pursuant to, and in accordance with, Section 14(a) of the Exchange Act by way of a solicitation statement filed on Schedule 14A), contract, arrangement, understanding, or relationship (x) pursuant to which such Proposing Person has a right to vote, directly or indirectly, any shares of the Corporation or (y) with respect to the proposal or nomination, as applicable, or the voting of shares of any class or series of capital stock of the Corporation between or among the Proposing Persons;
(7) any performance-related fees (other than an asset-based fee) that each Proposing Person is entitled to based on any increase or decrease in the value of shares of the Corporation, Debt, or any other instruments described under clause (ii)(D)(4) of this Section 2.10(a);
(8) any equity interests in any principal competitor of the Corporation (as defined for the purposes of Section 8 of the Clayton Antitrust Act of 1914) or any counterparty to any litigation in which the Corporation is involved that is material to the Corporation and its subsidiaries, taken as a whole held by or on behalf of any Proposing Person;
(9) the names and addresses of other stockholders (including beneficial owners) known by any Proposing Person to support such nomination, and to the extent known the class and number of all shares of the Corporation’s capital stock owned of record or beneficially by such other stockholder(s) or other beneficial owners(s);
(10) representation as to whether the stockholder, beneficial owner, if any, Related Person or any other participant (as defined in Item 4 of Schedule 14A under the Exchange Act) will engage in a solicitation with respect to such nomination or proposal and, if so, whether or not such solicitation will be conducted as an exempt solicitation under Rule 14a-2(b) of the Exchange Act, the name of each participant in such solicitation and the amount of the cost of solicitation that has been and will be borne, directly or indirectly, by each participant in such solicitation and (x) in the case of a proposal of business other than nominations, whether such person or group intends to deliver, through means satisfying each of the conditions that would be applicable to the Corporation under either Exchange Act Rule 14a-16(a) (Notice of Internet Availability of Proxy Materials) or Exchange Act Rule 14a-16(n) (Full Set Delivery), a proxy statement and form of proxy to holders (including any beneficial owners pursuant to Rule 14b-1 and Rule 14b-2 of the Exchange Act) of at least the percentage of the Corporation's voting shares required under applicable law to carry the proposal or (y) in the case of any solicitation that is subject to Rule 14a-19 of the Exchange Act, confirming that such person or group will deliver, through means satisfying each of the conditions that would be applicable to the Corporation under either Exchange Act Rule 14a-16(a) or Exchange Act Rule 14a-16(n), a proxy statement and form of proxy to holders (including any beneficial



owners pursuant to Rule 14b-1 and Rule 14b-2 of the Exchange Act) of at least 67% of the voting power of the Corporation’s stock entitled to vote generally in the election of directors;
(11) a representation that immediately after soliciting the stockholders referred to in the representation required under clause (10)(y) above, such stockholder, beneficial owner or Related Person will provide the Corporation with documents, which may take the form of a certified statement and documentation from a proxy solicitor, specifically demonstrating that the necessary steps have been taken to deliver a proxy statement and form of proxy to holders of such percentage of the Corporation’s stock;
(iii) Notwithstanding anything in Section 2.10 (a)(ii) above or Section 2.10(b) below to the contrary, if the record date for determining the stockholders entitled to vote at any meeting of stockholders is different from the record date for determining the stockholders entitled to notice of the meeting, a stockholder’s notice required by this Section 2.10 shall set forth a representation that the stockholder will notify the Corporation in writing within five business days after the record date for determining the stockholders entitled to vote at the meeting, or by the opening of business on the date of the meeting (whichever is earlier), of the information required under clause (ii) of this Section 2.10(a), and such information when provided to the Corporation shall be current as of the record date for determining the stockholders entitled to vote at the meeting.
(iv) This Section 2.10(a) shall not apply to a proposal proposed to be made by a stockholder if the stockholder has notified the Corporation of their intention to present the proposal at an annual or special meeting only pursuant to and in compliance with Rule 14a-8 under the Exchange Act and such proposal has been included in a proxy statement that has been prepared by the Corporation, and reviewed and approved by the Board of Directors, to solicit proxies for such meeting.
(v) Notwithstanding anything in this Section 2.10(a) to the contrary, in the event that the number of directors to be elected to the Board of Directors at an annual meeting is increased and there is no public announcement by the Corporation naming all of the nominees for directors or specifying the size of the increased Board of Directors made by the Corporation at least 10 days prior to the last day a stockholder may deliver a notice in accordance with Section 2.10(a)(ii) above, a stockholder’s notice required by this Section 2.10(a) shall also be considered timely, but only with respect to nominees for any new positions created by such increase, if it shall be delivered to the Secretary of the Corporation at the principal executive offices of the Corporation not later than the close of business on the 10th day following the day on which such public announcement is first made by the Corporation.
(b) Special Meeting. Only such business shall be conducted at a special meeting of stockholders as shall have been brought before the meeting by or at the direction of the Board of Directors. Nominations of persons for election to the Board of Directors may be made at a special meeting of stockholders at which directors are to be elected pursuant to the Corporation’s notice of meeting: (i) by or at the direction of the Board of Directors (or any authorized committee thereof); or (ii) provided that the Board of Directors has determined that one or more directors are to be elected at such meeting, by any stockholder of the Corporation who is a stockholder of record at the time the notice provided for in this Section 2.10(b) is delivered to the Secretary of the Corporation, who is entitled to vote at the meeting and upon such election and who delivers notice thereof in writing setting forth the information required by Section 2.10(a) above and provides the additional information required by Section 2.9 above. In the event the Corporation calls a special meeting of stockholders for the purpose of electing one or more directors to the Board of Directors, any stockholder entitled to vote in such election of directors may nominate a person or persons (as the case may be) for election to such position(s) as specified in the Corporation’s notice of meeting, if the notice required by this Section 2.10(b) shall be delivered to the Secretary at the principal executive offices of the Corporation not earlier than the close of business on the 150th day prior to such special meeting and not later than the close of business on the later of the 120th day prior to such special meeting or the 10th day following the date on which public announcement of the date of the special meeting and of the nominees proposed by the Board of Directors to be elected at such meeting is first made by the Corporation. The number of nominees a stockholder may nominate for election at the special meeting (or in the case of a stockholder giving the notice on behalf of a beneficial owner, the number of nominees a stockholder may nominate for election at the special meeting on behalf of such beneficial owner) shall not exceed the number of directors to be elected at such special meeting. In no event



shall an adjournment, recess or postponement of a special meeting commence a new time period (or extend any time period) for the giving of a stockholder’s notice as described above.
(c) General.
(i) Except as otherwise required by law, only such persons who are nominated in accordance with the procedures set forth in this Section 2.10 shall be eligible to be elected at any meeting of stockholders of the Corporation to serve as directors and only such other business shall be conducted at a meeting of stockholders as shall have been brought before the meeting in accordance with the procedures set forth in this Section 2.10. Notwithstanding any other provision of these Bylaws, a stockholder (and any beneficial owner on whose behalf a nomination is made or other business is proposed, and if such stockholder or beneficial owner is an entity, any Proposing Person), shall also comply with all applicable requirements of the Exchange Act and the rules and regulations thereunder with respect to the matters set forth in this Section 2.10. The Chairperson of the Board, the chairperson of the meeting, or any other person designated by the Board shall determine whether a nomination or any other business proposed to be brought before the meeting was made or proposed, as the case may be, in accordance with the procedures set forth in this Section 2.10 (including whether a stockholder or beneficial owner solicited (or is part of a group which solicited) or did not so solicit, as the case may be, proxies in compliance with such stockholder’s representation as required by clauses (a)(ii)(D)(10)-(11) of this Section 2.10) or complied or did not comply with the requirements of Rule 14a-19 under the Exchange Act. If any proposed nomination or other business is not in compliance with this Section 2.10, including due to failure to comply with the requirements of Rule 14a-19 under the Exchange Act, then except as otherwise required by law, the chairperson of the meeting shall declare that such nomination be disregarded or such other business shall not be transacted, notwithstanding that votes and proxies in respect of any such nomination or other business have been received by the Corporation. In furtherance and not by way of limitation of the foregoing provisions of this Section 2.10, unless otherwise required by law, or otherwise determined by the Chairperson of the Board, the chairperson of the meeting or any other person designated by the Board, if (A) the stockholder does not provide the information required under Section 2.9 or Section 2.10(a) or (b) to the Corporation within the time frames specified herein or (B) the stockholder (or a qualified representative of the stockholder) does not appear at the annual or special meeting of stockholders of the Corporation to present a nomination or other business, then any such nomination shall be disregarded or such other business shall not be transacted, notwithstanding that votes and proxies in respect of any such nomination or other business may have been received by the Corporation.
(ii) To be considered a qualified representative of a stockholder for purposes of these Bylaws, a person must be a duly authorized officer, manager or partner of such stockholder or authorized by a writing executed by such stockholder (or a reliable reproduction or electronic transmission of the writing) delivered to the Corporation prior to the making of such nomination or proposal at such meeting (and in any event not fewer than five business days before the meeting) stating that such person is authorized to act for such stockholder as proxy at the meeting of stockholders.
(iii) For purposes of this Section 2.10:
A.For purposes of clause (a)(ii)(D) of this Section 2.10, shares shall be treated as “beneficially owned” by a person if the person beneficially owns such shares, directly or indirectly, for purposes of Section 13(d) of the Exchange Act and Regulations 13D and 13G thereunder or has or shares pursuant to any agreement, arrangement or understanding (whether or not in writing): (A) the right to acquire such shares (whether such right is exercisable immediately or only after the passage of time or the fulfillment of a condition or both); (B) the right to vote such shares, alone or in concert with others; and/or (C) investment power with respect to such shares, including the power to dispose of, or to direct the disposition of, such shares;



B.The “close of business” shall mean 6:00 p.m. local time at the principal executive offices of the Corporation on any calendar day, whether or not the day is a business day;
C.Covered Person” shall mean each Proposing Person; provided, however, that if any Proposing Person that is a non-natural Person holds any instrument described under clause (ii)(D)(4) of Section 2.10(a), of record or beneficially for the economic benefit (direct or indirect) of any other Person (including, any Proposing Person that is (i) an investment fund or other investment vehicle (a “Holding Fund”) or (ii) an advisor or investment manager to a Holding Fund), then any Person that directly holds (or is known by the Proposing Person to indirectly hold) a 5% or larger member, limited partner or similar economic interest in any such Holding Fund shall be deemed a “Covered Person”; provided further, however, that if such Holding Fund has a “sidecar vehicle” or special purpose entity formed by an investment manager or adviser for purposes of co-investing with a Holding Fund that was created or raised proceeds principally to invest in any equity or debt securities of the Corporation, including any securities held through any agreements described under clause (ii)(D)(4) of Section 2.10(a), then each Person (and controlling Person thereof) that has invested or committed to invest in such fund or other investment vehicle shall be deemed a Covered Person;
D.Person” shall mean an individual, a corporation, a partnership, a limited liability company, an association, a trust or any other entity, group (as such term is used in Section 13 of the Exchange Act) or organization, and any permitted successors and assigns of such person;
E.public announcement” shall mean disclosure in a press release reported by the Dow Jones News Service, Associated Press or a comparable national news service or in a document publicly filed by the Corporation with the Securities and Exchange Commission pursuant to Sections 13, 14 or 15(d) of the Exchange Act;
F.Proposing Person” shall mean (i) the stockholder providing the notice of a proposed nomination or other business proposed to be brought before a meeting, (ii) the beneficial owner or beneficial owners, if different, on whose behalf the proposed nomination or other business proposed to be brought before a meeting is made, (iii) any affiliate or associate (for purposes of these Bylaws, each within the meaning of Rule 12b-2 under the Exchange Act) of such stockholder, beneficial owner or any other Proposing Person, (iv) any person directly or indirectly controlling, controlled by or under common control with such stockholder or beneficial owner, (v) any member of the immediate family of such stockholder or beneficial owner sharing the same household, (vi) any person or entity who is a member of a “group” (as such term is used in Rule 13d-5 under the Exchange Act (or any successor provision at law)) with, or is otherwise known by such stockholder or such beneficial owner to be acting in concert with, such stockholder, such beneficial owner or any other Proposing Person with respect to the securities of the Corporation, (vii) any Related Person, (viii) any participant (as defined in paragraphs (a)(ii)-(vi) of Instruction 3 to Item 4 of Schedule 14A) with such stockholder, beneficial owner or any other Proposing Person with respect to any proposed business or nominations, as applicable, and (ix) any Covered Person; and



G.Related Person” shall mean, if such stockholder or beneficial owner is an entity, as to each individual who is a director, executive officer, general partner or managing member of such entity or of any other entity that has or shares control of such entity.
(A) the right to acquire such shares (whether such right is exercisable immediately or only after the passage of time or the fulfillment of a condition or both); (B) the right to vote such shares, alone or in concert with others; and/or (C) investment power with respect to such shares, including the power to dispose of, or to direct the disposition of, such shares.
(iv) Nothing in this Section 2.10 shall be deemed to affect any rights (A) of stockholders to request the inclusion of proposals in the Corporation’s proxy statement pursuant to Rule 14a-8 promulgated under the Exchange Act or (B) of the holders of any series of Preferred Stock to elect directors pursuant to any applicable provisions of the Certificate of Incorporation (including any Preferred Stock Designation).
(v) Any stockholder directly or indirectly soliciting proxies from other stockholders must use a proxy card color other than white, which shall be reserved for the exclusive use for solicitation by the Board of Directors.
Section 2.11 Action by Written Consent.
(a) Except as otherwise provided for or fixed pursuant to the Certificate of Incorporation (including any Preferred Stock Designation), any action required or permitted to be taken at any annual or special meeting of stockholders of the Corporation may be taken without a meeting, without prior notice and without a vote, if a consent or consents in writing, setting forth the action so taken, are signed by the holders of the outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted. To be effective, a written consent must be delivered to the Corporation by delivery to its registered office in the State of Delaware, its principal place of business or an officer of agent of the Corporation having custody of the book in which proceedings of meetings of stockholders are recorded. Delivery made to the Corporation’s registered office shall be by hand or by certified or registered mail, return receipt requested. No written consent shall be effective to take the corporate action referred to therein unless written consents signed by a sufficient number of holders to take action are delivered to the Corporation in accordance with this Section 2.11 within 60 days of the first date on which a written consent is so delivered to the Corporation. Any person executing a consent may provide, whether through instruction to an agent or otherwise, that such a consent shall be effective at a future time including a time determined upon the happening of an event, occurring not later than 60 days after such instruction is given or such provision is made, if evidence of the instruction or provision is provided to the Corporation. If the person is not a stockholder of record when the consent is executed, the consent shall not be valid unless the person is a stockholder of record as of the record date for determining stockholders entitled to consent to the action. Unless otherwise provided, any such consent shall be revocable prior to its becoming effective.
(b) Prompt notice of the taking of the corporate action without a meeting by less than unanimous written consent shall be given to those stockholders who have not consented in writing and who, if the action had been taken at a meeting, would have been entitled to notice of the meeting if the record date for notice of such meeting had been the date that written consents signed by a sufficient number of stockholders to take the action were delivered to the Corporation in the manner required by this Section 2.11.
Section 2.12 Inspectors of Election. Before any meeting of stockholders, the Corporation may, and shall if required by law, appoint one or more inspectors of election to act at the meeting and make a written report thereof. Inspectors may be employees of the Corporation. The Corporation may designate one or more persons as alternate inspectors to replace any inspector who fails to act. If no inspector or alternate is able to act at a meeting of stockholders, the chairperson of the meeting may, and shall if required by law, appoint one or more inspectors to act at the meeting. Each inspector, before entering upon the discharge of their duties, shall take and sign an oath faithfully to execute the duties of inspector with strict impartiality and according to the best of their ability.



Inspectors need not be stockholders. No director or nominee for the office of director at an election shall be appointed as an inspector at such election.
Such inspectors shall:
(a) determine the number of shares outstanding and the voting power of each, the number of shares represented at the meeting, the existence of a quorum, and the validity of proxies and ballots;
(b) determine and retain for a reasonable period a record of the disposition of any challenges made to any determination by the inspectors;
(c) count and tabulate all votes and ballots; and
(d) certify their determination of the number of shares represented at the meeting, and their count of all votes and ballots.
Section 2.13 Meetings by Remote Communications. The Board of Directors may, in its sole discretion, determine that a meeting of stockholders shall not be held at any place, but may instead be held solely by means of remote communication in accordance with Section 211(a)(2) of the DGCL. If authorized by the Board of Directors in its sole discretion, and subject to such guidelines and procedures as the Board of Directors may adopt, stockholders and proxyholders not physically present at a meeting of stockholders may, by means of remote communication: (a) participate in a meeting of stockholders; and (b) be deemed present in person and vote at a meeting of stockholders whether such meeting is to be held at a designated place or solely by means of remote communication, provided that: (i) the Corporation shall implement reasonable measures to verify that each person deemed present and permitted to vote at the meeting by means of remote communication is a stockholder or proxyholder; (ii) the Corporation shall implement reasonable measures to provide such stockholders and proxyholders a reasonable opportunity to participate in the meeting and to vote on matters submitted to the stockholders, including an opportunity to read or hear the proceedings of the meeting substantially concurrently with such proceedings; and (iii) if any stockholder or proxyholder votes or takes other action at the meeting by means of remote communication, a record of such vote or other action shall be maintained by the Corporation.
Section 2.14 Delivery. Whenever this Article II requires one or more stockholders to deliver information to the Corporation (including any notices, requests, questionnaires or other documents or agreements) such information shall be set forth exclusively in writing (and not in an electronic transmission) and shall be delivered exclusively by hand or by certified or registered mail, return receipt requested. Notwithstanding the foregoing, any consent of a stockholder may be delivered in any manner provided by Section 228 of the DGCL, except that the Corporation shall not designate an information processing system for receiving consents of stockholders without the approval of the Board of Directors by a resolution adopted thereby.
Section 2.15 Stockholder Input. No later than the last day of the month in which stockholder proposals are due under Rule 14a-8, the Corporation shall distribute to the entire Board of Directors all proposals received by the Corporation. After the distribution to the Board of Directors, and before the making of any recommendation to the Board of Directors or any of its members concerning a response, approval or disapproval, the Corporation’s legal counsel and officers shall discuss with the Chairperson of the Board of Directors and the chairperson of any Board committee responsible for oversight of the subject matter of the proposal, if applicable, the financial, legal, practical and social implications of approval and implementation of the proposal.
(a) Where a stockholder proposal has been made, the Corporation shall timely contact the proponent of the proposal to arrange a meeting by means of conference telephone, other communications equipment which all persons participating in the meeting can hear each other, or an in-person meeting to discuss the proposal and its financial, legal, social and practical implications. If the proponent agrees to a meeting or teleconference, the Chairperson of the Board of Directors and/or chairperson of any Board committee responsible for the oversight of the subject matter of the proposal shall attend.



(b) The Corporation’s legal counsel and officers, with the authorization of the Chairperson of the Board of Directors or the chairperson of any Board committee responsible for oversight of the subject matter of the proposal, may prepare a response to the stockholder proposal and/or submit a no action request to the SEC pursuant to Section 14(a) of the Exchange Act, and SEC Rule 14a-8, promulgated thereunder.
(c) Before the filing of a proxy statement that makes a recommendation concerning any stockholder proposal submitted in accordance with Rule 14a-8, a draft of the recommendation shall be reviewed and approved by the Board of Directors.
ARTICLE III
DIRECTORS
Section 3.1 Powers. Except as otherwise required by the DGCL or as provided in the Certificate of Incorporation (including any Preferred Stock Designation), the business and affairs of the Corporation shall be managed by or under the direction of the Board of Directors. In addition to the powers and authorities these Bylaws expressly confer upon it, the Board of Directors may exercise all such powers of the Corporation and do all such lawful acts and things as are not by law, the Certificate of Incorporation (including any Preferred Stock Designation) or these Bylaws required to be exercised or done by the stockholders.
Section 3.2 Number and Residence.
(a) Except as otherwise provided for or fixed pursuant to the Certificate of Incorporation (including any Preferred Stock Designation), the Board of Directors shall consist of such a number to be determined from time to time solely by resolution adopted by the affirmative vote of a majority of the total number of directors then authorized (hereinafter referred to as the “Whole Board”).
(b) Directors need not be Delaware residents or stockholders unless so required by the Certificate of Incorporation (including any Preferred Stock Designation) or these Bylaws, wherein other qualifications for directors may be prescribed.
Section 3.3 Election. At any meeting of stockholders at which directors are to be elected, each nominee for election as a director in an uncontested election shall be elected if the number of votes cast for the nominee’s election exceeds the number of votes cast against the nominee’s election. In all director elections other than uncontested elections, the nominees for election as a director shall be elected by a plurality of the votes cast. For purposes of this Section 3.3, an “uncontested election” means any meeting of stockholders at which the number of candidates does not exceed the number of directors to be elected and with respect to which: (a) no stockholder has submitted notice of an intent to nominate a candidate for election at such meeting in accordance with Section 2.2 or Section 2.10; or (b) such a notice has been submitted, and on or before the fifth business day prior to the date that the Corporation files its definitive proxy statement relating to such meeting with the Securities and Exchange Commission (regardless of whether thereafter revised or supplemented), the notice has been: (i) withdrawn in writing to the Secretary of the Corporation; (ii) determined not to be a valid notice of nomination, with such determination to be made by the Board of Directors (or a committee thereof) pursuant to Section 2.10, or if challenged in court, by a final court order; or (iii) determined by the Board of Directors (or a committee thereof) not to create a bona fide election contest.
Section 3.4 Vacancies and Newly Created Directorships. Subject to the rights of the holders of any outstanding series of Preferred Stock, and unless otherwise required by law or resolution of the Board of Directors, newly created directorships resulting from any increase in the authorized number of directors and any vacancies in the Board of Directors resulting from death, resignation, retirement, disqualification, removal from office or other cause shall be filled solely by the affirmative vote of a majority of the remaining directors then in office and entitled to vote thereon, even though less than a quorum, or by the sole remaining director, and any director so chosen shall hold office until the next election of the class for which such director shall have been chosen and until their successor shall have been duly elected and qualified. No decrease in the authorized number of directors shall shorten the term of any incumbent director.



Section 3.5 Resignations and Removal.
(a) Any director may resign at any time upon notice given in writing or by electronic transmission to the Board of Directors, the Chairperson of the Board of Directors or the Secretary of the Corporation. Such resignation shall take effect upon delivery, unless the resignation specifies a later effective date or time or an effective date or time determined upon the happening of an event or events. Unless otherwise specified therein, the acceptance of such resignation shall not be necessary to make it effective.
(b) Except for such additional directors, if any, as are elected by the holders of any series of Preferred Stock as provided for or fixed pursuant to the Certificate of Incorporation (including any Preferred Stock Designation), any director, or the entire Board of Directors, may be removed from office at any time, but only for cause and only by the affirmative vote of at least a majority of the voting power of the stock outstanding and entitled to vote thereon.
Section 3.6 Regular Meetings. Regular meetings of the Board of Directors shall be held at such place or places, within or without the State of Delaware, on such date or dates and at such time or times, as shall have been established by the Board of Directors and publicized among all directors. A notice of each regular meeting shall not be required.
Section 3.7 Special Meetings. Special meetings of the Board of Directors for any purpose or purposes may be called at any time by the Chairperson of the Board of Directors, the Chief Executive Officer or a majority of the directors then in office. The person or persons authorized to call special meetings of the Board of Directors may fix the place, within or without the State of Delaware, date and time of such meetings. Notice of each such meeting shall be given to each director, if by mail, addressed to such director at their residence or usual place of business, at least five days before the day on which such meeting is to be held, or shall be sent to such director by electronic transmission, or be delivered personally or by telephone, in each case at least 24 hours prior to the time set for such meeting. A notice of special meeting need not state the purpose of such meeting, and, unless indicated in the notice thereof, any and all business may be transacted at a special meeting.
Section 3.8 Participation in Meetings by Conference Telephone. Members of the Board of Directors, or of any committee thereof, may participate in a meeting of such Board of Directors or committee by means of conference telephone or other communications equipment by means of which all persons participating in the meeting can hear each other, and such participation shall constitute presence in person at such meeting.
Section 3.9 Quorum and Voting. Except as otherwise required by law, the Certificate of Incorporation or these Bylaws, a majority of the Whole Board shall constitute a quorum for the transaction of business at any meeting of the Board of Directors, and the vote of a majority of the directors present at a duly held meeting at which a quorum is present shall be the act of the Board of Directors. The chairperson of the meeting or a majority of the directors present may adjourn the meeting to another time and place whether or not a quorum is present. At any adjourned meeting at which a quorum is present, any business may be transacted which might have been transacted at the meeting as originally called.
Section 3.10 Board of Directors Action by Written Consent Without a Meeting. Unless otherwise restricted by the Certificate of Incorporation or these Bylaws, any action required or permitted to be taken at any meeting of the Board of Directors, or any committee thereof, may be taken without a meeting; provided, that all members of the Board of Directors or committee, as the case may be, consent in writing or by electronic transmission to such action. After an action is taken the consent or consents relating thereto shall be filed with the minutes of the proceedings of the Board of Directors or the committee thereof, in the same paper or electronic form as the minutes are maintained. Such filing shall be in paper form if the minutes are maintained in paper form and shall be in electronic form if the minutes are maintained in electronic form. Any person (whether or not then a director) may provide, whether through instruction to an agent or otherwise, that a consent to action shall be effective at a future time (including a time determined upon the happening of an event), no later than 60 days after such instruction is given or such provision is made and such consent shall be deemed to have been given at such effective time so long as such person



is then a director and did not revoke the consent prior to such time. Any such consent shall be revocable prior to its becoming effective.
Section 3.11 Chairperson of the Board. The Chairperson of the Board shall preside at meetings of stockholders and directors and shall perform such other duties as the Board of Directors may from time to time determine. If the Chairperson of the Board is not present at a meeting of the Board of Directors, another director chosen by the Board of Directors shall preside.
Section 3.12 Rules and Regulations. The Board of Directors shall adopt such rules and regulations not inconsistent with the provisions of law, the Certificate of Incorporation or these Bylaws for the conduct of its meetings and management of the affairs of the Corporation as the Board of Directors shall deem proper.
Section 3.13 Fees and Compensation of Directors. Unless otherwise restricted by the Certificate of Incorporation, directors may receive such compensation, if any, for their services on the Board of Directors and its committees, and such reimbursement of expenses, as may be fixed or determined by resolution of the Board of Directors.
Section 3.14 Emergency Bylaws. In the event of any emergency, disaster or catastrophe, as referred to in Section 110 of the DGCL, or other similar emergency condition, as a result of which a quorum of the Board of Directors or a standing committee of the Board of Directors cannot readily be convened for action, then the director or directors in attendance at the meeting shall constitute a quorum. Such director or directors in attendance may further take action to appoint one or more of themselves or other directors to membership on any standing or temporary committees of the Board of Directors as they shall deem necessary and appropriate.
ARTICLE IV
COMMITTEES
Section 4.1 Committees of the Board of Directors. The Board of Directors may designate one or more committees, each such committee to consist of one or more of the directors of the Corporation. The Board of Directors may designate one or more directors as alternate members of any committee to replace any absent or disqualified member at any meeting of the committee. In the absence or disqualification of a member of a committee, the member or members present at any meeting and not disqualified from voting, whether or not he, she or they constitute a quorum, may unanimously appoint another member of the Board of Directors to act at the meeting in the place of any such absent or disqualified member. Any such committee, to the extent permitted by law and provided in the resolution of the Board of Directors establishing such committee, shall have and may exercise all the powers and authority of the Board of Directors in the management of the business and affairs of the Corporation, and may authorize the seal of the Corporation to be affixed to all papers which may require it; but no such committee shall have the power or authority in reference to the following matters: (a) approving or adopting, or recommending to the stockholders, any action or matter (other than the election or removal of directors) expressly required by the DGCL to be submitted to stockholders for approval; or (b) adopting, amending or repealing any bylaw of the Corporation. Each committee and its members shall serve at the pleasure of the Board, which may at any time change the members and powers of, or discharge, the committee. All committees of the Board of Directors shall keep minutes of their meetings and shall report their proceedings to the Board of Directors when requested or required by the Board of Directors.
Section 4.2 Meetings and Action of Committees. Unless the Board of Directors provides otherwise by resolution, any committee of the Board of Directors may adopt, alter and repeal such rules and regulations not inconsistent with the provisions of law, the Certificate of Incorporation or these Bylaws for the conduct of its meetings as such committee may deem proper. Except as otherwise required by law, the Certificate of Incorporation or these Bylaws, and except as otherwise provided in a resolution of the Board of Directors: (a) a majority of the directors then serving on a committee shall constitute a quorum for the transaction of business by the committee; provided, however, that in no case shall a quorum be less than one-third of the directors then serving on the committee. Unless the Certificate of Incorporation, these Bylaws or a resolution of the Board requires a greater



number, the vote of a majority of the members of a committee present at a meeting at which a quorum is present shall be the act of the committee.
ARTICLE V
OFFICERS
Section 5.1 Officers. The officers of the Corporation may consist of a Chief Executive Officer, a President, a Chief Financial Officer, and one or more Executive Vice Presidents, Vice Presidents, Assistant Vice Presidents, Assistant Secretaries and Assistant Treasurers and such other officers as the Board of Directors may from time to time determine, each of whom shall be elected by the Board of Directors, each to have such authority, functions or duties as set forth in these Bylaws or as determined by the Board of Directors. Each officer shall be elected by the Board of Directors and shall hold office for such term as may be prescribed by the Board of Directors and until such person’s successor shall have been duly elected and qualified, or until such person’s earlier death, disqualification, resignation or removal. Any number of offices may be held by the same person; provided, however, that no officer shall execute, acknowledge or verify any instrument in more than one capacity if such instrument is required by law, the Certificate of Incorporation or these Bylaws to be executed, acknowledged or verified by two or more officers. The Board of Directors may require any officer, agent or employee to give security for the faithful performance of their duties.
Section 5.2 Compensation. The salaries of the officers of the Corporation and the manner and time of the payment of such salaries shall be fixed and determined by the Board of Directors and may be altered by the Board of Directors from time to time as it deems appropriate, subject to the rights, if any, of such officers under any contract of employment.
Section 5.3 Removal, Resignation and Vacancies. Any officer of the Corporation may be removed, with or without cause, by the Board of Directors or by a duly authorized officer, without prejudice to the rights, if any, of such officer under any contract to which it is a party. Any officer may resign at any time upon notice given in writing or by electronic transmission to the Corporation, without prejudice to the rights, if any, of the Corporation under any contract to which such officer is a party. If any vacancy occurs in any office of the Corporation, the Board of Directors may elect a successor to fill such vacancy for the remainder of the unexpired term and until a successor shall have been duly elected and qualified.
Section 5.4 Chief Executive Officer. The Chief Executive Officer shall have general supervision and direction of the business and affairs of the Corporation, shall be responsible for corporate policy and strategy, and shall report directly to the Board of Directors. Unless otherwise provided in these Bylaws or determined by the Board of Directors, all other officers of the Corporation shall report directly to the Chief Executive Officer or as otherwise determined by the Chief Executive Officer. The Chief Executive Officer shall, if present and in the absence of the Chairperson of the Board of Directors, preside at meetings of the stockholders.
Section 5.5 President. The President shall be the chief operating officer of the Corporation, with general responsibility for the management and control of the operations of the Corporation. The President shall, when requested, counsel with and advise the other officers of the Corporation and shall perform such other duties as the Board of Directors or the Chief Executive Officer may from time to time determine.
Section 5.6 Chief Financial Officer. The Chief Financial Officer shall exercise all the powers and perform the duties of the office of the chief financial officer and in general have overall supervision of the financial operations of the Corporation. The Chief Financial Officer shall, when requested, counsel with and advise the other officers of the Corporation and shall perform such other duties as the Board of Directors, the Chief Executive Officer or the President may from time to time determine.
Section 5.7 Executive Vice Presidents and Vice Presidents. The Executive Vice Presidents and Vice Presidents shall assist and act under the direction of the Corporation’s chief executive officer, unless otherwise determined by the Board of Directors or the chief executive officer. The Board of Directors may designate one or more Executive Vice Presidents and may grant other Vice Presidents titles which describe their functions or specify



their order of seniority. In the absence or disability of the President, the authority of the President shall descend to the Executive Vice Presidents or, if there are none, to the Vice Presidents in the order of seniority indicated by their titles or otherwise specified by the Board. If not specified by their titles or the Board, the authority of the President shall descend to the Executive Vice Presidents or, if there are none, to the Vice Presidents, in the order of their seniority in such office.
Section 5.8 Treasurer. The Treasurer shall supervise and be responsible for all the funds and securities of the Corporation, the deposit of all moneys and other valuables to the credit of the Corporation in depositories of the Corporation, borrowings and compliance with the provisions of all indentures, agreements and instruments governing such borrowings to which the Corporation is a party, the disbursement of funds of the Corporation and the investment of its funds, and in general shall perform all of the duties incident to the office of the Treasurer. The Treasurer shall, when requested, counsel with and advise the other officers of the Corporation and shall perform such other duties as the Board of Directors, the Chief Executive Officer, the President or the Chief Financial Officer may from time to time determine.
Section 5.9 Controller. The Controller shall be the chief accounting officer of the Corporation. The Controller shall, when requested, counsel with and advise the other officers of the Corporation and shall perform such other duties as the Board of Directors, the Chief Executive Officer, the President, the Chief Financial Officer or the Treasurer may from time to time determine.
Section 5.10 Secretary. The powers and duties of the Secretary are: (i) to act as Secretary at all meetings of the Board of Directors, of the committees of the Board of Directors and of the stockholders and to record the proceedings of such meetings in a book or books to be kept for that purpose; (ii) to see that all notices required to be given by the Corporation are duly given and served; (iii) to act as custodian of the seal of the Corporation and affix the seal or cause it to be affixed to all certificates of stock of the Corporation and to all documents, the execution of which on behalf of the Corporation under its seal is duly authorized in accordance with the provisions of these Bylaws; (iv) to have charge of the books, records and papers of the Corporation and see that the reports, statements and other documents required by law to be kept and filed are properly kept and filed; and (v) to perform all of the duties incident to the office of Secretary. The Secretary shall, when requested, counsel with and advise the other officers of the Corporation and shall perform such other duties as the Board of Directors, the Chief Executive Officer or the President may from time to time determine.
Section 5.11 Additional Matters. The Assistant Vice Presidents, Assistant Secretaries and Assistant Treasurers, if any, shall act under the direction of the Corporation’s chief executive officer, the President and the officer they assist. In the order of their seniority, the Assistant Secretaries shall, in the absence or disability of the Secretary, perform the duties and exercise the authority of the Secretary. The Assistant Treasurers, in the order of their seniority, shall, in the absence or disability of the Treasurer, perform the duties and exercise the authority of the Treasurer. The persons upon whom such titles are conferred shall not be deemed officers of the Corporation unless elected by the Board of Directors.
Section 5.12 Checks; Drafts; Evidences of Indebtedness. From time to time, the Board of Directors shall determine the method, and designate (or authorize officers of the Corporation to designate) the person or persons who shall have authority, to sign or endorse all checks, drafts, other orders for payment of money and notes, bonds, debentures or other evidences of indebtedness that are issued in the name of or payable by the Corporation, and only the persons so authorized shall sign or endorse such instruments.
Section 5.13 Corporate Contracts and Instruments; How Executed. Except as otherwise provided in these Bylaws, the Board of Directors may determine the method, and designate (or authorize officers of the Corporation to designate) the person or persons who shall have authority to enter into any contract or execute any instrument in the name of and on behalf of the Corporation. Such authority may be general or confined to specific instances. Unless so authorized, or within the power incident to a person’s office or other position with the Corporation, no person shall have any power or authority to bind the Corporation by any contract or engagement or to pledge its credit or to render it liable for any purpose or for any amount.



Section 5.14 Signature Authority. Unless otherwise specifically determined by the Board of Directors or otherwise provided by law or these Bylaws, contracts, evidences of indebtedness and other instruments or documents of the Corporation may be executed, signed or endorsed: (i) by the Chief Executive Officer, Chief Financial Officer or the President; or (ii) by any Executive Vice President, Vice President, Treasurer, Secretary or Controller, in each case only with regard to such instruments or documents that pertain to or relate to such person’s duties or business functions.
Section 5.15 Action with Respect to Securities of Other Corporations or Entities. The Chief Executive Officer or any other officer of the Corporation authorized by the Board of Directors or the Chief Executive Officer is authorized to vote, represent, and exercise on behalf of the Corporation all rights incident to any and all shares or other equity interests of any other corporation or entity or corporations or entities, standing in the name of the Corporation. The authority herein granted may be exercised either by such person directly or by any other person authorized to do so by proxy or power of attorney duly executed by the person having such authority.
Section 5.16 Delegation. The Board of Directors may from time to time delegate the powers or duties of any officer to any other officers or agents, notwithstanding the foregoing provisions of this Article V.
ARTICLE VI
INDEMNIFICATION AND ADVANCEMENT OF EXPENSES
Section 6.1 Right to Indemnification.
(a) Each person who was or is a party or is threatened to be made a party to, or was or is otherwise involved in, any action, suit, arbitration, alternative dispute resolution mechanism, investigation, inquiry, judicial, administrative or legislative hearing, or any other threatened, pending or completed proceeding, whether brought by or in the right of the Corporation or otherwise, including any and all appeals, whether of a civil, criminal, administrative, legislative, investigative or other nature (hereinafter a “proceeding”), by reason of the fact that they are or was a director or an officer of the Corporation or while a director or officer of the Corporation is or was serving at the request of the Corporation as a director, officer, employee, agent or trustee of another corporation or of a partnership, joint venture, trust or other enterprise, including service with respect to an employee benefit plan (hereinafter an “indemnitee”), or by reason of anything done or not done by them in any such capacity, shall be indemnified and held harmless by the Corporation to the fullest extent authorized by the DGCL, as the same exists or may hereafter be amended, against all expense, liability and loss (including attorneys’ fees, judgments, fines, ERISA excise taxes, penalties and amounts paid in settlement by or on behalf of the indemnitee) actually and reasonably incurred by such indemnitee in connection therewith, all on the terms and conditions set forth in these Bylaws; provided, however, that, except as otherwise required by law or provided in Section 6.3 with respect to suits to enforce rights under this Article VI, the Corporation shall indemnify any such indemnitee in connection with a proceeding, or part thereof, voluntarily initiated by such indemnitee (including claims and counterclaims, whether such counterclaims are asserted by: (i) such indemnitee; or (ii) the Corporation in a proceeding initiated by such indemnitee) only if such proceeding, or part thereof, was authorized or ratified by the Board of Directors or the Board of Directors otherwise determines that indemnification or advancement of expenses is appropriate.
(b) To receive indemnification under this Section 6.1, an indemnitee shall submit a written request to the Secretary of the Corporation. Such request shall include documentation or information that is necessary to determine the entitlement of the indemnitee to indemnification and that is reasonably available to the indemnitee. Upon receipt by the Secretary of the Corporation of such a written request, the entitlement of the indemnitee to indemnification shall be determined by the following person or persons who shall be empowered to make such determination, as selected by the Board of Directors (except with respect to clause (v) of this Section 6.1(b)): (i) the Board of Directors by a majority vote of the directors who are not parties to such proceeding, whether or not such majority constitutes a quorum; (ii) a committee of such directors designated by a majority vote of such directors, whether or not such majority constitutes a quorum; (iii) if there are no such directors, or if such directors so direct, by independent legal counsel in a written opinion to the Board of Directors, a copy of which shall be delivered to the indemnitee; (iv) the stockholders of the Corporation; or (v) in the event that a change of control (as defined below) has occurred, by independent legal counsel in a written opinion to the Board of Directors, a copy of which shall be



delivered to the indemnitee. The determination of entitlement to indemnification shall be made and, unless a contrary determination is made, such indemnification shall be paid in full by the Corporation not later than 60 days after receipt by the Secretary of the Corporation of a written request for indemnification. For purposes of this Section 6.1(b), a “change of control” will be deemed to have occurred if, with respect to any particular 24-month period, the individuals who, at the beginning of such 24-month period, constituted the Board of Directors (the “incumbent board”), cease for any reason to constitute at least a majority of the Board of Directors; provided, however, that any individual becoming a director subsequent to the beginning of such 24-month period whose election, or nomination for election by the stockholders of the Corporation, was approved by a vote of at least a majority of the directors then comprising the incumbent board shall be considered as though such individual were a member of the incumbent board, but excluding, for this purpose, any such individual whose initial assumption of office occurs as a result of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents by or on behalf of a person other than the Board of Directors.
Section 6.2 Right to Advancement of Expenses.
(a) In addition to the right to indemnification conferred in Section 6.1, an indemnitee shall, to the fullest extent permitted by law, also have the right to be paid by the Corporation the expenses (including attorneys’ fees) incurred in defending any proceeding in advance of its final disposition (hereinafter an “advancement of expenses”); provided, however, that an advancement of expenses shall be made only upon delivery to the Corporation of an undertaking (hereinafter an “undertaking”), by or on behalf of such indemnitee, to repay all amounts so advanced if it shall ultimately be determined by final judicial decision of a court of competent jurisdiction from which there is no further right to appeal (hereinafter a “final adjudication”) that such indemnitee is not entitled to be indemnified for such expenses under this Article VI or otherwise.
(b) To receive an advancement of expenses under this Section 6.2, an indemnitee shall submit a written request to the Secretary of the Corporation. Such request shall reasonably evidence the expenses incurred by the indemnitee and shall include or be accompanied by the undertaking required by Section 6.2(a). Each such advancement of expenses shall be made within 30 days after the receipt by the Secretary of the Corporation of a written request for advancement of expenses.
(c) Notwithstanding the foregoing Section 6.2(a), the Corporation shall not make or continue to make advancements of expenses to an indemnitee (except by reason of the fact that the indemnitee is or was a director of the Corporation, in which event this Section 6.2(c) shall not apply) if a determination is reasonably made that the facts known at the time such determination is made demonstrate clearly and convincingly that the indemnitee acted in bad faith or in a manner that the indemnitee did not reasonably believe to be in or not opposed to the best interests of the Corporation, or, with respect to any criminal proceeding, that the indemnitee had reasonable cause to believe their conduct was unlawful. Such determination shall be made: (i) by the Board of Directors by a majority vote of directors who are not parties to such proceeding, whether or not such majority constitutes a quorum; (ii) by a committee of such directors designated by a majority vote of such directors, whether or not such majority constitutes a quorum; or (iii) if there are no such directors, or if such directors so direct, by independent legal counsel in a written opinion to the Board of Directors, a copy of which shall be delivered to the indemnitee.
Section 6.3 Right of Indemnitee to Bring Suit. In the event that a determination is made that the indemnitee is not entitled to indemnification or if payment is not timely made following a determination of entitlement to indemnification pursuant to Section 6.1(b) or if an advancement of expenses is not timely made under Section 6.2(b), the indemnitee may at any time thereafter bring suit against the Corporation in a court of competent jurisdiction in the State of Delaware seeking an adjudication of entitlement to such indemnification or advancement of expenses. If successful in whole or in part in any such suit, or in a suit brought by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the indemnitee shall be entitled to be paid also the expense of prosecuting or defending such suit to the fullest extent permitted by law. In any suit brought by the indemnitee to enforce a right to indemnification hereunder (but not in a suit brought by the indemnitee to enforce a right to an advancement of expenses) it shall be a defense that the indemnitee has not met any applicable standard of conduct for indemnification set forth in the DGCL. Further, in any suit brought by the Corporation to recover an



advancement of expenses pursuant to the terms of an undertaking, the Corporation shall be entitled to recover such expenses upon a final adjudication that the indemnitee has not met any applicable standard of conduct for indemnification set forth in the DGCL. Neither the failure of the Corporation (including its directors who are not parties to such action, a committee of such directors, independent legal counsel or its stockholders) to have made a determination prior to the commencement of such suit that indemnification of the indemnitee is proper in the circumstances because the indemnitee has met the applicable standard of conduct set forth in the DGCL, nor an actual determination by the Corporation (including its directors who are not parties to such action, a committee of such directors, independent legal counsel or its stockholders) that the indemnitee has not met such applicable standard of conduct, shall create a presumption that the indemnitee has not met the applicable standard of conduct or, in the case of such a suit brought by the indemnitee, be a defense to such suit. In any suit brought by the indemnitee to enforce a right to indemnification or to an advancement of expenses hereunder, or brought by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the burden of proving that the indemnitee is not entitled to be indemnified, or to such advancement of expenses, under applicable law, this Article VI or otherwise shall be on the Corporation.
Section 6.4 Non-Exclusivity of Rights. The rights to indemnification and to the advancement of expenses conferred in this Article VI shall not be exclusive of any other right which any person may have or hereafter acquire under any law, agreement, vote of stockholders or disinterested directors, provisions of a certificate of incorporation or bylaws, or otherwise.
Section 6.5 Insurance. The Corporation may maintain insurance, at its expense, to protect itself and any director, officer, employee or agent of the Corporation or another corporation, partnership, joint venture, trust or other enterprise against any expense, liability or loss, whether or not the Corporation would have the power to indemnify such person against such expense, liability or loss under the DGCL.
Section 6.6 Indemnification of Employees and Agents of the Corporation. The Corporation may, to the extent and in the manner permitted by law, and to the extent authorized from time to time, grant rights to indemnification and to the advancement of expenses to any employee or agent of the Corporation.
Section 6.7 Nature of Rights. The rights conferred upon indemnitees in this Article VI shall be contract rights and such rights shall continue as to an indemnitee who has ceased to be a director or officer and shall inure to the benefit of the indemnitee’s heirs, executors and administrators. Any amendment, alteration or repeal of this Article VI that adversely affects any right of an indemnitee or its successors shall be prospective only and shall not limit or eliminate any such right with respect to any proceeding involving any occurrence or alleged occurrence of any action or omission to act that took place prior to such amendment, alteration or repeal.
Section 6.8 Settlement of Claims. Notwithstanding anything in this Article VI to the contrary, the Corporation shall not be liable to indemnify any indemnitee under this Article VI for any amounts paid in settlement of any proceeding effected without the Corporation’s written consent, which consent shall not be unreasonably withheld.
Section 6.9 Subrogation. In the event of payment under this Article VI, the Corporation shall be subrogated to the extent of such payment to all of the rights of recovery of the indemnitee (excluding insurance obtained on the indemnitee’s own behalf), and the indemnitee shall execute all papers required and shall do everything that may be necessary to secure such rights, including the execution of such documents necessary to enable the Corporation effectively to bring suit to enforce such rights.
Section 6.10 Severability. If any provision or provisions of this Article VI shall be held to be invalid, illegal or unenforceable as applied to any person or entity or circumstance for any reason whatsoever, then, to the fullest extent permitted by law: (a) the validity, legality and enforceability of such provision in any other circumstance and of the remaining provisions of this Article VI (including, without limitation, all portions of any paragraph of this Article VI containing any such provision held to be invalid, illegal or unenforceable, that are not by themselves invalid, illegal or unenforceable) and the application of such provision to other persons or entities or circumstances shall not in any way be affected or impaired thereby; and (b) to the fullest extent possible, the provisions of this



Article VI (including, without limitation, all portions of any paragraph of this Article VI containing any such provision held to be invalid, illegal or unenforceable, that are not themselves invalid, illegal or unenforceable) shall be construed so as to give effect to the intent of the parties that the Corporation provide protection to the indemnitee to the fullest extent set forth in this Article VI.
ARTICLE VII
CAPITAL STOCK
Section 7.1 Certificates of Stock. The shares of the Corporation shall be represented by certificates; provided, however, that the Board of Directors may provide by resolution or resolutions that some or all of any or all classes or series of stock shall be uncertificated shares. Any such resolution shall not apply to shares represented by a certificate until such certificate is surrendered to the Corporation. Every holder of stock represented by certificates shall be entitled to have a certificate signed by or in the name of the Corporation by any two authorized officers of the Corporation, including, without limitation, the Chief Executive Officer, the President, the Chief Financial Officer, the Treasurer, the Controller, the Secretary, or an Assistant Treasurer or Assistant Secretary, of the Corporation certifying the number of shares owned by such holder in the Corporation. Any or all such signatures may be facsimiles. In case any officer, transfer agent or registrar who has signed or whose facsimile signature has been placed upon a certificate has ceased to be such officer, transfer agent or registrar before such certificate is issued, it may be issued by the Corporation with the same effect as if such person were such officer, transfer agent or registrar at the date of issue.
Section 7.2 Special Designation on Certificates. If the Corporation is authorized to issue more than one class of stock or more than one series of any class, then the powers, the designations, the preferences, and the relative, participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights shall be set forth in full or summarized on the face or back of the certificate that the Corporation shall issue to represent such class or series of stock; provided, however, that, except as otherwise provided in Section 202 of the DGCL, in lieu of the foregoing requirements there may be set forth on the face or back of the certificate that the Corporation shall issue to represent such class or series of stock a statement that the Corporation will furnish without charge to each stockholder who so requests the powers, the designations, the preferences, and the relative, participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights. Within a reasonable time after the issuance or transfer of uncertificated stock, the registered owner thereof shall be given a notice, in writing or by electronic transmission, containing the information required to be set forth or stated on certificates pursuant to this Section 7.2 or Sections 151, 156, 202(a) or 218(a) of the DGCL or with respect to this Section 7.2 and Section 151 of the DGCL a statement that the Corporation will furnish without charge to each stockholder who so requests the powers, the designations, the preferences, and the relative, participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights. Except as otherwise expressly provided by law, the rights and obligations of the holders of uncertificated stock and the rights and obligations of the holders of certificates representing stock of the same class and series shall be identical.
Section 7.3 Transfers of Stock. Transfers of shares of stock of the Corporation shall be made only on the books of the Corporation upon authorization by the registered holder thereof or by such holder’s attorney thereunto authorized by a power of attorney duly executed and filed with the Secretary of the Corporation or a transfer agent for such stock, and if such shares are represented by a certificate, upon surrender of the certificate or certificates for such shares properly endorsed or accompanied by a duly executed stock transfer power and the payment of any taxes thereon; provided, however, that the Corporation shall be entitled to recognize and enforce any lawful restriction on transfer.
Section 7.4 Lost Certificates. The Corporation may issue a new share certificate or uncertificated shares in the place of any certificate theretofore issued by it, alleged to have been lost, stolen or destroyed, and the Corporation may require the owner of the lost, stolen or destroyed certificate or the owner’s legal representative to give the Corporation a bond (or other adequate security) sufficient to indemnify it against any claim that may be made against it (including any expense or liability) on account of the alleged loss, theft or destruction of any such



certificate or the issuance of such new certificate or uncertificated shares. The Board of Directors may adopt such other provisions and restrictions with reference to lost certificates, not inconsistent with applicable law, as it shall in its discretion deem appropriate.
Section 7.5 Registered Stockholders. The Corporation shall be entitled to recognize the exclusive right of a person registered on its books as the owner of shares to receive dividends, and to vote as such owner, and shall not be bound to recognize any equitable or other claim to or interest in such share or shares on the part of any other person, whether or not it shall have express or other notice thereof, except as otherwise required by law.
Section 7.6 Record Date for Determining Stockholders.
(a) In order that the Corporation may determine the stockholders entitled to notice of any meeting of stockholders or any adjourned meeting, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors, and which record date shall, unless otherwise required by law, not be more than 60 nor less than 10 days before the date of such meeting. If the Board of Directors so fixes a date, such date shall also be the record date for determining the stockholders entitled to vote at such meeting unless the Board of Directors determines, at the time it fixes such record date, that a later date on or before the date of the meeting shall be the date for making such determination. If no record date is fixed by the Board of Directors, the record date for determining stockholders entitled to notice of and to vote at a meeting of stockholders shall be at the close of business on the day next preceding the day on which notice is given, or, if notice is waived, at the close of business on the day next preceding the day on which the meeting is held. A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjourned meeting; provided, however, that the Board of Directors may fix a new record date for the determination of stockholders entitled to vote at the adjourned meeting, and in such case shall also fix as the record date for stockholders entitled to notice of such adjourned meeting the same or an earlier date as that fixed for determination of stockholders entitled to vote in accordance herewith at the adjourned meeting.
(b) In order that the Corporation may determine the stockholders entitled to receive payment of any dividend or other distribution or allotment of any rights, or entitled to exercise any rights in respect of any change, conversion or exchange of stock or for the purpose of any other lawful action, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors, and which record date shall not be more than 60 days prior to such action. If no such record date is fixed, the record date for determining stockholders for any such purpose shall be at the close of business on the day on which the Board of Directors adopts the resolution relating thereto.
(c) Unless otherwise restricted by the Certificate of Incorporation (including any Preferred Stock Designation), in order that the Corporation may determine the stockholders entitled to express consent to corporate action in writing without a meeting, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors, and which record date shall not be more than 10 days after the date upon which the resolution fixing the record date is adopted by the Board of Directors. If no record date has been fixed by the Board of Directors, the record date for determining stockholders entitled to express consent to corporate action in writing without a meeting, when no prior action of the Board of Directors is required by law, shall be the first date on which a signed written consent setting forth the action taken or proposed to be taken was delivered to the Corporation in accordance with Section 2.11. If no record date has been fixed by the Board of Directors, the record date for determining stockholders entitled to express consent to corporate action in writing without a meeting, if prior action by the Board of Directors is required by law, shall be at the close of business on the day on which the Board of Directors adopts the resolution taking such prior action.
Section 7.7 Regulations. To the extent permitted by applicable law, the Board of Directors may make such additional rules and regulations as it may deem expedient concerning the issue, transfer and registration of shares of stock of the Corporation.



Section 7.8 Waiver of Notice. Whenever notice is required to be given under any provision of the DGCL or the Certificate of Incorporation or these Bylaws, a written waiver, signed by the person entitled to notice, or a waiver by electronic transmission by the person entitled to notice, whether before or after the time stated therein, shall be deemed equivalent to notice. Attendance of a person at a meeting shall constitute a waiver of notice of such meeting, except when the person attends a meeting for the express purpose of objecting at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. Neither the business to be transacted at, nor the purpose of, any regular or special meeting of the stockholders, the Board of Directors or a committee of the Board of Directors need be specified in any written waiver of notice or any waiver by electronic transmission unless so required by the Certificate of Incorporation or these Bylaws.
ARTICLE VIII
GENERAL MATTERS
Section 8.1 Fiscal Year. The fiscal year of the Corporation shall end on such date as the Board of Directors from time to time determines.
Section 8.2 Corporate Seal. The Board of Directors may provide a suitable seal, containing the name of the Corporation, which seal shall be in the charge of the Secretary of the Corporation. If and when so directed by the Board of Directors or a committee thereof, duplicates of the seal may be kept and used by the Treasurer or by an Assistant Secretary or Assistant Treasurer.
Section 8.3 Reliance Upon Books. Reports and Records. Each director and each member of any committee designated by the Board of Directors shall, in the performance of their duties, be fully protected in relying in good faith upon the books of account or other records of the Corporation and upon such information, opinions, reports or statements presented to the Corporation by any of its officers or employees, or committees of the Board of Directors so designated, or by any other person as to matters which such director or committee member reasonably believes are within such other person’s professional or expert competence and who has been selected with reasonable care by or on behalf of the Corporation.
Section 8.4 Subject to Law and Certificate of Incorporation. All powers, duties and responsibilities provided for in these Bylaws, whether or not explicitly so qualified, are qualified by the Certificate of Incorporation (including any Preferred Stock Designation) and applicable law.
ARTICLE IX
FORUM FOR ADJUDICATION OF DISPUTES
Section 9.1 Forum. Unless the Corporation, in writing, selects or consents to the selection of an alternative forum, the sole and exclusive forum for any current or former stockholder (including any current or former beneficial owner) to bring internal corporate claims (as defined below), to the fullest extent permitted by law, and subject to applicable jurisdictional requirements, shall be the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, another state court or a federal court located within the State of Delaware). For purposes of this Article IX, internal corporate claims means claims, including claims in the right of the Corporation: (a) that are based upon a violation of a duty by a current or former director, officer, employee or stockholder in such capacity; or (b) as to which the DGCL confers jurisdiction upon the Court of Chancery.
Section 9.2 Consent to Jurisdiction. If any action the subject matter of which is within the scope of this Article IX is filed in a court other than the Court of Chancery (or, if the Court of Chancery does not have jurisdiction, another state court or a federal court located within the State of Delaware) (a “foreign action”) by any current or former stockholder (including any current or former beneficial owner), such stockholder shall be deemed to have consented to: (a) the personal jurisdiction of the Court of Chancery (or such other state or federal court located within the State of Delaware, as applicable) in connection with any action brought in any such court to enforce this Article IX; and (b) having service of process made upon such stockholder in any such action by service upon such stockholder’s counsel in the foreign action as agent for such stockholder.



Section 9.3 Enforceability. If any provision of this Article IX shall be held to be invalid, illegal or unenforceable as applied to any person or entity or circumstance for any reason whatsoever, then, to the fullest extent permitted by law, the validity, legality and enforceability of such provision in any other circumstance and of the remaining provisions of this Article IX (including, without limitation, each portion of any sentence of this Article IX containing any such provision held to be invalid, illegal or unenforceable that is not itself held to be invalid, illegal or unenforceable) and the application of such provision to other persons or entities or circumstances shall not in any way be affected or impaired thereby.
ARTICLE X
AMENDMENTS
Section 10.1 Amendments. In furtherance and not in limitation of the powers conferred by the laws of the State of Delaware, the Board of Directors is expressly authorized to adopt, amend or repeal these Bylaws. Except as otherwise provided in the Certificate of Incorporation (including the terms of any Preferred Stock Designation that require an additional vote) or these Bylaws, and in addition to any requirements of law, the affirmative vote of at least a majority of the voting power of the stock outstanding and entitled to vote thereon, voting together as a single class, shall be required for the stockholders to adopt, amend or repeal, or adopt any provision inconsistent with, any provision of these Bylaws.
image_0a.jpg

EX-10.1 3 rmti-20220930xxshorttermin.htm EX-10.1 Document

Rockwell Medical, Inc.
Short-Term Incentive Plan
(Annual Bonus Plan)

SECTION 1: Establishment of Plan; Purpose of Plan
1.1. Establishment of Plan. The Company hereby establishes the SHORT-TERM INCENTIVE PLAN (ANNUAL BONUS PLAN) (the “Plan”), for its executive officers, senior corporate and divisional officers and other key employees. The Plan provides for the payment of Incentive Bonuses to Participants based upon the achievement of Performance Measures during a specified Performance Period.
1.2. Purpose of Plan. The purpose of the Plan is to motivate Participants to improve the Company’s value and growth through the attainment of carefully planned goals, to promote initiative and cooperation through awards based on corporate and divisional performance and to encourage outstanding individuals to enter and continue in the employ of the Company.
1.3. Effective Date. This Plan is effective as of January 1, 2023.
SECTION 2: Definitions
The following terms have the stated definitions unless a different meaning is plainly required by the context:
2.1. “Act” means the Securities Exchange Act of 1934, as amended.
2.2. “Beneficiary” means the individual, trust or other entity designated by the Participant to receive any amount payable with respect to the Participant under the Plan after the Participant’s death. A Participant may designate or change a Beneficiary by filing a signed designation with the Committee in a form approved by the Committee. A Participant’s will is not effective for this purpose. If a designation has not been completed properly and filed with the Committee or is ineffective for any other reason, the Beneficiary shall be the Participant’s Surviving Spouse. If there is no effective designation and the Participant does not have a Surviving Spouse, the remaining benefits, if any, shall be paid to the Participant’s estate.
2.3. “Board” means the Board of Directors of the Company.
2.4. “Code” means the Internal Revenue Code of 1986, as amended.





2.5. “Committee” means the Compensation Committee of the Board or such other committee as the Board shall designate to administer the Plan. The Committee shall consist of at least two members.
2.6. “Company” means Rockwell Medical, Inc., a Delaware corporation, and its successors and assigns.
2.7. “Eligible Employees” means executive officers, senior corporate and divisional officers and other key employees of the Company or a Subsidiary.
2.8. “Fiscal Year” means the fiscal year of the Company for financial reporting purposes as the Company may adopt from time to time.
2.9. “Incentive Bonus” means an annual bonus awarded and paid to a Participant for services to the Company during a Performance Period that is based upon the achievement of Performance Measures established in accordance with the Plan.
2.10. “Participant” means an Eligible Employee who is designated as a Participant by the Committee for a Performance Period.
2.11. “Performance” means the level of achievement of the Performance Measures as determined by the Committee pursuant to Section 6.1.
2.12. “Performance Measure” or “Performance Measures” means the performance measures established by the Committee pursuant to Section 5.
2.13. “Performance Period” means a Fiscal Year or other period determined by the Committee.
2.14. “Subsidiary” means any company or other entity of which 50% or more of the outstanding voting stock or voting ownership interest is directly or indirectly owned or controlled by the Company.
2.15. “Surviving Spouse” means the spouse of the Participant at the time of the Participant’s death who survives the Participant. If the Participant and spouse die under circumstances which prevent ascertainment of the order of their deaths, it shall be presumed for the Plan that the Participant survived the spouse.
2.16. “Target Bonus” means the bonus amount established by the Committee for each Participant under Section 5.1(a).
SECTION 3: Administration
3.1. Power and Authority. The Plan shall be administered by the Committee. The Committee may delegate recordkeeping, calculation, payment and other ministerial or administrative functions to individuals designated by the Committee, who may be employees of the Company or its Subsidiaries. Except as limited by the Plan, the Committee shall have all of
2


the express and implied powers and duties set forth in the Plan and shall have full authority and discretion to interpret the Plan and to make all other determinations deemed necessary or advisable for the administration of the Plan. Action may be taken by a written instrument signed by a majority of the members of the Committee and any action so taken shall be as effective as if it had been taken at a meeting. The Committee may make such other rules for the conduct of its business and may adopt such other rules, policies and forms for the administration, interpretation and implementation of the Plan as it deems advisable. Subject to the Compensation Committee Charter and applicable law, all determinations, interpretations and selections made by the Committee regarding the Plan shall be final and conclusive. Notwithstanding the foregoing, the Committee may delegate administration of the Plan with respect to those Participants who are not subject to Section 16 of the Act to individuals designated by the Committee, who may be employees of the Company or its Subsidiaries. References in the Plan to actions by the Committee shall refer to actions by any individual to whom authority is or has been delegated, as the context may require. Unless determined otherwise by the Committee, the Committee hereby delegates administration of the Plan with respect to those Participants who are not subject to Section 16 of the Act to such Participant’s manager.
3.2. Indemnification of Committee Members. Neither any member or former member of the Committee nor any individual to whom authority is or has been delegated shall be personally responsible or liable for any act or omission in connection with the performance of powers or duties or the exercise of discretion or judgment in the administration and implementation of the Plan or for any adverse tax or other consequence to any Participant or to the estate or beneficiary of a Participant, including by reason of the application of Section 7.10 or any acceleration of income or any additional tax (including interest and penalties) asserted by reason of the failure of an Incentive Bonus to satisfy the requirements of Section 409A of the Code or Section 4999 of the Code. Each individual who is or has been a member of the Committee, or delegated authority by the Committee, shall be indemnified and held harmless by the Company from and against any cost, liability or expense imposed or incurred in connection with any act or failure to act under the Plan. Each such individual shall be justified in relying on information furnished in connection with the Plan’s administration by any appropriate person or persons.
SECTION 4: Participation
4.1. Participation. The Committee shall select the Eligible Employees who will be Participants in the Plan for a Performance Period. If, following the commencement of a Performance Period, (a) an Eligible Employee commences employment with the Company or a Subsidiary, or (b) a current employee of the Company or a Subsidiary first becomes an Eligible Employee, and, in either case, such Eligible Employee is designated as a Participant by the Committee, unless otherwise determined by the Committee, the Performance Period applicable to such Eligible Employee’s Incentive Bonus for such Fiscal Year will begin on the date of such commencement of employment or eligibility, as applicable, and end on the last day of such Performance Period.
3


4.2. Continuing Participation. Selection as a Participant for a Performance Period by the Committee is limited to that Performance Period. An Eligible Employee will be a Participant for a Performance Period only if designated as a Participant by the Committee for such Performance Period.
SECTION 5: Incentive Bonus Terms; Performance Measures
5.1. Incentive Bonus Terms. The Committee shall establish the terms of the Incentive Bonus for each Participant or group of Participants in the manner specified in this Section 5. For each Participant or group of Participants for each Performance Period, the Committee shall specify:
(a) Target Bonus. A Target Bonus, expressed as a percentage of the Participant’s base salary or a specified dollar amount;
(b) Incentive Bonus. The amount that may be payable under an Incentive Bonus, expressed as a percentage of the Target Bonus, based on the level (or varying levels) of achievement of the Performance Measures; for these purposes, the Incentive Bonus payable based on varying levels of achievement may be expressed either as (i) a matrix of percentages of the Target Bonus that will be paid at specified levels of achievement of the Performance Measures or (ii) a mathematical formula that determines the percentage of the Target Bonus that will be paid at varying levels of achievement of the Performance Measures.
(c) Performance Measures. The Performance Measures applicable to the Incentive Bonus; and
(d) Conditions on Incentive Bonus. Any specific circumstances under which an Incentive Bonus specified under subsection (b) above may be increased, reduced or forfeited. In addition, notwithstanding anything in the Plan to the contrary, the Committee may at any time, and for any reason, exercise negative discretion to reduce or eliminate any Incentive Bonus.
5.2. Performance Measures. For purposes of the Plan, “Performance Measure” means any individual goals or objectives established by the Committee and communicated to the Participant and/or any measure (or measures) of performance relating to any one or more performance criteria, or derivations of such performance criteria, either individually, alternatively or in any combination, applied to either the Company as a whole or to a business unit, division, line or Subsidiary (and “Entity”), either individually, alternatively or in any combination, and measured either annually or cumulatively over a period of years, on an absolute basis or relative to a pre-established target, to previous years’ results or to an index or indices or a designated comparison group or groups, in each case as specified by the Committee. The Performance Measures applicable to an Entity may include, without limitation: (i) net earnings or earnings per share (including earnings before interest, taxes, depreciation and/or amortization); (ii) income, net income or operating income; (iii) revenues; (iv) net sales; (v) return on sales; (vi) return on equity; (vii) return on capital (including return on total capital or return on invested capital); (viii) return on assets or net assets; (ix) earnings per share; (x) economic or business value added measurements; (xi) return on invested capital; (xii) return on
4


operating revenue; (xiii) cash flow (before or after dividends); (xiv) stock price; (xv) total stockholder return; (xvi) market capitalization; (xvii) economic value added; (xviii) debt leverage (debt to capital); (xix) operating profit or net operating profit; (xx) operating margin or profit margin; (xxi) cash from operations; (xxii) market share; (xxiii) product development, release schedules, lead times, delivery or quality; (xxiv) new product innovation; (xxv) cost or expense controls; (xxvi) customer acquisition or retention; (xxvii) customer service; (xxviii) customer satisfaction; or (xxix) any other measure or metric, including any individual or strategic goal, specified by the Committee in its discretion. The Performance Measure and any targets with respect thereto determined by the Committee need not be based upon an increase, a positive or improved result or avoidance of loss.
The Committee (a) may appropriately adjust any evaluation of the satisfaction of Performance Measures to eliminate the effects of charges for restructurings, discontinued operations, unusual or infrequently occurring items and all items of gain, loss or expense determined to be unusual or infrequent in nature or related to the disposal of a segment of a business or related to a change in accounting principle, all as determined in accordance with applicable accounting provisions, as well as the cumulative effect of accounting changes, in each case as determined in accordance with generally accepted accounting principles or identified in the Company’s financial statements or notes to the financial statements, and (b) may appropriately adjust any evaluation of the achievement of Performance Measures to exclude any of the following events that occurs during a Performance Period: (i) asset write-downs; (ii) litigation, claims, judgments or settlements; (iii) the effect of changes in tax law or other such laws or provisions affecting reported results; (iv) corporate stock and asset acquisitions and dispositions; (v) accruals of any amounts for payment under this Plan or any other compensation arrangement maintained by the Company, and (vii) such other events as determined by the Committee in its discretion.
5.3. Time of Determination by Committee. The Committee shall establish in writing all terms applicable to an Incentive Bonus pursuant to this Section 5 at such times as it determines.
SECTION 6: Determination and Payment of Incentive Bonuses
6.1. Committee Determination. The Incentive Bonus, if any, payable to each Participant for any Performance Period shall be determined by the Committee on the basis of the Target Bonus and achievement of the Performance Measures established by the Committee pursuant to Section 5. After the end of the Performance Period, the Committee shall determine, prior to payment of any Incentive Bonus, the extent to which the applicable Performance Measures were achieved.
6.2. Eligibility for Payment. If the Participant’s employment terminates prior to the payment of an Incentive Bonus with respect to any Performance Period, unless provided otherwise by the Committee, whether in a written agreement between the Company and Participant or otherwise, the Participant will not be entitled to payment of the Incentive Bonus for such Performance Period.
5


6.3. Payment to Participant or Beneficiary. Any Incentive Bonus payable to a Participant shall be paid to the Participant, or the Beneficiary of any deceased Participant, by the Company as soon as reasonably feasible following final determination by the Committee of the amount payable as provided in Section 6.1; provided, however, in no event may an Incentive Bonus be paid later than the fifteenth day of the third month following the end of the Performance Period to which the Incentive Bonus relates.
6.4. Manner of Payment. Each Participant will receive his or her Incentive Bonus as determined by the Committee or the Board.
SECTION 7: General Provisions
7.1. Benefits Not Guaranteed. Neither the establishment and maintenance of the Plan nor participation in the Plan shall provide any guarantee or other assurance that an Incentive Bonus will be payable under the Plan.
7.2. No Right to Participate. Nothing in this Plan shall be deemed or interpreted to provide a Participant or any Eligible Employee any contractual right to participate in or receive benefits under the Plan. No designation of an employee as an Eligible Employee or a Participant for all or any part of a Performance Period shall create a right to an Incentive Bonus under the Plan for any other Performance Period. There is no obligation of uniformity of treatment of Eligible Employees or Participants under the Plan. The loss of any Incentive Bonus will not constitute an element of damages in the event of termination of employment for any reason, even if the termination is in violation of an obligation of the Company or a Subsidiary to a Participant.
7.3. No Employment Right. Participation in this Plan shall not be construed as constituting a commitment, guarantee, agreement or understanding of any kind that the Company or any Subsidiary will continue to employ any individual and this Plan shall not be construed or applied as an employment contract or obligation. Nothing in this Plan shall abridge or diminish the rights of the Company or any Subsidiary to determine the terms and conditions of employment of any Participant or Eligible Employee or to terminate the employment of any Participant or Eligible Employee with or without reason at any time.
7.4. No Assignment or Transfer. Neither a Participant nor any Beneficiary or other representative of a Participant shall have any right to assign, transfer, attach or hypothecate any amount or credit, potential payment or right to future payments of any amount or credit or any other benefit provided under this Plan. Payment of any amount due or to become due under this Plan shall not be subject to the claims of creditors of the Participant or to execution by attachment or garnishment or any other legal or equitable proceeding or process.
7.5. No Limit on Other Compensation Arrangements. Nothing contained in this Plan shall prevent the Company or any Subsidiary from adopting or continuing in effect other or additional compensation arrangements. A Participant may have other targets under other plans of the Company. However, no payment under any other plan or arrangement shall be contingent upon failure to attain the criteria for payment of an Incentive Bonus under this Plan.
6


7.6. Withholding and Payroll Taxes. The Company shall deduct from any payment made under this Plan all amounts required by federal, state, local and foreign tax laws to be withheld and shall subject any payments made under the Plan to all applicable payroll taxes and assessments.
7.7. Incompetent Payee. If the Committee determines that an individual entitled to a payment under this Plan is incompetent, it may cause benefits to be paid to another individual for the use or benefit of the Participant or Beneficiary at the time or times otherwise payable under this Plan in total discharge of the Plan’s obligations to the Participant or Beneficiary.
7.8. Governing Law. The validity, construction and effect of the Plan shall be determined in accordance with the laws of the State of Delaware and applicable federal law.
7.9. Severability. In the event any provision of the Plan shall be held illegal or invalid for any reason, the remaining provisions of the Plan shall not be affected and the Plan shall be construed and enforced as if the illegal or invalid provision had not been included.
7.10. Clawback. Incentive Bonuses are subject to forfeiture, termination and rescission, and a Participant will be obligated to return to the Company payments received with respect to Incentive Bonuses, in each case (a) to the extent provided by the Committee in connection with (i) a breach by the Participant any non-competition, non-solicitation, confidentiality or similar covenant or agreement with the Company or any of its affiliates or (ii) an overpayment to the Participant of incentive compensation due to inaccurate financial data, (b) in accordance with any applicable Company clawback or recoupment policy, as such policy may be amended and in effect from time to time, or (c) as otherwise required by law or applicable stock exchange listing standards, including, without limitation, Section 10D of the Act. Each Participant, by accepting an Incentive Bonus pursuant to the Plan, agrees to return the full amount required under this Section 7.10 at such time and in such manner as the Company shall determine in its sole discretion.
SECTION 8: Termination and Amendment
The Board may terminate the Plan at any time, or may from time to time amend the Plan as it deems proper and in the best interests of the Company. Except as otherwise provided in this Plan and the applicable Performance Measures established pursuant to this Plan for determining the amount of any Incentive Bonus for a Fiscal Year or part thereof, no Incentive Bonuses shall be payable for the Fiscal Year in which the Plan is terminated, or, if later, in which the termination is effective.
SECTION 9: Duration of the Plan
This Plan shall continue in effect until terminated by the Board.
image_0b.jpg
7
EX-10.2 4 rmti-20220930xxformofstock.htm EX-10.2 Document

Grantee:                    
Grant Date:                    
Number of Option Shares:                    
Exercise Price Per Share: $                 
STOCK OPTION AGREEMENT
THIS STOCK OPTION AGREEMENT, dated as of the grant date set forth above (the “Grant Date”), is made by and between Rockwell Medical, Inc., a Delaware corporation (the “Company”), and the individual set forth above, who is an employee of the Company or a Subsidiary (the “Optionee” or “Grantee”). Any capitalized terms used herein but not otherwise defined shall have the meaning set forth in the Company’s Amended and Restated 2018 Long Term Incentive Plan, as amended from time to time (the “Plan”).
WHEREAS, the Company wishes to afford the Optionee the opportunity to purchase shares of its common stock (the “Common Stock”) pursuant to the terms and conditions of this Agreement and the Plan, the terms of which are hereby incorporated by reference and made a part of this Agreement; and
WHEREAS, the Committee and the Board have determined that it would be in the best interest of the Company and its stockholders to grant this Option provided for herein to the Optionee as an incentive for increased efforts during his or her service with the Company or its Subsidiaries, have approved the grant of this Option on the Grant Date and have advised the Company thereof and instructed the undersigned officer to execute said Option.
NOW, THEREFORE, in consideration of the mutual covenants herein contained and other good and valuable consideration, receipt of which is hereby acknowledged, the parties hereto do hereby agree as follows:
ARTICLE I
OPTION GRANT
1.1.    Grant of Options.  For good and valuable consideration, as of the Grant Date, the Company grants to the Optionee a Nonqualified Stock Option to purchase the number of shares of Common Stock set forth above upon the terms and conditions set forth in this Agreement (this “Option”).
1.2    Exercise Price.  Subject to Section 2.1, the exercise price of the shares of Common Stock covered by this Option shall be the price per share set forth above without commission or other charge (which is the Fair Market Value per share of the Common Stock on the Grant Date).
ARTICLE II
ADJUSTMENTS
2.1.    Adjustments to Option.  In the event of a merger, statutory share exchange, reorganization, consolidation, recapitalization, dividend or distribution (whether in cash, shares or other property), stock split, reverse stock split, spin-off or similar transaction or other change in corporate structure affecting the Common Stock or the value thereof, such adjustments and other substitutions shall be made to this Option as the Committee, in its sole discretion, deems equitable or appropriate, including adjustments in the number, class, kind and exercise price of securities subject to this Option (including, if the Committee deems appropriate, the substitution of cash, similar options to purchase the shares of, or other awards denominated in the shares of, another company, or other property, as the Committee may determine to be appropriate in its sole discretion). Any of the foregoing adjustments may provide for the elimination of any fractional share.



ARTICLE III
PERIOD OF EXERCISABILITY
3.1.    Exercisability of Option.
(a)  This Option shall vest and become exercisable in accordance with the following vesting schedule: [_________________] (each anniversary, the “Vesting Date(s)”), so long as the Optionee continues to serve as an employee of the Company or any of its Subsidiaries through such dates. If the Optionee’s service as an employee terminates prior to the applicable Vesting Date, then the unvested portion of this Option shall terminate and shall not be exercisable.  If the Optionee’s service as an employee terminates after an applicable Vesting Date for any reason, then the vested portion of this Option shall continue to be exercisable for a period of ninety (90) days following the employee’s termination; provided, however, that if such termination is for Cause, the entire Option, whether vested or unvested, shall terminate and shall not be exercisable. Notwithstanding the foregoing, if the Optionee’s service as an employee terminates after the Grant Date and prior to the Vesting Date, the Committee shall have the discretion to vest all or any portion of this Option and all or any such portion so vested of this Option shall continue to be exercisable for a period of ninety (90) days following the employee’s termination (or, if earlier, until the tenth anniversary of the Grant Date (the “Expiration Date”)) or such later date as designated by the Committee (but, in no case later than the Expiration Date).
(b)  Notwithstanding (a), this Option shall become immediately vested and exercisable as to 100% of the shares of Common Stock subject to such Option if the Optionee ceases to be an employee due to Optionee’s death or Disability prior to the applicable Vesting Date.
3.2    Change in Control.  Upon a Change in Control, this Option shall be treated in accordance with the terms of Section 10.2 of the Plan.
3.3.    Expiration Date.  The Option may not be exercised after the first to occur of the following events and shall in no event be exercisable after the Expiration Date:
(a)  If, prior to the date when the Option first becomes exercisable, Optionee’s employment terminates for any reason or if Optionee’s employment is terminated for Cause, Optionee’s right to exercise the Option shall terminate and all rights thereunder shall cease; or
(b)  If, on or after the date when the Option first becomes exercisable, Optionee’s employment terminates for any reason, Optionee, or the person or persons to whom the Option shall have been transferred by will or the laws of descent and distribution, shall have the right, within three months after termination of employment, to exercise the Option to the extent that it was or became exercisable on the date of Optionee’s termination of employment, subject to any other limitation on the exercise of the Option in effect on the date of exercise; provided, however, that if such termination is for Cause, the entire Option, whether vested or unvested, shall terminate and shall not be exercisable.
ARTICLE IV
EXERCISE OF OPTION
4.1.    Person Eligible to Exercise.  During the lifetime of the Optionee, only the Optionee may exercise this Option or any portion thereof. After the death of the Optionee, any exercisable portion of this Option may, prior to the time when this Option becomes unexercisable under Section 3.3, be exercised by his or her personal representative or by any person empowered to do so under the Optionee’s will or under the then applicable laws of descent and distribution.
4.2.    Partial Exercise.  Any exercisable portion of this Option or the entire Option, if then wholly exercisable, may be exercised in whole or in part at any time (subject to any



Company trading window limitations) prior to the time when this Option becomes unexercisable under Section 3 of this Agreement; provided, however, that any partial exercise shall be for whole shares of Common Stock only.
4.3.    Manner of Exercise.  The exercise price for shares of Common Stock to be acquired upon exercise of this Option shall be paid in full in any manner permitted by the Plan.
4.4.    Conditions to Issuance of Stock.  The Company shall not be required to issue or deliver any stock purchased upon the exercise of this Option or portion thereof prior to fulfillment of all of the following conditions:
(a)    The obtaining of approval or other clearance from any state or federal governmental agency or Stock Exchange which the Committee shall, in its reasonable and good faith discretion, determine to be necessary or advisable; and
(b)    The receipt by the Company of such assurance of compliance with federal and state securities laws as it may deem necessary or advisable.
4.5.    Rights as Stockholder.  Optionee shall not be, nor have any of the rights or privileges of, a stockholder of the Company in respect of any shares purchasable upon the exercise of this Option or any portion thereof unless and until a certificate or certificates representing such shares shall have been issued by the Company to the Optionee or a book entry representing such shares has been made and such shares have been deposited with the appropriate registered book-entry custodian.  The Company shall not be liable to the Optionee for damages relating to any delay in issuing shares or a stock certificate to Optionee, any loss of a certificate, or any mistakes or errors in the issuance of shares or a certificate to Optionee.
4.6.    Withholding.  To the extent applicable, the Company shall have the right to withhold from Optionee’s compensation or to require Optionee to remit sufficient funds to satisfy applicable withholding tax obligations upon the exercise of this Option. Subject to the limitations in Section 11.5 of the Plan, Optionee may, in order to fulfill the withholding obligation, make payment to the Company in any manner permitted under Section 11.5 of the Plan and approval of the Board.  The Company shall not withhold from the exercise of this Option more shares than are necessary to meet the established tax withholding requirements of federal, state and local obligations and pay the exercise price of this Option.  The Company shall be authorized to take any such action as may be necessary, in the opinion of the Company’s counsel, to satisfy the Company’s obligations for payment of such taxes.
ARTICLE V
MISCELLANEOUS
5.1.    Option Not Transferable.  Neither this Option nor any interest or right therein or part thereof shall be liable for the debts, contracts or engagements of the Optionee or his or her successors in interest or shall be subject to disposition by transfer, alienation, anticipation, pledge, encumbrance, assignment or any other means whether such disposition be voluntary or involuntary or by operation of law by judgment, levy, attachment, garnishment or any other legal or equitable proceedings (including bankruptcy), and any attempted disposition thereof shall be null and void and of no effect; provided, however, that this Section 5.1 shall not prevent transfers by will or by the applicable laws of descent and distribution, or transfers to which the Committee has given prior written consent subject to the conditions set forth in Section 11.3(a) of the Plan.
5.2.    Notices.  Any notice to be given under the terms of this Agreement to the Company shall be addressed to the Company in care of its Secretary, and any notice to be given to the Optionee shall be addressed to him or her at the address stated in the Company’s records. By a notice given pursuant to this Section 5.2, either party may hereafter designate a different address



for notices to be given to the party. Any notice, which is required to be given to the Optionee, shall, if the Optionee is then deceased, be given to the Optionee’s personal representative if such representative has previously informed the Company of his or her status and address by written notice under this Section 5.2. Any notice shall have been deemed duly given when enclosed in a properly sealed envelope or wrapper addressed as aforesaid, deposited (with postage prepaid) in a post office or branch post office regularly maintained by the United States Postal Service or when delivered personally to the Secretary or Optionee.
5.3.    Amendment.  This Agreement may be amended only as provided herein or in the Plan.
5.4.    Governing Law.  The laws of the State of Delaware shall govern the interpretation, validity and performance of the terms of this Agreement regardless of the law that might be applied under principles of conflicts of laws.
5.5    No Guarantee of Employment.  Nothing in this Agreement or in the Plan shall confer upon the Optionee any right to continue in the employment or other service of the Company or any Subsidiary or shall interfere with or restrict in any way the rights of the Company and its Subsidiaries, which are hereby expressly reserved, to terminate the employment or other service of the Optionee at any time for any reason whatsoever, with or without Cause, subject to the applicable provisions of, if any, the Optionee’s employment agreement with the Company.
5.6    Plan Terms Control.  In the event of any conflict between the Plan and this Agreement, the terms of the Plan shall control, it being understood that variations in this Agreement from terms set forth in the Plan shall not be considered to be in conflict if the Plan permits such variations.
5.7    Clawback Policy.  This Agreement, the Option and any economic benefits recognized by Optionee in connection with the Option are subject to the Company’s Clawback Policy as provided in the Company’s Principles of Corporate Governance from time to time.
[Signatures on next page.]





IN WITNESS WHEREOF, the parties have executed this Agreement as of the Grant Date.
 
 ROCKWELL MEDICAL, INC.
  
  
 By: 
  Name: Mark Strobeck, Ph.D.
  Title:   President & CEO
  
  
 OPTIONEE:
  
 [Name]
 
image_01.jpg

EX-10.3 5 secondamendmenttoloanandse.htm EX-10.3 Document

SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT
THIS SECOND AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered into as of November 14, 2022 by and among INNOVATUS LIFE SCIENCES LENDING FUND I, LP, a Delaware limited partnership, as collateral agent (in such capacity, together with its successors and assigns in such capacity, “Collateral Agent”), and the Lenders listed on Schedule 1.1 hereof or otherwise a party hereto from time to time, and ROCKWELL MEDICAL, INC., a Delaware corporation (“Parent”) and ROCKWELL TRANSPORTATION, INC., a Michigan corporation and a wholly owned Subsidiary of Parent (“RTI”) (individually and collectively, jointly and severally, “Borrower”).
WHEREAS, Collateral Agent, Borrower and Lenders have entered into that certain Loan and Security Agreement, dated as of March 16, 2020 (as amended, supplemented or otherwise modified and in effect prior to this Amendment, the “Existing Loan Agreement”; as amended by this Amendment, the “Loan Agreement”) pursuant to which Lenders have provided to Borrower certain loans in accordance with the terms and conditions thereof; and
WHEREAS, Borrower, Lenders and Collateral Agent desire to amend certain provisions of the Existing Loan Agreement as provided herein and subject to the terms and conditions set forth herein;
NOW, THEREFORE, in consideration of the promises, covenants and agreements contained herein, and other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, Borrower, Lenders and Collateral Agent hereby agree as follows:
1.Capitalized terms used herein but not otherwise defined shall have the respective meanings given to them in the Loan Agreement.

2.Section 2.2(b) of the Existing Loan Agreement is hereby amended and restated as follows:

(b)    Repayment. Borrower shall make monthly payments of interest only commencing on the second (2nd) Payment Date following the Funding Date of any Term Loan, and continuing on the Payment Date of each successive month thereafter through and including the Payment Date immediately preceding the Amortization Date. Borrower agrees to pay, on the Funding Date of any Term Loan, any initial partial monthly interest payment otherwise due for the period between the Funding Date of such Term Loan and the first Payment Date after such Funding Date. Commencing on the Amortization Date, and continuing on the Payment Date of each month thereafter, Borrower shall make equal monthly payments of principal, together with applicable interest, in arrears, to each Lender, as calculated by Collateral Agent (which calculations shall be deemed correct absent manifest error) based upon: (1) the amount of such Lender’s Term Loan, (2) the effective rate of interest, as determined in Section 2.3(a), and (3) a repayment schedule equal to twenty (20) months, otherwise. Notwithstanding anything herein to the contrary, on November 1, 2022, in addition to interest payment, Borrower shall also make a principal payment in the amount of Five Hundred Thousand Dollars ($500,000) to the Lenders with respect to the Term Loans. All unpaid principal and accrued and unpaid interest with respect to the Term Loans is due and payable in full on the Maturity Date. The Term Loans may only be prepaid in accordance with Sections 2.2(c) and 2.2(d).

3.Section 2.2(d) of the Existing Loan Agreement is hereby amended and restated as follows:

(d)    Permitted Prepayment of Term Loan. After the first anniversary of the Effective Date, Borrower shall have the option to prepay all of the Term Loans advanced by the Lenders under this Agreement, provided Borrower (i) provides written notice to Collateral Agent of its election to prepay the Term Loans at least seven (7) Business Days prior to such prepayment, and (ii) pays to the Lenders on the date of such prepayment, payable to each Lender in accordance with its respective Pro Rata Share, an amount equal to the sum of (A) all outstanding principal of such Term Loans plus accrued and unpaid interest thereon through the prepayment date, (B) the Final Fee, (C) the Prepayment Fee, plus (D) all other Obligations that are due and payable, including, without limitation, Lenders’ Expenses and interest at the Default Rate with respect to any past due amounts.

Notwithstanding anything herein to the contrary, after the first anniversary of the Effective Date, Borrower shall also have the option to prepay part of Term Loans advanced by the Lenders under this Agreement, provided Borrower (i) provides written notice to Collateral Agent of its election to prepay the Term Loans at least seven (7) Business Days prior to such prepayment, (ii) prepays such part of the Term Loans in a principal amount of Five Million Dollars ($5,000,000.00) or a whole multiple of One Million Dollars
ACTIVE 682842814v4


($1,000,000.00) in excess thereof, and (iii) pays to the Lenders on the date of such prepayment, payable to each Lender in accordance with its respective Pro Rata Share, an amount equal to the sum of (A) the portion of outstanding principal of such Term Loans plus all accrued and unpaid interest thereon through the prepayment date, (B) the applicable Final Fee, and (C) all other Obligations that are then due and payable, including Lenders’ Expenses and interest at the Default Rate with respect to any past due amounts, and (D) the applicable Prepayment Fee with respect to the portion of such Term Loans being prepaid. For the purposes of clarity, any partial prepayment shall be applied pro-rata to all outstanding amounts under each Term Loan, and shall be applied pro-rata within each Term Loan tranche to reduce amortization payments under Section 2.2(b) on a pro-rata basis.

Furthermore, notwithstanding anything herein to the contrary, commencing on December 1, 2021, Borrower shall prepay an aggregate principal amount of Seven Million Five Hundred Thousand Dollars ($7,500,000.00) of the Term Loans advanced by the Lenders under this Agreement in ten consecutive equal monthly installments of Seven Hundred Fifty Thousand Dollars ($750,000.00) each, provided Borrower shall also pay to the Lenders on the date of each such prepayment, in accordance with its respective Pro Rata Share, an amount equal to the sum of all other Obligations that are then due and payable, including Lenders’ Expenses and interest at the Default Rate with respect to any past due amounts. No Prepayment Fee shall be due with respect to the prepayments made pursuant to this paragraph and the Final Fee with respect thereto shall be due and payable on the Maturity Date or the earliest of Maturity Date, the acceleration of any Term Loan or the earlier prepayment of all outstanding Term Loans pursuant to Section 2.2(c) or (d). For the purposes of clarity, all prepayments made pursuant to this paragraph shall be applied pro-rata to all outstanding amounts under each Term Loan, and shall be applied pro-rata within each Term Loan tranche to reduce amortization payments under Section 2.2(b) on a pro-rata basis.

Furthermore, notwithstanding anything herein to the contrary, on November 14, 2022, Borrower shall prepay an aggregate principal amount of Four Million Five Hundred Thousand Dollars ($4,500,000.00) of the Term Loans advanced by the Lenders under this Agreement, provided Borrower shall also pay to the Lenders on the date of such prepayment, in accordance with its respective Pro Rata Share, an amount equal to the sum of all other Obligations that are then due and payable, including Lenders’ Expenses and interest at the Default Rate with respect to any past due amounts. No Prepayment Fee shall be due with respect to the prepayments made pursuant to this paragraph and the Final Fee with respect thereto shall be due and payable on the Maturity Date or the earliest of Maturity Date, the acceleration of any Term Loan or the earlier prepayment of all outstanding Term Loans pursuant to Section 2.2(c) or (d). For the purposes of clarity, all prepayments made pursuant to this paragraph shall be applied pro-rata to all outstanding amounts under each Term Loan, and shall be applied pro-rata within each Term Loan tranche to reduce amortization payments under Section 2.2(b) on a pro-rata basis.


4.Section 6.12 of the Existing Loan Agreement is hereby amended and restated as follows:

6.12    Financial Covenant. Borrower shall achieve the following, as determined by Collateral Agent:

        (a)    As tested on September 30, 2020 (only if the Term B Loan has been funded hereunder prior to such date), and regardless of if and when the Term B Loan is funded, as tested on December 31, 2020, March 31, 2021 and June 30, 2021, actual consolidated revenue (as measured in accordance with GAAP) from the sale of Borrower’s product Triferic for the trailing twelve-month period (ended on the date when tested), in an amount not less than 72.50% of the projections for the same period as set forth in the Management Plan;

        (b)    As tested on September 30, 2022, December 31, 2022, March 31, 2023, June 30, 2023, September 30, 2023, December 31, 2023, March 31, 2024 and June 30, 2024, actual consolidated revenue (as measured in accordance with GAAP) from the sale and supply of Borrower’s hemodialysis products (a/k/a concentrate products) for the trailing six-month period (ended on the date when tested), in an amount not less than 85.00% of the projections for the same period as set forth in the Management Plan; and

        (c)    As tested on the last date of each quarter of beginning with the quarter ending September 30, 2024, actual consolidated revenue (as measured in accordance with GAAP) from the sale and supply of Borrower’s hemodialysis products (a/k/a concentrate products) for the trailing six-month period (ended on the date when tested), in an amount not less than 80.00% of the projections for the same period as set forth in the Management Plan.

    2
ACTIVE 682842814v4


5.Section 13 of the Existing Loan Agreement is hereby amended by amending and restating the definition of “Amortization Date” therein as follows:

Amortization Date” is September 1, 2023.
6.Annex X attached to the Existing Loan Agreement is hereby amended and restated as set forth on Annex X attached hereto.

7.Annex Y attached to the Existing Loan Agreement is hereby amended and restated as set forth on Annex Y attached hereto.

8.Collateral Agent and Lenders hereby consent to Borrower discontinuing its marketing, manufacture and/or sales of Borrower’s product Triferic in the United States and abandoning and/or discontinuing by Borrower of all Governmental Approvals (and applications for Governmental Approvals) related thereto.

9.Limitation of Amendment.

a.The amendments set forth above are effective for the purposes set forth herein and shall be limited precisely as written and shall not be deemed to (a) be a consent to any amendment, waiver or modification of any other term or condition of any Loan Document, or (b) otherwise prejudice any right, remedy or obligation which Lenders or Borrower may now have or may have in the future under or in connection with any Loan Document, as amended hereby.

b.This Amendment shall be construed in connection with and as part of the Loan Documents and all terms, conditions, representations, warranties, covenants and agreements set forth in the Loan Documents, are hereby ratified and confirmed and shall remain in full force and effect.

10.To induce Collateral Agent and Lenders to enter into this Amendment, Borrower hereby represents and warrants to Collateral Agent and Lenders as follows:

c.Immediately after giving effect to this Amendment (a) the representations and warranties contained in the Loan Documents are true, accurate and complete in all material respects as of the date hereof (except to the extent such representations and warranties relate to an earlier date, in which case they are true and correct as of such date), and (b) no Event of Default (other than the Existing Defaults) has occurred and is continuing;

d.Borrower has the power and due authority to execute and deliver this Amendment and to perform its obligations under the Loan Agreement;

e.The organizational documents of Borrower delivered to Collateral Agent on the Effective Date, and updated pursuant to subsequent deliveries by or on behalf of the Borrower to the Collateral Agent, remain true, accurate and complete and have not been amended, supplemented or restated and are and continue to be in full force and effect;

f.The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, do not contravene (i) any material law or regulation binding on or affecting Borrower, (ii) any material contractual restriction with a Person binding on Borrower, (iii) any material order, judgment or decree of any court or other governmental or public body or authority, or subdivision thereof, binding on Borrower, or (iv) the organizational documents of Borrower;

g.The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, do not require any order, consent, approval, license, authorization or validation of, or filing, recording or registration with, or exemption by any governmental or public body or authority, or subdivision thereof, binding on Borrower, except as already has been obtained or made; and

h.This Amendment has been duly executed and delivered by Borrower and is the binding obligation of Borrower, enforceable against Borrower in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, liquidation, moratorium
    3
ACTIVE 682842814v4


or other similar laws of general application and equitable principles relating to or affecting creditors’ rights.

11.Except as expressly set forth herein, the Loan Agreement shall continue in full force and effect without alteration or amendment. This Amendment and the Loan Documents represent the entire agreement about this subject matter and supersede prior negotiations or agreements.

12.The Borrower hereby remises, releases, acquits, satisfies and forever discharges the Lenders and Collateral Agent, their agents, employees, officers, directors, predecessors, attorneys and all others acting or purporting to act on behalf of or at the direction of the Lenders and Collateral Agent (“Releasees”), of and from any and all manner of actions, causes of action, suit, debts, accounts, covenants, contracts, controversies, agreements, variances, damages, judgments, claims and demands whatsoever, in law or in equity, which any of such parties ever had, now has or, to the extent arising from or in connection with any act, omission or state of facts taken or existing on or prior to the date hereof, may have after the date hereof against the Releasees, for, upon or by reason of any matter, cause or thing whatsoever relating to or arising out of the Loan Agreement or the other Loan Documents on or prior to the date hereof through the date hereof. Without limiting the generality of the foregoing, the Borrower waives and affirmatively agrees not to allege or otherwise pursue any defenses, affirmative defenses, counterclaims, claims, causes of action, setoffs or other rights they do, shall or may have as of the date hereof, including the rights to contest: (a) the right of Collateral Agent and each Lender to exercise its rights and remedies described in the Loan Documents; (b) any provision of this Amendment or the Loan Documents; or (c) any conduct of the Lenders or other Releasees relating to or arising out of the Loan Agreement or the other Loan Documents on or prior to the date hereof.

13.This Amendment shall be deemed effective as of the date first set forth above upon the due execution and delivery to Collateral Agent of this Amendment by each party hereto.

14.This Amendment may be executed in any number of counterparts, each of which shall be deemed an original, and all of which, taken together, shall constitute one and the same instrument.

15.This Amendment and the rights and obligations of the parties hereto shall be governed by and construed in accordance with the laws of the State of New York.


[Balance of Page Intentionally Left Blank]
    4
ACTIVE 682842814v4


IN WITNESS WHEREOF, the parties hereto have caused this Second Amendment to Loan and Security Agreement to be executed as of the date first set forth above.
BORROWER:

ROCKWELL MEDICAL, INC.


By     
Name:     
Title:     

BORROWER:

ROCKWELL TRANSPORTATION, INC.


By                        
Name:                        
Title:                        

COLLATERAL AGENT AND LENDER:

INNOVATUS LIFE SCIENCES LENDING FUND I, LP

By: Innovatus Life Sciences GP, LP
Its: General Partner

By     
Name:     
Title:     



ACTIVE 682842814v4



ANNEX X

Management Plan

image_0.jpg

ACTIVE 682842814v2
ACTIVE 682842814v4



ANNEX Y

LOAN INTEREST RATE AND PAYMENT OF PRINCIPAL
(Term Loan)
PLEASE SEE ATTACHED



ACTIVE 682842814v2
ACTIVE 682842814v4


image_1.jpg

ACTIVE 682842814v4
EX-31.1 6 rmti-20220930x10qex311.htm EX-31.1 Document

Exhibit 31.1
CERTIFICATION PURSUANT TO RULE 13a‑14(a)
I, Mark Strobeck, certify that:
1.have reviewed this quarterly report on Form 10‑Q of Rockwell Medical, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a‑15(e) and 15d‑15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a‑15(f) and 15d‑15(f)) for the registrant and have:
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date:November 14, 2022
/s/ Mark Strobeck
Mark Strobeck
Chief Executive Officer and Interim Financial Officer


EX-32.1 7 rmti-20220930x10qex321.htm EX-32.1 Document

EXHIBIT 32.1
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Rockwell Medical, Inc. (the “Company”) on Form 10‑Q for the quarter ending September 30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Periodic Report”), each of the undersigned, in the capacities and on the dates indicated below, hereby certifies pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that based on my knowledge:
1.the Periodic Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.the information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: November 14, 2022/s/ Mark Strobeck
Mark Strobeck
Chief Executive Officer and Interim Financial Officer

GRAPHIC 8 image_0.jpg GRAPHIC begin 644 image_0.jpg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end GRAPHIC 9 image_0a.jpg GRAPHIC begin 644 image_0a.jpg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end GRAPHIC 10 image_1.jpg GRAPHIC begin 644 image_1.jpg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�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�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�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�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end EX-101.SCH 11 rmti-20220930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - Description of Business link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Liquidity and Capital Resources link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Revenue Recognition link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Investments - Available-for-Sale link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Inventory link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Accrued Liabilities link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Deferred Revenue link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Stockholders’ Equity link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Licensing Agreements link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Loans and Security Agreement link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - Insurance Financing Note Payable link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Policies) link:presentationLink link:calculationLink link:definitionLink 0000025 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Tables) link:presentationLink link:calculationLink link:definitionLink 0000026 - Disclosure - Revenue Recognition (Tables) link:presentationLink link:calculationLink link:definitionLink 0000027 - Disclosure - Investments - Available-for-Sale (Tables) link:presentationLink link:calculationLink link:definitionLink 0000028 - Disclosure - Inventory (Tables) link:presentationLink link:calculationLink link:definitionLink 0000029 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 0000030 - Disclosure - Accrued Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 0000031 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 0000032 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 0000033 - Disclosure - Loans and Security Agreement (Tables) link:presentationLink link:calculationLink link:definitionLink 0000034 - Disclosure - Description of Business (Details) link:presentationLink link:calculationLink link:definitionLink 0000035 - Disclosure - Liquidity and Capital Resources (Details) link:presentationLink link:calculationLink link:definitionLink 0000036 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Details) link:presentationLink link:calculationLink link:definitionLink 0000037 - Disclosure - Revenue Recognition - Nature of Goods and Services (Details) link:presentationLink link:calculationLink link:definitionLink 0000038 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 0000039 - Disclosure - Revenue Recognition - Contract Balances (Details) link:presentationLink link:calculationLink link:definitionLink 0000040 - Disclosure - Revenue Recognition - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000041 - Disclosure - Investments - Available-for-Sale (Details) link:presentationLink link:calculationLink link:definitionLink 0000042 - Disclosure - Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 0000043 - Disclosure - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 0000044 - Disclosure - Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 0000045 - Disclosure - Deferred Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 0000046 - Disclosure - Stockholders’ Equity (Details) link:presentationLink link:calculationLink link:definitionLink 0000047 - Disclosure - Stock-Based Compensation - Share-Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 0000048 - Disclosure - Stock-Based Compensation - Restricted Stock Awards (Details) link:presentationLink link:calculationLink link:definitionLink 0000049 - Disclosure - Stock-Based Compensation - Service Based Restricted Stock Units (Details) link:presentationLink link:calculationLink link:definitionLink 0000050 - Disclosure - Stock-Based Compensation - Service Based Stock Options - Fair Value Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 0000051 - Disclosure - Stock-Based Compensation - Service Based Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 0000052 - Disclosure - Stock-Based Compensation - Service Based Stock Options - Others (Details) link:presentationLink link:calculationLink link:definitionLink 0000053 - Disclosure - Licensing Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 0000054 - Disclosure - Leases - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000055 - Disclosure - Leases - Summary of Lease Costs (Details) link:presentationLink link:calculationLink link:definitionLink 0000056 - Disclosure - Leases - Finance Lease and Operating Lease Maturities (Details) link:presentationLink link:calculationLink link:definitionLink 0000056 - Disclosure - Leases - Finance Lease and Operating Lease Maturities (Details) link:presentationLink link:calculationLink link:definitionLink 0000057 - Disclosure - Loans and Security Agreement - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000058 - Disclosure - Loans and Security Agreement - Schedule of Principal Payments on Term Loan (Details) link:presentationLink link:calculationLink link:definitionLink 0000059 - Disclosure - Insurance Financing Note Payable (Details) link:presentationLink link:calculationLink link:definitionLink 0000060 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 12 rmti-20220930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 13 rmti-20220930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 14 rmti-20220930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Inventory [Axis] Inventory [Axis] Ownership threshold Class of Warrant or Right, Ownership Threshold For Exercise Class of Warrant or Right, Ownership Threshold For Exercise Increase (Decrease) in Shareholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Total Lessee, Operating Lease, Liability, to be Paid Principal Payments Outstanding amount Long-Term Debt, Gross Entity Address, Postal Zip Code Entity Address, Postal Zip Code Drug product sales Drug Product Sales [Member] Drug Product Sales [Member] Facility sqft. Area of Real Estate Property Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Preferred shares, shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Preferred Stock, Shares Outstanding 2024 Long-Term Debt, Maturity, Year Two Proceeds from issuance of convertible preferred stock Proceeds from Issuance of Convertible Preferred Stock Debt Instrument [Axis] Debt Instrument [Axis] Finance lease liabilities Finance Lease, Liability Interest rate percentage Preferred Stock, Dividend Rate, Percentage Gross property and equipment Property, Plant and Equipment, Gross Additional Paid-in Capital Additional Paid in Capital Discount from stock price (dollars per share) Class of Warrant or Right, Purchase Price, Discount From Stock Price Per Share Class of Warrant or Right, Purchase Price, Discount From Stock Price Per Share Insurance Financing Note Payable Short-Term Debt [Text Block] Interest rate, additional percentage added to base percentage Debt Instrument, Basis Spread on Variable Rate Year ending December 31, 2026 Finance Lease, Liability, to be Paid, Year Four Range [Domain] Statistical Measurement [Domain] Depreciation expense Depreciation Vesting of Restricted Stock Units Issued, net of taxes withheld (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Short-term Debt, Type [Axis] Short-Term Debt, Type [Axis] Interest rate, base percentage Debt Instrument, Interest Rate, Stated Percentage Weighted-average discount rate – operating leases Operating Lease, Weighted Average Discount Rate, Percent Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Customers average payment term Average Payment Term of Customers Represents the average payment term of customers. Exercise price (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price Payments on Debt Repayments of Debt Year ending December 31, 2025 Finance Lease, Liability, to be Paid, Year Three Net Loss Net Loss Net Income (Loss) Attributable to Parent Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Net Earnings per Share Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Securities excluded from diluted loss per share calculation (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Leases Lessee, Finance Leases [Text Block] Year ending December 31, 2022 (remaining) Finance Lease, Liability, to be Paid, Remainder of Fiscal Year Remaining future payments Lessee, Operating Lease, Liability, To Be Paid, After Year Four Lessee, Operating Lease, Liability, To Be Paid, After Year Four Schedule of Principal Payments on Term Loan Schedule of Maturities of Long-Term Debt [Table Text Block] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Operating Lessee, Operating Lease, Liability, to be Paid [Abstract] Equity Component [Domain] Equity Component [Domain] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Maximum working capital line Preferred Stock, Convertible, Debt Financing Limitations, Maximum Working Capital Line Preferred Stock, Convertible, Debt Financing Limitations, Maximum Working Capital Line Leases Lessee, Operating Leases [Text Block] Accrued Research & Development Expense Research and Development Related Liabilities, Current Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Closing costs Payments of Financing Costs Amortization of right-of-use assets Finance Lease, Right-of-Use Asset, Amortization Warrant exercise price calculation, period immediately preceding relevant funding, number of trading days Class Of Warrant Or Right, Exercise Price Calculation, Period Immediately Preceding Relevant Funding, Trading Days Class Of Warrant Or Right, Exercise Price Calculation, Period Immediately Preceding Relevant Funding, Trading Days Wanbang Biopharmaceutical Wanbang Biopharmaceutical [Member] Represents exclusive licensing and manufacturing supply agreements with Wanbang Biopharmaceutical Co., Ltd. (“Wanbang”) for the rights to commercialize the Triferic and Calcitriol drugs. Registered Direct Offering Warrants Registered Direct Offering Warrants [Member] Registered Direct Offering Warrants Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Increase in Inventory Reserves Inventory, LIFO Reserve, Period Charge Contract assets Contract with Customer, Asset, after Allowance for Credit Loss Total Current And Non Current Inventory Represents the amount of current and non-current inventory. Lease Liability - Current Operating Lease And Finance Lease, Liability, Current Operating Lease And Finance Lease, Liability, Current Supplemental Disclosure of Cash Flow Information: Supplemental Cash Flow Information [Abstract] Forfeited (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Performance based awards Performance Based Awards [Member] Represents information pertaining to performance based awards. Unrecognized stock-based compensation expense Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Triferic Inventory Triferic Inventory [Member] Triferic Inventory [Member] Year ending December 31, 2022 (remaining) Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Statement [Line Items] Statement of Cash Flows [Abstract] Common Stock, $0.0001 par value; 170,000,000 shares authorized; 11,152,673 and 8,544,225 shares issued and outstanding at September 30, 2022 and December 31, 2021 Common Stock, Value, Outstanding Entity Address, State or Province Entity Address, State or Province Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Distributors average payment term Average Payment Term of Distributors Represents the average payment term of distributors. Deferred Revenue Arrangement, by Type [Table] Deferred Revenue Arrangement, by Type [Table] Baxter Healthcare Organization Baxter Healthcare Organization [Member] Baxter Healthcare Organization [Member] Award Type [Axis] Award Type [Axis] Cash Used In Operating Activities Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Expired (in shares) Expirations (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Investments Available-for-Sale Debt Securities, Available-for-Sale [Table Text Block] Other information Lease, Cost [Abstract] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Forfeited (in shares) Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Term Loan, Net of Issuance Costs Long-Term Debt, Excluding Current Maturities Total Liabilities Liabilities Conversion price (per share) Preferred Stock, Convertible, Conversion Price Period for which company is entitled to make interest-only payments Debt Instrument, Period Of Interest-Only Payments Debt Instrument, Period Of Interest-Only Payments Weighted-average remaining lease term – operating leases Operating Lease, Weighted Average Remaining Lease Term Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Stock option awards Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Geographical [Axis] Geographical [Axis] Cash Flows From Investing Activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Issuance of stock, net of offering costs (in dollars) Stock Issued During Period, Value, New Issues Entity Common Stock, Shares Outstanding (in shares) Entity Common Stock, Shares Outstanding Schedule of Major Classes of Property and Equipment Property, Plant and Equipment [Table Text Block] Fair Value Debt Securities, Available-for-Sale, Current Preferred shares, shares issued (in shares) Preferred Stock, Shares Issued Document Type Document Type Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Product Sales – Point-in-time Transferred at Point in Time [Member] Realized Gain on Investments Realized (Gain) Loss on Sale of Investments Available-for-Sale Debt Securities, Available-for-Sale, Realized Gain (Loss) Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Customer Deposits Contract with Customer, Refund Liability, Current Unvested at beginning of period (in dollars per share) Unvested at end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Loans and Security Agreement Debt Disclosure [Text Block] Finance Finance Lease, Liability, to be Paid [Abstract] Product and Service [Domain] Product and Service [Domain] Right of Use Assets, net Operating lease and finance lease, right of use assets, net Operating Lease And Finance Lease, Right of Use Assets, Net Operating Lease And Finance Lease, Right of Use Assets, Net Entity Shell Company Entity Shell Company Calculation for number of shares of common stock able to be purchased by warrant, percentage of principal amount of relevant term loan funded funded Class Of Warrant Or Right, Calculation For Number Of Securities Called By Warrants Or Right, Numerator, Percentage Of Principal Amount Of Debt Instrument Funded Class Of Warrant Or Right, Calculation For Number Of Securities Called By Warrants Or Right, Numerator, Percentage Of Principal Amount Of Debt Instrument Funded Percentage of investment owned Preferred Stock, Convertible, Debt Financing Limitations, Percentage of Investment Owned Preferred Stock, Convertible, Debt Financing Limitations, Percentage of Investment Owned Year ending December 31, 2023 Lessee, Operating Lease, Liability, to be Paid, Year One Term loan Medium-term Notes [Member] Gross proceeds Proceeds from Warrant Exercises 2025 Long-Term Debt, Maturity, Year Three Subsequent event Subsequent Event [Member] Contract Balances Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Document Period End Date Document Period End Date Lease Liability - Long-Term Operating Lease And Finance Lease, Liability, Noncurrent Operating Lease And Finance Lease, Liability, Noncurrent Share Issuance Axis [Domain] Share Issuance Axis [Domain] Share Issuance Axis [Domain] Wixom, Michigan Property One Wixom, Michigan Property One [Member] Wixom, Michigan Property One [Member] Preferred stock conversion to common stock Convertible Preferred Stock [Member] Total Assets Assets Debt Disclosure [Abstract] Debt Disclosure [Abstract] Master Services And Ip Agreement Master Services And Ip Agreement [Member] Represents information pertaining to Master services and Ip agreements. Change in Unrealized Loss on Marketable Securities Available-for-Sale OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax Antidilutive Securities [Axis] Antidilutive Securities [Axis] Weighted Average Remaining Contractual Term Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract] NA Accrued Liabilities Total Accrued Liabilities Accrued Liabilities, Current Term loan, third tranche Term Loan, Tranche Three [Member] Term Loan, Tranche Three [Member] Term Loan - Net of Issuance Costs Long-Term Debt, Current Maturities Cash Provided by (Used In) Financing Activities Net Cash Provided by (Used in) Financing Activities Accounting Policies [Abstract] Accounting Policies [Abstract] Interest expense Interest Expense, Debt Accrued Compensation and Benefits Employee-related Liabilities, Current Variable lease cost Variable Lease, Cost Upfront payment Revenue Recognition Received The amount of consideration received during the period for the milestone. Stockholders’ Equity: Stockholders' Equity Attributable to Parent [Abstract] Prepaid and Other Current Assets Prepaid Expense and Other Assets, Current Amortization of Debt Financing Costs and Accretion of Debt Discount Amortization of Debt Issuance Costs and Discounts Schedule of Stock Option Assumptions Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Decrease in Lease Liability Increase (Decrease) in Operating Lease Liability Equity Award [Domain] Award Type [Domain] Number of shares of common stock for which warrant is exercisable (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Unrecognized stock-based compensation expense, weighted average remaining term (in years) (less than) Unrecognized stock-based compensation expense, weighted average remaining term (in years) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Exercisable at end of the period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Gross Profit (Loss) Gross Profit Net Sales Net Revenue Revenue from Contract with Customer, Including Assessed Tax Entity Registrant Name Entity Registrant Name Convertible preferred stock (in shares) Preferred Stock, Convertible, Conversion Ratio Issuance of stock, net of offering costs (in shares) Stock Issued During Period, Shares, New Issues Triferic API Triferic API [Member] Triferic API [Member] Subsequent Events Subsequent Events [Text Block] Outstanding common stock, percentage Preferred Stock, Convertible, Ownership Limitation, Outstanding Common Stock, Percentage Preferred Stock, Convertible, Ownership Limitation, Outstanding Common Stock, Percentage Entity Address, City or Town Entity Address, City or Town Leases [Abstract] Leases [Abstract] Vesting of Restricted Stock Units Issued, net of taxes withheld Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Net draw down proceeds Proceeds from Debt, Net of Issuance Costs Minimum Minimum [Member] Stock option awards - service based awards Service Based Stock Option Awards [Member] na Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Common shares, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Raw Materials Inventory, Raw Materials, Net of Reserves Da Vita Healthcare Partners Inc Da Vita Healthcare Partners Inc [Member] Represents information pertaining to the DaVita Healthcare Partners, Inc., one of the key customers of the entity. Trading Symbol Trading Symbol Entity File Number Entity File Number Concentrates Products Concentrate Products [Member] Concentrate Products [Member] Deferred License Revenue - Long-Term Contract with Customer, Liability, Noncurrent Liquidity and Capital Resources Liquidity And Financial Condition [Text Block] The entire disclosure of liquidity position and financial conditions. Research and Product Development Research and Development Expense Minimum cash covenant Agreement Covenant, Minimum Cash Agreement Covenant, Minimum Cash Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Unvested restricted stock units Restricted Stock Units (RSUs) [Member] Sun Pharma Agreements Sun Pharma Agreements [Member] Sun Pharma Agreements [Member] Laboratory Equipment Other Machinery and Equipment [Member] Use of Estimates Use of Estimates, Policy [Policy Text Block] Share Issuance, Tranche Two Share Issuance, Tranche Two [Member] Share Issuance, Tranche Two Other (Expense) Income Other Nonoperating Income (Expense) [Abstract] (Decrease) Increase in Accounts Payable Increase (Decrease) in Accounts Payable Subsequent Events [Abstract] Subsequent Events [Abstract] Expected stock price volatility, maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Controlled Equity Offering Controlled Equity Offering [Member] Controlled Equity Offering Interest Income Investment Income, Net Number of additional agreements Number of additional agreements Represents the number of additional agreements. Reserve for returns Contract with Customer, Refund Liability Finished Goods Inventory, Finished Goods, Net of Reserves Preferred Stock, $0.0001 par value, 2,000,000 shares authorized; 15,000 and nil shares issued and outstanding at September 30, 2022 and December 31, 2021 Preferred Stock, Value, Outstanding Exercise price of warrant (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Cash Paid for Interest Interest Paid, Excluding Capitalized Interest, Operating Activities Basic Net Loss per Share (in dollars per share) Earnings Per Share, Basic Restricted stock units - service based awards Restricted stock units - service based awards Service Based Restricted Stock Units [Member] na Year ending December 31, 2025 Lessee, Operating Lease, Liability, to be Paid, Year Three Finance lease expense Finance Lease, Expense Finance Lease, Expense Cantor Fitzgerald & Co Cantor Fitzgerald & Co [Member] Cantor Fitzgerald & Co Counterparty Name [Domain] Counterparty Name [Domain] Selling and Marketing Selling and Marketing Expense Total Stockholders’ Equity Beginning balance Ending balance Stockholders' Equity Attributable to Parent Right of use assets exchanged for finance lease liabilities Right-of-Use Asset Obtained in Exchange for Finance Lease Liability Forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Entity Interactive Data Current Entity Interactive Data Current Number of shares issued Sale of Stock, Number of Shares Issued in Transaction Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, before Allowance for Credit Loss, Current Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Changes in Assets and Liabilities: Increase (Decrease) in Operating Capital [Abstract] Sale of Investments Available-for-Sale Proceeds from Sale of Debt Securities, Available-for-Sale ACCUMULATED DEFICIT Retained Earnings [Member] Unrecognized stock-based compensation expenses Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Total rent expense Lease, Cost COMMON STOCK Common Stock [Member] Schedule of Total Stock-Based Compensation Expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Repurchase of Common Stock to Pay Employee Withholding Taxes Repurchase Of Common Shares To Pay Employee Withholding Taxes Repurchase of common shares to pay employee withholding taxes. Summary of Lease Costs Lease, Cost [Table Text Block] Changes in Assets and Liabilities Increase (Decrease) in Operating Capital Class of Stock [Axis] Class of Stock [Axis] Statement [Table] Statement [Table] Cash, cash equivalents and investments available-for-sale Cash, Cash Equivalents, and Short-Term Investments Effective interest rate Debt Instrument, Interest Rate, Effective Percentage Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Document Quarterly Report Document Quarterly Report Series X Convertible Preferred Stock Series X Convertible Preferred Stock [Member] Series X Convertible Preferred Stock Operating leases Operating Lease, Liability [Abstract] Statistical Measurement [Axis] Statistical Measurement [Axis] Deferred Revenue Arrangement [Line Items] Deferred Revenue Arrangement [Line Items] Leasehold Improvements Leasehold Improvements [Member] Accumulated Deficit Retained Earnings (Accumulated Deficit) Accounts Receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Equity Components [Axis] Equity Components [Axis] Number of monthly installments Debt Instrument, Number of Monthly Installments Debt Instrument, Number of Monthly Installments Restricted stock awards - performance based awards Performance Based Restricted Stock Awards [Member] na Exercisable at end of the period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Minimum principal amount pursuant to liquidity covenant Debt Instrument, Covenant, Minimum Principal Amount Pursuant to Liquidity Covenant Debt Instrument, Covenant, Minimum Principal Amount Pursuant to Liquidity Covenant Timing of Transfer of Good or Service [Axis] Timing of Transfer of Good or Service [Axis] Expired (in dollar per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Document Fiscal Year Focus Document Fiscal Year Focus Cash Flows From Operating Activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Statement [Line Items] Statement [Line Items] Financing cash flows from finance leases Finance Lease, Principal Payments Unvested at beginning of period (in shares) Unvested at end of period (in shares) Unvested, number of shares (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Operating lease, right of use assets Operating Lease, Right-of-Use Asset Unrealized Loss Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax ACCUMULATED OTHER COMPREHENSIVE INCOME AOCI Attributable to Parent [Member] Accrued Unvouchered Receipts Accrued Unvouchered Receipts, Current Accrued Unvouchered Receipts, Current Operating lease expense Operating Lease, Expense Document Transition Report Document Transition Report Local Phone Number Local Phone Number Accrued Interest Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss, Current Schedule of Stock Options Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Operating Loss Operating Income (Loss) Increase in Inventory Increase (Decrease) in Inventories Proceeds from sale of equity, net Proceeds from Issuance or Sale of Equity, Net of Issuance Cost Proceeds from Issuance or Sale of Equity, Net of Issuance Cost Adoption of Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Decrease in Prepaid and Other Assets Increase (Decrease) in Prepaid Expense and Other Assets Common shares, shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding Goodwill Goodwill Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Insurance Financing Note Payable Notes Payable Name of Property [Domain] Name of Property [Domain] Adjustments To Reconcile Net Loss To Net Cash Used In Operating Activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Geographical [Domain] Geographical [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Liquidity and Capital Resources Liquidity and Going Concern Considerations [Abstract] No definition available. Preferred shares, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Year ending December 31, 2026 Lessee, Operating Lease, Liability, to be Paid, Year Four Income Statement [Abstract] Income Statement [Abstract] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Jeil Pharma Agreements Jeil Pharma Agreements [Member] Jeil Pharma Agreements ADDITIONAL PAID-IN CAPITAL Additional Paid-in Capital [Member] Document Fiscal Period Focus Document Fiscal Period Focus Sale of stock, aggregate consideration authorized Sale Of Stock, Aggregate Consideration Authorized Sale Of Stock, Aggregate Consideration Authorized Cost of Sales Cost of Goods and Services Sold Diluted Weighted Average Shares Outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted Expected stock price volatility, minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Accumulated Depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Schedule Components of Inventory Schedule of Inventory, Current [Table Text Block] Term (years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Drug products Drug Revenue [Member] Drug Revenue [Member] Service based awards Service Based Awards [Member] Represents information pertaining to service based awards. Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] PREFERRED STOCK Preferred Stock [Member] Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Short-term Debt [Line Items] Short-Term Debt [Line Items] Summary of Potentially Dilutive Securities Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Exercisable at end of the period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Short-term lease rent expense Short-Term Lease, Cost Private Placement Private Placement [Member] Preferred shares, shares authorized (in shares) Preferred Stock, Shares Authorized Wixom, Michigan Property Two Wixom, Michigan Property Two [Member] Wixom, Michigan Property Two [Member] Impairment losses Contract with Customer, Asset, Credit Loss Expense (Reversal) Cash and Cash Equivalents at Beginning of Period Cash and Cash Equivalents at End of Period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Foreign Currency Translation Adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Aggregate Intrinsic Value Aggregate intrinsic Value NA Common shares, shares issued (in shares) Common Stock, Shares, Issued Deferred License Revenue - Current Contract with Customer, Liability, Current Interest on lease obligations Finance Lease, Interest Expense Foreign Currency Translation Adjustment Foreign Currency Transaction Gain (Loss), before Tax License Fee – Over time Transferred over Time [Member] Amendment Flag Amendment Flag Cash Used In Investing Activities Net Cash Provided by (Used in) Investing Activities Operating lease cost Operating Lease, Cost Aggregate principal amount Short-term note payable Debt Instrument, Face Amount Finance leases Finance Lease, Liability [Abstract] Comprehensive Loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Proceeds from the Issuance of Common Stock for payment related to services provided Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised Unrealized Gain Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax PIPE Purchase Agreement Warrant PIPE Purchase Agreement Warrant [Member] PIPE Purchase Agreement Warrant Deferred Revenue Contract with Customer Deferred Revenue [Text Block] Contract with Customer Deferred Revenue [Text Block] Entity Current Reporting Status Entity Current Reporting Status Other Non-Current Assets Other Assets, Noncurrent Exercisable at end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Year ending December 31, 2023 Finance Lease, Liability, to be Paid, Year One Depreciation and Amortization Depreciation, Depletion and Amortization Weighted-average selling price (dollars per share) Sale of Stock, Weighted-Average Selling Price Per Share Sale of Stock, Weighted-Average Selling Price Per Share Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Payments on Short Term Note Payable Repayments of Notes Payable At-the-Market Offering At-The-Market Offering [Member] At-The-market Offering [Member] Number of distribution and license agreements Number of Distribution and License Agreements Represents the number of distribution and license agreements. Lease term Lessee, Operating Lease, Term of Contract Counterparty Name [Axis] Counterparty Name [Axis] Share Issuance Axis [Axis] Share Issuance Axis [Axis] Share Issuance Axis Unamortized issuance costs and unaccreted discount Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Outstanding at the beginning of the period (in shares) Outstanding at the end of the period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Liquidity and Going Concern Considerations [Table] Liquidity and Going Concern Considerations [Table] Liquidity and Capital Resources [Table] Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Year ending December 31, 2024 Finance Lease, Liability, to be Paid, Year Two Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Useful life Inventory, Raw Materials, Useful Life Inventory, Raw Materials, Useful Life Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Property and Equipment, net Property and Equipment, net Property, Plant and Equipment, Net Operating cash flows from operating leases Operating Lease, Payments Information Technology & Office Equipment Office Equipment [Member] Options to purchase common stock Share-Based Payment Arrangement, Option [Member] Operating lease and finance lease liabilities Operating Lease And Finance Lease, Liability Operating Lease And Finance Lease, Liability Stock option awards - performance based awards Performance Based Stock Option Awards [Member] na Wixom, Michigan MICHIGAN Outstanding balance, net of unamortized issuance costs and unaccreted discount Long-Term Debt Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Total Other Expense Other Nonoperating Income (Expense) Unrealized Gain (Loss) on Available-for-Sale Debt Instrument Investments Unrealized Gain (Loss) on Available-for-Sale Investments OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Common stock trading price (in dollars per share) Sale of Stock, Price Per Share Common shares, shares authorized (in shares) Common Stock, Shares Authorized Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Maximum Maximum [Member] Accumulated Other Comprehensive Income Accumulated Other Comprehensive Income (Loss), Net of Tax Inventory [Domain] Inventory [Domain] Cash and Cash Equivalents Cash and Cash Equivalents, at Carrying Value Warrant exercise price calculation, period immediately preceding execution of loan agreement, number of trading days Class Of Warrant Or Right, Exercise Price Calculation, Period Immediately Preceding Execution Of Agreement, Trading Days Class Of Warrant Or Right, Exercise Price Calculation, Period Immediately Preceding Execution Of Agreement, Trading Days Decrease in Deferred License Revenue Increase (Decrease) in Contract with Customer, Liability Total Current Assets Assets, Current Recognized deferred revenue Contract with Customer, Liability, Revenue Recognized Entity Small Business Entity Small Business Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] Amortization of Right of Use Asset Operating Lease, Right-of-Use Asset, Amortization Expense Hackensack, New Jersey NEW JERSEY Reverse Stock Split Stockholders' Equity, Policy [Policy Text Block] Purchase of Investments Available-for-Sale Payments to Acquire Debt Securities, Available-for-Sale Accrued Workers Compensation Workers' Compensation Liability, Current Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements Significant Accounting Policies [Text Block] Granted Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term 2 Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term 2 Shares Underlying Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Property and Equipment Property, Plant and Equipment Disclosure [Text Block] Term loan, first tranche Term Loan, Tranche One [Member] Term Loan, Tranche One [Member] Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Increase in Accounts Receivable, net Increase (Decrease) in Accounts Receivable Title of 12(b) Security Title of 12(b) Security Description of Business Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Collaborative arrangement, accrued reimbursement of IP expenses and sublicense royalty fees Collaborative Arrangement, Accrued Reimbursement of IP Expenses And Sublicense Royalty Fees Collaborative Arrangement, Accrued Reimbursement of IP Expenses And Sublicense Royalty Fees Payables and Accruals [Abstract] Payables and Accruals [Abstract] Subsequent Event [Line Items] Subsequent Event [Line Items] Debt Instrument [Line Items] Debt Instrument [Line Items] Class of Stock [Line Items] Class of Stock [Line Items] Stock-based Compensation (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Operating lease liabilities Operating Lease, Liability Total Finance Lease, Liability, to be Paid Prepayment premium percentage Debt Instrument, Prepayment Premium, Percent Debt Instrument, Prepayment Premium, Percent Receivables, which are included in "Trade and other receivables" Other Receivables Finance Lease Maturities Finance Lease, Liability, Fiscal Year Maturity [Table Text Block] Investments, Debt and Equity Securities [Abstract] Investments, Debt and Equity Securities [Abstract] LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 2022 Long-Term Debt, Maturity, Remainder of Fiscal Year Concentrates product sales Concentrate Product Sales [Member] Concentrate Product Sales [Member] Consideration received Sale of Stock, Consideration Received on Transaction Inventory, net Inventory, Net Accounts Payable Accounts Payable, Current Additional debt discount recognized Debt Instrument, Unamortized Discount Warrants to purchase common stock Warrant [Member] Entity Filer Category Entity Filer Category Proceeds from the Issuance of Common Stock Proceeds from the issuance of common stock Proceeds from Issuance of Common Stock Basic Weighted Average Shares Outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic U.S. UNITED STATES Total share based compensation expense Stock based compensation expenses Share-Based Payment Arrangement, Expense Supplemental Disclosure of Noncash Investing and Financing Activities: Noncash Investing and Financing Items [Abstract] Term of agreement Revenue, Performance Obligation, Term Revenue, Performance Obligation, Term Security Exchange Name Security Exchange Name Outstanding at the beginning of the period (in dollars per share) Outstanding at the end of the period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] (Gain) Loss on Disposal of Assets Gain (Loss) on Disposition of Assets Warrants excercised Class of Warrant or Right, Number Of Warrants Exercised Class of Warrant or Right, Number Of Warrants Exercised Public Offering Public Offering [Member] Public Offering [Member] Restricted stock awards Unvested restricted stock awards Restricted Stock [Member] Property and equipment Property, Plant and Equipment [Line Items] Concentrates product license fee Concentrate Product License Fee [Member] Concentrate Product License Fee [Member] Short-term Debt, Type [Domain] Short-Term Debt, Type [Domain] Greer, South Carolina SOUTH CAROLINA Cover [Abstract] Cover [Abstract] Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Leases Lessee, Leases [Policy Text Block] Stock-Based Compensation Share-Based Payment Arrangement [Text Block] Work in Process Inventory, Work in Process, Net of Reserves Weighted-average discount rate – finance leases Finance Lease, Weighted Average Discount Rate, Percent Revenue Recognition Revenue from Contract with Customer [Text Block] Share Issuance, Tranche One Share Issuance, Tranche One [Member] Share Issuance, Tranche One Offering Costs from the Issuance of Preferred Stock Payments of Stock Issuance Costs, Preferred Stock Payments of Stock Issuance Costs, Preferred Stock Total Liabilities and Stockholders’ Equity Liabilities and Equity Amortization period (in months) Debt Instrument, Term Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Timing of Transfer of Good or Service [Domain] Timing of Transfer of Good or Service [Domain] Common stock trading period Preferred Stock, Dividend, Cease Upon Common Stock Price, Trading Days Preferred Stock, Dividend, Cease Upon Common Stock Price, Trading Days Rest of World Non-US [Member] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Current Fiscal Year End Date Current Fiscal Year End Date Accrued Liabilities Accounts Payable and Accrued Liabilities Disclosure [Text Block] Less present value discount Lessee, Operating Lease, Liability, Undiscounted Excess Amount Diluted Net Loss per Share (in dollars per share) Earnings Per Share, Diluted Inventory [Line Items] Inventory [Line Items] Sale of Stock [Domain] Sale of Stock [Domain] Reverse stock split Stockholders' Equity Note, Stock Split, Conversion Ratio Vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Offering Costs from the Issuance of Common Stock Stock issuance costs Payments of Stock Issuance Costs Total Current Liabilities Liabilities, Current Risk-free interest rate, minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Year ending December 31, 2024 Lessee, Operating Lease, Liability, to be Paid, Year Two Inventory, Current [Table] Inventory, Current [Table] Schedule of Restricted Stock Awards Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Term loan Term Loan [Member] Term Loan [Member] Issued shares for services (in shares) Stock Issued During Period, Shares, Issued for Services Revenue performance obligation Revenue, Remaining Performance Obligation, Amount Risk-free interest rate, maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Proceeds from the Issuance of Preferred Stock Proceeds from Issuance of Preferred Stock and Preference Stock Operating Lease Maturities Lessee, Operating Lease, Liability, Maturity [Table Text Block] Entity Address, Address Line One Entity Address, Address Line One Investments - Available-for-Sale Investments in Debt and Equity Instruments, Cash and Cash Equivalents, Unrealized and Realized Gains (Losses) [Text Block] Contract liabilities Deferred revenue Contract with Customer, Liability Purchase of Equipment Payments to Acquire Machinery and Equipment Product and Service [Axis] Product and Service [Axis] Class of Stock [Domain] Class of Stock [Domain] Weighted-average remaining lease term – finance leases Finance Lease, Weighted Average Remaining Lease Term PIPE Purchase Agreement Pre-Funded Warrant PIPE Purchase Agreement Pre-Funded Warrant [Member] PIPE Purchase Agreement Pre-Funded Warrant Interest Expense Interest Expense Drug license fee Drug License Fee [Member] Drug License Fee [Member] Inventory, Non-Current Inventory, noncurrent Inventory, Noncurrent Schedule of Accrued Liabilities Schedule of Accrued Liabilities [Table Text Block] Inventory Inventory Disclosure [Text Block] Equity [Abstract] Equity [Abstract] Machinery and Equipment Machinery and Equipment [Member] Subsequent Event [Table] Subsequent Event [Table] Revenue Recognition [Table] Revenue Recognition [Table] Revenue Recognition [Table] Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Proceeds from issuance of warrants Proceeds from Issuance of Warrants Outstanding common stock, not to exceed, percentage Preferred Stock, Convertible, Ownership Limitations, Outstanding Common Stock, Not to Exceed, Percentage Preferred Stock, Convertible, Ownership Limitations, Outstanding Common Stock, Not to Exceed, Percentage Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Entity Tax Identification Number Entity Tax Identification Number Term loan, second tranche Term Loan, Tranche Two [Member] Term Loan, Tranche Two [Member] Schedule of Short-term Debt [Table] Schedule of Short-Term Debt [Table] Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Stock-based Compensation and modification expense APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition Number of facilities Number Of Facilities Number Of Facilities Initial interest rate percentage Debt Instrument, Interest Rate During Period Operating cash flows from finance leases Finance Lease, Interest Payment on Liability Decrease in Cash and Cash Equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Option to add interest rate amount to outstanding principal balance in lieu of paying such amount in cash, percentage Debt Instrument, Option To Add Interest Rate Amount To Outstanding Principal Balance In Lieu Of Payment, Percentage Debt Instrument, Option To Add Interest Rate Amount To Outstanding Principal Balance In Lieu Of Payment, Percentage Revenue Recognition [Line Items] Revenue Recognition [Line Items] Revenue Recognition [Line Items] Entity Central Index Key Entity Central Index Key Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Warrant price (dollars per share) Class of Warrant or Right, Purchase Price Class of Warrant or Right, Purchase Price Weighted Average Grant-Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Name of Property [Axis] Name of Property [Axis] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Licensing Agreements Collaborative Arrangement Disclosure [Text Block] Other Accrued Liabilities Other Accrued Liabilities, Current Term loan, second and third tranches Term Loan, Tranche Two And Tranche Three [Member] Term Loan, Tranche Two And Tranche Three [Member] Common stock trading price (per share) Preferred Stock, Dividend, Cease Upon Common Stock Price, Threshold Preferred Stock, Dividend, Cease Upon Common Stock Price, Threshold City Area Code City Area Code Milestone payments Asset Acquisition Milestone Payments Represents the amount of milestone payments related to asset acquisition. General and Administrative General and Administrative Expense ASSETS Assets [Abstract] Registered Direct Offering Registered Direct Offering [Member] Registered Direct Offering Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Remaining future payments Finance Lease, Liability, To Be Paid, After Year Four Finance Lease, Liability, To Be Paid, After Year Four Liquidity and Going Concern Considerations [Line Items] Liquidity and Going Concern Considerations [Line Items] Liquidity and Capital Resources [Line Items] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Notes Payable to Banks Notes Payable to Banks [Member] Sale of Stock [Axis] Sale of Stock [Axis] Working capital Working Capital Net Represents the monetary amount of working capital, as of the indicated date. Minimum liquidity floor Debt Instrument, Covenant, Minimum Liquidity Floor Debt Instrument, Covenant, Minimum Liquidity Floor Cash Flows From Financing Activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Loss Per Share Earnings Per Share, Policy [Policy Text Block] 2023 Long-Term Debt, Maturity, Year One Stock-based Compensation Share-Based Payment Arrangement, Noncash Expense Less present value discount Finance Lease, Liability, Undiscounted Excess Amount Pre-funded warrants outstanding (in shares) Class of Warrant or Right, Outstanding Long Term Liability - Other Other Liabilities, Noncurrent Increase (Decrease) in Other Liabilities Increase (Decrease) in Other Operating Liabilities Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Milestone consideration Proceeds from Collaborators Drogsan Agreements Drogsan Agreements [Member] Drogsan Agreements Operating space Area of Operating Space Area of Operating Space Grapevine, Texas TEXAS Right of use assets exchanged for operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 5.40% Note Payable 5.40% Note Payable [Member] 5.40% Note Payable Sale of stock, capital proceeds threshold Sale Of Stock, Contingent, Capital Proceeds Threshold Sale Of Stock, Contingent, Capital Proceeds Threshold EX-101.PRE 15 rmti-20220930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 16 image_01.jpg begin 644 image_01.jpg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end GRAPHIC 17 image_0b.jpg begin 644 image_0b.jpg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end XML 18 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover - shares
9 Months Ended
Sep. 30, 2022
Nov. 11, 2022
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2022  
Document Transition Report false  
Entity File Number 000-23661  
Entity Registrant Name ROCKWELL MEDICAL, INC.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 38-3317208  
Entity Address, Address Line One 30142 S. Wixom Road  
Entity Address, City or Town Wixom  
Entity Address, State or Province MI  
Entity Address, Postal Zip Code 48393  
City Area Code 248  
Local Phone Number 960-9009  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Title of 12(b) Security Common Stock, par value $0.0001  
Trading Symbol RMTI  
Security Exchange Name NASDAQ  
Entity Common Stock, Shares Outstanding (in shares)   11,632,673
Entity Central Index Key 0001041024  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2022  
Document Fiscal Period Focus Q3  

XML 19 R2.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
ASSETS    
Cash and Cash Equivalents $ 12,980 $ 13,280
Fair Value 14,584 9,158
Accounts Receivable, net 7,367 5,913
Inventory, net 5,020 4,076
Prepaid and Other Current Assets 2,407 2,861
Total Current Assets 42,358 35,288
Property and Equipment, net 2,264 2,486
Inventory, Non-Current 1,193 1,523
Right of Use Assets, net 6,928 7,737
Goodwill 921 921
Other Non-Current Assets 522 619
Total Assets 54,186 48,574
LIABILITIES AND STOCKHOLDERS’ EQUITY    
Accounts Payable 3,051 3,739
Accrued Liabilities 5,887 5,090
Lease Liability - Current 1,992 2,004
Deferred License Revenue - Current 2,164 2,171
Term Loan - Net of Issuance Costs 5,131 7,381
Insurance Financing Note Payable 1,006 437
Customer Deposits 107 144
Total Current Liabilities 19,338 20,966
Lease Liability - Long-Term 5,171 5,887
Term Loan, Net of Issuance Costs 8,962 13,186
Deferred License Revenue - Long-Term 4,565 5,986
Long Term Liability - Other 14 14
Total Liabilities 38,050 46,039
Stockholders’ Equity:    
Preferred Stock, $0.0001 par value, 2,000,000 shares authorized; 15,000 and nil shares issued and outstanding at September 30, 2022 and December 31, 2021 0 0
Common Stock, $0.0001 par value; 170,000,000 shares authorized; 11,152,673 and 8,544,225 shares issued and outstanding at September 30, 2022 and December 31, 2021 1 1
Additional Paid-in Capital 402,480 372,562
Accumulated Deficit (386,399) (370,080)
Accumulated Other Comprehensive Income 54 52
Total Stockholders’ Equity 16,136 2,535
Total Liabilities and Stockholders’ Equity $ 54,186 $ 48,574
XML 20 R3.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Sep. 30, 2022
Dec. 31, 2021
Statement of Financial Position [Abstract]    
Preferred shares, par value (in dollars per share) $ 0.0001 $ 0.0001
Preferred shares, shares authorized (in shares) 2,000,000 2,000,000
Preferred shares, shares issued (in shares) 15,000 0
Preferred shares, shares outstanding (in shares) 15,000 0
Common shares, par value (in dollars per share) $ 0.0001 $ 0.0001
Common shares, shares authorized (in shares) 170,000,000 170,000,000
Common shares, shares issued (in shares) 11,152,673 8,544,225
Common shares, shares outstanding (in shares) 11,152,673 8,544,225
XML 21 R4.htm IDEA: XBRL DOCUMENT v3.22.2.2
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Statement [Abstract]        
Net Sales $ 18,691 $ 15,988 $ 53,497 $ 46,599
Cost of Sales 17,914 16,317 51,760 46,788
Gross Profit (Loss) 777 (329) 1,737 (189)
Research and Product Development 469 1,221 2,963 5,445
Selling and Marketing 762 1,541 1,743 4,860
General and Administrative 3,254 3,881 11,845 11,483
Operating Loss (3,708) (6,972) (14,814) (21,977)
Other (Expense) Income        
Realized Gain on Investments 0 0 4 (1)
Interest Expense (476) (609) (1,497) (1,772)
Interest Income (6) 0 (10) 17
Total Other Expense (482) (609) (1,503) (1,756)
Net Loss $ (4,190) $ (7,581) $ (16,317) $ (23,733)
Basic Net Loss per Share (in dollars per share) $ (0.40) $ (0.89) $ (1.75) $ (2.79)
Diluted Net Loss per Share (in dollars per share) $ (0.40) $ (0.89) $ (1.75) $ (2.79)
Basic Weighted Average Shares Outstanding (in shares) 10,528,148 8,534,740 9,299,788 8,520,603
Diluted Weighted Average Shares Outstanding (in shares) 10,528,148 8,534,740 9,299,788 8,520,603
XML 22 R5.htm IDEA: XBRL DOCUMENT v3.22.2.2
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Statement of Comprehensive Income [Abstract]        
Net Loss $ (4,190) $ (7,581) $ (16,317) $ (23,733)
Unrealized Gain (Loss) on Available-for-Sale Debt Instrument Investments 5 4 5 (4)
Foreign Currency Translation Adjustments 0 0 (3) 3
Comprehensive Loss $ (4,185) $ (7,577) $ (16,315) $ (23,734)
XML 23 R6.htm IDEA: XBRL DOCUMENT v3.22.2.2
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Total
Public Offering
At-the-Market Offering
PREFERRED STOCK
COMMON STOCK
COMMON STOCK
Public Offering
COMMON STOCK
At-the-Market Offering
ADDITIONAL PAID-IN CAPITAL
ADDITIONAL PAID-IN CAPITAL
Public Offering
ADDITIONAL PAID-IN CAPITAL
At-the-Market Offering
ACCUMULATED DEFICIT
ACCUMULATED OTHER COMPREHENSIVE INCOME
Beginning balance (in shares) at Dec. 31, 2020         8,506,651              
Beginning balance at Dec. 31, 2020 $ 34,170       $ 1     $ 371,518     $ (337,406) $ 57
Increase (Decrease) in Shareholders' Equity                        
Net Loss (7,752)                   (7,752)  
Foreign Currency Translation Adjustments 3                     3
Unrealized Gain (Loss) on Available-for-Sale Investments (7)                     (7)
Stock-based Compensation (in shares)         2,396              
Stock-based Compensation and modification expense (236)             (236)        
Ending balance (in shares) at Mar. 31, 2021         8,509,047              
Ending balance at Mar. 31, 2021 26,178       $ 1     371,282     (345,158) 53
Beginning balance (in shares) at Dec. 31, 2020         8,506,651              
Beginning balance at Dec. 31, 2020 34,170       $ 1     371,518     (337,406) 57
Increase (Decrease) in Shareholders' Equity                        
Net Loss (23,733)                      
Foreign Currency Translation Adjustments 3                      
Unrealized Gain (Loss) on Available-for-Sale Investments (4)                      
Ending balance (in shares) at Sep. 30, 2021         8,542,397              
Ending balance at Sep. 30, 2021 11,094       $ 1     372,176     (361,139) 56
Beginning balance (in shares) at Mar. 31, 2021         8,509,047              
Beginning balance at Mar. 31, 2021 26,178       $ 1     371,282     (345,158) 53
Increase (Decrease) in Shareholders' Equity                        
Net Loss (8,400)                   (8,400)  
Unrealized Gain (Loss) on Available-for-Sale Investments (1)                     (1)
Stock-based Compensation and modification expense 433             433        
Vesting of Restricted Stock Units Issued, net of taxes withheld (in shares)         19,260              
Vesting of Restricted Stock Units Issued, net of taxes withheld (7)             (7)        
Ending balance (in shares) at Jun. 30, 2021         8,528,307              
Ending balance at Jun. 30, 2021 18,203       $ 1     371,708     (353,558) 52
Increase (Decrease) in Shareholders' Equity                        
Net Loss (7,581)                   (7,581)  
Foreign Currency Translation Adjustments 0                      
Unrealized Gain (Loss) on Available-for-Sale Investments 4                     4
Issuance of stock, net of offering costs (in shares)             14,090          
Issuance of stock, net of offering costs (in dollars)     $ 107             $ 107    
Stock-based Compensation and modification expense 361             361        
Ending balance (in shares) at Sep. 30, 2021         8,542,397              
Ending balance at Sep. 30, 2021 $ 11,094       $ 1     372,176     (361,139) 56
Beginning balance (in shares) at Dec. 31, 2021 0     0                
Beginning balance (in shares) at Dec. 31, 2021 8,544,225       8,544,225              
Beginning balance at Dec. 31, 2021 $ 2,535       $ 1     372,562     (370,080) 52
Increase (Decrease) in Shareholders' Equity                        
Net Loss (7,162)                   (7,162)  
Foreign Currency Translation Adjustments (1)                     (1)
Stock-based Compensation and modification expense (179)             (179)        
Ending balance (in shares) at Mar. 31, 2022       0                
Ending balance (in shares) at Mar. 31, 2022         8,544,225              
Ending balance at Mar. 31, 2022 $ (4,807)       $ 1     372,383     (377,242) 51
Beginning balance (in shares) at Dec. 31, 2021 0     0                
Beginning balance (in shares) at Dec. 31, 2021 8,544,225       8,544,225              
Beginning balance at Dec. 31, 2021 $ 2,535       $ 1     372,562     (370,080) 52
Increase (Decrease) in Shareholders' Equity                        
Net Loss (16,317)                      
Foreign Currency Translation Adjustments (3)                      
Unrealized Gain (Loss) on Available-for-Sale Investments $ 5                      
Ending balance (in shares) at Sep. 30, 2022 15,000     15,000                
Ending balance (in shares) at Sep. 30, 2022 11,152,673       11,152,673              
Ending balance at Sep. 30, 2022 $ 16,136       $ 1     402,480     (386,399) 54
Beginning balance (in shares) at Mar. 31, 2022       0                
Beginning balance (in shares) at Mar. 31, 2022         8,544,225              
Beginning balance at Mar. 31, 2022 (4,807)       $ 1     372,383     (377,242) 51
Increase (Decrease) in Shareholders' Equity                        
Net Loss (4,967)                   (4,967)  
Foreign Currency Translation Adjustments (2)                     (2)
Issuance of stock, net of offering costs (in shares)       15,000   844,613 7,500          
Issuance of stock, net of offering costs (in dollars) 14,916 $ 14,893 $ 15         14,916 $ 14,893 $ 15    
Stock-based Compensation and modification expense 97             97        
Vesting of Restricted Stock Units Issued, net of taxes withheld (in shares)         10,958              
Ending balance (in shares) at Jun. 30, 2022       15,000                
Ending balance (in shares) at Jun. 30, 2022         9,407,296              
Ending balance at Jun. 30, 2022 20,145       $ 1     402,304     (382,209) 49
Increase (Decrease) in Shareholders' Equity                        
Net Loss (4,190)                   (4,190)  
Foreign Currency Translation Adjustments 0                      
Unrealized Gain (Loss) on Available-for-Sale Investments 5                     5
Issued shares for services (in shares)         1,745,377              
Stock-based Compensation and modification expense $ 176             176        
Ending balance (in shares) at Sep. 30, 2022 15,000     15,000                
Ending balance (in shares) at Sep. 30, 2022 11,152,673       11,152,673              
Ending balance at Sep. 30, 2022 $ 16,136       $ 1     $ 402,480     $ (386,399) $ 54
XML 24 R7.htm IDEA: XBRL DOCUMENT v3.22.2.2
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Cash Flows From Operating Activities:    
Net Loss $ (16,317) $ (23,733)
Adjustments To Reconcile Net Loss To Net Cash Used In Operating Activities:    
Depreciation and Amortization 422 535
Stock-based Compensation 95 558
Increase in Inventory Reserves 307 89
Amortization of Right of Use Asset 1,518 1,312
Amortization of Debt Financing Costs and Accretion of Debt Discount 276 276
(Gain) Loss on Disposal of Assets (3) 7
Realized (Gain) Loss on Sale of Investments Available-for-Sale (4) 1
Foreign Currency Translation Adjustment (3) 3
Changes in Assets and Liabilities:    
Increase in Accounts Receivable, net (1,454) (1,865)
Increase in Inventory (921) (554)
Decrease in Prepaid and Other Assets 2,058 1,760
(Decrease) Increase in Accounts Payable (688) 679
Decrease in Lease Liability (1,435) (1,266)
Increase (Decrease) in Other Liabilities 756 (825)
Decrease in Deferred License Revenue (1,427) (1,485)
Changes in Assets and Liabilities (3,111) (3,556)
Cash Used In Operating Activities (16,820) (24,508)
Cash Flows From Investing Activities:    
Purchase of Investments Available-for-Sale (17,389) (19,107)
Sale of Investments Available-for-Sale 11,972 19,286
Purchase of Equipment (197) (408)
Cash Used In Investing Activities (5,614) (229)
Cash Flows From Financing Activities:    
Payments on Debt (6,750) 0
Payments on Short Term Note Payable (941) (656)
Proceeds from the Issuance of Common Stock 15,016 0
Offering Costs from the Issuance of Common Stock (106) 0
Proceeds from the Issuance of Preferred Stock 15,000 0
Offering Costs from the Issuance of Preferred Stock (85) 0
Proceeds from the Issuance of Common Stock for payment related to services provided 0 107
Repurchase of Common Stock to Pay Employee Withholding Taxes 0 (6)
Cash Provided by (Used In) Financing Activities 22,134 (555)
Decrease in Cash and Cash Equivalents (300) (25,292)
Cash and Cash Equivalents at Beginning of Period 13,280 48,682
Cash and Cash Equivalents at End of Period 12,980 23,390
Supplemental Disclosure of Cash Flow Information:    
Cash Paid for Interest 1,261 1,318
Supplemental Disclosure of Noncash Investing and Financing Activities:    
Change in Unrealized Loss on Marketable Securities Available-for-Sale $ 5 $ (4)
XML 25 R8.htm IDEA: XBRL DOCUMENT v3.22.2.2
Description of Business
9 Months Ended
Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Description of Business Description of Business
Rockwell Medical, Inc. (“Rockwell Medical,” “Rockwell,” or the “Company”) is a commercial healthcare company focused on providing life-sustaining products for patients suffering from blood disorders and diseases associated with the kidney. Rockwell is a revenue-generating business and the second largest supplier of acid and bicarbonate concentrates for dialysis patients in the United States. Hemodialysis is the most common form of end-stage kidney disease treatment and is usually performed at a freestanding outpatient dialysis center, at a hospital-based outpatient center, or in a patient’s home. This represents a large market opportunity for which Rockwell's products are well-positioned to meet the needs of patients.
Rockwell manufactures hemodialysis concentrates under cGMP regulations at its three facilities in Michigan, Texas, and South Carolina totaling approximately 175,000 square feet, and manufactures mixers in its Iowa facility. Rockwell delivers the majority of its hemodialysis concentrates products and mixers to dialysis clinics throughout the United States and internationally utilizing its own delivery trucks and third-party carriers. Rockwell has developed a core expertise in manufacturing and delivering hemodialysis concentrates, and has built a longstanding reputation for reliability, quality, and excellent customer service.
Rockwell has a proprietary parenteral iron product, TRIFERIC® (ferric pyrophosphate citrate, "FPC"), which is indicated to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease. The Company has established several international partnerships with companies seeking to develop and commercialize TRIFERIC® outside the United States and is working closely with these international partners to develop and commercialize TRIFERIC® in their respective regions.
Rockwell continues to evaluate the viability of its FPC platform and FPC's potential to treat iron deficiency and iron deficiency anemia and for acute heart failure.
Rockwell’s strategy is focused on growing the Company's revenue-generating business, which currently includes hemodialysis concentrates and international partnerships for TRIFERIC® and achieving profitability in 2024 to put the Company in a stronger and more stable financial position.
XML 26 R9.htm IDEA: XBRL DOCUMENT v3.22.2.2
Liquidity and Capital Resources
9 Months Ended
Sep. 30, 2022
Liquidity and Going Concern Considerations [Abstract]  
Liquidity and Capital Resources Liquidity and Capital Resources
As of September 30, 2022, Rockwell had approximately $27.6 million of cash, cash equivalents and investments available-for-sale, and working capital of $23.0 million. Net cash used in operating activities for the nine months ended September 30, 2022 was approximately $16.8 million. Based on the currently available working capital and capital raises described below, management believes the Company currently has sufficient funds to meet its operating requirements for at least the next twelve months from the date of the filing of this report.
On April 6, 2022, the Company and DaVita, Inc. ("DaVita") entered into an amendment (the "Amendment") to the Products Purchase Agreement, dated July 1, 2019, under which the Company supplies DaVita with certain dialysis concentrates. Under the Amendment, the Company and DaVita agreed to certain price increases, effective May 1, 2022, as well as the pass-through of certain inflationary costs, determined on a quarterly basis. Certain costs are subject to a cap. The Amendment also requires the Company to implement certain cost containment and cost-cutting measures. The Amendment contains certain covenants with respect to the Company’s ongoing operations, including a minimum cash covenant of $10 million, or the Company will be in default under the Products Purchase Agreement. An event of default could result in termination of that agreement.
On April 6, 2022, the Company and DaVita entered into a Securities Purchase Agreement (the “SPA”), pursuant to which the Company issued $15 million of preferred stock to DaVita in two separate tranches. The Company initially issued 7,500 shares of a newly designated series of preferred stock, which is designated “Series X Convertible Preferred Stock” (the “Series X Preferred Stock”) for gross proceeds of $7.5 million. On June 15, 2022, the Company issued to DaVita an additional 7,500 shares of Series X Preferred Stock in a second closing (the “Second Tranche”) for an additional $7.5 million. The Second Tranche was conditioned upon the Company raising an additional $15 million in capital within a certain timeline, which took place on June 2, 2022.
On April 8, 2022, the Company entered into a sales agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), pursuant to which the Company may offer and sell from time to time up to $12,200,000 of shares of Company’s common stock through the Agent. The offering and sale of such shares has been registered under the Securities Act of 1933, as amended (the “Securities Act”), pursuant to the Company’s Registration Statement on Form S-3 (File No. 333-259923) (the “Registration Statement”), which was originally filed with the Securities and Exchange Commission (“SEC”) on September 30, 2021 and declared effective by the SEC on October 8, 2021, the base prospectus contained within the Registration Statement, and a prospectus supplement that was filed with the SEC on April 8, 2022. During the three months ended September 30, 2022, the Company did not make any sales pursuant to the Sales Agreement. Approximately $12.2 million remains available for sale under the ATM facility.
On May 30, 2022, the Company entered into a Securities Purchase Agreement (the “RD Purchase Agreement”) with the purchaser named therein (the “Purchaser”), pursuant to which the Company agreed to issue and sell, in a registered direct offering (the “Offering”), 844,613 shares of its common stock at price of $1.39 per share, and prefunded warrants to purchase up to an aggregate of 7,788,480 shares of common stock (the “Pre-Funded Warrants” and the shares of common stock underlying the Pre-Funded Warrants, the “Warrant Shares”). The purchase price of each Pre-Funded Warrant was equal to the price at which a share of common stock was sold to the public in the Offering, minus $0.0001, and the exercise price of each Pre-Funded Warrant is $0.0001 per share.
Also on May 30, 2022, concurrently with the Offering, the Company entered into a Securities Purchase Agreement with the Purchaser (the “PIPE Purchase Agreement”) relating to the offering and sale (the “Private Placement”) of warrants to purchase up to a total of 9,900,990 shares of common stock and pre-funded warrants to purchase up to a total of 1,267,897 shares of common stock (the “PIPE Warrants”). Each warrant was sold at a price of $0.125 per underlying warrant share and is exercisable at an exercise price of $1.39 per share. The purchase price of each Pre-Funded Warrant was equal to the price at which a share of common stock was sold to the public in the Offering, minus $0.0001, and the exercise price of each prefunded warrant is $0.0001 per share. The Offering and the Private Placement closed on June 2, 2022. The net proceeds to the Company from the Offering and the Private Placement were approximately $14.9 million, after deducting fees and expenses.
The Company may require additional capital to sustain its operations and make the investments it needs to execute its strategic plan. If the Company attempts to obtain additional debt or equity financing, the Company cannot assume such financing will be available on favorable terms, if at all.
Currently, because the Company's public float is less than $75 million, it is subject to the baby shelf limitations under its current registration statement on Form S-3, which limit the amount the Company may offer under the Form S-3. This could limit its ability to raise capital under this registration statement.

In addition, the Company is subject to certain covenants and cure provisions under its Loan Agreement with Innovatus. As of the date of this report, the Company is in compliance with all covenants (See Note 14 for further detail).

The COVID-19 pandemic and resulting domestic and global disruptions, particularly in the supply chain and labor market, among other areas, have adversely affected the Company's business and operations, including, but not limited to, its sales and marketing efforts and its research and development activities, its plant and transportation operations and the operations of third parties upon whom the Company relies. The Company's international business development activities may also continue to be negatively impacted by COVID-19.

The COVID-19 pandemic and the resulting global disruptions and recent inflationary pressures have caused significant volatility in financial and credit markets. Rockwell has utilized a range of financing methods to fund its operations in the past; however, current conditions in the financial and credit markets may limit the availability of funding, refinancing or increase the cost of funding. Due to the rapidly evolving nature of the global situation, it is not possible to predict the extent to which these conditions could adversely affect the Company's liquidity and capital resources in the future.
XML 27 R10.htm IDEA: XBRL DOCUMENT v3.22.2.2
Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements
9 Months Ended
Sep. 30, 2022
Accounting Policies [Abstract]  
Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements
The accompanying condensed consolidated financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the instructions to Form 10-Q and Rule 10-01 of Regulation S-X of the U. S. Securities and Exchange Commission (“SEC”) and on the same basis as the Company prepares its annual audited consolidated financial statements.

The condensed consolidated balance sheet at September 30, 2022, condensed consolidated statements of operations for the three and nine months ended September 30, 2022 and 2021, condensed consolidated statements of comprehensive loss for the three and nine months ended September 30, 2022 and 2021, condensed consolidated statement of changes in stockholders' equity for the three and nine months ended September 30, 2022 and 2021, and condensed consolidated statements of cash flows for the nine months ended September 30, 2022 and 2021 are unaudited, but include all adjustments, consisting of normal recurring adjustments, the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The results for the three and nine months ended September 30, 2022 are not necessarily indicative of results to be expected for the year ending December 31, 2022 or for any future interim period. The condensed consolidated balance sheet at December 31, 2021 has been derived from audited financial statements, however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying condensed consolidated financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2021 and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 as filed with the SEC on April 8, 2022. The Company’s consolidated subsidiaries consisted of its wholly-owned subsidiaries, Rockwell Transportation, Inc. and Rockwell Medical India Private Limited.

The accompanying condensed consolidated interim financial statements include the accounts of the Company and its subsidiaries. All material intercompany balances and transactions have been eliminated in consolidation.
Reverse Stock Split
On May 9, 2022, the stockholders of the Company authorized the Board of Directors to effect a reverse stock split of all outstanding shares of common stock. The Board of Directors subsequently approved the implementation of a reverse stock split as a ratio of one-for-eleven shares, which became effective on May 13, 2022. The Company’s outstanding stock options were also adjusted to reflect the one-for-eleven reverse stock split of the Company’s common stock. Outstanding stock options were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased. The reverse stock split resulted in an adjustment to the Series X convertible preferred stock conversion prices to reflect a proportional decrease in the number of shares of common stock to be issued upon conversion. All share and per share data in these condensed consolidated financial statements and related notes hereto have been retroactively adjusted to account for the effect of the reverse stock split for the three and nine month periods ended September 30, 2022 and 2021, respectively, and the balance sheet at September 30, 2022 and December 31, 2021.
Use of Estimates
The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates.
Leases
The Company accounts for its leases under Accounting Standards Codification (“ASC”) 842, Leases. Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the consolidated balance sheet as both a right-of-use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term. Variable lease expenses, if any, are recorded when incurred.
In calculating the right-of-use asset and lease liability, the Company elects to combine lease and non-lease components. The Company excludes short-term leases having initial terms of 12 months or less from the new guidance as an accounting policy election and recognizes rent expense on a straight-line basis over the lease term.
Loss Per Share
ASC 260, Earnings Per Share, requires dual presentation of basic and diluted earnings per share (“EPS”), with a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS computation. Basic EPS excludes dilution. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that are then sharing in the earnings of the entity.
Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding plus the effect of dilutive potential common shares outstanding during the period determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss per share calculation, common stock warrants, unvested restricted stock units and stock options are considered to be potentially dilutive securities but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive, and therefore, basic and diluted net loss per share were the same for all periods presented.
The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share for the nine months ended September 30, 2022 and 2021, respectively, because to do so would be anti-dilutive (in common equivalent shares):
As of September 30,
20222021
Options to purchase common stock1,311,691 533,784 
Unvested restricted stock awards891 7,118 
Unvested restricted stock units125,000 31,116 
Preferred stock conversion to common stock1,363,636 — 
Warrants to purchase common stock17,507,268 2,402,442 
Total20,308,486 2,974,460 
Adoption of Recent Accounting Pronouncements
The Company continually assesses new accounting pronouncements to determine their applicability. When it is determined a new accounting pronouncement affects the Company’s financial reporting, the Company undertakes a review to determine the consequences of the change to its consolidated financial statements and assures there are sufficient controls in place to ascertain the Company’s consolidated financial statements properly reflect the change.
In August 2020, the FASB issued ASU No. 2020-06, “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity”, which simplifies the accounting for convertible instruments by eliminating the requirement to separate embedded conversion features from the host contract when the conversion features are not required to be accounted for as derivatives under Topic 815, Derivatives and Hedging, or do not result in substantial premiums accounted for as paid-in capital. By removing the separation model, a convertible debt instrument will be reported as a single liability instrument with no separate accounting for embedded conversion features. This new standard also removes certain settlement conditions required for contracts to qualify for equity classification and simplifies the diluted earnings per share calculations by requiring an entity use the if-converted method and the effect of potential share settlement be included in diluted earnings per share calculations. This new standard will be effective for the Company for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently assessing the impact of adopting this standard on the consolidated financial statements.
XML 28 R11.htm IDEA: XBRL DOCUMENT v3.22.2.2
Revenue Recognition
9 Months Ended
Sep. 30, 2022
Revenue from Contract with Customer [Abstract]  
Revenue Recognition Revenue Recognition
The Company recognizes revenue under ASC 606, Revenue from Contracts with Customers. The core principle of the new revenue standard is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The following five steps are applied to achieve that core principle:

Step 1: Identify the contract with the customer
Step 2: Identify the performance obligations in the contract
Step 3: Determine the transaction price
Step 4: Allocate the transaction price to the performance obligations in the contract
Step 5: Recognize revenue when the company satisfies a performance obligation
Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by us from a customer, are excluded from revenue.
Shipping and handling costs associated with outbound freight related to contracts with customers are accounted for as a fulfillment cost and are included in cost of sales when control of the goods transfers to the customer.
Nature of goods and services
The following is a description of principal activities from which the Company generates its revenue.
Product sales –The Company accounts for individual products and services separately if they are distinct (i.e., if a product or service is separately identifiable from other items and if a customer can benefit from it on its own or with other resources that are readily available to the customer). The consideration, including any discounts, is allocated between separate products and services based on their stand-alone selling prices. The stand-alone selling prices are determined based on the cost plus margin approach.
Drug and dialysis concentrates products are sold directly to dialysis clinics and to wholesale distributors in both domestic and international markets. Distribution and license agreements for which upfront fees are received are evaluated upon execution or modification of the agreement to determine if the agreement creates a separate performance obligation from the underlying product sales.  For all existing distribution and license agreements, the distribution and license agreement is not a distinct performance obligation from the product sales.  In instances where regulatory approval of the product has not been established and the Company does not have sufficient experience with the foreign regulatory body to conclude regulatory approval is probable, the revenue for the performance obligation is recognized over the term of the license agreement (over time recognition). Conversely, when regulatory approval already exists or is probable, revenue is recognized at the point in time control of the product transfers to the customer.
The Company received upfront fees under five distribution and license agreements that have been deferred as a contract liability.  The amounts received from Wanbang Biopharmaceuticals Co., Ltd. (“Wanbang”), Sun Pharmaceutical Industries Ltd. ("Sun Pharma"), Jeil Pharmaceutical Co., Ltd. ("Jeil Pharma") and Drogsan Pharmaceuticals ("Drogsan Pharma") are recognized as revenue over the estimated term of the applicable distribution and license agreement as regulatory approval was not received and the Company did not have sufficient experience in China, India, South Korea and Turkey, respectively, to determine regulatory approval was probable as of the execution of the agreement.  The amounts received from Baxter Healthcare Corporation (“Baxter”) are recognized as revenue at the point in time the estimated product sales under the agreement occur. 
For the business under the Company’s Distribution Agreement with Baxter (the “Baxter Agreement”) and for the majority of the Company’s international customers, the Company recognizes revenue at the shipping point, which is generally the Company’s plant or warehouse. For other business, the Company recognizes revenue based on when the customer takes control of the product. The amount of revenue recognized is based on the purchase order less returns and adjusted for any rebates, discounts, chargebacks or other amounts paid to customers. There were no such adjustments for the periods reported. Customers typically pay for the product based on customary business practices with payment terms averaging 30 days, while distributor payment terms average 45 days.
Disaggregation of revenue
Revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition.
In thousands of U.S. dollars ($) Three Months Ended September 30, 2022Nine Months Ended September 30, 2022
Products By Geographic AreaTotalU.S.Rest of WorldTotalU.S.Rest of World
Drug Revenues
Product Sales – Point-in-time$193 $193 $— $834 $561 $273 
License Fee – Over time65 — 65 192 — 192 
Total Drug Products258 193 65 1,026 561 465 
Concentrates Products
Product Sales – Point-in-time17,953 16,619 1,334 51,035 46,334 4,701 
License Fee – Over time480 480 — 1,436 1,436 — 
Total Concentrate Products18,433 17,099 1,334 52,471 47,770 4,701 
Net Revenue$18,691 $17,292 $1,399 $53,497 $48,331 $5,166 
In thousands of U.S. dollars ($)Three Months Ended September 30, 2021Nine Months Ended September 30, 2021
Products By Geographic AreaTotalU.S.Rest of WorldTotalU.S.Rest of World
Drug Revenues
Product Sales – Point-in-time$217 $217 $— $656 $656 $— 
License Fee – Over time62 — 62 179 — 179 
Total Drug Products279 217 62 835 656 179 
Concentrates Products
Product Sales – Point-in-time15,224 13,541 1,683 44,308 39,768 4,540 
License Fee – Over time485 485 — 1,456 1,456 — 
Total Concentrate Products15,709 14,026 1,683 45,764 41,224 4,540 
Net Revenue$15,988 $14,243 $1,745 $46,599 $41,880 $4,719 
Contract balances
The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers.
In thousands of U.S. dollars ($)September 30, 2022December 31, 2021
Receivables, which are included in "Trade and other receivables"$7,367 $5,913 
Contract liabilities$6,729 $8,157 
There were no impairment losses recognized related to any receivables arising from the Company’s contracts with customers for the three and nine months ended September 30, 2022 and 2021.
For the three and nine months ended September 30, 2022 and September 30, 2021, the Company did not recognize any material bad-debt expense. There were no material contract assets recorded on the condensed consolidated balance sheet as of September 30, 2022 and December 31, 2021.  The Company does not generally accept returns of its concentrates products and no material reserve for returns of concentrates products was established as of September 30, 2022 or December 31, 2021. 
The contract liabilities primarily relate to upfront payments and consideration received from customers that are received in advance of the customer assuming control of the related products
Transaction price allocated to remaining performance obligations
For the three and nine months ended September 30, 2022, revenue recognized from performance obligations related to prior periods was not material.
Revenue expected to be recognized in any future year related to remaining performance obligations, excluding revenue pertaining to contracts that have an original expected duration of one year or less, contracts where revenue is recognized as invoiced, and contracts with variable consideration related to undelivered performance obligations, totaled $6.7 million as of September 30, 2022. The amount relates primarily to upfront payments and consideration received from customers in advance of the customer assuming control of the related products. The Company applies the practical expedient in paragraph 606-10-50-14 and does not disclose information about remaining performance obligations having original expected durations of one year or less. The Baxter Agreement includes minimum commitments of product sales over the duration of the agreement. Unfulfilled minimum commitments related to the Baxter Agreement are product sales of $3.8 million as of September 30, 2022, which is amortized ratably through expiration of the Baxter Agreement on October 2, 2024.
XML 29 R12.htm IDEA: XBRL DOCUMENT v3.22.2.2
Investments - Available-for-Sale
9 Months Ended
Sep. 30, 2022
Investments, Debt and Equity Securities [Abstract]  
Investments - Available-for-Sale Investments - Available-for-Sale
Investments available-for-sale consisted of the following as of September 30, 2022 and December 31, 2021 (table in thousands):
September 30, 2022
Amortized CostUnrealized GainUnrealized LossAccrued InterestFair Value
Available-for-Sale Securities
Bonds$14,578 $$(1)$$14,584 

December 31, 2021
Amortized CostUnrealized GainUnrealized LossAccrued InterestFair Value
Available-for-Sale Securities
Bonds$9,143 $$— $14 $9,158 
The fair value of investments available-for-sale are determined using quoted market prices from daily exchange-traded markets based on the closing price as of the balance sheet date and are classified as a Level 1 measurement under ASC 820 Fair Value Measurements.
As of September 30, 2022 and December 31, 2021, the amortized cost and estimated fair value of our available-for-sale securities were due within one year.
XML 30 R13.htm IDEA: XBRL DOCUMENT v3.22.2.2
Inventory
9 Months Ended
Sep. 30, 2022
Inventory Disclosure [Abstract]  
Inventory Inventory
Components of inventory, net of reserves, as of September 30, 2022 and December 31, 2021 are as follows (table in thousands):
September 30,
2022
December 31,
2021
Raw Materials$4,074 $3,434 
Work in Process336 201 
Finished Goods1,803 1,964 
Total$6,213 $5,599 
As of September 30, 2022, the Company classified $1.2 million of inventory as non-current, all of which was related to the active pharmaceutical ingredient and raw materials for TRIFERIC®. As of September 30, 2022, the total TRIFERIC® inventory net of reserve was $1.2 million.
The $1.2 million net value of TRIFERIC® inventory consisted of $0.3 million of TRIFERIC® API with an estimated useful life extending through 2023, and $0.9 million of raw materials for TRIFERIC® with an estimated useful life of 25 years.
XML 31 R14.htm IDEA: XBRL DOCUMENT v3.22.2.2
Property and Equipment
9 Months Ended
Sep. 30, 2022
Property, Plant and Equipment [Abstract]  
Property and Equipment Property and Equipment
As of September 30, 2022 and December 31, 2021, the Company’s property and equipment consisted of the following (table in thousands):
September 30,
2022
December 31,
2021
Leasehold Improvements$1,257 $1,204 
Machinery and Equipment5,985 5,864 
Information Technology & Office Equipment1,845 1,845 
Laboratory Equipment660 676 
9,747 9,589 
Accumulated Depreciation(7,483)(7,103)
Property and Equipment, net$2,264 $2,486 
Depreciation expense for both the three months ended September 30, 2022 and 2021 was $0.1 million. Depreciation expense for nine months end September 30, 2022 and 2021 was $0.4 million and $0.5 million, respectively.
XML 32 R15.htm IDEA: XBRL DOCUMENT v3.22.2.2
Accrued Liabilities
9 Months Ended
Sep. 30, 2022
Payables and Accruals [Abstract]  
Accrued Liabilities Accrued Liabilities
Accrued liabilities as of September 30, 2022 and December 31, 2021 consisted of the following (table in thousands):
September 30,
2022
December 31,
2021
Accrued Research & Development Expense$65 $366 
Accrued Compensation and Benefits3,006 1,791 
Accrued Unvouchered Receipts581 796 
Accrued Workers Compensation294 382 
Other Accrued Liabilities1,941 1,755 
Total Accrued Liabilities$5,887 $5,090 
XML 33 R16.htm IDEA: XBRL DOCUMENT v3.22.2.2
Deferred Revenue
9 Months Ended
Sep. 30, 2022
Revenue from Contract with Customer [Abstract]  
Deferred Revenue Deferred Revenue
In October 2014, the Company entered into the Baxter Agreement, which has a term of 10 years and received an upfront fee of $20 million. The upfront fee was recorded as deferred revenue and is being recognized based on the proportion of product shipments to Baxter in each period, compared with total expected sales volume over the term of the Distribution Agreement. The Company recognized revenue of approximately $0.5 million and $1.4 million for the three and nine months ended September 30, 2022, respectively. The Company recognized revenue of approximately $0.5 million and $1.5 million for the three and nine month ended September 30, 2021, respectively. Deferred revenue related to the Baxter Agreement totaled $3.8 million as of September 30, 2022 and $5.2 million as of December 31, 2021.
In 2016, the Company entered into a distribution agreement with Wanbang (the "Wanbang Agreement") and received an upfront fee of $4.0 million. The upfront fee was recorded as deferred revenue and is being recognized as revenue based on the agreement term. The Company recognized revenue of approximately $0.1 million and $0.2 million during each of the three and nine months ended September 30, 2022 and 2021, respectively. Deferred revenue related to the Wanbang Agreement totaled $2.3 million as of September 30, 2022 and $2.5 million as of December 31, 2021.

In January 2020, the Company entered into license and supply agreements with Sun Pharma (the "Sun Pharma Agreements"), for the rights to commercialize TRIFERIC® (dialysate) (ferric pyrophosphate citrate) in India. In consideration for the license, the Company received an upfront fee of $0.1 million. The upfront fee was recorded as deferred revenue and is being recognized as revenue based on the agreement term. The Company recognized revenue of approximately $2,500 and $7,500 for each of the three and nine months ended September 30, 2022 and 2021, respectively. Deferred revenue related to the Sun Pharma Agreement totaled $72,500 and $80,000 as of September 30, 2022 and December 31, 2021, respectively.

In September 2020, the Company entered into a license and supply agreements with Jeil Pharma (the "Jeil Pharma Agreements"), for the rights to commercialize TRIFERIC® (dialysate) (ferric pyrophosphate citrate) in South Korea. In consideration for the license, the Company received an upfront fee of $0.2 million. In May 2022, Jeil Pharma obtained regulatory approval in South Korea and paid the Company $0.2 million in consideration of reaching the milestone. The upfront fee and milestone payments were recorded as deferred revenue and are being recognized as revenue based on the agreement term. The Company recognized revenue of $5,200 and $13,000 for the three and nine months ended September 30, 2022, respectively, and $2,500 and $7,500 for the three and nine months ended September 30, 2021, respectively. Deferred revenue related to the Jeil Pharma Agreement totaled approximately $0.4 million and $0.2 million as of September 30, 2022 and December 31, 2021 respectively.

In June 2021, the Company entered into license and supply agreements with Drogsan Pharma (the "Drogsan Agreements"), for the rights to commercialize TRIFERIC® (dialysate) and TRIFERIC® AVNU in Turkey. In consideration for the license, the Company received an upfront fee of $0.15 million. The upfront fee was recorded as deferred revenue and will be recognized as revenue based on the agreement term. The Company recognized revenue of $3,750 and $11,250 for each of the three and nine months ended September 30, 2022 and 2021, respectively. Deferred revenue related to the Drogsan Agreements totaled approximately $0.13 million and $0.15 million as of September 30, 2022 and December 31, 2021, respectively.
XML 34 R17.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stockholders’ Equity
9 Months Ended
Sep. 30, 2022
Equity [Abstract]  
Stockholders' Equity Stockholders’ Equity
Reverse Stock Split
On May 9, 2022, the stockholders of the Company authorized the Board of Directors to effect a reverse stock split of all outstanding shares of common stock. The Board of Directors subsequently approved the implementation of a reverse stock split as a ratio of one-for-eleven shares, which became effective on May 13, 2022. The Company’s outstanding stock options were also adjusted to reflect the one-for-eleven reverse stock split of the Company’s common stock. Outstanding stock options were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased.
Preferred Stock
On April 6, 2022, the Company and DaVita entered into the SPA, which provided for the issuance by the Company of up to $15 million of preferred stock to DaVita. On April 6, 2022, the Company issued 7,500 shares of Series X Preferred Stock for gross proceeds of $7.5 million. On June 2, 2022, the Company met the conditions for the Second Tranche through a Registered Direct and Private Placement Offering by raising $15 million in additional capital. As a result, on June 16, 2022 the Company issued an additional 7,500 shares of the Series X Preferred Stock to DaVita for gross proceeds of $7.5 million.

The Series X Preferred Stock was issued for a price of $1,000 per share (the "Face Amount"), subject to accretion at a rate of 1% per annum, compounded annually. If the Company’s common stock trades above $22.00 for a period of 30 calendar days, the accretion will thereafter cease.

The Series X Convertible Preferred Stock is convertible to common stock at rate equal to the Face Amount, divided by a conversion price of $11.00 per share (subject to adjustment for future stock splits, reverse stock splits and similar recapitalization events). As a result, each share of Series X Preferred Stock will initially convert into approximately 91 shares of common stock. DaVita’s right to convert to common stock is subject to a beneficial ownership limitation, which is initially set at 9.9% of the outstanding common stock, which limitation may be reset (not to exceed 19.9%) at DaVita’s option and upon providing prior written notice to the Company. In addition, any debt financing is limited by the terms of our Securities Purchase Agreement with DaVita. Specifically, until DaVita owns less than 50% of its investment, the Company may only incur additional debt in the form of a purchase money loan, a working capital line of up to $5 million or to refinance existing debt, unless DaVita consents.
Additionally, the Series X Preferred Stock has a deemed liquidation event and redemption clause which could be triggered if the sale of all or substantially all of the Company's assets relating to the Company's dialysis concentrates business line. Since the Series X Preferred Stock may be redeemed if certain assets are sold at the option of the holder, but is not mandatorily redeemable, the preferred stock has been classified as permanent equity and initially recognized at fair value of $15 million (the proceeds on the date of issuance) less issuance costs of $0.1 million, resulting in an initial value of $14.9 million. The Company will assess at each reporting period whether conditions have changed to now meet the mandatorily redemptive definition which could trigger liability classification.
As of September 30, 2022 and December 31, 2021, there were 2,000,000 shares of preferred stock, $0.0001 par value per share, authorized and 15,000 and nil shares of preferred stock issued and outstanding, respectively.
Common Stock
As of September 30, 2022 and December 31, 2021, there were 170,000,000 shares of common stock, $0.0001 par value per share, authorized and 11,152,673 and 8,544,225 shares issued and outstanding, respectively.
Controlled Equity Offering

On April 8, 2022, the Company entered into the Sales Agreement with Cantor Fitzgerald & Co. as Agent, pursuant to which the Company may offer and sell from time to time up to $12,200,000 of shares of Company’s common stock through the Agent. The offering and sale of such shares has been registered under the Securities Act of 1933, as amended, pursuant to the Company’s Registration Statement on Form S-3 (File No. 333-259923) (the “Registration Statement”), which was originally filed with the SEC on September 30, 2021 and declared effective by the SEC on October 8, 2021, the base prospectus contained within the Registration Statement, and a prospectus supplement that was filed with the SEC on April 8, 2022.

In May 2022, the Company sold 7,500 shares of its common stock pursuant to the Sales Agreement for gross proceeds of $15,135, at a weighted average selling price of approximately $2.02. The Company paid $378 in commissions and offering fees related to the sale of shares of common stock.

Under the RD Purchase Agreement and the PIPE Purchase Agreement discussed below, the Company has agreed not to make any sales under any at-the-market offering facility, including pursuant to the Sales Agreement, until at least January 1, 2023 (or until such later time when the Company is permitted to make additional sales under Instruction I.B.6 to Form S-3).
Registered Direct Offering

On May 30, 2022, the Company entered into the RD Purchase Agreement with the Purchaser named therein, pursuant to which the Company agreed to issue and sell, in a registered direct offering (the “Offering”), 844,613 shares of its common stock at price of $1.39 per share, and pre-funded warrants to purchase up to an aggregate of 7,788,480 shares of common stock (the “Pre-Funded Warrants” and the shares of common stock underlying the Pre-Funded Warrants, the “Warrant Shares”). The purchase price of each Pre-Funded Warrant is equal to the price at which a share of common stock was sold to the public in the Offering, minus $0.0001, and the exercise price of each Pre-Funded Warrant is $0.0001 per share.

A holder (together with its affiliates) may not exercise any portion of the Pre-Funded Warrants to the extent the holder would own more than 9.99% of the Company’s outstanding common stock immediately after exercise, as such percentage ownership is determined in accordance with the terms of the Pre-Funded Warrant. The RD Purchase Agreement contains customary representations and warranties and agreements of the Company and the Purchaser and customary indemnification rights and obligations of the parties.

A total of 7,311,000 Pre-Funded Warrants remained outstanding as of September 30, 2022.
Private Placement

Also on May 30, 2022, concurrently with the Offering, the Company entered into the PIPE Purchase Agreement relating to the offering and sale (the “Private Placement”) of warrants to purchase up to a total of 9,900,990 shares of common stock and pre-funded warrants to purchase up to a total of 1,267,897 shares of common stock (the “PIPE Warrants”). Each warrant was sold at a price of $0.125 per underlying warrant share and is exercisable at an exercise price of $1.39 per share. The purchase price of each Pre-Funded Warrant was equal to the price at which a share of common stock was sold to the public in the Offering, minus $0.0001, and the exercise price of each prefunded warrant is $0.0001 per share.

As of September 30, 2022 9,900,990 PIPE Warrants and no Pre-Funded PIPE Warrants remained outstanding.

In connection with the Private Placement, the Company entered into a Registration Rights Agreement with the Purchaser, dated as of June 2, 2022 (the “RRA”). Pursuant to the RRA, the Company was required to prepare and file a registration statement with the SEC no later than July 1, 2022, and to use its reasonable best efforts to have the registration statement declared effective as promptly as possible, subject to certain specified penalties if timely effectiveness is not achieved. The Company filed a registration statement on June 22, 2022 which became effective on July 5, 2022.

The Offering and the Private Placement closed on June 2, 2022. The net proceeds to the Company from the Offering and the Private Placement were approximately $14.9 million, after deducting fees and expenses. Subject to certain ownership limitations, the PIPE Warrants are exercisable upon issuance.

The Company has accounted for the common stock related to the Offering and Private Placement as equity on the accompanying consolidated balance sheets as of September 30, 2022. The amount allocated to common stock was $2.0 million. This allocation is equal to the total proceeds of $15.0 million less the amount allocated to Warrants of $12.9 million and is also net of the direct and incremental costs associated with the Offering and Private Placement of $0.1 million. The Black-Scholes pricing model was used to calculate the value of Warrants relating to the Offering and Private Placement.
XML 35 R18.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stock-Based Compensation
9 Months Ended
Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]  
Stock-Based Compensation Stock-Based Compensation
The Company recognized total stock-based compensation expense during the three and nine months ended September 30, 2022 and 2021 as follows (table in thousands):
Three Months Ended
September 30,
Nine Months Ended
September 30,
2022202120222021
Service-based awards:
Restricted stock units$46 $81 $84 $263 
Stock option awards130 315 401 1,050 
176 396 485 1,313 
Performance-based awards:
Restricted stock awards— — (391)(391)
Stock option awards— (35)— (364)
— (35)(391)(755)
Total$176 $361 $94 $558 
Performance Based Restricted Stock
A summary of the Company’s restricted stock awards during the nine months ended September 30, 2022 is as follows:
Number of SharesWeighted Average
Grant-Date
Fair Value
Unvested at January 1, 20227,118 $62.70 
Forfeited(6,227)$62.70 
Unvested at September 30, 2022891 $62.70 
A summary of the Company’s restricted stock awards during the nine months ended September 30, 2021 is as follows:
Number of SharesWeighted Average
Grant-Date
Fair Value
Unvested at January 1, 202113,345 $62.70 
Forfeited(6,227)$62.70 
Unvested at September 30, 20217,118 $62.70 
The fair value of restricted stock awards are measured based on their fair value on the date of grant and amortized over the vesting period of 20 months. As of September 30, 2022, unvested restricted stock awards of 891 were related to performance-based awards. The forfeited performance-based restricted stock awards of 6,227 was due to the resignation of the Company's Chief Development Officer on March 25, 2022. These forfeited awards reduced stock-based compensation expense by $0.4 million. As of September 30, 2021, unvested restricted stock awards of 7,118 were related to performance-based awards. The forfeited performance-based restricted stock awards of 6,227 was due to the termination of the Company's former Chief Science Officer on January 19, 2021. These forfeited awards reduced stock-based compensation expense by $0.4 million.
Service-Based Restricted Stock Units
A summary of the Company’s service-based restricted stock units during the nine months ended September 30, 2022 is as follows:
Number of SharesWeighted Average
Grant-Date
Fair Value
Unvested at January 1, 202229,289 $12.87 
Granted125,000 1.47 
Vested(23,515)11.33 
Forfeited(5,774)19.00 
Unvested at September 30, 2022125,000 $1.47 

A summary of the Company’s service-based restricted stock units during the nine months ended September 30, 2021 is as follows:
Number of SharesWeighted Average
Grant-Date
Fair Value
Unvested at January 1, 202124,136 $28.60 
Granted28,186 9.90 
Vested(20,134)26.18 
Forfeited(1,073)52.91 
Unvested at September 30, 202131,115 $12.87 
The fair value of service based restricted stock units are measured based on their fair value on the date of grant and amortized over the vesting period. The vesting periods range from 1 to 3 years. Stock-based compensation expense of $46,193 and $83,607 was recognized for the three and nine months ended September 30, 2022, respectively. Stock-based compensation expense of $0.1 million and $0.3 million was recognized for the three and nine months ended September 30, 2021, respectively. As of September 30, 2022, the unrecognized stock-based compensation expense was $0.1 million, which is expected to be recognized over an estimated weighted average remaining term of less than 1 year.
Service-Based Stock Options
The fair value of the service-based stock options granted for the nine months ended September 30, 2022 were based on the following assumptions:
September 30,
2022
Exercise price
$1.28 - $1.66
Expected stock price volatility
76.2% - 78.5%
Risk-free interest rate
1.97% - 3.44%
Term (years)
5.5 - 6
A summary of the Company’s service-based stock option activity for the nine months ended September 30, 2022 is as follows:
Shares
Underlying
Options
Weighted
Average Exercise
Price
Weighted
Average
Remaining
Contractual
Term
Aggregate
Intrinsic
Value
Outstanding at January 1, 2022528,591 $32.01 7.5$— 
Granted898,659 1.49 5.5— 
Forfeited(30,093)15.11 — — 
Expired(85,466)82.09 — — 
Outstanding at September 30, 20221,311,691 $8.23 9.1$— 
Exercisable at September 30, 2022243,973 $29.31 6.9$— 
A summary of the Company’s service-based stock option activity for the nine months ended September 30, 2021 is as follows:
Shares
Underlying
Options
Weighted
Average Exercise
Price
Weighted
Average
Remaining
Contractual
Term
Aggregate
Intrinsic
Value
Outstanding at January 1, 2021519,814 $50.05 6.6$— 
Granted170,197 9.79 6.0— 
Forfeited(35,025)25.30 — — 
Expired(121,202)78.76 — — 
Outstanding at September 30, 2021533,784 $32.45 7.7$— 
Exercisable at September 30, 2021230,858 $54.56 5.8$— 
The aggregate intrinsic value in the table above is calculated as the difference between the closing price of the Company's common stock and the exercise price of the stock options that had strike prices below the closing price.
During the nine months ended September 30, 2022, the Company granted stock options to purchase up to 898,659 shares of common stock to certain employees. During the nine months ended September 30, 2022, 30,093 shares were forfeited and 85,466 shares expired. Forfeitures are recorded in the period of occurrence; compensation expense is adjusted accordingly.
Stock-based compensation expense recognized for service-based stock options was $0.1 million and $0.4 million for the three and nine months ended September 30, 2022, respectively. Stock-based compensation expense recognized for service-based stock options was $0.3 million and $1.0 million for the three and nine months ended September 30, 2021, respectively. As of September 30, 2022, total stock-based compensation expense related to unvested options not yet recognized totaled approximately $1.4 million, which is expected to be recognized over an estimated weighted average remaining term of 3.6 years.
XML 36 R19.htm IDEA: XBRL DOCUMENT v3.22.2.2
Licensing Agreements
9 Months Ended
Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Licensing Agreements Licensing Agreements
Product License Agreements
The Company is a party to a Licensing Agreement between the Company and Charak, LLC ("Charak") dated January 7, 2002 (the "2002 Agreement") that grants the Company exclusive worldwide rights to certain patents and information related to our TRIFERIC® product. On October 7, 2018, the Company entered into a Master Services and IP Agreement (the “Charak MSA”) with Charak and Dr. Ajay Gupta, a former Officer of the Company. Pursuant to the MSA, the parties entered into three additional agreements described below related to the license of certain soluble ferric pyrophosphate (“SFP”) intellectual property owned by Charak. As of September 30, 2022, the Company has accrued $85,400 relating to certain IP reimbursement expenses and certain sublicense royalty fees and is included within accrued liabilities on the condensed consolidated balance sheet.
Pursuant to the Charak MSA, the aforementioned parties entered into an Amendment, dated as of October 7, 2018 (the “Charak Amendment”), to the 2002 Agreement, under which Charak granted the Company an exclusive, worldwide, non-transferable license to commercialize SFP for the treatment of patients with renal failure. The Charak Amendment amends the royalty payments due to Charak under the 2002 Agreement such that the Company is liable to pay Charak royalties on net sales by the Company of products developed under the license, which includes the Company’s TRIFERIC® product, at a specified rate until December 31, 2021 and thereafter at a reduced rate from January 1, 2022 until February 1, 2034. Additionally, the Company shall pay Charak a percentage of any sublicense income during the term of the agreement, which amount shall not be less than a minimum specified percentage of net sales of the licensed products by the sublicensee in jurisdictions where there exists a valid claim, on a country-by-country basis, and be no less than a lower rate of the net sales of the licensed products by the sublicensee in jurisdictions where there exists no valid claim, on a country-by-country basis.
Also pursuant to the Charak MSA, the Company and Charak entered into a Commercialization and Technology License Agreement I.V. TRIFERIC®, dated as of October 7, 2018 (the “IV Agreement”), under which Charak granted the Company an exclusive, sublicensable, royalty-bearing license to SFP for the purpose of commercializing certain intravenous-delivered products incorporating SFP for the treatment of iron disorders worldwide for a term that expires on the later of February 1, 2034 or upon the expiration or termination of a valid claim of a licensed patent. The Company is liable to pay Charak royalties on net sales by the Company of products developed under the license at a specified rate until December 31, 2021. From January 1, 2022 until February 1, 2034, the Company is liable to pay Charak a base royalty at a reduced rate on net sales and an additional royalty on net sales while there exists a valid claim of a licensed patent, on a country-by-country basis. The Company shall also pay to Charak a percentage of any sublicense income received during the term of the IV Agreement, which amount shall not be less than a minimum specified percentage of net sales of the licensed products by the sublicensee in jurisdictions where there exists a valid claim, on a country-by-country basis, and not be less than a lower rate of the net sales of the licensed products by the sublicensee in jurisdictions where there exists no valid claim, on a country-by-country basis.
Also pursuant to the Charak MSA, the Company and Charak entered into a Technology License Agreement TPN TRIFERIC®, dated as of October 7, 2018 (the “TPN Agreement”), pursuant to which Charak granted the Company an exclusive, sublicensable, royalty-bearing license to SFP for the purpose of commercializing worldwide certain TPN products incorporating SFP. The license grant under the TPN Agreement continues for a term that expires on the later of February 1, 2034 or upon the expiration or termination of a valid claim of a licensed patent. During the term of the TPN Agreement, the Company is liable to pay Charak a base royalty on net sales and an additional royalty on net sales while there exists a valid claim of a licensed patent, on a country-by-country basis. The Company shall also pay to Charak a percentage of any sublicense income received during the term of the TPN Agreement, which amount shall not be less than a minimum royalty on net sales of the licensed products by the sublicensee in jurisdictions where there exists a valid claim, on a country-by-country basis, and not be less than a lower rate of the net sales of the licensed products by the sublicensee in jurisdictions where there exists no valid claim, on a country-by-country basis.
The potential milestone payments are not yet considered probable, and no milestone payments have been accrued at September 30, 2022.
XML 37 R20.htm IDEA: XBRL DOCUMENT v3.22.2.2
Leases
9 Months Ended
Sep. 30, 2022
Leases [Abstract]  
Leases Leases
Rockwell leases its production facilities and administrative offices as well as certain equipment used in its operations including leases on transportation equipment used in the delivery of its products. The lease terms range from monthly to six years. Rockwell occupies a 51,000 square foot facility and a 17,500 square foot facility in Wixom, Michigan under a lease expiring in August 2024. Rockwell also occupies two other manufacturing facilities, a 51,000 square foot facility in Grapevine, Texas under a lease expiring in December 2025, and a 57,000 square foot facility in Greer, South Carolina under a lease expiring February 2026. In addition, Rockwell occupied 4,100 square feet of office space in Hackensack, New Jersey under a lease expiring on October 31, 2024. This lease was subleased on December 15, 2021 with an expiration date of October 31, 2024.
At September 30, 2022, the Company had operating and finance lease liabilities of $7.2 million and right-of-use assets of $6.9 million, which are included in the consolidated balance sheet.
At December 31, 2021, the Company had operating lease liabilities of $7.9 million and right-of-use assets of $7.7 million, which are included in the consolidated balance sheet.
The following summarizes quantitative information about the Company’s operating leases (table in thousands):
Three Months Ended September 30, 2022Three Months Ended September 30, 2021Nine Months Ended September 30, 2022Nine Months Ended September 30, 2021
Operating leases
Operating lease cost$410 $457 $1,289 $1,309 
Variable lease cost101 94 287 286 
Operating lease expense511 551 1,576 1,595 
Finance leases
Amortization of right-of-use assets141 73 424 184 
Interest on lease obligations44 22 136 55 
Finance lease expense185 95 560 239 
Short-term lease rent expense14 12 
Total rent expense$701 $650 $2,150 $1,846 
Other information
Operating cash flows from operating leases$427 $444 $1,338 $1,298 
Operating cash flows from finance leases$44 $22 $136 $56 
Financing cash flows from finance leases$121 $59 $359 $152 
Right of use assets exchanged for operating lease liabilities$768 $718 $768 $4,089 
Right of use assets exchanged for finance lease liabilities$— $588 $— $1,365 
Weighted-average remaining lease term – operating leases3.23.73.23.7
Weighted-average remaining lease term – finance leases4.75.54.75.5
Weighted-average discount rate – operating leases6.4 %6.3 %6.4 %6.3 %
Weighted-average discount rate – finance leases6.4 %5.9 %6.4 %5.9 %
Future minimum rental payments under operating lease agreements are as follows (in thousands):
OperatingFinance
Year ending December 31, 2022 (remaining)$434 $165 
Year ending December 31, 20231,692 669 
Year ending December 31, 20241,404 672 
Year ending December 31, 2025937 676 
Year ending December 31, 2026310 666 
Remaining future payments120 311 
Total$4,897 $3,159 
Less present value discount(467)(426)
Operating and finance lease liabilities$4,430 $2,733 
Leases Leases
Rockwell leases its production facilities and administrative offices as well as certain equipment used in its operations including leases on transportation equipment used in the delivery of its products. The lease terms range from monthly to six years. Rockwell occupies a 51,000 square foot facility and a 17,500 square foot facility in Wixom, Michigan under a lease expiring in August 2024. Rockwell also occupies two other manufacturing facilities, a 51,000 square foot facility in Grapevine, Texas under a lease expiring in December 2025, and a 57,000 square foot facility in Greer, South Carolina under a lease expiring February 2026. In addition, Rockwell occupied 4,100 square feet of office space in Hackensack, New Jersey under a lease expiring on October 31, 2024. This lease was subleased on December 15, 2021 with an expiration date of October 31, 2024.
At September 30, 2022, the Company had operating and finance lease liabilities of $7.2 million and right-of-use assets of $6.9 million, which are included in the consolidated balance sheet.
At December 31, 2021, the Company had operating lease liabilities of $7.9 million and right-of-use assets of $7.7 million, which are included in the consolidated balance sheet.
The following summarizes quantitative information about the Company’s operating leases (table in thousands):
Three Months Ended September 30, 2022Three Months Ended September 30, 2021Nine Months Ended September 30, 2022Nine Months Ended September 30, 2021
Operating leases
Operating lease cost$410 $457 $1,289 $1,309 
Variable lease cost101 94 287 286 
Operating lease expense511 551 1,576 1,595 
Finance leases
Amortization of right-of-use assets141 73 424 184 
Interest on lease obligations44 22 136 55 
Finance lease expense185 95 560 239 
Short-term lease rent expense14 12 
Total rent expense$701 $650 $2,150 $1,846 
Other information
Operating cash flows from operating leases$427 $444 $1,338 $1,298 
Operating cash flows from finance leases$44 $22 $136 $56 
Financing cash flows from finance leases$121 $59 $359 $152 
Right of use assets exchanged for operating lease liabilities$768 $718 $768 $4,089 
Right of use assets exchanged for finance lease liabilities$— $588 $— $1,365 
Weighted-average remaining lease term – operating leases3.23.73.23.7
Weighted-average remaining lease term – finance leases4.75.54.75.5
Weighted-average discount rate – operating leases6.4 %6.3 %6.4 %6.3 %
Weighted-average discount rate – finance leases6.4 %5.9 %6.4 %5.9 %
Future minimum rental payments under operating lease agreements are as follows (in thousands):
OperatingFinance
Year ending December 31, 2022 (remaining)$434 $165 
Year ending December 31, 20231,692 669 
Year ending December 31, 20241,404 672 
Year ending December 31, 2025937 676 
Year ending December 31, 2026310 666 
Remaining future payments120 311 
Total$4,897 $3,159 
Less present value discount(467)(426)
Operating and finance lease liabilities$4,430 $2,733 
XML 38 R21.htm IDEA: XBRL DOCUMENT v3.22.2.2
Loans and Security Agreement
9 Months Ended
Sep. 30, 2022
Debt Disclosure [Abstract]  
Loans and Security Agreement Loan and Security Agreement
On March 16, 2020, the Company and Rockwell Transportation, Inc., as Borrowers, entered into a Loan and Security Agreement (the "Loan Agreement") with Innovatus Life Sciences Lending Fund I, LP ("Innovatus"), as collateral agent and the lenders party thereto, pursuant to which Innovatus, as a lender, agreed to make certain term loans to the Company in the aggregate principal amount of up to $35.0 million (the "Term Loans"). Funding of the first $22.5 million tranche was completed on March 16, 2020. The Company is no longer eligible to draw on a second tranche of $5.0 million or a third tranche of $7.5 million, which were tied to the achievement of certain milestones by a specific date. Net draw down proceeds were $21.2 million with closing costs of $1.3 million.
In connection with each funding of the Term Loans, the Company is required to issue to Innovatus a warrant (the “Warrants”) to purchase a number of shares of the Company’s common stock equal to 3.5% of the principal amount of the relevant Term Loan funded divided by the exercise price, which will be based on the lower of (i) the volume weighted average closing price of the Company’s stock for the 5-trading day period ending on the last trading day immediately preceding the execution of the Loan Agreement or (ii) the closing price on the last trading day immediately preceding the execution of the Loan Agreement (or for the second and third tranches only at the lower of (i) $18.15 per share or (ii) the volume weighted average closing price of the Company’s stock for the 5-trading day period ending on the last trading day immediately preceding the relevant Term Loan funding). The Warrants may be exercised on a cashless basis and are immediately exercisable through the seventh anniversary of the applicable funding date. The number of shares of common stock for which each Warrant is exercisable and the associated exercise price are subject to certain proportional adjustments as set forth in such Warrant. In connection with the first tranche of the Term Loans, the Company issued a Warrant to Innovatus, exercisable for an aggregate of 43,388 shares of the Company’s common stock at an exercise price of $18.15 per share. The Company evaluated the warrant under ASC 470, Debt, and recognized an additional debt discount of approximately $0.5 million based on the relative fair value of the base instruments and warrants. The Company calculated the fair value of the warrant using the Black-Scholes model.

The Company is entitled to make interest-only payments for thirty months, or up to thirty-six months if certain conditions are met. The Term Loans will mature on March 16, 2025, and will bear interest at the greater of (i) Prime Rate (as defined in the Loan Agreement) and (ii) 4.75%, plus 4.00% with an initial interest rate of 8.75% per annum and an effective interest rate of 10.9%. The Company has the option, under certain circumstances, to add 1.00% of such interest rate amount to the then outstanding principal balance in lieu of paying such amount in cash. For the three months ended September 30, 2022 and 2021, interest expense amounted to $0.4 million and $0.6 million, respectively. For the nine months ended September 30, 2022 and 2021, interest expense amounted to $1.2 million and $1.8 million, respectively.

The Loan Agreement is secured by all assets of the Company and Rockwell Transportation, Inc. Proceeds are used for working capital purposes. The Loan Agreement contains customary representations and warranties and covenants, subject to customary carve outs, and includes financial covenants related to liquidity and trailing twelve months sales of TRIFERIC®, with the latter beginning with the period ending December 31, 2020. The Company cannot assure you that we can maintain compliance with the covenants under our Loan Agreement, which may result in an event of default. The Company's ability to comply with these covenants may be adversely affected by events beyond its control. For example, the Loan Agreement contains certain financial covenants relating to sales and, as a result of the ongoing COVID-19 pandemic and its effect on the Company's sales activities, among other factors, the Company may not be able to satisfy such covenants in the future. If the Company is unable to comply with the covenants under the Loan Agreement, it would pursue all available cure options in order to regain compliance. However, the Company may not be able to mutually agree with Innovatus on appropriate remedies to cure a future breach of a covenant, which could give rise to an event of default. If the Company is unable to avoid an event of default, any required repayments could have an adverse effect on its liquidity.

In September 2021, the Company entered into an amendment to the Loan Agreement in which the Company, in exchange for Innovatus lowering the sales covenants, agreed to (i) prepay an aggregate principal amount of $7,500,000 in ten installments commencing on December 1, 2021; (ii) pay an additional prepayment premium of 5% on prepaid amounts if the Company elects to prepay all outstanding Term Loans on or before September 24, 2023 and (iii) maintain minimum liquidity of no less than $5,000,000 if the aggregate principal amount of Term Loans is greater than $15,000,000 pursuant to the liquidity covenant in the Loan Agreement.

On March 31, 2022, the Collateral Agent and Lenders consented to the delivery to Collateral Agent and Lenders of its annual audited financial statements for the fiscal year 2021 by April 15, 2022 as opposed to within 90 days of December 31, 2021, as required pursuant to Loan Agreement.

As of September 30, 2022, the Company was in compliance with all covenants under the Loan Agreement.

As of September 30, 2022, the outstanding balance of the Term Loan was $14.1 million, net of unamortized issuance costs and discount of $0.9 million.

The following table reflects the schedule of principal payments on the Term Loan as of September 30, 2022 (in thousands):
Principal Payments
2022$1,000 
20236,000 
20246,000 
20252,000 
$15,000 
XML 39 R22.htm IDEA: XBRL DOCUMENT v3.22.2.2
Insurance Financing Note Payable
9 Months Ended
Sep. 30, 2022
Debt Disclosure [Abstract]  
Insurance Financing Note Payable Insurance Financing Note PayableOn June 2, 2022, the Company entered into a short-term note payable for $1.5 million, bearing interest at 5.40% per annum to finance various insurance policies. Principal and interest payments related to this note began on July 3, 2022 and were paid on a straight-line amortization over 9 months with the final payment due on March 3, 2023. As of September 30, 2022, the Company's insurance note payable balance was $1.0 million.
XML 40 R23.htm IDEA: XBRL DOCUMENT v3.22.2.2
Subsequent Events
9 Months Ended
Sep. 30, 2022
Subsequent Events [Abstract]  
Subsequent Events Subsequent Events
On October 28, 2022, 480,000 Pre-Funded Warrants to purchase common stock pursuant the SPA entered into on May 30, 2022 were exercised. The exercise price of each Pre-Funded Warrant is $0.0001 per share and resulted in gross proceeds of $48.00 (See Note 10 for more detail on the SPA).
On November 9, 2022, Rockwell reacquired its distribution rights to its hemodialysis concentrates products from Baxter and has agreed to terminate the exclusive distribution agreement dated October 2, 2014. Exclusivity and other provisions associated with the distribution agreement terminated November 9, 2022 and the remaining operational elements of the agreement terminate December 31, 2022. Under the exclusive distribution agreement, Baxter distributed and commercialized Rockwell’s hemodialysis concentrates products and provided customer service and order delivery to nearly all United States customers. Following the reacquisition of these rights, Rockwell will now be able to sell its hemodialysis concentrates products to dialysis clinics throughout the United States and around the world.
Rockwell will pay Baxter a fee for the reacquisition of its distribution rights. This fee will be payable in two equal installments on January 1, 2023 and April 1, 2023. To ensure that customer needs continue to be met after January 1, 2023, Baxter and Rockwell are working closely together to transition customers’ purchases of Rockwell’s hemodialysis concentrates from Baxter to Rockwell.
On November 10, 2022, the Company entered into a Second Amendment to the Loan and Security Agreement (the “Second Amendment”) dated as of November 14, 2022 with Innovatus, which amended the Loan Agreement. Pursuant to the Second Amendment, the Company (i) shall prepay an aggregate principal amount of $5.0 million in Term Loans (as defined in the Loan Agreement) in one installment on November 14, 2022; (ii) shall pay interest only payments until September 2023 at which time will resume scheduled debt payments.
Separation of Chief Financial Officer
On November 10, 2022, the Board of Directors of Rockwell terminated the employment of Russell Skibsted as Chief Financial Officer of the Company, effective immediately. The termination of employment of Mr. Skibsted by the Company without cause entitles Mr. Skibsted to severance in accordance with the Employment Agreement, dated September 15, 2020, by and between the Company and Mr. Skibsted (the “Employment Agreement”). The severance benefits under the Employment Agreement are subject to the execution and non-revocation of a release of claims in favor of the Company. In connection with Mr. Skibsted’s termination, the Board of Directors appointed Mark Strobeck, the Company’s Chief Executive Officer, as interim principal financial officer.
XML 41 R24.htm IDEA: XBRL DOCUMENT v3.22.2.2
Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Policies)
9 Months Ended
Sep. 30, 2022
Accounting Policies [Abstract]  
Basis of Presentation The accompanying condensed consolidated interim financial statements include the accounts of the Company and its subsidiaries. All material intercompany balances and transactions have been eliminated in consolidation.
Reverse Stock Split
Reverse Stock Split
On May 9, 2022, the stockholders of the Company authorized the Board of Directors to effect a reverse stock split of all outstanding shares of common stock. The Board of Directors subsequently approved the implementation of a reverse stock split as a ratio of one-for-eleven shares, which became effective on May 13, 2022. The Company’s outstanding stock options were also adjusted to reflect the one-for-eleven reverse stock split of the Company’s common stock. Outstanding stock options were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased. The reverse stock split resulted in an adjustment to the Series X convertible preferred stock conversion prices to reflect a proportional decrease in the number of shares of common stock to be issued upon conversion. All share and per share data in these condensed consolidated financial statements and related notes hereto have been retroactively adjusted to account for the effect of the reverse stock split for the three and nine month periods ended September 30, 2022 and 2021, respectively, and the balance sheet at September 30, 2022 and December 31, 2021.
Use of Estimates
Use of Estimates
The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates.
Leases
Leases
The Company accounts for its leases under Accounting Standards Codification (“ASC”) 842, Leases. Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the consolidated balance sheet as both a right-of-use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term. Variable lease expenses, if any, are recorded when incurred.
In calculating the right-of-use asset and lease liability, the Company elects to combine lease and non-lease components. The Company excludes short-term leases having initial terms of 12 months or less from the new guidance as an accounting policy election and recognizes rent expense on a straight-line basis over the lease term.
Loss Per Share
Loss Per Share
ASC 260, Earnings Per Share, requires dual presentation of basic and diluted earnings per share (“EPS”), with a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS computation. Basic EPS excludes dilution. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that are then sharing in the earnings of the entity.
Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding plus the effect of dilutive potential common shares outstanding during the period determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss per share calculation, common stock warrants, unvested restricted stock units and stock options are considered to be potentially dilutive securities but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive, and therefore, basic and diluted net loss per share were the same for all periods presented.
Adoption of Recent Accounting Pronouncements
Adoption of Recent Accounting Pronouncements
The Company continually assesses new accounting pronouncements to determine their applicability. When it is determined a new accounting pronouncement affects the Company’s financial reporting, the Company undertakes a review to determine the consequences of the change to its consolidated financial statements and assures there are sufficient controls in place to ascertain the Company’s consolidated financial statements properly reflect the change.
In August 2020, the FASB issued ASU No. 2020-06, “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity”, which simplifies the accounting for convertible instruments by eliminating the requirement to separate embedded conversion features from the host contract when the conversion features are not required to be accounted for as derivatives under Topic 815, Derivatives and Hedging, or do not result in substantial premiums accounted for as paid-in capital. By removing the separation model, a convertible debt instrument will be reported as a single liability instrument with no separate accounting for embedded conversion features. This new standard also removes certain settlement conditions required for contracts to qualify for equity classification and simplifies the diluted earnings per share calculations by requiring an entity use the if-converted method and the effect of potential share settlement be included in diluted earnings per share calculations. This new standard will be effective for the Company for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently assessing the impact of adopting this standard on the consolidated financial statements.
XML 42 R25.htm IDEA: XBRL DOCUMENT v3.22.2.2
Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Tables)
9 Months Ended
Sep. 30, 2022
Accounting Policies [Abstract]  
Summary of Potentially Dilutive Securities
The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share for the nine months ended September 30, 2022 and 2021, respectively, because to do so would be anti-dilutive (in common equivalent shares):
As of September 30,
20222021
Options to purchase common stock1,311,691 533,784 
Unvested restricted stock awards891 7,118 
Unvested restricted stock units125,000 31,116 
Preferred stock conversion to common stock1,363,636 — 
Warrants to purchase common stock17,507,268 2,402,442 
Total20,308,486 2,974,460 
XML 43 R26.htm IDEA: XBRL DOCUMENT v3.22.2.2
Revenue Recognition (Tables)
9 Months Ended
Sep. 30, 2022
Revenue from Contract with Customer [Abstract]  
Disaggregation of Revenue
Revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition.
In thousands of U.S. dollars ($) Three Months Ended September 30, 2022Nine Months Ended September 30, 2022
Products By Geographic AreaTotalU.S.Rest of WorldTotalU.S.Rest of World
Drug Revenues
Product Sales – Point-in-time$193 $193 $— $834 $561 $273 
License Fee – Over time65 — 65 192 — 192 
Total Drug Products258 193 65 1,026 561 465 
Concentrates Products
Product Sales – Point-in-time17,953 16,619 1,334 51,035 46,334 4,701 
License Fee – Over time480 480 — 1,436 1,436 — 
Total Concentrate Products18,433 17,099 1,334 52,471 47,770 4,701 
Net Revenue$18,691 $17,292 $1,399 $53,497 $48,331 $5,166 
In thousands of U.S. dollars ($)Three Months Ended September 30, 2021Nine Months Ended September 30, 2021
Products By Geographic AreaTotalU.S.Rest of WorldTotalU.S.Rest of World
Drug Revenues
Product Sales – Point-in-time$217 $217 $— $656 $656 $— 
License Fee – Over time62 — 62 179 — 179 
Total Drug Products279 217 62 835 656 179 
Concentrates Products
Product Sales – Point-in-time15,224 13,541 1,683 44,308 39,768 4,540 
License Fee – Over time485 485 — 1,456 1,456 — 
Total Concentrate Products15,709 14,026 1,683 45,764 41,224 4,540 
Net Revenue$15,988 $14,243 $1,745 $46,599 $41,880 $4,719 
Contract Balances
The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers.
In thousands of U.S. dollars ($)September 30, 2022December 31, 2021
Receivables, which are included in "Trade and other receivables"$7,367 $5,913 
Contract liabilities$6,729 $8,157 
XML 44 R27.htm IDEA: XBRL DOCUMENT v3.22.2.2
Investments - Available-for-Sale (Tables)
9 Months Ended
Sep. 30, 2022
Investments, Debt and Equity Securities [Abstract]  
Investments Available-for-Sale
Investments available-for-sale consisted of the following as of September 30, 2022 and December 31, 2021 (table in thousands):
September 30, 2022
Amortized CostUnrealized GainUnrealized LossAccrued InterestFair Value
Available-for-Sale Securities
Bonds$14,578 $$(1)$$14,584 

December 31, 2021
Amortized CostUnrealized GainUnrealized LossAccrued InterestFair Value
Available-for-Sale Securities
Bonds$9,143 $$— $14 $9,158 
XML 45 R28.htm IDEA: XBRL DOCUMENT v3.22.2.2
Inventory (Tables)
9 Months Ended
Sep. 30, 2022
Inventory Disclosure [Abstract]  
Schedule Components of Inventory
Components of inventory, net of reserves, as of September 30, 2022 and December 31, 2021 are as follows (table in thousands):
September 30,
2022
December 31,
2021
Raw Materials$4,074 $3,434 
Work in Process336 201 
Finished Goods1,803 1,964 
Total$6,213 $5,599 
XML 46 R29.htm IDEA: XBRL DOCUMENT v3.22.2.2
Property and Equipment (Tables)
9 Months Ended
Sep. 30, 2022
Property, Plant and Equipment [Abstract]  
Schedule of Major Classes of Property and Equipment
As of September 30, 2022 and December 31, 2021, the Company’s property and equipment consisted of the following (table in thousands):
September 30,
2022
December 31,
2021
Leasehold Improvements$1,257 $1,204 
Machinery and Equipment5,985 5,864 
Information Technology & Office Equipment1,845 1,845 
Laboratory Equipment660 676 
9,747 9,589 
Accumulated Depreciation(7,483)(7,103)
Property and Equipment, net$2,264 $2,486 
XML 47 R30.htm IDEA: XBRL DOCUMENT v3.22.2.2
Accrued Liabilities (Tables)
9 Months Ended
Sep. 30, 2022
Payables and Accruals [Abstract]  
Schedule of Accrued Liabilities
Accrued liabilities as of September 30, 2022 and December 31, 2021 consisted of the following (table in thousands):
September 30,
2022
December 31,
2021
Accrued Research & Development Expense$65 $366 
Accrued Compensation and Benefits3,006 1,791 
Accrued Unvouchered Receipts581 796 
Accrued Workers Compensation294 382 
Other Accrued Liabilities1,941 1,755 
Total Accrued Liabilities$5,887 $5,090 
XML 48 R31.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stock-Based Compensation (Tables)
9 Months Ended
Sep. 30, 2022
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]  
Schedule of Total Stock-Based Compensation Expense
The Company recognized total stock-based compensation expense during the three and nine months ended September 30, 2022 and 2021 as follows (table in thousands):
Three Months Ended
September 30,
Nine Months Ended
September 30,
2022202120222021
Service-based awards:
Restricted stock units$46 $81 $84 $263 
Stock option awards130 315 401 1,050 
176 396 485 1,313 
Performance-based awards:
Restricted stock awards— — (391)(391)
Stock option awards— (35)— (364)
— (35)(391)(755)
Total$176 $361 $94 $558 
Restricted stock awards  
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]  
Schedule of Restricted Stock Awards
A summary of the Company’s restricted stock awards during the nine months ended September 30, 2022 is as follows:
Number of SharesWeighted Average
Grant-Date
Fair Value
Unvested at January 1, 20227,118 $62.70 
Forfeited(6,227)$62.70 
Unvested at September 30, 2022891 $62.70 
A summary of the Company’s restricted stock awards during the nine months ended September 30, 2021 is as follows:
Number of SharesWeighted Average
Grant-Date
Fair Value
Unvested at January 1, 202113,345 $62.70 
Forfeited(6,227)$62.70 
Unvested at September 30, 20217,118 $62.70 
Restricted stock units - service based awards  
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]  
Schedule of Restricted Stock Awards
A summary of the Company’s service-based restricted stock units during the nine months ended September 30, 2022 is as follows:
Number of SharesWeighted Average
Grant-Date
Fair Value
Unvested at January 1, 202229,289 $12.87 
Granted125,000 1.47 
Vested(23,515)11.33 
Forfeited(5,774)19.00 
Unvested at September 30, 2022125,000 $1.47 

A summary of the Company’s service-based restricted stock units during the nine months ended September 30, 2021 is as follows:
Number of SharesWeighted Average
Grant-Date
Fair Value
Unvested at January 1, 202124,136 $28.60 
Granted28,186 9.90 
Vested(20,134)26.18 
Forfeited(1,073)52.91 
Unvested at September 30, 202131,115 $12.87 
Stock option awards - service based awards  
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]  
Schedule of Stock Option Assumptions
The fair value of the service-based stock options granted for the nine months ended September 30, 2022 were based on the following assumptions:
September 30,
2022
Exercise price
$1.28 - $1.66
Expected stock price volatility
76.2% - 78.5%
Risk-free interest rate
1.97% - 3.44%
Term (years)
5.5 - 6
Schedule of Stock Options Activity
A summary of the Company’s service-based stock option activity for the nine months ended September 30, 2022 is as follows:
Shares
Underlying
Options
Weighted
Average Exercise
Price
Weighted
Average
Remaining
Contractual
Term
Aggregate
Intrinsic
Value
Outstanding at January 1, 2022528,591 $32.01 7.5$— 
Granted898,659 1.49 5.5— 
Forfeited(30,093)15.11 — — 
Expired(85,466)82.09 — — 
Outstanding at September 30, 20221,311,691 $8.23 9.1$— 
Exercisable at September 30, 2022243,973 $29.31 6.9$— 
A summary of the Company’s service-based stock option activity for the nine months ended September 30, 2021 is as follows:
Shares
Underlying
Options
Weighted
Average Exercise
Price
Weighted
Average
Remaining
Contractual
Term
Aggregate
Intrinsic
Value
Outstanding at January 1, 2021519,814 $50.05 6.6$— 
Granted170,197 9.79 6.0— 
Forfeited(35,025)25.30 — — 
Expired(121,202)78.76 — — 
Outstanding at September 30, 2021533,784 $32.45 7.7$— 
Exercisable at September 30, 2021230,858 $54.56 5.8$— 
XML 49 R32.htm IDEA: XBRL DOCUMENT v3.22.2.2
Leases (Tables)
9 Months Ended
Sep. 30, 2022
Leases [Abstract]  
Summary of Lease Costs
The following summarizes quantitative information about the Company’s operating leases (table in thousands):
Three Months Ended September 30, 2022Three Months Ended September 30, 2021Nine Months Ended September 30, 2022Nine Months Ended September 30, 2021
Operating leases
Operating lease cost$410 $457 $1,289 $1,309 
Variable lease cost101 94 287 286 
Operating lease expense511 551 1,576 1,595 
Finance leases
Amortization of right-of-use assets141 73 424 184 
Interest on lease obligations44 22 136 55 
Finance lease expense185 95 560 239 
Short-term lease rent expense14 12 
Total rent expense$701 $650 $2,150 $1,846 
Other information
Operating cash flows from operating leases$427 $444 $1,338 $1,298 
Operating cash flows from finance leases$44 $22 $136 $56 
Financing cash flows from finance leases$121 $59 $359 $152 
Right of use assets exchanged for operating lease liabilities$768 $718 $768 $4,089 
Right of use assets exchanged for finance lease liabilities$— $588 $— $1,365 
Weighted-average remaining lease term – operating leases3.23.73.23.7
Weighted-average remaining lease term – finance leases4.75.54.75.5
Weighted-average discount rate – operating leases6.4 %6.3 %6.4 %6.3 %
Weighted-average discount rate – finance leases6.4 %5.9 %6.4 %5.9 %
Operating Lease Maturities
Future minimum rental payments under operating lease agreements are as follows (in thousands):
OperatingFinance
Year ending December 31, 2022 (remaining)$434 $165 
Year ending December 31, 20231,692 669 
Year ending December 31, 20241,404 672 
Year ending December 31, 2025937 676 
Year ending December 31, 2026310 666 
Remaining future payments120 311 
Total$4,897 $3,159 
Less present value discount(467)(426)
Operating and finance lease liabilities$4,430 $2,733 
Finance Lease Maturities
Future minimum rental payments under operating lease agreements are as follows (in thousands):
OperatingFinance
Year ending December 31, 2022 (remaining)$434 $165 
Year ending December 31, 20231,692 669 
Year ending December 31, 20241,404 672 
Year ending December 31, 2025937 676 
Year ending December 31, 2026310 666 
Remaining future payments120 311 
Total$4,897 $3,159 
Less present value discount(467)(426)
Operating and finance lease liabilities$4,430 $2,733 
XML 50 R33.htm IDEA: XBRL DOCUMENT v3.22.2.2
Loans and Security Agreement (Tables)
9 Months Ended
Sep. 30, 2022
Debt Disclosure [Abstract]  
Schedule of Principal Payments on Term Loan
The following table reflects the schedule of principal payments on the Term Loan as of September 30, 2022 (in thousands):
Principal Payments
2022$1,000 
20236,000 
20246,000 
20252,000 
$15,000 
XML 51 R34.htm IDEA: XBRL DOCUMENT v3.22.2.2
Description of Business (Details)
9 Months Ended
Sep. 30, 2022
ft²
facility
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Number of facilities | facility 3
Operating space | ft² 175,000
XML 52 R35.htm IDEA: XBRL DOCUMENT v3.22.2.2
Liquidity and Capital Resources (Details) - USD ($)
9 Months Ended
Jun. 30, 2022
Jun. 16, 2022
Jun. 15, 2022
Jun. 02, 2022
May 30, 2022
Apr. 06, 2022
Sep. 30, 2022
Sep. 30, 2021
Apr. 08, 2022
Liquidity and Going Concern Considerations [Line Items]                  
Cash, cash equivalents and investments available-for-sale             $ 27,600,000    
Working capital             23,000,000    
Net cash used in operating activities             (16,820,000) $ (24,508,000)  
Minimum cash covenant             10,000,000    
Proceeds from sale of equity, net       $ 14,900,000          
Series X Convertible Preferred Stock                  
Liquidity and Going Concern Considerations [Line Items]                  
Consideration received           $ 15,000,000      
Proceeds from sale of equity, net           14,900,000      
Registered Direct Offering Warrants                  
Liquidity and Going Concern Considerations [Line Items]                  
Number of shares of common stock for which warrant is exercisable (in shares)         7,788,480        
Discount from stock price (dollars per share)         $ 0.0001        
Exercise price of warrant (in dollars per share)         $ 0.0001        
PIPE Purchase Agreement Pre-Funded Warrant                  
Liquidity and Going Concern Considerations [Line Items]                  
Number of shares of common stock for which warrant is exercisable (in shares)         1,267,897        
Discount from stock price (dollars per share)         $ 0.0001        
Exercise price of warrant (in dollars per share)         $ 0.0001        
PIPE Purchase Agreement Warrant                  
Liquidity and Going Concern Considerations [Line Items]                  
Number of shares of common stock for which warrant is exercisable (in shares)         9,900,990        
Exercise price of warrant (in dollars per share)         $ 1.39        
Warrant price (dollars per share)         $ 0.125        
Registered Direct Offering                  
Liquidity and Going Concern Considerations [Line Items]                  
Number of shares issued         844,613        
Common stock trading price (in dollars per share)         $ 1.39        
Registered Direct Offering | Registered Direct Offering Warrants                  
Liquidity and Going Concern Considerations [Line Items]                  
Discount from stock price (dollars per share)         0.0001        
Exercise price of warrant (in dollars per share)         $ 0.0001        
Da Vita Healthcare Partners Inc | Share Issuance, Tranche One                  
Liquidity and Going Concern Considerations [Line Items]                  
Proceeds from issuance of convertible preferred stock           7,500,000      
Da Vita Healthcare Partners Inc | Share Issuance, Tranche Two                  
Liquidity and Going Concern Considerations [Line Items]                  
Proceeds from issuance of convertible preferred stock   $ 7,500,000 $ 7,500,000            
Da Vita Healthcare Partners Inc | Private Placement | Series X Convertible Preferred Stock                  
Liquidity and Going Concern Considerations [Line Items]                  
Sale of stock, aggregate consideration authorized           $ 15,000,000      
Consideration received     $ 15,000,000            
Common stock trading price (in dollars per share)           $ 1,000      
Da Vita Healthcare Partners Inc | Private Placement | Share Issuance, Tranche One | Series X Convertible Preferred Stock                  
Liquidity and Going Concern Considerations [Line Items]                  
Number of shares issued           7,500      
Da Vita Healthcare Partners Inc | Private Placement | Share Issuance, Tranche Two | Series X Convertible Preferred Stock                  
Liquidity and Going Concern Considerations [Line Items]                  
Number of shares issued   7,500 7,500            
Cantor Fitzgerald & Co | Controlled Equity Offering                  
Liquidity and Going Concern Considerations [Line Items]                  
Sale of stock, aggregate consideration authorized             $ 12,200,000   $ 12,200,000
Number of shares issued 7,500                
Consideration received $ 15,135                
XML 53 R36.htm IDEA: XBRL DOCUMENT v3.22.2.2
Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Details)
9 Months Ended
May 09, 2022
Sep. 30, 2022
shares
Sep. 30, 2021
shares
Accounting Policies [Abstract]      
Reverse stock split 0.09    
Net Earnings per Share      
Securities excluded from diluted loss per share calculation (in shares)   20,308,486 2,974,460
Options to purchase common stock      
Net Earnings per Share      
Securities excluded from diluted loss per share calculation (in shares)   1,311,691 533,784
Unvested restricted stock awards      
Net Earnings per Share      
Securities excluded from diluted loss per share calculation (in shares)   891 7,118
Unvested restricted stock units      
Net Earnings per Share      
Securities excluded from diluted loss per share calculation (in shares)   125,000 31,116
Preferred stock conversion to common stock      
Net Earnings per Share      
Securities excluded from diluted loss per share calculation (in shares)   1,363,636 0
Warrants to purchase common stock      
Net Earnings per Share      
Securities excluded from diluted loss per share calculation (in shares)   17,507,268 2,402,442
XML 54 R37.htm IDEA: XBRL DOCUMENT v3.22.2.2
Revenue Recognition - Nature of Goods and Services (Details)
9 Months Ended
Sep. 30, 2022
agreement
Revenue from Contract with Customer [Abstract]  
Number of distribution and license agreements 5
Customers average payment term 30 days
Distributors average payment term 45 days
XML 55 R38.htm IDEA: XBRL DOCUMENT v3.22.2.2
Revenue Recognition - Disaggregation of Revenue (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Disaggregation of Revenue [Line Items]        
Net Revenue $ 18,691 $ 15,988 $ 53,497 $ 46,599
Drug products        
Disaggregation of Revenue [Line Items]        
Net Revenue 258 279 1,026 835
Concentrates Products        
Disaggregation of Revenue [Line Items]        
Net Revenue 18,433 15,709 52,471 45,764
U.S.        
Disaggregation of Revenue [Line Items]        
Net Revenue 17,292 14,243 48,331 41,880
U.S. | Drug products        
Disaggregation of Revenue [Line Items]        
Net Revenue 193 217 561 656
U.S. | Concentrates Products        
Disaggregation of Revenue [Line Items]        
Net Revenue 17,099 14,026 47,770 41,224
Rest of World        
Disaggregation of Revenue [Line Items]        
Net Revenue 1,399 1,745 5,166 4,719
Rest of World | Drug products        
Disaggregation of Revenue [Line Items]        
Net Revenue 65 62 465 179
Rest of World | Concentrates Products        
Disaggregation of Revenue [Line Items]        
Net Revenue 1,334 1,683 4,701 4,540
Product Sales – Point-in-time | Drug product sales        
Disaggregation of Revenue [Line Items]        
Net Revenue 193 217 834 656
Product Sales – Point-in-time | Concentrates product sales        
Disaggregation of Revenue [Line Items]        
Net Revenue 17,953 15,224 51,035 44,308
Product Sales – Point-in-time | U.S. | Drug product sales        
Disaggregation of Revenue [Line Items]        
Net Revenue 193 217 561 656
Product Sales – Point-in-time | U.S. | Concentrates product sales        
Disaggregation of Revenue [Line Items]        
Net Revenue 16,619 13,541 46,334 39,768
Product Sales – Point-in-time | Rest of World | Drug product sales        
Disaggregation of Revenue [Line Items]        
Net Revenue 0 0 273 0
Product Sales – Point-in-time | Rest of World | Concentrates product sales        
Disaggregation of Revenue [Line Items]        
Net Revenue 1,334 1,683 4,701 4,540
License Fee – Over time | Drug license fee        
Disaggregation of Revenue [Line Items]        
Net Revenue 65 62 192 179
License Fee – Over time | Concentrates product license fee        
Disaggregation of Revenue [Line Items]        
Net Revenue 480 485 1,436 1,456
License Fee – Over time | U.S. | Drug license fee        
Disaggregation of Revenue [Line Items]        
Net Revenue 0 0 0 0
License Fee – Over time | U.S. | Concentrates product license fee        
Disaggregation of Revenue [Line Items]        
Net Revenue 480 485 1,436 1,456
License Fee – Over time | Rest of World | Drug license fee        
Disaggregation of Revenue [Line Items]        
Net Revenue 65 62 192 179
License Fee – Over time | Rest of World | Concentrates product license fee        
Disaggregation of Revenue [Line Items]        
Net Revenue $ 0 $ 0 $ 0 $ 0
XML 56 R39.htm IDEA: XBRL DOCUMENT v3.22.2.2
Revenue Recognition - Contract Balances (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Revenue from Contract with Customer [Abstract]    
Receivables, which are included in "Trade and other receivables" $ 7,367 $ 5,913
Contract liabilities $ 6,729 $ 8,157
XML 57 R40.htm IDEA: XBRL DOCUMENT v3.22.2.2
Revenue Recognition - Narrative (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Revenue Recognition [Line Items]          
Impairment losses $ 0 $ 0 $ 0 $ 0  
Contract assets 0   0   $ 0
Revenue performance obligation 6,700,000   6,700,000    
Baxter Healthcare Organization          
Revenue Recognition [Line Items]          
Revenue performance obligation 3,800,000   3,800,000    
Concentrates Products          
Revenue Recognition [Line Items]          
Reserve for returns $ 0   $ 0   $ 0
XML 58 R41.htm IDEA: XBRL DOCUMENT v3.22.2.2
Investments - Available-for-Sale (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Investments, Debt and Equity Securities [Abstract]    
Amortized Cost $ 14,578 $ 9,143
Unrealized Gain 6 1
Unrealized Loss (1) 0
Accrued Interest 1 14
Fair Value $ 14,584 $ 9,158
XML 59 R42.htm IDEA: XBRL DOCUMENT v3.22.2.2
Inventory (Details) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2022
Dec. 31, 2021
Inventory [Line Items]    
Raw Materials $ 4,074 $ 3,434
Work in Process 336 201
Finished Goods 1,803 1,964
Total 6,213 5,599
Inventory, noncurrent 1,193 1,523
Inventory, net 5,020 $ 4,076
Triferic Inventory    
Inventory [Line Items]    
Raw Materials 900  
Inventory, noncurrent 1,200  
Inventory, net $ 1,200  
Useful life 25 years  
Triferic API    
Inventory [Line Items]    
Inventory, net $ 300  
XML 60 R43.htm IDEA: XBRL DOCUMENT v3.22.2.2
Property and Equipment (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Property and equipment          
Gross property and equipment $ 9,747   $ 9,747   $ 9,589
Accumulated Depreciation (7,483)   (7,483)   (7,103)
Property and Equipment, net 2,264   2,264   2,486
Depreciation expense 100 $ 100 400 $ 500  
Leasehold Improvements          
Property and equipment          
Gross property and equipment 1,257   1,257   1,204
Machinery and Equipment          
Property and equipment          
Gross property and equipment 5,985   5,985   5,864
Information Technology & Office Equipment          
Property and equipment          
Gross property and equipment 1,845   1,845   1,845
Laboratory Equipment          
Property and equipment          
Gross property and equipment $ 660   $ 660   $ 676
XML 61 R44.htm IDEA: XBRL DOCUMENT v3.22.2.2
Accrued Liabilities (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Payables and Accruals [Abstract]    
Accrued Research & Development Expense $ 65 $ 366
Accrued Compensation and Benefits 3,006 1,791
Accrued Unvouchered Receipts 581 796
Accrued Workers Compensation 294 382
Other Accrued Liabilities 1,941 1,755
Total Accrued Liabilities $ 5,887 $ 5,090
XML 62 R45.htm IDEA: XBRL DOCUMENT v3.22.2.2
Deferred Revenue (Details) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
May 31, 2022
Jun. 30, 2021
Sep. 30, 2020
Jan. 31, 2020
Oct. 31, 2014
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2016
Dec. 31, 2021
Deferred Revenue Arrangement [Line Items]                      
Deferred revenue           $ 6,729,000   $ 6,729,000     $ 8,157,000
Baxter Healthcare Organization                      
Deferred Revenue Arrangement [Line Items]                      
Term of agreement         10 years            
Upfront payment         $ 20,000,000            
Recognized deferred revenue           500,000 $ 500,000 1,400,000 $ 1,500,000    
Deferred revenue           3,800,000   3,800,000     5,200,000
Wanbang Biopharmaceutical                      
Deferred Revenue Arrangement [Line Items]                      
Upfront payment                   $ 4,000,000  
Recognized deferred revenue           100,000 100,000 200,000 200,000    
Deferred revenue           2,300,000   2,300,000     2,500,000
Sun Pharma Agreements                      
Deferred Revenue Arrangement [Line Items]                      
Upfront payment       $ 100,000              
Recognized deferred revenue           2,500 2,500 7,500 7,500    
Deferred revenue           72,500   72,500     80,000
Jeil Pharma Agreements                      
Deferred Revenue Arrangement [Line Items]                      
Upfront payment     $ 200,000                
Recognized deferred revenue           5,200 2,500 13,000 7,500    
Deferred revenue           400,000   400,000     200,000
Milestone consideration $ 200,000                    
Drogsan Agreements                      
Deferred Revenue Arrangement [Line Items]                      
Upfront payment   $ 150,000                  
Recognized deferred revenue           3,750 $ 3,750 11,250 $ 11,250    
Deferred revenue           $ 130,000   $ 130,000     $ 150,000
XML 63 R46.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stockholders’ Equity (Details)
9 Months Ended
Jun. 30, 2022
USD ($)
$ / shares
shares
Jun. 16, 2022
USD ($)
shares
Jun. 15, 2022
USD ($)
shares
Jun. 02, 2022
USD ($)
May 30, 2022
$ / shares
shares
May 09, 2022
Apr. 06, 2022
USD ($)
$ / shares
shares
Sep. 30, 2022
USD ($)
$ / shares
shares
Sep. 30, 2021
USD ($)
Apr. 08, 2022
USD ($)
Dec. 31, 2021
$ / shares
shares
Class of Stock [Line Items]                      
Reverse stock split           0.09          
Stock issuance costs | $       $ 100,000       $ 106,000 $ 0    
Proceeds from sale of equity, net | $       14,900,000              
Preferred shares, shares authorized (in shares) | shares               2,000,000     2,000,000
Preferred shares, par value (in dollars per share) | $ / shares               $ 0.0001     $ 0.0001
Preferred shares, shares issued (in shares) | shares               15,000     0
Preferred shares, shares outstanding (in shares) | shares               15,000     0
Common shares, shares authorized (in shares) | shares               170,000,000     170,000,000
Common shares, par value (in dollars per share) | $ / shares               $ 0.0001     $ 0.0001
Common shares, shares outstanding (in shares) | shares               11,152,673     8,544,225
Common shares, shares issued (in shares) | shares               11,152,673     8,544,225
Proceeds from the issuance of common stock | $       2,000,000       $ 15,016,000 $ 0    
Proceeds from issuance of warrants | $       $ 12,900,000              
Registered Direct Offering Warrants                      
Class of Stock [Line Items]                      
Number of shares of common stock for which warrant is exercisable (in shares) | shares         7,788,480            
Discount from stock price (dollars per share) | $ / shares         $ 0.0001            
Exercise price of warrant (in dollars per share) | $ / shares         $ 0.0001            
Ownership threshold         9.99%            
Pre-funded warrants outstanding (in shares) | shares               7,311,000      
PIPE Purchase Agreement Warrant                      
Class of Stock [Line Items]                      
Number of shares of common stock for which warrant is exercisable (in shares) | shares         9,900,990            
Exercise price of warrant (in dollars per share) | $ / shares         $ 1.39            
Pre-funded warrants outstanding (in shares) | shares               9,900,990      
Warrant price (dollars per share) | $ / shares         $ 0.125            
PIPE Purchase Agreement Pre-Funded Warrant                      
Class of Stock [Line Items]                      
Number of shares of common stock for which warrant is exercisable (in shares) | shares         1,267,897            
Discount from stock price (dollars per share) | $ / shares         $ 0.0001            
Exercise price of warrant (in dollars per share) | $ / shares         $ 0.0001            
Pre-funded warrants outstanding (in shares) | shares               0      
Series X Convertible Preferred Stock                      
Class of Stock [Line Items]                      
Interest rate percentage             1.00%        
Common stock trading price (per share) | $ / shares             $ 22.00        
Common stock trading period             30 days        
Conversion price (per share) | $ / shares             $ 11.00        
Convertible preferred stock (in shares)             91        
Outstanding common stock, percentage             9.90%        
Outstanding common stock, not to exceed, percentage             19.90%        
Percentage of investment owned             50.00%        
Maximum working capital line | $             $ 5,000,000        
Consideration received | $             15,000,000        
Stock issuance costs | $             100,000        
Proceeds from sale of equity, net | $             14,900,000        
Da Vita Healthcare Partners Inc | Share Issuance, Tranche One                      
Class of Stock [Line Items]                      
Proceeds from issuance of convertible preferred stock | $             7,500,000        
Da Vita Healthcare Partners Inc | Share Issuance, Tranche Two                      
Class of Stock [Line Items]                      
Proceeds from issuance of convertible preferred stock | $   $ 7,500,000 $ 7,500,000                
Private Placement | Da Vita Healthcare Partners Inc | Series X Convertible Preferred Stock                      
Class of Stock [Line Items]                      
Sale of stock, aggregate consideration authorized | $             15,000,000        
Sale of stock, capital proceeds threshold | $             $ 15,000,000        
Common stock trading price (in dollars per share) | $ / shares             $ 1,000        
Consideration received | $     $ 15,000,000                
Private Placement | Da Vita Healthcare Partners Inc | Series X Convertible Preferred Stock | Share Issuance, Tranche One                      
Class of Stock [Line Items]                      
Number of shares issued | shares             7,500        
Private Placement | Da Vita Healthcare Partners Inc | Series X Convertible Preferred Stock | Share Issuance, Tranche Two                      
Class of Stock [Line Items]                      
Number of shares issued | shares   7,500 7,500                
Controlled Equity Offering | Cantor Fitzgerald & Co                      
Class of Stock [Line Items]                      
Sale of stock, aggregate consideration authorized | $               $ 12,200,000   $ 12,200,000  
Number of shares issued | shares 7,500                    
Consideration received | $ $ 15,135                    
Stock issuance costs | $ $ 378                    
Weighted-average selling price (dollars per share) | $ / shares $ 2.02                    
Registered Direct Offering                      
Class of Stock [Line Items]                      
Number of shares issued | shares         844,613            
Common stock trading price (in dollars per share) | $ / shares         $ 1.39            
Registered Direct Offering | Registered Direct Offering Warrants                      
Class of Stock [Line Items]                      
Discount from stock price (dollars per share) | $ / shares         0.0001            
Exercise price of warrant (in dollars per share) | $ / shares         $ 0.0001            
XML 64 R47.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stock-Based Compensation - Share-Based Compensation Expense (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Total share based compensation expense $ 176,000 $ 361,000 $ 94,000 $ 558,000
Service based awards        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Total share based compensation expense 176,000 396,000 485,000 1,313,000
Restricted stock units - service based awards        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Total share based compensation expense 46,193 81,000 83,607 263,000
Stock option awards - service based awards        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Total share based compensation expense 130,000 315,000 401,000 1,050,000
Performance based awards        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Total share based compensation expense 0 (35,000) (391,000) (755,000)
Restricted stock awards - performance based awards        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Total share based compensation expense 0 0 (391,000) (391,000)
Stock option awards - performance based awards        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Total share based compensation expense $ 0 $ (35,000) $ 0 $ (364,000)
XML 65 R48.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stock-Based Compensation - Restricted Stock Awards (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Weighted Average Grant-Date Fair Value        
Stock based compensation expenses $ 176 $ 361 $ 94 $ 558
Restricted stock awards        
Weighted Average Grant-Date Fair Value        
Vesting period     20 months  
Restricted stock awards - performance based awards        
Number of Shares        
Unvested at beginning of period (in shares)     7,118 13,345
Forfeited (in shares)     (6,227) (6,227)
Unvested at end of period (in shares) 891 7,118 891 7,118
Weighted Average Grant-Date Fair Value        
Unvested at beginning of period (in dollars per share)     $ 62.70 $ 62.70
Forfeited (in dollars per share)     62.70 62.70
Unvested at end of period (in dollars per share) $ 62.70 $ 62.70 $ 62.70 $ 62.70
Unvested, number of shares (in shares) 891 7,118 891 7,118
Forfeited (in shares)     (6,227) (6,227)
Stock based compensation expenses $ 0 $ 0 $ (391) $ (391)
XML 66 R49.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stock-Based Compensation - Service Based Restricted Stock Units (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Weighted Average Grant-Date Fair Value        
Stock based compensation expenses $ 176,000 $ 361,000 $ 94,000 $ 558,000
Restricted stock units - service based awards        
Number of Shares        
Unvested at beginning of period (in shares)     29,289 24,136
Granted (in shares)     125,000 28,186
Vested (in shares)     (23,515) (20,134)
Forfeited (in shares)     (5,774) (1,073)
Unvested at end of period (in shares) 125,000 31,115 125,000 31,115
Weighted Average Grant-Date Fair Value        
Unvested at beginning of period (in dollars per share)     $ 12.87 $ 28.60
Granted (in dollars per share)     1.47 9.90
Vested (in dollars per share)     11.33 26.18
Forfeited (in dollars per share)     19.00 52.91
Unvested at end of period (in dollars per share) $ 1.47 $ 12.87 $ 1.47 $ 12.87
Stock based compensation expenses $ 46,193 $ 81,000 $ 83,607 $ 263,000
Unrecognized stock-based compensation expense $ 100,000   $ 100,000  
Unrecognized stock-based compensation expense, weighted average remaining term (in years) (less than)     1 year  
Restricted stock units - service based awards | Minimum        
Weighted Average Grant-Date Fair Value        
Vesting period     1 year  
Restricted stock units - service based awards | Maximum        
Weighted Average Grant-Date Fair Value        
Vesting period     3 years  
XML 67 R50.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stock-Based Compensation - Service Based Stock Options - Fair Value Assumptions (Details) - Stock option awards - service based awards
9 Months Ended
Sep. 30, 2022
$ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Expected stock price volatility, minimum 76.20%
Expected stock price volatility, maximum 78.50%
Risk-free interest rate, minimum 1.97%
Risk-free interest rate, maximum 3.44%
Minimum  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Exercise price (in dollars per share) $ 1.28
Term (years) 5 years 6 months
Maximum  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Exercise price (in dollars per share) $ 1.66
Term (years) 6 years
XML 68 R51.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stock-Based Compensation - Service Based Stock Options (Details) - Stock option awards - service based awards - USD ($)
9 Months Ended 12 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Dec. 31, 2020
Shares Underlying Options        
Outstanding at the beginning of the period (in shares) 528,591 519,814 519,814  
Granted (in shares) 898,659 170,197    
Forfeited (in shares) (30,093) (35,025)    
Expired (in shares) (85,466) (121,202)    
Outstanding at the end of the period (in shares) 1,311,691 533,784 528,591 519,814
Exercisable at end of period (in shares) 243,973 230,858    
Weighted Average Exercise Price        
Outstanding at the beginning of the period (in dollars per share) $ 32.01 $ 50.05 $ 50.05  
Granted (in dollars per share) 1.49 9.79    
Forfeited (in dollars per share) 15.11 25.30    
Expired (in dollar per share) 82.09 78.76    
Outstanding at the end of the period (in dollars per share) 8.23 32.45 $ 32.01 $ 50.05
Exercisable at end of the period (in dollars per share) $ 29.31 $ 54.56    
Weighted Average Remaining Contractual Term        
Outstanding 9 years 1 month 6 days 7 years 8 months 12 days 7 years 6 months 6 years 7 months 6 days
Granted 5 years 6 months 6 years    
Exercisable at end of the period 6 years 10 months 24 days 5 years 9 months 18 days    
Aggregate Intrinsic Value        
Outstanding $ 0 $ 0 $ 0 $ 0
Exercisable at end of the period $ 0 $ 0    
XML 69 R52.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stock-Based Compensation - Service Based Stock Options - Others (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock based compensation expenses $ 176 $ 361 $ 94 $ 558
Stock option awards - service based awards        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Granted (in shares)     898,659 170,197
Forfeited (in shares)     30,093 35,025
Expirations (in shares)     85,466 121,202
Stock based compensation expenses 130 $ 315 $ 401 $ 1,050
Unrecognized stock-based compensation expenses $ 1,400   $ 1,400  
Unrecognized stock-based compensation expense, weighted average remaining term (in years)     3 years 7 months 6 days  
XML 70 R53.htm IDEA: XBRL DOCUMENT v3.22.2.2
Licensing Agreements (Details)
Oct. 07, 2018
agreement
Sep. 30, 2022
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Number of additional agreements | agreement 3  
Master Services And Ip Agreement    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Collaborative arrangement, accrued reimbursement of IP expenses and sublicense royalty fees   $ 85,400
Milestone payments   $ 0
XML 71 R54.htm IDEA: XBRL DOCUMENT v3.22.2.2
Leases - Narrative (Details)
$ in Thousands
Sep. 30, 2022
USD ($)
ft²
Dec. 31, 2021
USD ($)
Lessee, Lease, Description [Line Items]    
Operating lease and finance lease liabilities | $ $ 7,200  
Operating lease and finance lease, right of use assets, net | $ 6,928 $ 7,737
Operating lease liabilities | $ $ 4,430 7,900
Operating lease, right of use assets | $   $ 7,700
Wixom, Michigan | Wixom, Michigan Property One    
Lessee, Lease, Description [Line Items]    
Facility sqft. 51,000  
Wixom, Michigan | Wixom, Michigan Property Two    
Lessee, Lease, Description [Line Items]    
Facility sqft. 17,500  
Grapevine, Texas    
Lessee, Lease, Description [Line Items]    
Facility sqft. 51,000  
Greer, South Carolina    
Lessee, Lease, Description [Line Items]    
Facility sqft. 57,000  
Hackensack, New Jersey    
Lessee, Lease, Description [Line Items]    
Facility sqft. 4,100  
Maximum    
Lessee, Lease, Description [Line Items]    
Lease term 6 years  
XML 72 R55.htm IDEA: XBRL DOCUMENT v3.22.2.2
Leases - Summary of Lease Costs (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Operating leases        
Operating lease cost $ 410 $ 457 $ 1,289 $ 1,309
Variable lease cost 101 94 287 286
Operating lease expense 511 551 1,576 1,595
Finance leases        
Amortization of right-of-use assets 141 73 424 184
Interest on lease obligations 44 22 136 55
Finance lease expense 185 95 560 239
Short-term lease rent expense 5 4 14 12
Total rent expense 701 650 2,150 1,846
Other information        
Operating cash flows from operating leases 427 444 1,338 1,298
Operating cash flows from finance leases 44 22 136 56
Financing cash flows from finance leases 121 59 359 152
Right of use assets exchanged for operating lease liabilities 768 718 768 4,089
Right of use assets exchanged for finance lease liabilities $ 0 $ 588 $ 0 $ 1,365
Weighted-average remaining lease term – operating leases 3 years 2 months 12 days 3 years 8 months 12 days 3 years 2 months 12 days 3 years 8 months 12 days
Weighted-average remaining lease term – finance leases 4 years 8 months 12 days 5 years 6 months 4 years 8 months 12 days 5 years 6 months
Weighted-average discount rate – operating leases 6.40% 6.30% 6.40% 6.30%
Weighted-average discount rate – finance leases 6.40% 5.90% 6.40% 5.90%
XML 73 R56.htm IDEA: XBRL DOCUMENT v3.22.2.2
Leases - Finance Lease and Operating Lease Maturities (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Operating    
Year ending December 31, 2022 (remaining) $ 434  
Year ending December 31, 2023 1,692  
Year ending December 31, 2024 1,404  
Year ending December 31, 2025 937  
Year ending December 31, 2026 310  
Remaining future payments 120  
Total 4,897  
Less present value discount (467)  
Operating lease liabilities 4,430 $ 7,900
Finance    
Year ending December 31, 2022 (remaining) 165  
Year ending December 31, 2023 669  
Year ending December 31, 2024 672  
Year ending December 31, 2025 676  
Year ending December 31, 2026 666  
Remaining future payments 311  
Total 3,159  
Less present value discount (426)  
Finance lease liabilities $ 2,733  
XML 74 R57.htm IDEA: XBRL DOCUMENT v3.22.2.2
Loans and Security Agreement - Narrative (Details) - Term loan
1 Months Ended 3 Months Ended 9 Months Ended
Mar. 16, 2020
USD ($)
$ / shares
shares
Sep. 30, 2021
USD ($)
installment
Sep. 30, 2022
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2021
USD ($)
Term loan            
Debt Instrument [Line Items]            
Aggregate principal amount $ 35,000,000 $ 7,500,000   $ 7,500,000   $ 7,500,000
Calculation for number of shares of common stock able to be purchased by warrant, percentage of principal amount of relevant term loan funded funded 3.50%          
Warrant exercise price calculation, period immediately preceding execution of loan agreement, number of trading days 5 days          
Interest rate, base percentage 4.75%          
Interest rate, additional percentage added to base percentage 4.00%          
Initial interest rate percentage 8.75%          
Effective interest rate 10.90%          
Option to add interest rate amount to outstanding principal balance in lieu of paying such amount in cash, percentage 1.00%          
Interest expense     $ 400,000 $ 600,000 $ 1,200,000 $ 1,800,000
Number of monthly installments | installment   10        
Prepayment premium percentage   5.00%   5.00%   5.00%
Minimum liquidity floor   $ 5,000,000   $ 5,000,000   $ 5,000,000
Minimum principal amount pursuant to liquidity covenant   $ 15,000,000   $ 15,000,000   $ 15,000,000
Outstanding balance, net of unamortized issuance costs and unaccreted discount     14,100,000   14,100,000  
Unamortized issuance costs and unaccreted discount     $ 900,000   $ 900,000  
Term loan | Minimum            
Debt Instrument [Line Items]            
Period for which company is entitled to make interest-only payments 30 months          
Term loan | Maximum            
Debt Instrument [Line Items]            
Period for which company is entitled to make interest-only payments 36 months          
Term loan, first tranche            
Debt Instrument [Line Items]            
Aggregate principal amount $ 22,500,000          
Net draw down proceeds 21,200,000          
Closing costs $ 1,300,000          
Exercise price of warrant (in dollars per share) | $ / shares $ 18.15          
Number of shares of common stock for which warrant is exercisable (in shares) | shares 43,388          
Additional debt discount recognized $ 500,000          
Term loan, second and third tranches            
Debt Instrument [Line Items]            
Warrant exercise price calculation, period immediately preceding relevant funding, number of trading days 5 days          
Term loan, second and third tranches | Maximum            
Debt Instrument [Line Items]            
Exercise price of warrant (in dollars per share) | $ / shares $ 18.15          
Term loan, second tranche            
Debt Instrument [Line Items]            
Aggregate principal amount $ 5,000,000          
Term loan, third tranche            
Debt Instrument [Line Items]            
Aggregate principal amount $ 7,500,000          
XML 75 R58.htm IDEA: XBRL DOCUMENT v3.22.2.2
Loans and Security Agreement - Schedule of Principal Payments on Term Loan (Details) - Term loan - Term loan
$ in Thousands
Sep. 30, 2022
USD ($)
Debt Instrument [Line Items]  
2022 $ 1,000
2023 6,000
2024 6,000
2025 2,000
Principal Payments $ 15,000
XML 76 R59.htm IDEA: XBRL DOCUMENT v3.22.2.2
Insurance Financing Note Payable (Details) - 5.40% Note Payable - Notes Payable to Banks - USD ($)
$ in Millions
Jun. 02, 2022
Sep. 30, 2022
Short-term Debt [Line Items]    
Short-term note payable $ 1.5  
Interest rate, base percentage 5.40%  
Amortization period (in months) 9 months  
Outstanding amount   $ 1.0
XML 77 R60.htm IDEA: XBRL DOCUMENT v3.22.2.2
Subsequent Events (Details) - USD ($)
$ / shares in Units, shares in Thousands
Oct. 28, 2022
Nov. 10, 2022
May 30, 2022
Sep. 30, 2021
Mar. 16, 2020
Term loan | Term loan          
Subsequent Event [Line Items]          
Aggregate principal amount       $ 7,500,000 $ 35,000,000
PIPE Purchase Agreement Pre-Funded Warrant          
Subsequent Event [Line Items]          
Exercise price of warrant (in dollars per share)     $ 0.0001    
Subsequent event          
Subsequent Event [Line Items]          
Gross proceeds $ 48.00        
Subsequent event | Term loan | Term loan          
Subsequent Event [Line Items]          
Aggregate principal amount   $ 5,000,000      
Subsequent event | PIPE Purchase Agreement Pre-Funded Warrant          
Subsequent Event [Line Items]          
Warrants excercised 480        
Exercise price of warrant (in dollars per share) $ 0.0001        
XML 78 rmti-20220930_htm.xml IDEA: XBRL DOCUMENT 0001041024 2022-01-01 2022-09-30 0001041024 2022-11-11 0001041024 2022-09-30 0001041024 2021-12-31 0001041024 2022-07-01 2022-09-30 0001041024 2021-07-01 2021-09-30 0001041024 2021-01-01 2021-09-30 0001041024 us-gaap:PreferredStockMember 2021-12-31 0001041024 us-gaap:CommonStockMember 2021-12-31 0001041024 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001041024 us-gaap:RetainedEarningsMember 2021-12-31 0001041024 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001041024 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001041024 2022-01-01 2022-03-31 0001041024 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001041024 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001041024 us-gaap:PreferredStockMember 2022-03-31 0001041024 us-gaap:CommonStockMember 2022-03-31 0001041024 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001041024 us-gaap:RetainedEarningsMember 2022-03-31 0001041024 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001041024 2022-03-31 0001041024 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001041024 2022-04-01 2022-06-30 0001041024 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0001041024 us-gaap:CommonStockMember rmti:PublicOfferingMember 2022-04-01 2022-06-30 0001041024 us-gaap:AdditionalPaidInCapitalMember rmti:PublicOfferingMember 2022-04-01 2022-06-30 0001041024 rmti:PublicOfferingMember 2022-04-01 2022-06-30 0001041024 us-gaap:CommonStockMember rmti:AtTheMarketOfferingMember 2022-04-01 2022-06-30 0001041024 us-gaap:AdditionalPaidInCapitalMember rmti:AtTheMarketOfferingMember 2022-04-01 2022-06-30 0001041024 rmti:AtTheMarketOfferingMember 2022-04-01 2022-06-30 0001041024 us-gaap:PreferredStockMember 2022-04-01 2022-06-30 0001041024 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001041024 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001041024 us-gaap:PreferredStockMember 2022-06-30 0001041024 us-gaap:CommonStockMember 2022-06-30 0001041024 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001041024 us-gaap:RetainedEarningsMember 2022-06-30 0001041024 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001041024 2022-06-30 0001041024 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001041024 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-01 2022-09-30 0001041024 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001041024 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001041024 us-gaap:PreferredStockMember 2022-09-30 0001041024 us-gaap:CommonStockMember 2022-09-30 0001041024 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001041024 us-gaap:RetainedEarningsMember 2022-09-30 0001041024 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0001041024 us-gaap:CommonStockMember 2020-12-31 0001041024 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001041024 us-gaap:RetainedEarningsMember 2020-12-31 0001041024 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001041024 2020-12-31 0001041024 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001041024 2021-01-01 2021-03-31 0001041024 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001041024 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001041024 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001041024 us-gaap:CommonStockMember 2021-03-31 0001041024 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001041024 us-gaap:RetainedEarningsMember 2021-03-31 0001041024 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001041024 2021-03-31 0001041024 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001041024 2021-04-01 2021-06-30 0001041024 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-04-01 2021-06-30 0001041024 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001041024 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001041024 us-gaap:CommonStockMember 2021-06-30 0001041024 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001041024 us-gaap:RetainedEarningsMember 2021-06-30 0001041024 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0001041024 2021-06-30 0001041024 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001041024 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-01 2021-09-30 0001041024 us-gaap:CommonStockMember rmti:AtTheMarketOfferingMember 2021-07-01 2021-09-30 0001041024 us-gaap:AdditionalPaidInCapitalMember rmti:AtTheMarketOfferingMember 2021-07-01 2021-09-30 0001041024 rmti:AtTheMarketOfferingMember 2021-07-01 2021-09-30 0001041024 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001041024 us-gaap:CommonStockMember 2021-09-30 0001041024 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001041024 us-gaap:RetainedEarningsMember 2021-09-30 0001041024 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0001041024 2021-09-30 0001041024 rmti:DaVitaHealthcarePartnersIncMember rmti:SeriesXConvertiblePreferredStockMember us-gaap:PrivatePlacementMember 2022-04-06 0001041024 rmti:DaVitaHealthcarePartnersIncMember rmti:SeriesXConvertiblePreferredStockMember us-gaap:PrivatePlacementMember rmti:ShareIssuanceTrancheOneMember 2022-04-06 2022-04-06 0001041024 rmti:DaVitaHealthcarePartnersIncMember rmti:ShareIssuanceTrancheOneMember 2022-04-06 2022-04-06 0001041024 rmti:DaVitaHealthcarePartnersIncMember rmti:SeriesXConvertiblePreferredStockMember us-gaap:PrivatePlacementMember rmti:ShareIssuanceTrancheTwoMember 2022-06-15 2022-06-15 0001041024 rmti:DaVitaHealthcarePartnersIncMember rmti:ShareIssuanceTrancheTwoMember 2022-06-15 2022-06-15 0001041024 rmti:DaVitaHealthcarePartnersIncMember rmti:SeriesXConvertiblePreferredStockMember us-gaap:PrivatePlacementMember 2022-06-15 2022-06-15 0001041024 rmti:CantorFitzgeraldCoMember rmti:ControlledEquityOfferingMember 2022-04-08 0001041024 rmti:CantorFitzgeraldCoMember rmti:ControlledEquityOfferingMember 2022-09-30 0001041024 rmti:RegisteredDirectOfferingMember 2022-05-30 2022-05-30 0001041024 rmti:RegisteredDirectOfferingMember 2022-05-30 0001041024 rmti:RegisteredDirectOfferingWarrantsMember 2022-05-30 0001041024 rmti:RegisteredDirectOfferingWarrantsMember rmti:RegisteredDirectOfferingMember 2022-05-30 0001041024 rmti:PIPEPurchaseAgreementWarrantMember 2022-05-30 0001041024 rmti:PIPEPurchaseAgreementPreFundedWarrantMember 2022-05-30 0001041024 2022-05-30 2022-06-02 0001041024 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-09-30 0001041024 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-09-30 0001041024 us-gaap:RestrictedStockMember 2022-01-01 2022-09-30 0001041024 us-gaap:RestrictedStockMember 2021-01-01 2021-09-30 0001041024 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-09-30 0001041024 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-09-30 0001041024 us-gaap:ConvertiblePreferredStockMember 2022-01-01 2022-09-30 0001041024 us-gaap:ConvertiblePreferredStockMember 2021-01-01 2021-09-30 0001041024 us-gaap:WarrantMember 2022-01-01 2022-09-30 0001041024 us-gaap:WarrantMember 2021-01-01 2021-09-30 0001041024 2022-05-09 2022-05-09 0001041024 rmti:DrugProductSalesMember us-gaap:TransferredAtPointInTimeMember 2022-07-01 2022-09-30 0001041024 rmti:DrugProductSalesMember country:US us-gaap:TransferredAtPointInTimeMember 2022-07-01 2022-09-30 0001041024 rmti:DrugProductSalesMember us-gaap:NonUsMember us-gaap:TransferredAtPointInTimeMember 2022-07-01 2022-09-30 0001041024 rmti:DrugProductSalesMember us-gaap:TransferredAtPointInTimeMember 2022-01-01 2022-09-30 0001041024 rmti:DrugProductSalesMember country:US us-gaap:TransferredAtPointInTimeMember 2022-01-01 2022-09-30 0001041024 rmti:DrugProductSalesMember us-gaap:NonUsMember us-gaap:TransferredAtPointInTimeMember 2022-01-01 2022-09-30 0001041024 rmti:DrugLicenseFeeMember us-gaap:TransferredOverTimeMember 2022-07-01 2022-09-30 0001041024 rmti:DrugLicenseFeeMember country:US us-gaap:TransferredOverTimeMember 2022-07-01 2022-09-30 0001041024 rmti:DrugLicenseFeeMember us-gaap:NonUsMember us-gaap:TransferredOverTimeMember 2022-07-01 2022-09-30 0001041024 rmti:DrugLicenseFeeMember us-gaap:TransferredOverTimeMember 2022-01-01 2022-09-30 0001041024 rmti:DrugLicenseFeeMember country:US us-gaap:TransferredOverTimeMember 2022-01-01 2022-09-30 0001041024 rmti:DrugLicenseFeeMember us-gaap:NonUsMember us-gaap:TransferredOverTimeMember 2022-01-01 2022-09-30 0001041024 rmti:DrugRevenueMember 2022-07-01 2022-09-30 0001041024 rmti:DrugRevenueMember country:US 2022-07-01 2022-09-30 0001041024 rmti:DrugRevenueMember us-gaap:NonUsMember 2022-07-01 2022-09-30 0001041024 rmti:DrugRevenueMember 2022-01-01 2022-09-30 0001041024 rmti:DrugRevenueMember country:US 2022-01-01 2022-09-30 0001041024 rmti:DrugRevenueMember us-gaap:NonUsMember 2022-01-01 2022-09-30 0001041024 rmti:ConcentrateProductSalesMember us-gaap:TransferredAtPointInTimeMember 2022-07-01 2022-09-30 0001041024 rmti:ConcentrateProductSalesMember country:US us-gaap:TransferredAtPointInTimeMember 2022-07-01 2022-09-30 0001041024 rmti:ConcentrateProductSalesMember us-gaap:NonUsMember us-gaap:TransferredAtPointInTimeMember 2022-07-01 2022-09-30 0001041024 rmti:ConcentrateProductSalesMember us-gaap:TransferredAtPointInTimeMember 2022-01-01 2022-09-30 0001041024 rmti:ConcentrateProductSalesMember country:US us-gaap:TransferredAtPointInTimeMember 2022-01-01 2022-09-30 0001041024 rmti:ConcentrateProductSalesMember us-gaap:NonUsMember us-gaap:TransferredAtPointInTimeMember 2022-01-01 2022-09-30 0001041024 rmti:ConcentrateProductLicenseFeeMember us-gaap:TransferredOverTimeMember 2022-07-01 2022-09-30 0001041024 rmti:ConcentrateProductLicenseFeeMember country:US us-gaap:TransferredOverTimeMember 2022-07-01 2022-09-30 0001041024 rmti:ConcentrateProductLicenseFeeMember us-gaap:NonUsMember us-gaap:TransferredOverTimeMember 2022-07-01 2022-09-30 0001041024 rmti:ConcentrateProductLicenseFeeMember us-gaap:TransferredOverTimeMember 2022-01-01 2022-09-30 0001041024 rmti:ConcentrateProductLicenseFeeMember country:US us-gaap:TransferredOverTimeMember 2022-01-01 2022-09-30 0001041024 rmti:ConcentrateProductLicenseFeeMember us-gaap:NonUsMember us-gaap:TransferredOverTimeMember 2022-01-01 2022-09-30 0001041024 rmti:ConcentrateProductsMember 2022-07-01 2022-09-30 0001041024 rmti:ConcentrateProductsMember country:US 2022-07-01 2022-09-30 0001041024 rmti:ConcentrateProductsMember us-gaap:NonUsMember 2022-07-01 2022-09-30 0001041024 rmti:ConcentrateProductsMember 2022-01-01 2022-09-30 0001041024 rmti:ConcentrateProductsMember country:US 2022-01-01 2022-09-30 0001041024 rmti:ConcentrateProductsMember us-gaap:NonUsMember 2022-01-01 2022-09-30 0001041024 country:US 2022-07-01 2022-09-30 0001041024 us-gaap:NonUsMember 2022-07-01 2022-09-30 0001041024 country:US 2022-01-01 2022-09-30 0001041024 us-gaap:NonUsMember 2022-01-01 2022-09-30 0001041024 rmti:DrugProductSalesMember us-gaap:TransferredAtPointInTimeMember 2021-07-01 2021-09-30 0001041024 rmti:DrugProductSalesMember country:US us-gaap:TransferredAtPointInTimeMember 2021-07-01 2021-09-30 0001041024 rmti:DrugProductSalesMember us-gaap:NonUsMember us-gaap:TransferredAtPointInTimeMember 2021-07-01 2021-09-30 0001041024 rmti:DrugProductSalesMember us-gaap:TransferredAtPointInTimeMember 2021-01-01 2021-09-30 0001041024 rmti:DrugProductSalesMember country:US us-gaap:TransferredAtPointInTimeMember 2021-01-01 2021-09-30 0001041024 rmti:DrugProductSalesMember us-gaap:NonUsMember us-gaap:TransferredAtPointInTimeMember 2021-01-01 2021-09-30 0001041024 rmti:DrugLicenseFeeMember us-gaap:TransferredOverTimeMember 2021-07-01 2021-09-30 0001041024 rmti:DrugLicenseFeeMember country:US us-gaap:TransferredOverTimeMember 2021-07-01 2021-09-30 0001041024 rmti:DrugLicenseFeeMember us-gaap:NonUsMember us-gaap:TransferredOverTimeMember 2021-07-01 2021-09-30 0001041024 rmti:DrugLicenseFeeMember us-gaap:TransferredOverTimeMember 2021-01-01 2021-09-30 0001041024 rmti:DrugLicenseFeeMember country:US us-gaap:TransferredOverTimeMember 2021-01-01 2021-09-30 0001041024 rmti:DrugLicenseFeeMember us-gaap:NonUsMember us-gaap:TransferredOverTimeMember 2021-01-01 2021-09-30 0001041024 rmti:DrugRevenueMember 2021-07-01 2021-09-30 0001041024 rmti:DrugRevenueMember country:US 2021-07-01 2021-09-30 0001041024 rmti:DrugRevenueMember us-gaap:NonUsMember 2021-07-01 2021-09-30 0001041024 rmti:DrugRevenueMember 2021-01-01 2021-09-30 0001041024 rmti:DrugRevenueMember country:US 2021-01-01 2021-09-30 0001041024 rmti:DrugRevenueMember us-gaap:NonUsMember 2021-01-01 2021-09-30 0001041024 rmti:ConcentrateProductSalesMember us-gaap:TransferredAtPointInTimeMember 2021-07-01 2021-09-30 0001041024 rmti:ConcentrateProductSalesMember country:US us-gaap:TransferredAtPointInTimeMember 2021-07-01 2021-09-30 0001041024 rmti:ConcentrateProductSalesMember us-gaap:NonUsMember us-gaap:TransferredAtPointInTimeMember 2021-07-01 2021-09-30 0001041024 rmti:ConcentrateProductSalesMember us-gaap:TransferredAtPointInTimeMember 2021-01-01 2021-09-30 0001041024 rmti:ConcentrateProductSalesMember country:US us-gaap:TransferredAtPointInTimeMember 2021-01-01 2021-09-30 0001041024 rmti:ConcentrateProductSalesMember us-gaap:NonUsMember us-gaap:TransferredAtPointInTimeMember 2021-01-01 2021-09-30 0001041024 rmti:ConcentrateProductLicenseFeeMember us-gaap:TransferredOverTimeMember 2021-07-01 2021-09-30 0001041024 rmti:ConcentrateProductLicenseFeeMember country:US us-gaap:TransferredOverTimeMember 2021-07-01 2021-09-30 0001041024 rmti:ConcentrateProductLicenseFeeMember us-gaap:NonUsMember us-gaap:TransferredOverTimeMember 2021-07-01 2021-09-30 0001041024 rmti:ConcentrateProductLicenseFeeMember us-gaap:TransferredOverTimeMember 2021-01-01 2021-09-30 0001041024 rmti:ConcentrateProductLicenseFeeMember country:US us-gaap:TransferredOverTimeMember 2021-01-01 2021-09-30 0001041024 rmti:ConcentrateProductLicenseFeeMember us-gaap:NonUsMember us-gaap:TransferredOverTimeMember 2021-01-01 2021-09-30 0001041024 rmti:ConcentrateProductsMember 2021-07-01 2021-09-30 0001041024 rmti:ConcentrateProductsMember country:US 2021-07-01 2021-09-30 0001041024 rmti:ConcentrateProductsMember us-gaap:NonUsMember 2021-07-01 2021-09-30 0001041024 rmti:ConcentrateProductsMember 2021-01-01 2021-09-30 0001041024 rmti:ConcentrateProductsMember country:US 2021-01-01 2021-09-30 0001041024 rmti:ConcentrateProductsMember us-gaap:NonUsMember 2021-01-01 2021-09-30 0001041024 country:US 2021-07-01 2021-09-30 0001041024 us-gaap:NonUsMember 2021-07-01 2021-09-30 0001041024 country:US 2021-01-01 2021-09-30 0001041024 us-gaap:NonUsMember 2021-01-01 2021-09-30 0001041024 rmti:ConcentrateProductsMember 2021-12-31 0001041024 rmti:ConcentrateProductsMember 2022-09-30 0001041024 rmti:BaxterHealthcareOrganizationMember 2022-09-30 0001041024 rmti:TrifericInventoryMember 2022-09-30 0001041024 rmti:TrifericAPIMember 2022-09-30 0001041024 rmti:TrifericInventoryMember 2022-01-01 2022-09-30 0001041024 us-gaap:LeaseholdImprovementsMember 2022-09-30 0001041024 us-gaap:LeaseholdImprovementsMember 2021-12-31 0001041024 us-gaap:MachineryAndEquipmentMember 2022-09-30 0001041024 us-gaap:MachineryAndEquipmentMember 2021-12-31 0001041024 us-gaap:OfficeEquipmentMember 2022-09-30 0001041024 us-gaap:OfficeEquipmentMember 2021-12-31 0001041024 us-gaap:OtherMachineryAndEquipmentMember 2022-09-30 0001041024 us-gaap:OtherMachineryAndEquipmentMember 2021-12-31 0001041024 rmti:BaxterHealthcareOrganizationMember 2014-10-01 2014-10-31 0001041024 rmti:BaxterHealthcareOrganizationMember 2022-07-01 2022-09-30 0001041024 rmti:BaxterHealthcareOrganizationMember 2022-01-01 2022-09-30 0001041024 rmti:BaxterHealthcareOrganizationMember 2021-07-01 2021-09-30 0001041024 rmti:BaxterHealthcareOrganizationMember 2021-01-01 2021-09-30 0001041024 rmti:BaxterHealthcareOrganizationMember 2021-12-31 0001041024 rmti:WanbangBiopharmaceuticalMember 2016-01-01 2016-12-31 0001041024 rmti:WanbangBiopharmaceuticalMember 2021-07-01 2021-09-30 0001041024 rmti:WanbangBiopharmaceuticalMember 2022-07-01 2022-09-30 0001041024 rmti:WanbangBiopharmaceuticalMember 2021-01-01 2021-09-30 0001041024 rmti:WanbangBiopharmaceuticalMember 2022-01-01 2022-09-30 0001041024 rmti:WanbangBiopharmaceuticalMember 2022-09-30 0001041024 rmti:WanbangBiopharmaceuticalMember 2021-12-31 0001041024 rmti:SunPharmaAgreementsMember 2020-01-01 2020-01-31 0001041024 rmti:SunPharmaAgreementsMember 2021-07-01 2021-09-30 0001041024 rmti:SunPharmaAgreementsMember 2022-07-01 2022-09-30 0001041024 rmti:SunPharmaAgreementsMember 2022-01-01 2022-09-30 0001041024 rmti:SunPharmaAgreementsMember 2021-01-01 2021-09-30 0001041024 rmti:SunPharmaAgreementsMember 2022-09-30 0001041024 rmti:SunPharmaAgreementsMember 2021-12-31 0001041024 rmti:JeilPharmaAgreementsMember 2020-09-01 2020-09-30 0001041024 rmti:JeilPharmaAgreementsMember 2022-05-01 2022-05-31 0001041024 rmti:JeilPharmaAgreementsMember 2022-07-01 2022-09-30 0001041024 rmti:JeilPharmaAgreementsMember 2022-01-01 2022-09-30 0001041024 rmti:JeilPharmaAgreementsMember 2021-07-01 2021-09-30 0001041024 rmti:JeilPharmaAgreementsMember 2021-01-01 2021-09-30 0001041024 rmti:JeilPharmaAgreementsMember 2022-09-30 0001041024 rmti:JeilPharmaAgreementsMember 2021-12-31 0001041024 rmti:DrogsanAgreementsMember 2021-06-01 2021-06-30 0001041024 rmti:DrogsanAgreementsMember 2021-07-01 2021-09-30 0001041024 rmti:DrogsanAgreementsMember 2022-07-01 2022-09-30 0001041024 rmti:DrogsanAgreementsMember 2022-01-01 2022-09-30 0001041024 rmti:DrogsanAgreementsMember 2021-01-01 2021-09-30 0001041024 rmti:DrogsanAgreementsMember 2022-09-30 0001041024 rmti:DrogsanAgreementsMember 2021-12-31 0001041024 rmti:DaVitaHealthcarePartnersIncMember rmti:SeriesXConvertiblePreferredStockMember us-gaap:PrivatePlacementMember rmti:ShareIssuanceTrancheTwoMember 2022-06-16 2022-06-16 0001041024 rmti:DaVitaHealthcarePartnersIncMember rmti:ShareIssuanceTrancheTwoMember 2022-06-16 2022-06-16 0001041024 rmti:SeriesXConvertiblePreferredStockMember 2022-04-06 2022-04-06 0001041024 rmti:SeriesXConvertiblePreferredStockMember 2022-04-06 0001041024 rmti:CantorFitzgeraldCoMember rmti:ControlledEquityOfferingMember 2022-06-30 2022-06-30 0001041024 rmti:CantorFitzgeraldCoMember rmti:ControlledEquityOfferingMember 2022-06-30 0001041024 rmti:RegisteredDirectOfferingWarrantsMember 2022-09-30 0001041024 rmti:PIPEPurchaseAgreementWarrantMember 2022-09-30 0001041024 rmti:PIPEPurchaseAgreementPreFundedWarrantMember 2022-09-30 0001041024 rmti:ServiceBasedRestrictedStockUnitsMember 2022-07-01 2022-09-30 0001041024 rmti:ServiceBasedRestrictedStockUnitsMember 2021-07-01 2021-09-30 0001041024 rmti:ServiceBasedRestrictedStockUnitsMember 2022-01-01 2022-09-30 0001041024 rmti:ServiceBasedRestrictedStockUnitsMember 2021-01-01 2021-09-30 0001041024 rmti:ServiceBasedStockOptionAwardsMember 2022-07-01 2022-09-30 0001041024 rmti:ServiceBasedStockOptionAwardsMember 2021-07-01 2021-09-30 0001041024 rmti:ServiceBasedStockOptionAwardsMember 2022-01-01 2022-09-30 0001041024 rmti:ServiceBasedStockOptionAwardsMember 2021-01-01 2021-09-30 0001041024 rmti:ServiceBasedAwardsMember 2022-07-01 2022-09-30 0001041024 rmti:ServiceBasedAwardsMember 2021-07-01 2021-09-30 0001041024 rmti:ServiceBasedAwardsMember 2022-01-01 2022-09-30 0001041024 rmti:ServiceBasedAwardsMember 2021-01-01 2021-09-30 0001041024 rmti:PerformanceBasedRestrictedStockAwardsMember 2022-07-01 2022-09-30 0001041024 rmti:PerformanceBasedRestrictedStockAwardsMember 2021-07-01 2021-09-30 0001041024 rmti:PerformanceBasedRestrictedStockAwardsMember 2022-01-01 2022-09-30 0001041024 rmti:PerformanceBasedRestrictedStockAwardsMember 2021-01-01 2021-09-30 0001041024 rmti:PerformanceBasedStockOptionAwardsMember 2022-07-01 2022-09-30 0001041024 rmti:PerformanceBasedStockOptionAwardsMember 2021-07-01 2021-09-30 0001041024 rmti:PerformanceBasedStockOptionAwardsMember 2022-01-01 2022-09-30 0001041024 rmti:PerformanceBasedStockOptionAwardsMember 2021-01-01 2021-09-30 0001041024 rmti:PerformanceBasedAwardsMember 2022-07-01 2022-09-30 0001041024 rmti:PerformanceBasedAwardsMember 2021-07-01 2021-09-30 0001041024 rmti:PerformanceBasedAwardsMember 2022-01-01 2022-09-30 0001041024 rmti:PerformanceBasedAwardsMember 2021-01-01 2021-09-30 0001041024 us-gaap:RestrictedStockMember 2022-01-01 2022-09-30 0001041024 rmti:PerformanceBasedRestrictedStockAwardsMember 2021-12-31 0001041024 rmti:PerformanceBasedRestrictedStockAwardsMember 2022-09-30 0001041024 rmti:PerformanceBasedRestrictedStockAwardsMember 2020-12-31 0001041024 rmti:PerformanceBasedRestrictedStockAwardsMember 2021-09-30 0001041024 rmti:ServiceBasedRestrictedStockUnitsMember 2021-12-31 0001041024 rmti:ServiceBasedRestrictedStockUnitsMember 2022-09-30 0001041024 rmti:ServiceBasedRestrictedStockUnitsMember 2020-12-31 0001041024 rmti:ServiceBasedRestrictedStockUnitsMember 2021-09-30 0001041024 srt:MinimumMember rmti:ServiceBasedRestrictedStockUnitsMember 2022-01-01 2022-09-30 0001041024 srt:MaximumMember rmti:ServiceBasedRestrictedStockUnitsMember 2022-01-01 2022-09-30 0001041024 srt:MinimumMember rmti:ServiceBasedStockOptionAwardsMember 2022-09-30 0001041024 srt:MaximumMember rmti:ServiceBasedStockOptionAwardsMember 2022-09-30 0001041024 srt:MinimumMember rmti:ServiceBasedStockOptionAwardsMember 2022-01-01 2022-09-30 0001041024 srt:MaximumMember rmti:ServiceBasedStockOptionAwardsMember 2022-01-01 2022-09-30 0001041024 rmti:ServiceBasedStockOptionAwardsMember 2021-12-31 0001041024 rmti:ServiceBasedStockOptionAwardsMember 2021-01-01 2021-12-31 0001041024 rmti:ServiceBasedStockOptionAwardsMember 2022-09-30 0001041024 rmti:ServiceBasedStockOptionAwardsMember 2020-12-31 0001041024 rmti:ServiceBasedStockOptionAwardsMember 2020-01-01 2020-12-31 0001041024 rmti:ServiceBasedStockOptionAwardsMember 2021-09-30 0001041024 2018-10-07 2018-10-07 0001041024 rmti:MasterServicesAndIpAgreementMember 2022-09-30 0001041024 srt:MaximumMember 2022-09-30 0001041024 rmti:WixomMichiganPropertyOneMember stpr:MI 2022-09-30 0001041024 rmti:WixomMichiganPropertyTwoMember stpr:MI 2022-09-30 0001041024 stpr:TX 2022-09-30 0001041024 stpr:SC 2022-09-30 0001041024 stpr:NJ 2022-09-30 0001041024 rmti:TermLoanMember us-gaap:MediumTermNotesMember 2020-03-16 0001041024 rmti:TermLoanTrancheOneMember us-gaap:MediumTermNotesMember 2020-03-16 0001041024 rmti:TermLoanTrancheTwoMember us-gaap:MediumTermNotesMember 2020-03-16 0001041024 rmti:TermLoanTrancheThreeMember us-gaap:MediumTermNotesMember 2020-03-16 0001041024 rmti:TermLoanTrancheOneMember us-gaap:MediumTermNotesMember 2020-03-16 2020-03-16 0001041024 rmti:TermLoanMember us-gaap:MediumTermNotesMember 2020-03-16 2020-03-16 0001041024 srt:MaximumMember rmti:TermLoanTrancheTwoAndTrancheThreeMember us-gaap:MediumTermNotesMember 2020-03-16 0001041024 rmti:TermLoanTrancheTwoAndTrancheThreeMember us-gaap:MediumTermNotesMember 2020-03-16 2020-03-16 0001041024 srt:MinimumMember rmti:TermLoanMember us-gaap:MediumTermNotesMember 2020-03-16 2020-03-16 0001041024 srt:MaximumMember rmti:TermLoanMember us-gaap:MediumTermNotesMember 2020-03-16 2020-03-16 0001041024 rmti:TermLoanMember us-gaap:MediumTermNotesMember 2022-07-01 2022-09-30 0001041024 rmti:TermLoanMember us-gaap:MediumTermNotesMember 2021-07-01 2021-09-30 0001041024 rmti:TermLoanMember us-gaap:MediumTermNotesMember 2022-01-01 2022-09-30 0001041024 rmti:TermLoanMember us-gaap:MediumTermNotesMember 2021-01-01 2021-09-30 0001041024 rmti:TermLoanMember us-gaap:MediumTermNotesMember 2021-09-30 0001041024 rmti:TermLoanMember us-gaap:MediumTermNotesMember 2021-09-01 2021-09-30 0001041024 rmti:TermLoanMember us-gaap:MediumTermNotesMember 2022-09-30 0001041024 rmti:A540NotePayableMember us-gaap:NotesPayableToBanksMember 2022-06-02 0001041024 rmti:A540NotePayableMember us-gaap:NotesPayableToBanksMember 2022-06-02 2022-06-02 0001041024 rmti:A540NotePayableMember us-gaap:NotesPayableToBanksMember 2022-09-30 0001041024 rmti:PIPEPurchaseAgreementPreFundedWarrantMember us-gaap:SubsequentEventMember 2022-10-28 0001041024 us-gaap:SubsequentEventMember 2022-10-28 2022-10-28 0001041024 rmti:TermLoanMember us-gaap:MediumTermNotesMember us-gaap:SubsequentEventMember 2022-11-10 shares iso4217:USD iso4217:USD shares rmti:facility utr:sqft pure rmti:agreement rmti:installment 0001041024 false --12-31 2022 Q3 0.09 0.09 10-Q true 2022-09-30 false 000-23661 ROCKWELL MEDICAL, INC. DE 38-3317208 30142 S. Wixom Road Wixom MI 48393 248 960-9009 Yes Yes Non-accelerated Filer true false false Common Stock, par value $0.0001 RMTI NASDAQ 11632673 12980000 13280000 14584000 9158000 7367000 5913000 5020000 4076000 2407000 2861000 42358000 35288000 2264000 2486000 1193000 1523000 6928000 7737000 921000 921000 522000 619000 54186000 48574000 3051000 3739000 5887000 5090000 1992000 2004000 2164000 2171000 5131000 7381000 1006000 437000 107000 144000 19338000 20966000 5171000 5887000 8962000 13186000 4565000 5986000 14000 14000 38050000 46039000 0.0001 0.0001 2000000 2000000 15000 15000 0 0 0 0 0.0001 0.0001 170000000 170000000 11152673 11152673 8544225 8544225 1000 1000 402480000 372562000 -386399000 -370080000 54000 52000 16136000 2535000 54186000 48574000 18691000 15988000 53497000 46599000 17914000 16317000 51760000 46788000 777000 -329000 1737000 -189000 469000 1221000 2963000 5445000 762000 1541000 1743000 4860000 3254000 3881000 11845000 11483000 -3708000 -6972000 -14814000 -21977000 0 0 4000 -1000 476000 609000 1497000 1772000 -6000 0 -10000 17000 -482000 -609000 -1503000 -1756000 -4190000 -7581000 -16317000 -23733000 -0.40 -0.40 -0.89 -0.89 -1.75 -1.75 -2.79 -2.79 10528148 10528148 8534740 8534740 9299788 9299788 8520603 8520603 -4190000 -7581000 -16317000 -23733000 5000 4000 5000 -4000 0 0 -3000 3000 -4185000 -7577000 -16315000 -23734000 0 8544225 1000 372562000 -370080000 52000 2535000 -7162000 -7162000 -1000 -1000 -179000 -179000 0 8544225 1000 372383000 -377242000 51000 -4807000 -4967000 -4967000 -2000 -2000 844613 14893000 14893000 7500 15000 15000 15000 14916000 14916000 10958 97000 97000 15000 9407296 1000 402304000 -382209000 49000 20145000 -4190000 -4190000 5000 5000 1745377 176000 176000 15000 11152673 1000 402480000 -386399000 54000 16136000 8506651 1000 371518000 -337406000 57000 34170000 -7752000 -7752000 -7000 -7000 3000 3000 2396 -236000 -236000 8509047 1000 371282000 -345158000 53000 26178000 -8400000 -8400000 -1000 -1000 19260 -7000 -7000 433000 433000 8528307 1000 371708000 -353558000 52000 18203000 -7581000 -7581000 4000 4000 14090 107000 107000 361000 361000 8542397 1000 372176000 -361139000 56000 11094000 -16317000 -23733000 422000 535000 95000 558000 307000 89000 1518000 1312000 276000 276000 3000 -7000 4000 -1000 3000 -3000 1454000 1865000 921000 554000 -2058000 -1760000 -688000 679000 -1435000 -1266000 756000 -825000 -1427000 -1485000 3111000 3556000 -16820000 -24508000 17389000 19107000 11972000 19286000 197000 408000 -5614000 -229000 6750000 0 941000 656000 15016000 0 106000 0 15000000 0 85000 0 0 107000 0 6000 22134000 -555000 -300000 -25292000 13280000 48682000 12980000 23390000 1261000 1318000 5000 -4000 Description of Business<div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rockwell Medical, Inc. (“Rockwell Medical,” “Rockwell,” or the “Company”) is a commercial healthcare company focused on providing life-sustaining products for patients suffering from blood disorders and diseases associated with the kidney. Rockwell is a revenue-generating business and the second largest supplier of acid and bicarbonate concentrates for dialysis patients in the United States. Hemodialysis is the most common form of end-stage kidney disease treatment and is usually performed at a freestanding outpatient dialysis center, at a hospital-based outpatient center, or in a patient’s home. This represents a large market opportunity for which Rockwell's products are well-positioned to meet the needs of patients.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rockwell manufactures hemodialysis concentrates under cGMP regulations at its three facilities in Michigan, Texas, and South Carolina totaling approximately 175,000 square feet, and manufactures mixers in its Iowa facility. Rockwell delivers the majority of its hemodialysis concentrates products and mixers to dialysis clinics throughout the United States and internationally utilizing its own delivery trucks and third-party carriers. Rockwell has developed a core expertise in manufacturing and delivering hemodialysis concentrates, and has built a longstanding reputation for reliability, quality, and excellent customer service.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rockwell has a proprietary parenteral iron product, TRIFERIC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ferric pyrophosphate citrate, "FPC"), which is indicated to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease. The Company has established several international partnerships with companies seeking to develop and commercialize TRIFERIC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> outside the United States and is working closely with these international partners to develop and commercialize TRIFERIC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in their respective regions. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rockwell continues to evaluate the viability of its FPC platform and FPC's potential to treat iron deficiency and iron deficiency anemia and for acute heart failure. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rockwell’s strategy is focused on growing the Company's revenue-generating business, which currently includes hemodialysis concentrates and international partnerships for TRIFERIC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">® </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and achieving profitability in 2024 to put the Company in a stronger and more stable financial position.</span></div> 3 175000 Liquidity and Capital Resources<div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, Rockwell had approximately $27.6 million of cash, cash equivalents and investments available-for-sale, and working capital of $23.0 million. Net cash used in operating activities for the nine months ended September 30, 2022 was approximately $16.8 million. Based on the currently available working capital and capital raises described below, management believes the Company currently has sufficient funds to meet its operating requirements for at least the next twelve months from the date of the filing of this report.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 6, 2022, the Company and DaVita, Inc. ("DaVita") entered into an amendment (the "Amendment") to the Products Purchase Agreement, dated July 1, 2019, under which the Company supplies DaVita with certain dialysis concentrates. Under the Amendment, the Company and DaVita agreed to certain price increases, effective May 1, 2022, as well as the pass-through of certain inflationary costs, determined on a quarterly basis. Certain costs are subject to a cap. The Amendment also requires the Company to implement certain cost containment and cost-cutting measures. The Amendment contains certain covenants with respect to the Company’s ongoing operations, including a minimum cash covenant of $10 million, or the Company will be in default under the Products Purchase Agreement. An event of default could result in termination of that agreement. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 6, 2022, the Company and DaVita entered into a Securities Purchase Agreement (the “SPA”), pursuant to which the Company issued $15 million of preferred stock to DaVita in two separate tranches. The Company initially issued 7,500 shares of a newly designated series of preferred stock, which is designated “Series X Convertible Preferred Stock” (the “Series X Preferred Stock”) for gross proceeds of $7.5 million. On June 15, 2022, the Company issued to DaVita an additional 7,500 shares of Series X Preferred Stock in a second closing (the “Second Tranche”) for an additional $7.5 million. The Second Tranche was conditioned upon the Company raising an additional $15 million in capital within a certain timeline, which took place on June 2, 2022.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 8, 2022, the Company entered into a sales agreement (the “Sales Agreement”) with Cantor Fitzgerald &amp; Co. (the “Agent”), pursuant to which the Company may offer and sell from time to time up to $12,200,000 of shares of Company’s common stock through the Agent. The offering and sale of such shares has been registered under the Securities Act of 1933, as amended (the “Securities Act”), pursuant to the Company’s Registration Statement on Form S-3 (File No. 333-259923) (the “Registration Statement”), which was originally filed with the Securities and Exchange Commission (“SEC”) on September 30, 2021 and declared effective by the SEC on October 8, 2021, the base prospectus contained within the Registration Statement, and a prospectus supplement that was filed with the SEC on April 8, 2022. During the three months ended September 30, 2022, the Company did not make any sales pursuant to the Sales Agreement. Approximately $12.2 million remains available for sale under the ATM facility.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 30, 2022, the Company entered into a Securities Purchase Agreement (the “RD Purchase Agreement”) with the purchaser named therein (the “Purchaser”), pursuant to which the Company agreed to issue and sell, in a registered direct offering (the “Offering”), 844,613 shares of its common stock at price of $1.39 per share, and prefunded warrants to purchase up to an aggregate of 7,788,480 shares of common stock (the “Pre-Funded Warrants” and the shares of common stock underlying the Pre-Funded Warrants, the “Warrant Shares”). The purchase price of each Pre-Funded Warrant was equal to the price at which a share of common stock was sold to the public in the Offering, minus $0.0001, and the exercise price of each Pre-Funded Warrant is $0.0001 per share.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also on May 30, 2022, concurrently with the Offering, the Company entered into a Securities Purchase Agreement with the Purchaser (the “PIPE Purchase Agreement”) relating to the offering and sale (the “Private Placement”) of warrants to purchase up to a total of 9,900,990 shares of common stock and pre-funded warrants to purchase up to a total of 1,267,897 shares of common stock (the “PIPE Warrants”). Each warrant was sold at a price of $0.125 per underlying warrant share and is exercisable at an exercise price of $1.39 per share. The purchase price of each Pre-Funded Warrant was equal to the price at which a share of common stock was sold to the public in the Offering, minus $0.0001, and the exercise price of each prefunded warrant is $0.0001 per share. The Offering and the Private Placement closed on June 2, 2022. The net proceeds to the Company from the Offering and the Private Placement were approximately $14.9 million, after deducting fees and expenses.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may require additional capital to sustain its operations and make the investments it needs to execute its strategic plan. If the Company attempts to obtain additional debt or equity financing, the Company cannot assume such financing will be available on favorable terms, if at all.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Currently, because the Company's public float is less than $75 million, it is subject to the baby shelf limitations under its current registration statement on Form S-3, which limit the amount the Company may offer under the Form S-3. This could limit its ability to raise capital under this registration statement. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, the Company is subject to certain covenants and cure provisions under its Loan Agreement with Innovatus. As of the date of this report, the Company is in compliance with all covenants (See Note 14 for further detail).</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The COVID-19 pandemic and resulting domestic and global disruptions, particularly in the supply chain and labor market, among other areas, have adversely affected the Company's business and operations, including, but not limited to, its sales and marketing efforts and its research and development activities, its plant and transportation operations and the operations of third parties upon whom the Company relies. The Company's international business development activities may also continue to be negatively impacted by COVID-19. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic and the resulting global disruptions and recent inflationary pressures have caused significant volatility in financial and credit markets. Rockwell has utilized a range of financing methods to fund its operations in the past; however, current conditions in the financial and credit markets may limit the availability of funding, refinancing or increase the cost of funding. Due to the rapidly evolving nature of the global situation, it is not possible to predict the extent to which these conditions could adversely affect the Company's liquidity and capital resources in the future.</span></div> 27600000 23000000 -16800000 10000000 15000000 7500 7500000 7500 7500000 15000000 12200000 12200000 844613 1.39 7788480 0.0001 0.0001 9900990 1267897 0.125 1.39 0.0001 0.0001 14900000 Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements<div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the instructions to Form 10-Q and Rule 10-01 of Regulation S-X of the U. S. Securities and Exchange Commission (“SEC”) and on the same basis as the Company prepares its annual audited consolidated financial statements.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated balance sheet at September 30, 2022, condensed consolidated statements of operations for the three and nine months ended September 30, 2022 and 2021, condensed consolidated statements of comprehensive loss for the three and nine months ended September 30, 2022 and 2021, condensed consolidated statement of changes in stockholders' equity for the three and nine months ended September 30, 2022 and 2021, and condensed consolidated statements of cash flows for the nine months ended September 30, 2022 and 2021 are unaudited, but include all adjustments, consisting of normal recurring adjustments, the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The results for the three and nine months ended September 30, 2022 are not necessarily indicative of results to be expected for the year ending December 31, 2022 or for any future interim period. The condensed consolidated balance sheet at December 31, 2021 has been derived from audited financial statements, however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying condensed consolidated financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2021 and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 as filed with the SEC on April 8, 2022. The Company’s consolidated subsidiaries consisted of its wholly-owned subsidiaries, Rockwell Transportation, Inc. and Rockwell Medical India Private Limited.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated interim financial statements include the accounts of the Company and its subsidiaries. All material intercompany balances and transactions have been eliminated in consolidation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reverse Stock Split</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 9, 2022, the stockholders of the Company authorized the Board of Directors to effect a reverse stock split of all outstanding shares of common stock. The Board of Directors subsequently approved the implementation of a reverse stock split as a ratio of one-for-eleven shares, which became effective on May 13, 2022. The Company’s outstanding stock options were also adjusted to reflect the one-for-eleven reverse stock split of the Company’s common stock. Outstanding stock options were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased. The reverse stock split resulted in an adjustment to the Series X convertible preferred stock conversion prices to reflect a proportional decrease in the number of shares of common stock to be issued upon conversion. All share and per share data in these condensed consolidated financial statements and related notes hereto have been retroactively adjusted to account for the effect of the reverse stock split for the three and nine month periods ended September 30, 2022 and 2021, respectively, and the balance sheet at September 30, 2022 and December 31, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its leases under Accounting Standards Codification (“ASC”) 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the consolidated balance sheet as both a right-of-use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term. Variable lease expenses, if any, are recorded when incurred.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In calculating the right-of-use asset and lease liability, the Company elects to combine lease and non-lease components. The Company excludes short-term leases having initial terms of 12 months or less from the new guidance as an accounting policy election and recognizes rent expense on a straight-line basis over the lease term.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss Per Share</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 260, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings Per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, requires dual presentation of basic and diluted earnings per share (“EPS”), with a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS computation. Basic EPS excludes dilution. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that are then sharing in the earnings of the entity.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding plus the effect of dilutive potential common shares outstanding during the period determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss per share calculation, common stock warrants, unvested restricted stock units and stock options are considered to be potentially dilutive securities but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive, and therefore, basic and diluted net loss per share were the same for all periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share for the nine months ended September 30, 2022 and 2021, respectively, because to do so would be anti-dilutive (in common equivalent shares):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,311,691 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">533,784 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested restricted stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">891 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,118 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested restricted stock units</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125,000 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,116 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock conversion to common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,363,636 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants to purchase common stock</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,507,268 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,402,442 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,308,486 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,974,460 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of Recent Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually assesses new accounting pronouncements to determine their applicability. When it is determined a new accounting pronouncement affects the Company’s financial reporting, the Company undertakes a review to determine the consequences of the change to its consolidated financial statements and assures there are sufficient controls in place to ascertain the Company’s consolidated financial statements properly reflect the change.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU No. 2020-06, “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity”, which simplifies the accounting for convertible instruments by eliminating the requirement to separate embedded conversion features from the host contract when the conversion features are not required to be accounted for as derivatives under Topic 815, Derivatives and Hedging, or do not result in substantial premiums accounted for as paid-in capital. By removing the separation model, a convertible debt instrument will be reported as a single liability instrument with no separate accounting for embedded conversion features. This new standard also removes certain settlement conditions required for contracts to qualify for equity classification and simplifies the diluted earnings per share calculations by requiring an entity use the if-converted method and the effect of potential share settlement be included in diluted earnings per share calculations. This new standard will be effective for the Company for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently assessing the impact of adopting this standard on the consolidated financial statements.</span></div> The accompanying condensed consolidated interim financial statements include the accounts of the Company and its subsidiaries. All material intercompany balances and transactions have been eliminated in consolidation. <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reverse Stock Split</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 9, 2022, the stockholders of the Company authorized the Board of Directors to effect a reverse stock split of all outstanding shares of common stock. The Board of Directors subsequently approved the implementation of a reverse stock split as a ratio of one-for-eleven shares, which became effective on May 13, 2022. The Company’s outstanding stock options were also adjusted to reflect the one-for-eleven reverse stock split of the Company’s common stock. Outstanding stock options were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased. The reverse stock split resulted in an adjustment to the Series X convertible preferred stock conversion prices to reflect a proportional decrease in the number of shares of common stock to be issued upon conversion. All share and per share data in these condensed consolidated financial statements and related notes hereto have been retroactively adjusted to account for the effect of the reverse stock split for the three and nine month periods ended September 30, 2022 and 2021, respectively, and the balance sheet at September 30, 2022 and December 31, 2021.</span></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</span></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its leases under Accounting Standards Codification (“ASC”) 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the consolidated balance sheet as both a right-of-use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term. Variable lease expenses, if any, are recorded when incurred.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In calculating the right-of-use asset and lease liability, the Company elects to combine lease and non-lease components. The Company excludes short-term leases having initial terms of 12 months or less from the new guidance as an accounting policy election and recognizes rent expense on a straight-line basis over the lease term.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss Per Share</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 260, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings Per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, requires dual presentation of basic and diluted earnings per share (“EPS”), with a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS computation. Basic EPS excludes dilution. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that are then sharing in the earnings of the entity.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding plus the effect of dilutive potential common shares outstanding during the period determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss per share calculation, common stock warrants, unvested restricted stock units and stock options are considered to be potentially dilutive securities but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive, and therefore, basic and diluted net loss per share were the same for all periods presented.</span></div> <div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share for the nine months ended September 30, 2022 and 2021, respectively, because to do so would be anti-dilutive (in common equivalent shares):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,311,691 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">533,784 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested restricted stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">891 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,118 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested restricted stock units</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125,000 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,116 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock conversion to common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,363,636 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants to purchase common stock</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,507,268 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,402,442 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,308,486 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,974,460 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1311691 533784 891 7118 125000 31116 1363636 0 17507268 2402442 20308486 2974460 <div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of Recent Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually assesses new accounting pronouncements to determine their applicability. When it is determined a new accounting pronouncement affects the Company’s financial reporting, the Company undertakes a review to determine the consequences of the change to its consolidated financial statements and assures there are sufficient controls in place to ascertain the Company’s consolidated financial statements properly reflect the change.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU No. 2020-06, “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity”, which simplifies the accounting for convertible instruments by eliminating the requirement to separate embedded conversion features from the host contract when the conversion features are not required to be accounted for as derivatives under Topic 815, Derivatives and Hedging, or do not result in substantial premiums accounted for as paid-in capital. By removing the separation model, a convertible debt instrument will be reported as a single liability instrument with no separate accounting for embedded conversion features. This new standard also removes certain settlement conditions required for contracts to qualify for equity classification and simplifies the diluted earnings per share calculations by requiring an entity use the if-converted method and the effect of potential share settlement be included in diluted earnings per share calculations. This new standard will be effective for the Company for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently assessing the impact of adopting this standard on the consolidated financial statements.</span></div> Revenue Recognition<div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue under ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The core principle of the new revenue standard is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The following five steps are applied to achieve that core principle:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Step 1: Identify the contract with the customer</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Step 2: Identify the performance obligations in the contract</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Step 3: Determine the transaction price</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Step 4: Allocate the transaction price to the performance obligations in the contract</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Step 5: Recognize revenue when the company satisfies a performance obligation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by us from a customer, are excluded from revenue.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shipping and handling costs associated with outbound freight related to contracts with customers are accounted for as a fulfillment cost and are included in cost of sales when control of the goods transfers to the customer.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Nature of goods and services</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a description of principal activities from which the Company generates its revenue.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product sales –</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for individual products and services separately if they are distinct (i.e., if a product or service is separately identifiable from other items and if a customer can benefit from it on its own or with other resources that are readily available to the customer). The consideration, including any discounts, is allocated between separate products and services based on their stand-alone selling prices. The stand-alone selling prices are determined based on the cost plus margin approach.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug and dialysis concentrates products are sold directly to dialysis clinics and to wholesale distributors in both domestic and international markets. Distribution and license agreements for which upfront fees are received are evaluated upon execution or modification of the agreement to determine if the agreement creates a separate performance obligation from the underlying product sales.  For all existing distribution and license agreements, the distribution and license agreement is not a distinct performance obligation from the product sales.  In instances where regulatory approval of the product has not been established and the Company does not have sufficient experience with the foreign regulatory body to conclude regulatory approval is probable, the revenue for the performance obligation is recognized over the term of the license agreement (over time recognition). Conversely, when regulatory approval already exists or is probable, revenue is recognized at the point in time control of the product transfers to the customer.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received upfront fees under five distribution and license agreements that have been deferred as a contract liability.  The amounts received from Wanbang Biopharmaceuticals Co., Ltd. (“Wanbang”), Sun Pharmaceutical Industries Ltd. ("Sun Pharma"), Jeil Pharmaceutical Co., Ltd. ("Jeil Pharma") and Drogsan Pharmaceuticals ("Drogsan Pharma") are recognized as revenue over the estimated term of the applicable distribution and license agreement as regulatory approval was not received and the Company did not have sufficient experience in China, India, South Korea and Turkey, respectively, to determine regulatory approval was probable as of the execution of the agreement.  The amounts received from Baxter Healthcare Corporation (“Baxter”) are recognized as revenue at the point in time the estimated product sales under the agreement occur. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the business under the Company’s Distribution Agreement with Baxter (the “Baxter Agreement”) and for the majority of the Company’s international customers, the Company recognizes revenue at the shipping point, which is generally the Company’s plant or warehouse. For other business, the Company recognizes revenue based on when the customer takes control of the product. The amount of revenue recognized is based on the purchase order less returns and adjusted for any rebates, discounts, chargebacks or other amounts paid to customers. There were no such adjustments for the periods reported. Customers typically pay for the product based on customary business practices with payment terms averaging 30 days, while distributor payment terms average 45 days.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Disaggregation of revenue</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.952%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.901%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.926%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">In thousands of U.S. dollars ($) </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products By Geographic Area</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 6.62pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Rest of World</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 6.62pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Rest of World</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product Sales – Point-in-time</span></td><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">193 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">193 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">834 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">561 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">273 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License Fee – Over time</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">192 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">192 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Drug Products</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">258 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">193 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,026 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">561 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">465 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concentrates Products</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product Sales – Point-in-time</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,953 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,619 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,334 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51,035 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46,334 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,701 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License Fee – Over time</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">480 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">480 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,436 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,436 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Concentrate Products</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,433 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,099 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,334 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52,471 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47,770 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,701 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net Revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,691 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,292 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,399 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53,497 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48,331 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,166 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.179%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.179%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.980%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.179%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.179%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.987%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">In thousands of U.S. dollars ($)</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products By Geographic Area</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Rest of World</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Rest of World</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product Sales – Point-in-time</span></td><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">217 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">217 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">656 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">656 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License Fee – Over time</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">179 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">179 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Drug Products</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">835 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">656 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">179 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concentrates Products</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product Sales – Point-in-time</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,224 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,541 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,683 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44,308 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39,768 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,540 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License Fee – Over time</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">485 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">485 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,456 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,456 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Concentrate Products</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,709 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,026 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,683 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45,764 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41,224 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,540 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net Revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,988 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,243 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,745 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46,599 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41,880 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,719 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Contract balances</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">In thousands of U.S. dollars ($)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables, which are included in "Trade and other receivables"</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,367 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,913 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,729 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,157 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no impairment losses recognized related to any receivables arising from the Company’s contracts with customers for the three and nine months ended September 30, 2022 and 2021.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2022 and September 30, 2021, the Company did not recognize any material bad-debt expense. There were no material contract assets recorded on the condensed consolidated balance sheet as of September 30, 2022 and December 31, 2021.  The Company does not generally accept returns of its concentrates products and no material reserve for returns of concentrates products was established as of September 30, 2022 or December 31, 2021. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contract liabilities primarily relate to upfront payments and consideration received from customers that are received in advance of the customer assuming control of the related products</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Transaction price allocated to remaining performance obligations</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2022, revenue recognized from performance obligations related to prior periods was not material.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue expected to be recognized in any future year related to remaining performance obligations, excluding revenue pertaining to contracts that have an original expected duration of one year or less, contracts where revenue is recognized as invoiced, and contracts with variable consideration related to undelivered performance obligations, totaled $6.7 million as of September 30, 2022. The amount relates primarily to upfront payments and consideration received from customers in advance of the customer assuming control of the related products. The Company applies the practical expedient in paragraph 606-10-50-14 and does not disclose information about remaining performance obligations having original expected durations of one year or less. The Baxter Agreement includes minimum commitments of product sales over the duration of the agreement. Unfulfilled minimum commitments related to the Baxter Agreement are product sales of $3.8 million as of September 30, 2022, which is amortized ratably through expiration of the Baxter Agreement on October 2, 2024.</span></div> 5 P30D P45D <div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.952%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.901%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.926%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">In thousands of U.S. dollars ($) </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products By Geographic Area</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 6.62pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Rest of World</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 6.62pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Rest of World</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product Sales – Point-in-time</span></td><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">193 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">193 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">834 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">561 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">273 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License Fee – Over time</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">192 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">192 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Drug Products</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">258 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">193 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,026 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">561 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">465 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concentrates Products</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product Sales – Point-in-time</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,953 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,619 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,334 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51,035 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46,334 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,701 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License Fee – Over time</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">480 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">480 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,436 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,436 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Concentrate Products</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,433 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,099 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,334 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52,471 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47,770 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,701 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net Revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,691 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,292 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,399 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53,497 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48,331 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,166 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.179%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.179%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.980%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.179%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.179%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.987%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">In thousands of U.S. dollars ($)</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products By Geographic Area</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Rest of World</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Rest of World</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product Sales – Point-in-time</span></td><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">217 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">217 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">656 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">656 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License Fee – Over time</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">179 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">179 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Drug Products</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">835 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">656 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">179 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concentrates Products</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product Sales – Point-in-time</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,224 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,541 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,683 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44,308 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39,768 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,540 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License Fee – Over time</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">485 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">485 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,456 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,456 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Concentrate Products</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,709 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,026 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,683 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45,764 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41,224 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,540 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net Revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,988 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,243 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,745 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46,599 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41,880 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,719 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 193000 193000 0 834000 561000 273000 65000 0 65000 192000 0 192000 258000 193000 65000 1026000 561000 465000 17953000 16619000 1334000 51035000 46334000 4701000 480000 480000 0 1436000 1436000 0 18433000 17099000 1334000 52471000 47770000 4701000 18691000 17292000 1399000 53497000 48331000 5166000 217000 217000 0 656000 656000 0 62000 0 62000 179000 0 179000 279000 217000 62000 835000 656000 179000 15224000 13541000 1683000 44308000 39768000 4540000 485000 485000 0 1456000 1456000 0 15709000 14026000 1683000 45764000 41224000 4540000 15988000 14243000 1745000 46599000 41880000 4719000 <div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">In thousands of U.S. dollars ($)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables, which are included in "Trade and other receivables"</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,367 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,913 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,729 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,157 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 7367000 5913000 6729000 8157000 0 0 0 0 0 0 0 0 6700000 3800000 Investments - Available-for-Sale<div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments available-for-sale consisted of the following as of September 30, 2022 and December 31, 2021 (table in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:37.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.469%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized Gain</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accrued Interest</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Available-for-Sale Securities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bonds</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,578 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,584 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:37.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.469%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accrued Interest</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Available-for-Sale Securities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bonds</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,143 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,158 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of investments available-for-sale are determined using quoted market prices from daily exchange-traded markets based on the closing price as of the balance sheet date and are classified as a Level 1 measurement under ASC 820 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022 and December 31, 2021, the amortized cost and estimated fair value of our available-for-sale securities were due within one year.</span></div> <div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments available-for-sale consisted of the following as of September 30, 2022 and December 31, 2021 (table in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:37.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.469%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized Gain</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accrued Interest</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Available-for-Sale Securities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bonds</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,578 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,584 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:37.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.469%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accrued Interest</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Available-for-Sale Securities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bonds</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,143 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,158 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 14578000 6000 1000 1000 14584000 9143000 1000 0 14000 9158000 Inventory<div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of inventory, net of reserves, as of September 30, 2022 and December 31, 2021 are as follows (table in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"><tr><td style="width:1.0%"/><td style="width:74.125%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.912%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.913%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Raw Materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,074 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,434 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Work in Process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">336 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">201 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finished Goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,803 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,964 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,213 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,599 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, the Company classified $1.2 million of inventory as non-current, all of which was related to the active pharmaceutical ingredient and raw materials for TRIFERIC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As of September 30, 2022, the total TRIFERIC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> inventory net of reserve was $1.2 million.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $1.2 million net value of TRIFERIC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> inventory consisted of $0.3 million of TRIFERIC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> API with an estimated useful life extending through 2023, and $0.9 million of raw materials for TRIFERIC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with an estimated useful life of 25 years.</span></div> <div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of inventory, net of reserves, as of September 30, 2022 and December 31, 2021 are as follows (table in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"><tr><td style="width:1.0%"/><td style="width:74.125%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.912%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.913%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Raw Materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,074 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,434 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Work in Process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">336 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">201 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finished Goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,803 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,964 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,213 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,599 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 4074000 3434000 336000 201000 1803000 1964000 6213000 5599000 1200000 1200000 1200000 300000 900000 P25Y Property and Equipment<div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022 and December 31, 2021, the Company’s property and equipment consisted of the following (table in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold Improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,257 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,204 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Machinery and Equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,985 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,864 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information Technology &amp; Office Equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,845 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,845 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laboratory Equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">660 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">676 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,747 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,589 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated Depreciation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,483)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,103)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and Equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,264 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,486 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for both the three months ended September 30, 2022 and 2021 was $0.1 million. Depreciation expense for nine months end September 30, 2022 and 2021 was $0.4 million and $0.5 million, respectively.</span></div> <div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022 and December 31, 2021, the Company’s property and equipment consisted of the following (table in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold Improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,257 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,204 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Machinery and Equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,985 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,864 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information Technology &amp; Office Equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,845 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,845 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laboratory Equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">660 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">676 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,747 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,589 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated Depreciation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,483)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,103)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and Equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,264 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,486 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1257000 1204000 5985000 5864000 1845000 1845000 660000 676000 9747000 9589000 7483000 7103000 2264000 2486000 100000 100000 400000 500000 Accrued Liabilities<div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities as of September 30, 2022 and December 31, 2021 consisted of the following (table in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued Research &amp; Development Expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">366 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued Compensation and Benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,006 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,791 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued Unvouchered Receipts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">581 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">796 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued Workers Compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">294 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">382 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Accrued Liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,941 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,755 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Accrued Liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,887 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,090 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities as of September 30, 2022 and December 31, 2021 consisted of the following (table in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued Research &amp; Development Expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">366 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued Compensation and Benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,006 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,791 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued Unvouchered Receipts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">581 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">796 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued Workers Compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">294 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">382 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Accrued Liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,941 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,755 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Accrued Liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,887 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,090 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 65000 366000 3006000 1791000 581000 796000 294000 382000 1941000 1755000 5887000 5090000 Deferred Revenue<div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2014, the Company entered into the Baxter Agreement, which has a term of 10 years and received an upfront fee of $20 million. The upfront fee was recorded as deferred revenue and is being recognized based on the proportion of product shipments to Baxter in each period, compared with total expected sales volume over the term of the Distribution Agreement. The Company recognized revenue of approximately $0.5 million and $1.4 million for the three and nine months ended September 30, 2022, respectively. The Company recognized revenue of approximately $0.5 million and $1.5 million for the three and nine month ended September 30, 2021, respectively. Deferred revenue related to the Baxter Agreement totaled $3.8 million as of September 30, 2022 and $5.2 million as of December 31, 2021.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, the Company entered into a distribution agreement with Wanbang (the "Wanbang Agreement") and received an upfront fee of $4.0 million. The upfront fee was recorded as deferred revenue and is being recognized as revenue based on the agreement term. The Company recognized revenue of approximately $0.1 million and $0.2 million during each of the three and nine months ended September 30, 2022 and 2021, respectively. Deferred revenue related to the Wanbang Agreement totaled $2.3 million as of September 30, 2022 and $2.5 million as of December 31, 2021.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the Company entered into license and supply agreements with Sun Pharma (the "Sun Pharma Agreements"), for the rights to commercialize TRIFERIC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (dialysate) (ferric pyrophosphate citrate) in India. In consideration for the license, the Company received an upfront fee of $0.1 million. The upfront fee was recorded as deferred revenue and is being recognized as revenue based on the agreement term. The Company recognized revenue of approximately $2,500 and $7,500 for each of the three and nine months ended September 30, 2022 and 2021, respectively. Deferred revenue related to the Sun Pharma Agreement totaled $72,500 and $80,000 as of September 30, 2022 and December 31, 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, the Company entered into a license and supply agreements with Jeil Pharma (the "Jeil Pharma Agreements"), for the rights to commercialize TRIFERIC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (dialysate) (ferric pyrophosphate citrate) in South Korea. In consideration for the license, the Company received an upfront fee of $0.2 million. In May 2022, Jeil Pharma obtained regulatory approval in South Korea and paid the Company $0.2 million in consideration of reaching the milestone. The upfront fee and milestone payments were recorded as deferred revenue and are being recognized as revenue based on the agreement term. The Company recognized revenue of $5,200 and $13,000 for the three and nine months ended September 30, 2022, respectively, and $2,500 and $7,500 for the three and nine months ended September 30, 2021, respectively. Deferred revenue related to the Jeil Pharma Agreement totaled approximately $0.4 million and $0.2 million as of September 30, 2022 and December 31, 2021 respectively.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2021, the Company entered into license and supply agreements with Drogsan Pharma (the "Drogsan Agreements"), for the rights to commercialize TRIFERIC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (dialysate) and TRIFERIC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> AVNU in Turkey. In consideration for the license, the Company received an upfront fee of $0.15 million. The upfront fee was recorded as deferred revenue and will be recognized as revenue based on the agreement term. The Company recognized revenue of $3,750 and $11,250 for each of the three and nine months ended September 30, 2022 and 2021, respectively. Deferred revenue related to the Drogsan Agreements totaled approximately $0.13 million and $0.15 million as of September 30, 2022 and December 31, 2021, respectively.</span></div> P10Y 20000000 500000 1400000 500000 1500000 3800000 5200000 4000000 100000 100000 200000 200000 2300000 2500000 100000 2500 2500 7500 7500 72500 80000 200000 200000 5200 13000 2500 7500 400000 200000 150000 3750 3750 11250 11250 130000 150000 Stockholders’ Equity<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reverse Stock Split</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 9, 2022, the stockholders of the Company authorized the Board of Directors to effect a reverse stock split of all outstanding shares of common stock. The Board of Directors subsequently approved the implementation of a reverse stock split as a ratio of one-for-eleven shares, which became effective on May 13, 2022. The Company’s outstanding stock options were also adjusted to reflect the one-for-eleven reverse stock split of the Company’s common stock. Outstanding stock options were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 6, 2022, the Company and DaVita entered into the SPA, which provided for the issuance by the Company of up to $15 million of preferred stock to DaVita. On April 6, 2022, the Company issued 7,500 shares of Series X Preferred Stock for gross proceeds of $7.5 million. On June 2, 2022, the Company met the conditions for the Second Tranche through a Registered Direct and Private Placement Offering by raising $15 million in additional capital. As a result, on June 16, 2022 the Company issued an additional 7,500 shares of the Series X Preferred Stock to DaVita for gross proceeds of $7.5 million. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Series X Preferred Stock was issued for a price of $1,000 per share (the "Face Amount"), subject to accretion at a rate of 1% per annum, compounded annually. If the Company’s common stock trades above $22.00 for a period of 30 calendar days, the accretion will thereafter cease.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Series X Convertible Preferred Stock is convertible to common stock at rate equal to the Face Amount, divided by a conversion price of $11.00 per share (subject to adjustment for future stock splits, reverse stock splits and similar recapitalization events). As a result, each share of Series X Preferred Stock will initially convert into approximately 91 shares of common stock. DaVita’s right to convert to common stock is subject to a beneficial ownership limitation, which is initially set at 9.9% of the outstanding common stock, which limitation may be reset (not to exceed 19.9%) at DaVita’s option and upon providing prior written notice to the Company. In addition, any debt financing is limited by the terms of our Securities Purchase Agreement with DaVita. Specifically, until DaVita owns less than 50% of its investment, the Company may only incur additional debt in the form of a purchase money loan, a working capital line of up to $5 million or to refinance existing debt, unless DaVita consents.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Series X Preferred Stock has a deemed liquidation event and redemption clause which could be triggered if the sale of all or substantially all of the Company's assets relating to the Company's dialysis concentrates business line. Since the Series X Preferred Stock may be redeemed if certain assets are sold at the option of the holder, but is not mandatorily redeemable, the preferred stock has been classified as permanent equity and initially recognized at fair value of $15 million (the proceeds on the date of issuance) less issuance costs of $0.1 million, resulting in an initial value of $14.9 million. The Company will assess at each reporting period whether conditions have changed to now meet the mandatorily redemptive definition which could trigger liability classification.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022 and December 31, 2021, there were 2,000,000 shares of preferred stock, $0.0001 par value per share, authorized and 15,000 and nil shares of preferred stock issued and outstanding, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022 and December 31, 2021, there were 170,000,000 shares of common stock, $0.0001 par value per share, authorized and 11,152,673 and 8,544,225 shares issued and outstanding, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Controlled Equity Offering</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 8, 2022, the Company entered into the Sales Agreement with Cantor Fitzgerald &amp; Co. as Agent, pursuant to which the Company may offer and sell from time to time up to $12,200,000 of shares of Company’s common stock through the Agent. The offering and sale of such shares has been registered under the Securities Act of 1933, as amended, pursuant to the Company’s Registration Statement on Form S-3 (File No. 333-259923) (the “Registration Statement”), which was originally filed with the SEC on September 30, 2021 and declared effective by the SEC on October 8, 2021, the base prospectus contained within the Registration Statement, and a prospectus supplement that was filed with the SEC on April 8, 2022.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, the Company sold 7,500 shares of its common stock pursuant to the Sales Agreement for gross proceeds of $15,135, at a weighted average selling price of approximately $2.02. The Company paid $378 in commissions and offering fees related to the sale of shares of common stock.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the RD Purchase Agreement and the PIPE Purchase Agreement discussed below, the Company has agreed not to make any sales under any at-the-market offering facility, including pursuant to the Sales Agreement, until at least January 1, 2023 (or until such later time when the Company is permitted to make additional sales under Instruction I.B.6 to Form S-3).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Registered Direct Offering</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 30, 2022, the Company entered into the RD Purchase Agreement with the Purchaser named therein, pursuant to which the Company agreed to issue and sell, in a registered direct offering (the “Offering”), 844,613 shares of its common stock at price of $1.39 per share, and pre-funded warrants to purchase up to an aggregate of 7,788,480 shares of common stock (the “Pre-Funded Warrants” and the shares of common stock underlying the Pre-Funded Warrants, the “Warrant Shares”). The purchase price of each Pre-Funded Warrant is equal to the price at which a share of common stock was sold to the public in the Offering, minus $0.0001, and the exercise price of each Pre-Funded Warrant is $0.0001 per share.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A holder (together with its affiliates) may not exercise any portion of the Pre-Funded Warrants to the extent the holder would own more than 9.99% of the Company’s outstanding common stock immediately after exercise, as such percentage ownership is determined in accordance with the terms of the Pre-Funded Warrant. The RD Purchase Agreement contains customary representations and warranties and agreements of the Company and the Purchaser and customary indemnification rights and obligations of the parties.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A total of 7,311,000 Pre-Funded Warrants remained outstanding as of September 30, 2022.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Private Placement</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also on May 30, 2022, concurrently with the Offering, the Company entered into the PIPE Purchase Agreement relating to the offering and sale (the “Private Placement”) of warrants to purchase up to a total of 9,900,990 shares of common stock and pre-funded warrants to purchase up to a total of 1,267,897 shares of common stock (the “PIPE Warrants”). Each warrant was sold at a price of $0.125 per underlying warrant share and is exercisable at an exercise price of $1.39 per share. The purchase price of each Pre-Funded Warrant was equal to the price at which a share of common stock was sold to the public in the Offering, minus $0.0001, and the exercise price of each prefunded warrant is $0.0001 per share.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022 9,900,990 PIPE Warrants and no Pre-Funded PIPE Warrants remained outstanding.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Private Placement, the Company entered into a Registration Rights Agreement with the Purchaser, dated as of June 2, 2022 (the “RRA”). Pursuant to the RRA, the Company was required to prepare and file a registration statement with the SEC no later than July 1, 2022, and to use its reasonable best efforts to have the registration statement declared effective as promptly as possible, subject to certain specified penalties if timely effectiveness is not achieved. The Company filed a registration statement on June 22, 2022 which became effective on July 5, 2022.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Offering and the Private Placement closed on June 2, 2022. The net proceeds to the Company from the Offering and the Private Placement were approximately $14.9 million, after deducting fees and expenses. Subject to certain ownership limitations, the PIPE Warrants are exercisable upon issuance.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has accounted for the common stock related to the Offering and Private Placement as equity on the accompanying consolidated balance sheets as of September 30, 2022. The amount allocated to common stock was $2.0 million. This allocation is equal to the total proceeds of $15.0 million less the amount allocated to Warrants of $12.9 million and is also net of the direct and incremental costs associated with the Offering and Private Placement of $0.1 million. The Black-Scholes pricing model was used to calculate the value of Warrants relating to the Offering and Private Placement.</span></div> 15000000 7500 7500000 15000000 7500 7500000 1000 0.01 22.00 P30D 11.00 91 0.099 0.199 0.50 5000000 15000000 100000 14900000 2000000 2000000 0.0001 0.0001 15000 15000 0 0 170000000 170000000 0.0001 0.0001 11152673 11152673 8544225 8544225 12200000 7500 15135 2.02 378 844613 1.39 7788480 0.0001 0.0001 0.0999 7311000 9900990 1267897 0.125 1.39 0.0001 0.0001 9900990 0 14900000 2000000 15000000 12900000 100000 Stock-Based Compensation<div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized total stock-based compensation expense during the three and nine months ended September 30, 2022 and 2021 as follows (table in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.630%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Service-based awards:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">263 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">130 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">315 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">401 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,050 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">176 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">396 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">485 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,313 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Performance-based awards:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(391)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(391)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(364)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(35)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(391)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(755)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">176 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">361 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">558 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance Based Restricted Stock</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company’s restricted stock awards during the nine months ended September 30, 2022 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average <br/>Grant-Date <br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,118 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62.70 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,227)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">891 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62.70 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company’s restricted stock awards during the nine months ended September 30, 2021 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average<br/>Grant-Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,345 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.70 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,227)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,118 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.70 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of restricted stock awards are measured based on their fair value on the date of grant and amortized over the vesting period of 20 months. As of September 30, 2022, unvested restricted stock awards of 891 were related to performance-based awards. The forfeited performance-based restricted stock awards of 6,227 was due to the resignation of the Company's Chief Development Officer on March 25, 2022. These forfeited awards reduced stock-based compensation expense by $0.4 million. As of September 30, 2021, unvested restricted stock awards of 7,118 were related to performance-based awards. The forfeited performance-based restricted stock awards of 6,227 was due to the termination of the Company's former Chief Science Officer on January 19, 2021. These forfeited awards reduced stock-based compensation expense by $0.4 million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Service-Based Restricted Stock Units</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company’s service-based restricted stock units during the nine months ended September 30, 2022 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average<br/>Grant-Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,289 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.87 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,515)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,774)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.47 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company’s service-based restricted stock units during the nine months ended September 30, 2021 is as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:74.635%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.666%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average<br/>Grant-Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24,136 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.60 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,186 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,134)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,073)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.91 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,115 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.87 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:7pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of service based restricted stock units are measured based on their fair value on the date of grant and amortized over the vesting period. The vesting periods range from 1 to 3 years. Stock-based compensation expense of $46,193 and $83,607 was recognized for the three and nine months ended September 30, 2022, respectively. Stock-based compensation expense of $0.1 million and $0.3 million was recognized for the three and nine months ended September 30, 2021, respectively. As of September 30, 2022, the unrecognized stock-based compensation expense was $0.1 million, which is expected to be recognized over an estimated weighted average remaining term of less than 1 year. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Service-Based Stock Options</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the service-based stock options granted for the nine months ended September 30, 2022 were based on the following assumptions:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:83.118%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.682%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercise price</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.28 - $1.66</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected stock price volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76.2% - 78.5%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.97% - 3.44%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Term (years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5 - 6</span></div></td></tr></table></div><div style="margin-top:7pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company’s service-based stock option activity for the nine months ended September 30, 2022 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:49.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares<br/>Underlying<br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate <br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">528,591 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.01 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">898,659 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.49 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,093)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85,466)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.09 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,311,691 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.23 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,973 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.31 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company’s service-based stock option activity for the nine months ended September 30, 2021 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:49.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares<br/>Underlying<br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate <br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">519,814 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.05 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,197 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.79 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,025)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121,202)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.76 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533,784 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.45 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230,858 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.56 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value in the table above is calculated as the difference between the closing price of the Company's common stock and the exercise price of the stock options that had strike prices below the closing price.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2022, the Company granted stock options to purchase up to 898,659 shares of common stock to certain employees. During the nine months ended September 30, 2022, 30,093 shares were forfeited and 85,466 shares expired. Forfeitures are recorded in the period of occurrence; compensation expense is adjusted accordingly.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized for service-based stock options was $0.1 million and $0.4 million for the three and nine months ended September 30, 2022, respectively. Stock-based compensation expense recognized for service-based stock options was $0.3 million and $1.0 million for the three and nine months ended September 30, 2021, respectively. As of September 30, 2022, total stock-based compensation expense related to unvested options not yet recognized totaled approximately $1.4 million, which is expected to be recognized over an estimated weighted average remaining term of 3.6 years.</span></div> <div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized total stock-based compensation expense during the three and nine months ended September 30, 2022 and 2021 as follows (table in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.630%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Service-based awards:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">263 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">130 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">315 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">401 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,050 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">176 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">396 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">485 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,313 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Performance-based awards:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(391)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(391)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(364)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(35)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(391)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(755)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">176 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">361 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">558 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 46000 81000 84000 263000 130000 315000 401000 1050000 176000 396000 485000 1313000 0 0 -391000 -391000 0 -35000 0 -364000 0 -35000 -391000 -755000 176000 361000 94000 558000 <div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company’s restricted stock awards during the nine months ended September 30, 2022 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average <br/>Grant-Date <br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,118 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62.70 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,227)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">891 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62.70 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company’s restricted stock awards during the nine months ended September 30, 2021 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average<br/>Grant-Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,345 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.70 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,227)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,118 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.70 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 7118 62.70 6227 62.70 891 62.70 13345 62.70 6227 62.70 7118 62.70 P20M 891 6227 -400000 7118 6227 -400000 <div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company’s service-based restricted stock units during the nine months ended September 30, 2022 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average<br/>Grant-Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,289 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.87 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,515)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,774)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.47 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company’s service-based restricted stock units during the nine months ended September 30, 2021 is as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:74.635%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.666%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average<br/>Grant-Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24,136 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.60 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,186 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,134)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,073)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.91 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,115 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.87 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div> 29289 12.87 125000 1.47 23515 11.33 5774 19.00 125000 1.47 24136 28.60 28186 9.90 20134 26.18 1073 52.91 31115 12.87 P1Y P3Y 46193 83607 100000 300000 100000 P1Y <div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the service-based stock options granted for the nine months ended September 30, 2022 were based on the following assumptions:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:83.118%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.682%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercise price</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.28 - $1.66</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected stock price volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76.2% - 78.5%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.97% - 3.44%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Term (years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5 - 6</span></div></td></tr></table></div> 1.28 1.66 0.762 0.785 0.0197 0.0344 P5Y6M P6Y <div style="margin-top:7pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company’s service-based stock option activity for the nine months ended September 30, 2022 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:49.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares<br/>Underlying<br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate <br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">528,591 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.01 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">898,659 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.49 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,093)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85,466)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.09 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,311,691 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.23 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,973 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.31 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company’s service-based stock option activity for the nine months ended September 30, 2021 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:49.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares<br/>Underlying<br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate <br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">519,814 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.05 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,197 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.79 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,025)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121,202)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.76 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533,784 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.45 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230,858 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.56 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 528591 32.01 P7Y6M 0 898659 1.49 P5Y6M 30093 15.11 85466 82.09 1311691 8.23 P9Y1M6D 0 243973 29.31 P6Y10M24D 0 519814 50.05 P6Y7M6D 0 170197 9.79 P6Y 35025 25.30 121202 78.76 533784 32.45 P7Y8M12D 0 230858 54.56 P5Y9M18D 0 898659 30093 85466 100000 400000 300000 1000000 1400000 P3Y7M6D Licensing Agreements<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product License Agreements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a party to a Licensing Agreement between the Company and Charak, LLC ("Charak") dated January 7, 2002 (the "2002 Agreement") that grants the Company exclusive worldwide rights to certain patents and information related to our TRIFERIC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product. On October 7, 2018, the Company entered into a Master Services and IP Agreement (the “Charak MSA”) with Charak and Dr. Ajay Gupta, a former Officer of the Company. Pursuant to the MSA, the parties entered into three additional agreements described below related to the license of certain soluble ferric pyrophosphate (“SFP”) intellectual property owned by Charak. As of September 30, 2022, the Company has accrued $85,400 relating to certain IP reimbursement expenses and certain sublicense royalty fees and is included within accrued liabilities on the condensed consolidated balance sheet.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Charak MSA, the aforementioned parties entered into an Amendment, dated as of October 7, 2018 (the “Charak Amendment”), to the 2002 Agreement, under which Charak granted the Company an exclusive, worldwide, non-transferable license to commercialize SFP for the treatment of patients with renal failure. The Charak Amendment amends the royalty payments due to Charak under the 2002 Agreement such that the Company is liable to pay Charak royalties on net sales by the Company of products developed under the license, which includes the Company’s TRIFERIC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product, at a specified rate until December 31, 2021 and thereafter at a reduced rate from January 1, 2022 until February 1, 2034. Additionally, the Company shall pay Charak a percentage of any sublicense income during the term of the agreement, which amount shall not be less than a minimum specified percentage of net sales of the licensed products by the sublicensee in jurisdictions where there exists a valid claim, on a country-by-country basis, and be no less than a lower rate of the net sales of the licensed products by the sublicensee in jurisdictions where there exists no valid claim, on a country-by-country basis.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also pursuant to the Charak MSA, the Company and Charak entered into a Commercialization and Technology License Agreement I.V. TRIFERIC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, dated as of October 7, 2018 (the “IV Agreement”), under which Charak granted the Company an exclusive, sublicensable, royalty-bearing license to SFP for the purpose of commercializing certain intravenous-delivered products incorporating SFP for the treatment of iron disorders worldwide for a term that expires on the later of February 1, 2034 or upon the expiration or termination of a valid claim of a licensed patent. The Company is liable to pay Charak royalties on net sales by the Company of products developed under the license at a specified rate until December 31, 2021. From January 1, 2022 until February 1, 2034, the Company is liable to pay Charak a base royalty at a reduced rate on net sales and an additional royalty on net sales while there exists a valid claim of a licensed patent, on a country-by-country basis. The Company shall also pay to Charak a percentage of any sublicense income received during the term of the IV Agreement, which amount shall not be less than a minimum specified percentage of net sales of the licensed products by the sublicensee in jurisdictions where there exists a valid claim, on a country-by-country basis, and not be less than a lower rate of the net sales of the licensed products by the sublicensee in jurisdictions where there exists no valid claim, on a country-by-country basis.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also pursuant to the Charak MSA, the Company and Charak entered into a Technology License Agreement TPN TRIFERIC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, dated as of October 7, 2018 (the “TPN Agreement”), pursuant to which Charak granted the Company an exclusive, sublicensable, royalty-bearing license to SFP for the purpose of commercializing worldwide certain TPN products incorporating SFP. The license grant under the TPN Agreement continues for a term that expires on the later of February 1, 2034 or upon the expiration or termination of a valid claim of a licensed patent. During the term of the TPN Agreement, the Company is liable to pay Charak a base royalty on net sales and an additional royalty on net sales while there exists a valid claim of a licensed patent, on a country-by-country basis. The Company shall also pay to Charak a percentage of any sublicense income received during the term of the TPN Agreement, which amount shall not be less than a minimum royalty on net sales of the licensed products by the sublicensee in jurisdictions where there exists a valid claim, on a country-by-country basis, and not be less than a lower rate of the net sales of the licensed products by the sublicensee in jurisdictions where there exists no valid claim, on a country-by-country basis.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The potential milestone payments are not yet considered probable, and no milestone payments have been accrued at September 30, 2022.</span></div> 3 85400 0 Leases<div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rockwell leases its production facilities and administrative offices as well as certain equipment used in its operations including leases on transportation equipment used in the delivery of its products. The lease terms range from monthly to six years. Rockwell occupies a 51,000 square foot facility and a 17,500 square foot facility in Wixom, Michigan under a lease expiring in August 2024. Rockwell also occupies two other manufacturing facilities, a 51,000 square foot facility in Grapevine, Texas under a lease expiring in December 2025, and a 57,000 square foot facility in Greer, South Carolina under a lease expiring February 2026. In addition, Rockwell occupied 4,100 square feet of office space in Hackensack, New Jersey under a lease expiring on October 31, 2024. This lease was subleased on December 15, 2021 with an expiration date of October 31, 2024.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2022, the Company had operating and finance lease liabilities of $7.2 million and right-of-use assets of $6.9 million, which are included in the consolidated balance sheet.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2021, the Company had operating lease liabilities of $7.9 million and right-of-use assets of $7.7 million, which are included in the consolidated balance sheet.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes quantitative information about the Company’s operating leases (table in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.993%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.033%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.497%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.033%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.776%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.033%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.497%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.038%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nine Months Ended September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nine Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">410 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">457 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,289 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,309 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">287 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">511 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">551 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,576 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,595 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">141 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">424 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">184 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on lease obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">136 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">185 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">560 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">239 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Short-term lease rent expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total rent expense</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">701 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">650 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,150 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,846 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Other information</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">427 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,338 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,298 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from finance leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing cash flows from finance leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right of use assets exchanged for operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">768 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">718 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">768 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,089 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right of use assets exchanged for finance lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">588 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,365 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average remaining lease term – operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.7</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average remaining lease term – finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average discount rate – operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average discount rate – finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:7pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum rental payments under operating lease agreements are as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.035%"><tr><td style="width:1.0%"/><td style="width:71.806%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.036%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.621%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.037%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2022 (remaining)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">434 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,692 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">669 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,404 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">672 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">937 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">310 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">666 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remaining future payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,897 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,159 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less present value discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(467)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(426)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating and finance lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,430 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,733 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> Leases<div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rockwell leases its production facilities and administrative offices as well as certain equipment used in its operations including leases on transportation equipment used in the delivery of its products. The lease terms range from monthly to six years. Rockwell occupies a 51,000 square foot facility and a 17,500 square foot facility in Wixom, Michigan under a lease expiring in August 2024. Rockwell also occupies two other manufacturing facilities, a 51,000 square foot facility in Grapevine, Texas under a lease expiring in December 2025, and a 57,000 square foot facility in Greer, South Carolina under a lease expiring February 2026. In addition, Rockwell occupied 4,100 square feet of office space in Hackensack, New Jersey under a lease expiring on October 31, 2024. This lease was subleased on December 15, 2021 with an expiration date of October 31, 2024.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2022, the Company had operating and finance lease liabilities of $7.2 million and right-of-use assets of $6.9 million, which are included in the consolidated balance sheet.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2021, the Company had operating lease liabilities of $7.9 million and right-of-use assets of $7.7 million, which are included in the consolidated balance sheet.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes quantitative information about the Company’s operating leases (table in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.993%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.033%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.497%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.033%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.776%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.033%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.497%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.038%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nine Months Ended September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nine Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">410 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">457 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,289 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,309 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">287 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">511 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">551 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,576 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,595 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">141 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">424 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">184 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on lease obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">136 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">185 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">560 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">239 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Short-term lease rent expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total rent expense</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">701 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">650 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,150 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,846 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Other information</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">427 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,338 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,298 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from finance leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing cash flows from finance leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right of use assets exchanged for operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">768 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">718 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">768 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,089 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right of use assets exchanged for finance lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">588 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,365 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average remaining lease term – operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.7</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average remaining lease term – finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average discount rate – operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average discount rate – finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:7pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum rental payments under operating lease agreements are as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.035%"><tr><td style="width:1.0%"/><td style="width:71.806%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.036%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.621%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.037%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2022 (remaining)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">434 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,692 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">669 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,404 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">672 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">937 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">310 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">666 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remaining future payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,897 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,159 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less present value discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(467)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(426)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating and finance lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,430 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,733 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> P6Y 51000 17500 51000 57000 4100 7200000 6900000 7900000 7700000 <div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes quantitative information about the Company’s operating leases (table in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.993%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.033%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.497%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.033%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.776%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.033%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.497%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.038%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nine Months Ended September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nine Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">410 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">457 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,289 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,309 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">287 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">511 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">551 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,576 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,595 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">141 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">424 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">184 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on lease obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">136 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">185 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">560 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">239 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Short-term lease rent expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total rent expense</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">701 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">650 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,150 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,846 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Other information</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">427 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,338 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,298 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from finance leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing cash flows from finance leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right of use assets exchanged for operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">768 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">718 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">768 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,089 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right of use assets exchanged for finance lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">588 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,365 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average remaining lease term – operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.7</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average remaining lease term – finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average discount rate – operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average discount rate – finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 410000 457000 1289000 1309000 101000 94000 287000 286000 511000 551000 1576000 1595000 141000 73000 424000 184000 44000 22000 136000 55000 185000 95000 560000 239000 5000 4000 14000 12000 701000 650000 2150000 1846000 427000 444000 1338000 1298000 44000 22000 136000 56000 121000 59000 359000 152000 768000 718000 768000 4089000 0 588000 0 1365000 P3Y2M12D P3Y8M12D P3Y2M12D P3Y8M12D P4Y8M12D P5Y6M P4Y8M12D P5Y6M 0.064 0.063 0.064 0.063 0.064 0.059 0.064 0.059 <div style="margin-top:7pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum rental payments under operating lease agreements are as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.035%"><tr><td style="width:1.0%"/><td style="width:71.806%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.036%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.621%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.037%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2022 (remaining)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">434 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,692 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">669 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,404 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">672 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">937 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">310 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">666 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remaining future payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,897 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,159 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less present value discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(467)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(426)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating and finance lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,430 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,733 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-top:7pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum rental payments under operating lease agreements are as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.035%"><tr><td style="width:1.0%"/><td style="width:71.806%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.036%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.621%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.037%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2022 (remaining)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">434 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,692 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">669 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,404 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">672 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">937 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">310 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">666 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remaining future payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,897 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,159 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less present value discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(467)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(426)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating and finance lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,430 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,733 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 434000 165000 1692000 669000 1404000 672000 937000 676000 310000 666000 120000 311000 4897000 3159000 467000 426000 4430000 2733000 Loan and Security Agreement<div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 16, 2020, the Company and Rockwell Transportation, Inc., as Borrowers, entered into a Loan and Security Agreement (the "Loan Agreement") with Innovatus Life Sciences Lending Fund I, LP ("Innovatus"), as collateral agent and the lenders party thereto, pursuant to which Innovatus, as a lender, agreed to make certain term loans to the Company in the aggregate principal amount of up to $35.0 million (the "Term Loans"). Funding of the first $22.5 million tranche was completed on March 16, 2020. The Company is no longer eligible to draw on a second tranche of $5.0 million or a third tranche of $7.5 million, which were tied to the achievement of certain milestones by a specific date. Net draw down proceeds were $21.2 million with closing costs of $1.3 million. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with each funding of the Term Loans, the Company is required to issue to Innovatus a warrant (the “Warrants”) to purchase a number of shares of the Company’s common stock equal to 3.5% of the principal amount of the relevant Term Loan funded divided by the exercise price, which will be based on the lower of (i) the volume weighted average closing price of the Company’s stock for the 5-trading day period ending on the last trading day immediately preceding the execution of the Loan Agreement or (ii) the closing price on the last trading day immediately preceding the execution of the Loan Agreement (or for the second and third tranches only at the lower of (i) $18.15 per share or (ii) the volume weighted average closing price of the Company’s stock for the 5-trading day period ending on the last trading day immediately preceding the relevant Term Loan funding). The Warrants may be exercised on a cashless basis and are immediately exercisable through the seventh anniversary of the applicable funding date. The number of shares of common stock for which each Warrant is exercisable and the associated exercise price are subject to certain proportional adjustments as set forth in such Warrant. In connection with the first tranche of the Term Loans, the Company issued a Warrant to Innovatus, exercisable for an aggregate of 43,388 shares of the Company’s common stock at an exercise price of $18.15 per share. The Company evaluated the warrant under ASC 470, Debt, and recognized an additional debt discount of approximately $0.5 million based on the relative fair value of the base instruments and warrants. The Company calculated the fair value of the warrant using the Black-Scholes model.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is entitled to make interest-only payments for thirty months, or up to thirty-six months if certain conditions are met. The Term Loans will mature on March 16, 2025, and will bear interest at the greater of (i) Prime Rate (as defined in the Loan Agreement) and (ii) 4.75%, plus 4.00% with an initial interest rate of 8.75% per annum and an effective interest rate of 10.9%. The Company has the option, under certain circumstances, to add 1.00% of such interest rate amount to the then outstanding principal balance in lieu of paying such amount in cash. For the three months ended September 30, 2022 and 2021, interest expense amounted to $0.4 million and $0.6 million, respectively. For the nine months ended September 30, 2022 and 2021, interest expense amounted to $1.2 million and $1.8 million, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Loan Agreement is secured by all assets of the Company and Rockwell Transportation, Inc. Proceeds are used for working capital purposes. The Loan Agreement contains customary representations and warranties and covenants, subject to customary carve outs, and includes financial covenants related to liquidity and trailing twelve months sales of TRIFERIC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, with the latter beginning with the period ending December 31, 2020. The Company cannot assure you that we can maintain compliance with the covenants under our Loan Agreement, which may result in an event of default. The Company's ability to comply with these covenants may be adversely affected by events beyond its control. For example, the Loan Agreement contains certain financial covenants relating to sales and, as a result of the ongoing COVID-19 pandemic and its effect on the Company's sales activities, among other factors, the Company may not be able to satisfy such covenants in the future. If the Company is unable to comply with the covenants under the Loan Agreement, it would pursue all available cure options in order to regain compliance. However, the Company may not be able to mutually agree with Innovatus on appropriate remedies to cure a future breach of a covenant, which could give rise to an event of default. If the Company is unable to avoid an event of default, any required repayments could have an adverse effect on its liquidity. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the Company entered into an amendment to the Loan Agreement in which the Company, in exchange for Innovatus lowering the sales covenants, agreed to (i) prepay an aggregate principal amount of $7,500,000 in ten installments commencing on December 1, 2021; (ii) pay an additional prepayment premium of 5% on prepaid amounts if the Company elects to prepay all outstanding Term Loans on or before September 24, 2023 and (iii) maintain minimum liquidity of no less than $5,000,000 if the aggregate principal amount of Term Loans is greater than $15,000,000 pursuant to the liquidity covenant in the Loan Agreement. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 31, 2022, the Collateral Agent and Lenders consented to the delivery to Collateral Agent and Lenders of its annual audited financial statements for the fiscal year 2021 by April 15, 2022 as opposed to within 90 days of December 31, 2021, as required pursuant to Loan Agreement. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, the Company was in compliance with all covenants under the Loan Agreement.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, the outstanding balance of the Term Loan was $14.1 million, net of unamortized issuance costs and discount of $0.9 million.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the schedule of principal payments on the Term Loan as of September 30, 2022 (in thousands):</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:29.385%"><tr><td style="width:1.0%"/><td style="width:47.158%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.642%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal Payments</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ccffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#ccffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#ccffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ccffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,000 </span></td><td style="background-color:#ccffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ccffff;padding:0 1pt"/><td style="background-color:#ccffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000 </span></td><td style="background-color:#ccffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 35000000 22500000 5000000 7500000 21200000 1300000 0.035 P5D 18.15 P5D 43388 18.15 500000 P30M P36M 0.0475 0.0400 0.0875 0.109 0.0100 400000 600000 1200000 1800000 7500000 10 0.05 5000000 15000000 14100000 900000 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the schedule of principal payments on the Term Loan as of September 30, 2022 (in thousands):</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:29.385%"><tr><td style="width:1.0%"/><td style="width:47.158%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.642%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal Payments</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ccffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#ccffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#ccffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ccffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,000 </span></td><td style="background-color:#ccffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ccffff;padding:0 1pt"/><td style="background-color:#ccffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000 </span></td><td style="background-color:#ccffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1000000 6000000 6000000 2000000 15000000 Insurance Financing Note PayableOn June 2, 2022, the Company entered into a short-term note payable for $1.5 million, bearing interest at 5.40% per annum to finance various insurance policies. Principal and interest payments related to this note began on July 3, 2022 and were paid on a straight-line amortization over 9 months with the final payment due on March 3, 2023. As of September 30, 2022, the Company's insurance note payable balance was $1.0 million. 1500000 0.0540 P9M 1000000 Subsequent Events<div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 28, 2022, 480,000 Pre-Funded Warrants to purchase common stock pursuant the SPA entered into on May 30, 2022 were exercised. The exercise price of each Pre-Funded Warrant is $0.0001 per share and resulted in gross proceeds of $48.00 (See Note 10 for more detail on the SPA).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 9, 2022, Rockwell reacquired its distribution rights to its hemodialysis concentrates products from Baxter and has agreed to terminate the exclusive distribution agreement dated October 2, 2014. Exclusivity and other provisions associated with the distribution agreement terminated November 9, 2022 and the remaining operational elements of the agreement terminate December 31, 2022. Under the exclusive distribution agreement, Baxter distributed and commercialized Rockwell’s hemodialysis concentrates products and provided customer service and order delivery to nearly all United States customers. Following the reacquisition of these rights, Rockwell will now be able to sell its hemodialysis concentrates products to dialysis clinics throughout the United States and around the world. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rockwell will pay Baxter a fee for the reacquisition of its distribution rights. This fee will be payable in two equal installments on January 1, 2023 and April 1, 2023. To ensure that customer needs continue to be met after January 1, 2023, Baxter and Rockwell are working closely together to transition customers’ purchases of Rockwell’s hemodialysis concentrates from Baxter to Rockwell.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 10, 2022, the Company entered into a Second Amendment to the Loan and Security Agreement (the “Second Amendment”) dated as of November 14, 2022 with Innovatus, which amended the Loan Agreement. Pursuant to the Second Amendment, the Company (i) shall prepay an aggregate principal amount of $5.0 million in Term Loans (as defined in the Loan Agreement) in one installment on November 14, 2022; (ii) shall pay interest only payments until September 2023 at which time will resume scheduled debt payments.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Separation of Chief Financial Officer </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 10, 2022, the Board of Directors of Rockwell terminated the employment of Russell Skibsted as Chief Financial Officer of the Company, effective immediately. The termination of employment of Mr. Skibsted by the Company without cause entitles Mr. Skibsted to severance in accordance with the Employment Agreement, dated September 15, 2020, by and between the Company and Mr. Skibsted (the “Employment Agreement”). The severance benefits under the Employment Agreement are subject to the execution and non-revocation of a release of claims in favor of the Company. In connection with Mr. Skibsted’s termination, the Board of Directors appointed Mark Strobeck, the Company’s Chief Executive Officer, as interim principal financial officer.</span></div> 480000 0.0001 48.00 5000000 EXCEL 79 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

>.2!W&SP-H6 MVU0(W9'% ;GMMXW43H#$=;:PJRPZEE2];0 .2ZPE*1MWUY'G(]V^+_=P-SPA M5ZS!2PMW/+YU#]\E,7UVNVR1/^?8-&!H0!CMY'$#TH7?<;&7=\,1HM6&Z$K; M\[\3M^?8" +B8=R=[PC+"YW)!FFF[')R$%0RC.@QCJ$[WEP_4-X>JE9"C!;] M^-;U98.]AK C1%$UE4M_5,&2K^V6;+N'V \YGZ/+M02VN=>U[Q) MYFVM_H%=&8G:;0KW%YV GG:>?F93)W3E@0#W<85(@F024)),>NE0Y5[D1Y2D M02\=ND>8@BKII4IPX4-G0A^ZY)BUSNR\QP(?5&S36FPIC">V[$-TD@G](K3= MV&*OCMA]XV6S$\JG49(^PS%(GNWXL'_38.5'8=NITC"DGF$D[H:1^#\.([U\ MQV'D.(P"(Y\L =[;+>;VQBKH/G^>_P-02P,$% @ ZT)N55AH;6CK"@ MT1P !D !X;"]W;W)K&ULS5E;;QLW%OXKA.IT M8T"1)5F.[?@"V$F+!DBWAIUM'Q;[0,U0$NN9X93D2%9__7[GD'.396<+]&$? M$DLSY.&Y?N<[U.7&V$>W4LJ+ISPKW-5@Y7WYX>C()2N52S/S^*)>Z&%Q?\K,[>WUI*I_I0MU9X:H\EW9[JS*SN1I, M!O6#>[U<>7IP='U9RJ5Z4/Y?Y9W%MZ-&2JIS53AM"F'5XFIP,_EP.Z/UO.!7 MK3:N\UF0)7-C'NG+Y_1J,":%5*823Q(D_JS51Y5E) AJ_!%E#IHC:6/WIJ<#80J5K(*O/W9O.3BO:/Q4$S'T^DK\HX;?M$LRXRJKQ+]OYLY;I,9_]AD;9,WVRZ)R^>!*F:BK >K!*;M6 M@^OOOYN\'U^\HNFLT73VFO2_')A7I>W7E8YXX03Q2R%^EC99B,&Y22^6JA:&NLE%=I0?"Z2T5!()VZ-A=7*NJ& 3&55*G3A MC9#BM:/?TD$#7M$\'!RB+OP*H@NSEKYRXHM>*/&0:%4D"M]4D>IB*7ZL(//S M4'RY$V\'S>+!(:N#6LDDU)"9 -[@)%* #LNP&UJ*4EIH@B=6>3,4965=);$. M*F]6.ND=\)<&<(8/#$1M-QF,+O5UHZ[PX MF$Y')\TVY'@!/!<;=D->9LI#7[,;Y)'XVE72B<) _V*IK%"97NIYIDBEU,H- M;9;"J<20$Z-X:'#0U=98K/$K;?M+3EO-AM&SR!*(UL&)[)IDI=4Z9 3VU"[% M-@50+!#S^984*%6B%SH1*;PX$O]$&V/M4K,IX%23("XN2#^83D;31C5.)X(! M\EQBG'>LVF1T7"\9(=QX4Q2Q@? .!;W$HN_P-AK](H'_K/JCTC98I9VKV'UM M$DL$Q%I9)_WWWYU-I^.+W\(SQU\G%X>T![F8K-!]L*6H\CD"@L/=2J*8:S7B ML;1K2$M7$$OX3<\7=DI.,:XR @ YXJP_YP=ID58Z,Y+Z)=7*-RERJ M)B8L\B7;@E'@)/SVY!VRBR.2RJTHE=4F%1$1ZN,E:J*[2N>Y2C62)L,.JQ+% M;Z)12<41CX?WH8B2^JV.1NPH^[>?]1:'U5;&6@N@U2DI)$ !P=(_]_/!Y&PT M.2&/A%SIZ?Y_&X 7T@^O#P- U04"M-U2HM5IF 902J1; 24<): ./91L[QX8 M=T@&M)4UU7(5?;R&VU?84X L6@>>6GM EF6F$]Y1UW_ '-)H7TWVZH\\%:J# M$21:0!#15:5N2-(YDY"JZ4Z)L2&NFO\.3*)JKF$12$<-&(E$Q9S^#N)(^>.H M33E@(HZ'55CHJO;TO0#7=I .8K^.+BQJ8MPPYYYY 3J^TW7@^C9\?#X M[.RO0)FDQKWK%\;N?K+WFQDR*JO8HY[[8-"54,V*FX>/8G8*BD/T<,A10$*: M9:'_),N@<9KJZ-R4&&0*!ED#)O+"FB>=A\0Z&'>Z;@\ D=62)A"QD-H*TJ9Q M+:U#<,!$JQ@U:!!5='TS$IDE5=;8\5Q68YFKR^DVD\GCNX=D95 4(C>IRI[U M>9RJ?=:A,)KYFO/O&%M*N0V*A8+71)-R9OI#@I1 5,+S=TX_Q7="MWV;H(M= MZ#B%<^6##FU6A;8!-Q(OWV4F)R$JL;-(V^A7PQXRBJA=#7QW%I.CN*<<>XL2 MP)@&0IS6M*L/LH0/BEZ$WST;C\9M0$UBM"VB/\#?GVIB_9[2% MDPZ84>4!;9">BX7B@?/YCLEX=/ZF'P%T=E;,E(%!A[1L?*=M4N7.2Z*Z0W(U M\E%,6#]"'"KI_BFQG4283*N*Q"'6M(:E1CFD M S 53#/B/2!3J3K*BID!)C6O& 3K<8U=@0^38:N=>BHQT-<*AGQ#R/"^Y8?85P979MM6@P+Q_-L4Z/)"5F R.GM)@:_/F[0FC,48$WB11(H"OY7? M1;-O#TU(VTA8J48J @_N&\8^,DN5I?8(&KA@:9QR>Y5!H5'2N'AY0 W,*I[Y MBG!4#UVT"E\3@[Y':#/L=9=&1"(Q,7(.A4)$_F15BLVH*R00548C(B!=<&VF MP7]3FN]D&!-TQK $%ZR;^#F9!>C_>O_YQQ_N/W\$$9Z=N78 MF1@P1#2.P='8F.Z8%PTM_/C+KY\_O9N< U'@L!PSFHR:!7"L&V/KARB7:DU3 M:@ZI3(E"TDB.7I=X8W?8!_F$(DI^B=.I@YYNL0T(UAH0L7]148,!]5GLL!B$ MM9:P$X1GH7_N0R ,LLA461IN#52 @37RG84FW-3*4'^:!F.68P01H5["C<1/ M8/!KNE7XAITY+,$IVW#[L'L_0E!&S 183QW!*B*_RH6RMC1'!D^(N65&2DRF M,;3.Y(0M6E(;L\2UJ/7L2^?7G"G71J?[MA&2;-L)&2A5LXQP[ H#22!?G.^= MK*$<:I"%66P+_@'ON]KTKYX@#X>DG/BQ/^[">1&M[PBA#H(:P@A>+ ./;3W- M$U=-MD(*=^"TO1HB7E*RE7T2O&\*/S@=GHS'P_%XS'FK"J:'B';M(,PRV!3& MJP;S N1-+@*9J0]JN6O9^)@^YAIT!6?1?4 1WE&@6 ?F;CTGTC4Z9T]M O*[ MRRDZ1"Y<_,P5W*2ZD9FQ>L#FX%!E&35E;WCH_[3*- '''/E3.DAA'IA;8.L8, M-4"'X1_0PA=O2O[1:FX\*"A_7"F)/* %>+\PQM=?Z(#F5\SK_P)02P,$% M @ ZT)N569]=]#J @ >@8 !D !X;"]W;W)K&ULI57;;MLP#/T5PKN]M+'KI%W;)0%Z6;$.Z!:TV/8P[$&VF5BH+IY$Q^V^ M?I2-05#%(JS3/LH-4"VF2Z3C:9FXZMBTI:7#FP+=:"W=_BLIVDV0O M61NNY:*F8$BGXT8L\ ;I6S-SO$LW*)74:+RT!AS.)\G)WO'I*/A'A^\2.[^U MAJ"DL/8V;"ZK29(%0JBPI( @^+7$,U0J #&-WRO,9),R!&ZOU^@743MK*83' M,ZM^R(KJ27*80(5ST2JZMMTG7.G9#WBE53X^H>M]A\,$RM:3U:M@9J"EZ=_B M;E6'K8##[)F ?!601]Y]HLCR7)"8CIWMP 5O1@N+*#5&,SEIPD>Y(<>GDN-H M>FE\ZX0I$2ZDX;8#. 8;8#>9;G+^ --Y*'$6_X#-XY%@3GTI?*LG:$ MGR>%)\?M\>LIL3W6Z&FL<&6.?2-*G"1\)SRZ)2;3MZ_V#K(/+S =;9B.7D+_ MIX_S?XA?#7QN#4+>5WL'J$8XL[H1YA[0$#JL0!JR(,#7UM$NFS28 -'T$,"3 M E[O#?:Y797BF[<#!0H7,LD(X D$P?Y@E+V!!AT(8UH-##F/E!"6[&U;S^YK MLHU5LI3H!S!CH%(V0G%8]0#(N7E2D.68$+8< &;>H>AKVV M"-!Q. ?+*IRR).Z#<(UW0]U :!8H_X@X/NR2J1Z![GN[DU3'V@3.:IT>JA8# MT)5P9;W*,QS B0<[!VYC0EV@Z]MCW="/2OQN6_2CHA9"16,G?"ANMB[NX*DV M2[?F@4:WB%//0VE;0_UHV%@W@_6DGR%;%9&ULE5==;]LX M$/PKA*\H$B"U9<=IT^8#2-($U\.U#>KV^G"X!UI:6[Q(I$I2=GR__F9)2;93 M)TA?$HOB+F=W9V>ITZ6Q=RXG\N*^++0[Z^7>5^\& Y?F5$K7-Q5IO)D96TJ/ M1SL?N,J2S()160Q&2?)Z4$JE>^>G8>W6GI^:VA=*TZT5KBY+:5>75)CE66_8 M:Q>^J'GN>6%P?EK).4W(?ZMN+9X&G9=,E:2=,EI8FIWU+H;O+L>\/VSX2]'2 M;?P6',G4F#M^^)"=]1(&1 6EGCU(_%O0%14%.P*,'XW/7G7"_PUYT./-SRRT':N+B,+D:/N'@K/AKMN=4;9 MMOT <#I,HQ;3Y>A)AQ.J^N(P.1"C9#1ZPM]A%^-A\'?XW!C%WQ=3YRT8\<^N M<*.W\6YOW"7O7"53.NNA#1S9!?7.7_XV?)V?7X11?BLQ:? M4V^F9,7H.*;U0(R/DX,D2<2MI5)'U '(H*R%TNX4WJ#%K@T'/A4#&WQCGX,BE1YMC=B_$QC,3> MA$A\,I[$,!$0+U$:F&?DI2H8:!/ ?I^S\\DLJ.3TO&VS\P71+J$5.$RF/VH5 M8D1F,@7BJ&D=),5RRX=L\2O(I#J//OO@&!MAGA7_0YK%[#9",B?G*%).%^@]+;2%? M_G8\&KXY>5:9V$U(&-,QBC 3$*W.E U)M8PSHP( [8J+ITG: AD'9;YIQ6 F M/GAM[5U?W)@"0Y!3%1,7F.54""SF"7T12;7!P*7"'PT9F>+L:4%\FN,7SR0= MMJ]W0"Q4BK78TH'*-N(.4")]TV!,58+-.\VG@I]WA)9S-!JW&([HWJD M:U@- (A-@T,$!Y\A/K2U7QH!#0.1E'8>26W(I,4?4M>X/8A(F<, ]@):4K0K M< Q;[6K+?23]NH Z2 22Y)6N0QIQ:(F+CYQQ' \\'VPV:A<\:Q#?,[B(:6%0 M!Z[^G$*3<0]#NIK8N\(WU.LD-33%+_!R4S5P1&NYK5S#I)4NKL*5*2NI5]OR M+,6$X!CY0C:SV(PF;/_32!WBQ(;:LG)<=/VZQQL8Y2@Y>6@?EH-IHVJ#=H@Y7(:F "?7'K\=$^\MHW:?*X M \<6X;F'WWPQS^H"\#*:^LY-GSW(*, .RJ7="DR9W"U2IRX3$$S4AHJG<@:#:C M<#D7"M*=\6@J5O&VT)[9Q+1]YD?;7Y\W76U1@BG'ZI;*&IH* ^4+M-*62=!1 MZ#?@!=&1:0I=#T_=8+Q>GWBQ'CV1[NN*#8]"'I'-:1RZ4_)+(KT%B=>WSM_L MK%WGM-T54[&&.B4-?@;BM--REWG0*E=/_T5RVS["[2MM!BG0:*-?65J8M$NP M!,D*XFL?'M)"JM)Q9F9R81[6K8^.9IW2S?=52-EF?)VR;13Q4:+)JC+<'DB1 MM'>81!:WFO1NJ\\[AY%8US$6T*8AU@&3+O28*C>Z?M81T,1]_5WW],'&-Q1$ M>QZ^%%F(T9WQ^^!-%;[( MIL9C0H2?.3ZHR?(&O)\9W%N;!SZ@^T0__Q]02P,$% @ ZT)N5?"X50> M"P _B !D !X;"]W;W)K&ULO5IK;]LX%OTK MA <83 ';<=SW*T#2=G8*[&R#>CJSP&(_T!(52E.1$\;3 M8H&BM43R\C[.?:JO;JS[['=*!?&UJ8U_/=N%T+XX.?'%3C72+VVK#%8JZQH9 M\.BN3GSKE"SY4%.?K%>K)R>-U&9V]HK?7;JS5[8+M3;JT@G?-8UT^PM5VYO7 ML]-9?O%17^T"O3@Y>]7**[51X5-[Z?!TTE,I=:.,U]8(IZK7L_/3%Q?/:3]O M^%VK&S_Z+4B2K;6?Z>%]^7JV(H94K8I %"3^N59O5%T3(;#Q)=&<]5?2P?'O M3/UGEAVR;*57;VS]AR[#[O7LV4R4JI)='3[:FU]4DNQ%R^E4&>O7+V1CC:#6KT@T7ETV!. M&S+*)CBL:IP+9Q?2:R]L)2Z=\LH$2;J:BTVT$2UL])71E2ZD">*\*&QG@C97 MXM+6NM#*"VE*\5$5ZM:RLP:_"P4#!B]^RML?O#H)8)LN/RD2BQ>1Q?4]+#X7 MOUH3=EZ\,Z4J#\^?0-Q>YG66^6)]E.!&M4OQ<#47Z]5Z?83>PUZ'#YG>PWOH M36GE7^=;'QPP]^\I@2.]1]/TR ]?^%86ZO6L):NX:S4[^_&'TR>KET>X?=1S M^^@8]6F+3S%YG,QO.P67*FS32K,GT0L+\QBO2OKEH8=2!CQH$Y33C:BTD:;0 MLA8>5R98:%/47:E$2,0Z>@G6Z/E-),WXTGCMNZW7I98.ZEV*\[J&&Q!I4.0[ M$BOPT1H7)6#"!,9+#@!>[.2U$ENEC%"UAB\E_D;\8MORB(H?]RI^?%0W']6U M_$\0G?.>O*TOK-UB=UW=->%G77Z3\A) MKR^L="7M>:L=HJ+%@6"%JBH\"(D8&V]DBL+SC=@LH6J$RMD^1]$8^+<4C*BK,)"W&+G'AV&B5L/M??A. ]06VL=O0!J MH4BGRJX -PQR$(<.VB2R^@IGT)[.Z()4HRO2.P*3W-9J/DT/GHB<#N^-&IH2 M U<@U467D28IA,Q'*B$>-HI\4_R3' K'@\9UN$A5RH'=1"NN<4Z/_(T5*L=\ MU8.Q 1SMH%QP,80:/#H;:P_"_PA%*> )H(>E2WZ8T#)E@;PS M[)R*0A@$#=%0>B1YM"V]4)0E88L63)*VPBEP"EB,2C# M?33>(MG'MZ?\]O18R'S2A\PG1Z/=)X@*R=_YH"FL^ZEX^7T4&,= 7RM='U]( MS.^Q;TP.5/KJL$=E!C5_6FZ6XF_GYY?0XI=.$PH;:5"_9D]HY&?8LN>"-"8! MR"9Y<]A!LPU"DHSFCK8FS),W-WT*Q!F5$%9KN=6P?ZZV2NV+VOK.J>@ 7'K0 M[?>=B;>0G%D)1]!\EQ7UM26%>5%VCL+3P#(]1=S!NXK0@5Z,$A3=NII8A91. M5,XV.&;]2#/'4/.T1\W3HS;_.T6'2:Q\R[EQ+AC*#W(RJC?JN*<#6MRXLMU0 ME$:6\SA:4#K=Q'*9'_8QB+[U&Z-1FBCB!*90&*Z)"C?MR60M_M),IYBVN( M&FP[X(?N)3K+J/E#3W!JR'3$+%>.@&3"?LRI>-\SJV210^L0*2<4 Z/"8^ 1 M5&M-2+@4:")'QHKVF0\,V+&PO7+[*Q/Q@T@VP4;T/M(<=1^\3MC'>X2'Y,?3 M[/V.PIKJ@_0R^WRL'@REB3&,;G9(;=!D1YE]*=Z;'@1]@/A&\(S+5>[5N2! M5M\2WPGUE.FL6<0G*O11=<$Z!]4<6.9F A4G:MZP8%PE-T Z)K[8H0 46N+( M=KJ.R=,3O&KE?8Y4J#743>^F7(&:'"(XZ%&?EQCFX0+#I[!HE?_$?8?JQO(M MC4ZF> M]4RN16%H&'=YYG88([!-5Q#<\M&&@RPN]4TL0A62?L4I,5'2A6JMF(26$D7MAG_1BX M>DT8&DP,L-].$M>ZS*&B/R!#<'H+=5,$X@PSIG0UVJ5"=6K,:1+@CBU[*.$2>;^?\JY>)[I&SKSM]J M*"+PKL=8O/_\J,J+BH*/4&Q"F$!3Y?-:H"S:N?TB*HG'--5BP%^CH-S2Q\37 M=JZU7OG;+C:AQ3Z1T!SR$.U<+ 7DI Z7-M%,.9DY MME_;D3;J_:"BD1_"2'PP>7LY9(<1D[U^I\6AB02E0)S2+IODAEU_2YDMZ$6^ MNB\P$#ZLP^/=\#EQ << '@31Y(/ 2P.;W VFB(PD?22S/.\SR_.CF>&\C.HD MD?]JY#N5=_YWU \2?^R .C8C51KTA_/W.&$?'H?]>U GT^01"=IA6#,Q4[:B$X M17#C]2U3"VI)R?$9;0QRWU45S:Y-B&G'UMS_MK4LF+;T!;&74L#=8=9?W4J3 M'>5X=#5,SR+K7$">=U<=ZN#U:KV*>OGY?'.19SGGFT_B'W;)JXO5D[E(-<-; MM0W,PYI_QK+AS3!B(E$_<"K]D +!3YMN&VP+OWKT=+58KQZDF89#B"/%X]6#UZ,$4RN^68T&7MO M$+NZP20'E\@C]Z0J*<\\/3=,E8[6'(.S&@H"OE&/;MSN^RGXT--S+9<'&3Z. M3A#^D'/*,@Y,LF(K)0,#J ^)Z.Y#7[#$!B$!]LX9@INQ(5^8PW'BG !$48P< M;[!*[,-_R]J=WV>R.94YI4WT^VZHVU)^X\R'D-CH#@W G?M:JAY"I.D')]Q#'!ZI^$?9DX$8;R81 ?M83(J4,Z=JBKXI'@J>:9\?CQ[*#-HZT1'3PW M4MEY5#O7WB6)Y34VS-[H%A7M[+1IF*.IV2>V--^B^MFM#LV1 J42# MR@JMP.!N'BVSN]7(VP>#OP4>[-D8?"9;K1_]Y,]J'J6>$$KDSB,P^CSA1Y32 M Q&-[T?,: CI'<_')_0_0NZ4RY99_*CE-U&Y>AY-(ZAPQSKI[O7A,Q[S&7L\ MKJ4-_W XVJ81\,XZW1R=B4$C5/]ES\3G%BMFA06]@[5!B\HQ7ZL8-OT9^8V-V"NQ$YPI M!TO.=:><4'M8:RFX0 M,57"/''_9-EK1F",=H+/P[H%M)=KWL\01:1\ZX4>" MJYY@_@K!6_BBE:LM_*XJK'[V3RC9(>/\E/$JOPJXP?8&BC2&/,WS*WC%4,$B MX!6OX%VJR3_+K76&.N[?2PGW>*/+>/X6WMF6<9Q'K3\3\X31XNV;K$P_7&$[ M&MB.KJ$OS@YVK1V=C6!2OL G(3M_/6"#O#/"41*7F%_%OLS\H4;8:4F7WU?( M^38 B]02)"BN!D?;I!7641MY@_:,5'4B90=29,\ATF UB5 G*UHF#R=^&U)X)Q1PW5 8P.^= M>&+27YA Q+Z_@V6X@Q?B^ICP5^O3L3Y(VQE>DPJ=P$@@^"-D<9%E<7F;P;@H MXLET!%_5$UJ?..$[([@?]K;LP$QE84K&DSC+IE=,.R7HH+)\'*=I"D5&YJ47 MBAT:,QAQ3?XFB#3Q^Y566<1E4<+;-],\RS_ -V8,\X+P>BJ3>)Q.XKR<0AZ/ M4OJ-6N:\$ !<# &0 'AL+W=O MS!%4N?R'?([.L>3O9!?5<68 MAN_KNE%3I])ZJ[QB:ZI&8L,:?+,2^OO;>P8RY(J=B/J+[S0U=1)'2C8BFYK MO1#[7U@7CP68BUK9$?:M;)@XD&^5%NM.&1&L>=,^Z??N'(X44O<)!;]3\"WN MUI%%>4LUG4VDV(,TTFC-3&RH5AO!\<9;$00N =_U_3/V@B'L*;NQA,PE_7"^5W?_S MU &T]L/3]DT*7:H-S=G4P1Q13.Z8,WO]RHO=JS/HPP%]>,[Z[)8K6I:2E=3> MDUA!%\\IH&=-G0;:GPY74!Q0 M*"**+1ZG\46 -@5HCI0M#5#9F98'GHW@0P.Z$EN%HLH(?1[=CZ 0=4VE@C<7 M;^&ADHS]P"E 1FBV7N(]];2 3^CO6:&[%IR"^2/\/,0 U_@E@P>A,1CK?<&4 M-E"^"%D73[^XE=NR/WS5VX9[BFD#KU^EON==P9W@C7['FW=X"@PNP,N"8;0R M_A7.TB#$,8H]'/TD@%]YCI\\!N\Q\-[2;SN,Q%J)HT$5IU[F#TLS;^%:;$.X M?I1:GT:"25,7?L; B!A$'=CO]<&=(3T -1+43(P6-QL .&3,,'H$I(D;@?B$Q:V MGM<71BO.S%&CGH\G=F$T41]O("!AEN D3-&6$8F(%\?_#4>]EW#4^Q]PU/>2 M83QP-([B8>QWG^'I@9@X]9+L<,TX/\E3W#=^43Q%(AEG1O1?L#0BOA^"%Y H M]/":XS2 ,"2!FT*0D21.D2!1Z#[+TLC^CE@:Q=WX$I9&2$*D9VA3KP.!>S'F MB&?QM2#^P=*(9&EJ)B'Q0_O5($D8&7+&)+)T1>T4D^?"L!R3\$QQB8;B$ITM M+D,UG-.:8BCJ5%$Y:^)T47FHL-QBOHB]*07:M!:F4NQX@5?'F[:OM W:$IM& M4R 8W]D&A$#>8Z)*,:W:HC)LUIPN>8VU! W9@MZ_46U%S[N*KEY0:4Y4C%M$ MTNYX77XNCK'M,34KH!++99/76Y/2O 'G0=*"69Q"5ZA\%(^#UY60($[LQR7S M@D,'([W+?=]_Y[,MP:^QWMT(D>"R4=J-H1;0> MQ+'+5E@(=V;6J/G-PMA"$)MV&;NU19$'4*'BM-T^CPLA=30>!M^='0]-24IJ MO+/@RJ(0]N<4E=F.HB1Z+6[:S!5S(WYKLW;O-1U/:"4&%&GD'P8X-7J)0G8AD_:LZH M2>F!N^LG]IM0.]C>;-]C74_/\V5&N? /VRJV MQQFSTI$I:C#;A=354SS6^[ #Z+=? *0U( VZJT1!Y;4@,1Y:LP7KHYG-+T*I M =B?#F#B= M!\5933VMJ-,7J-_ 1Z-IY>"MSC%_CH]99J,U?=(Z30\2SG!]!IUV"])VFA[@ MZS2U=P)?Y]^UM^ :YP1"Y_#V1RGI)\PP*ZTDB0Z^3N:.+)^?;_LVH SMVA^,XYW),ENR<:L)N2J" M&R$M?!:JQ'TG?J?S4\,:X#4DW5;OHL^+<_X=)R?>5;O[W3V5_'>!;UI)MU.K M.GK53Y/T,NBK7O7ZL.^PQ3MCHT"[#,/1<4-+3=4$:;S-_)U48^=/>#6\/PJ[ ME-J!P@5#VV<7O0AL-1 K@\PZ#*&Y(1YI8;GB;PA:'\#O%\;0D^$3-%^E\6]0 M2P,$% @ ZT)N59W@BIJ9 @ M 4 !D !X;"]W;W)K&ULA93?3]LP$,?_E5,V32!%Y&<+[=I(%,;& U)%V7B8]N FU];" ML3/;H?#?[YRD69E*]Q+;Y[N/OV?G;K)5^LEL$"V\E$*:J;>QMAH'@[7]AET^ \?+E3#-%[:M;Y)XD-?&JK(+ M)@4EE^W(7KI[V NX"-\)B+N N-'='M2HO&:691.MMJ"=-]'GI1\4[4+#X*7&!U!DGH0QS&\1%>TB>9-+SDOTE>UM&U1]=:^)5VVE?C7O>UG=TRO MN30@<$6AX=GYP /=]HAV8575U.526:KR9KJAMHK:.=#^2BF[6[@#^D:=_0%0 M2P,$% @ ZT)N52)^. [Z @ AP8 !D !X;"]W;W)K&ULA55M3]LP$/XKIPPAD"*2IFF;EK92"TQ# JVB;/LP[8.;7)H, MQPZV0^'?[YR44%#IOOCLR]USS^.7RW@CU8/.$ T\%USHB9,94XX\3\<9%DR? MR1(%?4FE*IBAI5I[NE3(DCJIX%[@^WVO8+EPIN/:MU#3L:P,SP4N%.BJ*)AZ MF2.7FXG3<5X==_DZ,];A3<K9"7E@UU<)Q/'MX208VPL B/SA!?(N04B&H];3*+0 ]&HGM"9'G_I]/WS [S# MEG=X"'VZI/>85!Q!IG#+_DH%%YQIC=HZ]A_C/@D'B^R7,*M+T#D8+%:HVL.H MBUUBO/5V:B^-)D.XD$7)Q,OQERCH#,XUE+L$L=WN6-+SU@836\'FI9)3G\C% M&DZ,O8*0"_++2E.>/AU]8/&N^ W2Z\PD3^"ZH')/:"MH.(*.&_0&C?5#VKLX M(]7JXY7ON<.H1V/4#^%:-.W.]HU[C#,AN5R_P#$KRG/XGJ9YC#N9'3<*>]OQ MAJVD8D82_%M O^]#?]"'H3L(!S3VHB',XK@J*LZL]DNDS8[SIM[)P VC[JFU M'9_L_J-U05#'/H+ #8BOM6'4AWW7S-MI#@6J==T"->U\)4S3)UIOVV5G37-Y M"V]:]"U3ZUQHX)A2JG\VZ#F@FK;7+(PLZU:SDH8:5SW-Z$^!R@;0]U1*\[JP M!=I_S_0?4$L#!!0 ( .M";E6<:*;VT ( $L& 9 >&PO=V]R:W-H M965T6M+"VTE"DR;-+2*PO@P M[8.;7!L+Q\YLIX5_O[/3AC*5?HGM\]USS]F^)\.UTB^F0+3P6@II1D%A;749 MAB8KL&3F7%4H:6>A=,DL+?4R-)5&EON@4H1)%/7"DG$9C(?>-M7CH:JMX!*G M&DQ=EDR_35"H]2B(@ZWA@2\+ZPSA>%BQ)<[0/E533:NP13CO/W#K\XKLW.'%PEW.)[/@HB1P@%9M8A,!I6>(-".""B\7>#&;0I M7>#N?(O^U==.MP$]*-/ I)-0.)Y-XD\RUMFV7BHU1JT\R8T-_&E M^F@BQZ6[E)G5M,LISHZOLTS7F,,/SN9<<,O1P,DCFPLTI\/04@;G%V8;M$F# MEGR"-H![)6UAX$[FF'^,#XE92R_9TILD!P%G6)U#&IU!$B7) ;RT+3?U>.DG M>%/VYFL#)G/PM3-AX/?UW%A-#^3/OI(;Q,Y^1-H7!^/A+ MW(NN#O#MM'P[A]#',VK"O!8(:@%[KFH?W8. ^^END<7.(V#&Y:3SMUC.4;>7 MX$_N%K.--?;6&#)%?6HL@5"4+1 62E##<[F$$^N.'+@DNZH-Q9O3R_^0/P!N MZ3P0/Z:S HY965V1SXHTI")%L'#W2JID$(Z@UZ5/VNNU43>J='NL:7HB.T&) M"VX-I&>D5!"?70SBUOM)KE1-AZQ]O@QY18[=?@P7@W?(9Q(6U.8C=#+H0-I/ MX"=5J_==#F4:=&*7K]N%1V69V.MU!-VS?O_"C]$@@GVO)MQI\!+UTLN8H4.O MI6UZO;6V2GG=",2[>R.S]TPON30@<$&AT?E%-P#=2%>SL*KR]3.@?872MGMPB5H_Q_C?U!+ P04 " #K0FY5$E4&<40& #6%P &0 M 'AL+W=O,X+IERQX"5^F0I9,(V/9S3B.1]K \'P[Y*_X7END%"/KVO07KVFF=@<;]!_M\:C,>=,\3L3L?J3KPT*#=Y8Y,K^PJJ2C=,>C)=*BV(]&34HLK+Z9U=K M1S0F)-X]$^AZ K5Z5PM9+7]CF@T/I%B!--*(9@;65#L;E$=HU@3>BP& K9MVU>\;.51!TGL@4W@O2CU7 M\+:<\,G-^0-4K]:1;G0\HIV IWSA@N\Y0#U*._#\VF;?XOGWX'ME_(!?68E>88M,LSS[CT\<&!5BB=+__(V0\$[S0OW; MYJ!J_:!]?5-H^VK!QORPAY6DN+SDO>&K%R3R7G=8%]36!5WHPU,LW,DRYR"F M<"90<[@WQFL[VRSH7*/=@K,YM_"LO,9Z'8M9:7P&VNJ@K Z5S\=-'7BE TR6 M,BMGH!%$SR7GUO>E<7-191,WV028"^CU;[(6L M1#"Q5"BB^OMP9H&;V0D?S HWWEA,B[<=G:*%V7B3,VS%Y$3MPPE76F9CC:^L M>; L,ZU@!X((?Q)B?@+\H9%?Q0#$HJ(B"P#$]\ G(00> >)XH0?8WZZD5""7U=_^_Z*>FO?]NTV,J%_<9#%/1O?EKCQ"&. MJ[S:L?KN@!\94U-C:A@FT)'#89W#86<.WV-;6Z)V CVQU*):S>B9B23Z"=;% MM77Q@XFD$9 JAT;W!J03M%WET>908);26QJQ^1>_5D@G[;G>((T'446F&B2Q M#Q^6]C,N:B.IX(O=Q''NZ))+/)3 I_(2ES8!U/ 7*Y=&1[(&BQU"$LSYB+JQ M!WA&F/+,B.Y&#J5QO_[2Q&C1*4E)+?J+'$%^I".0NWS'#\+O]02YY=".#$[J M#$X>1R,50>^!JO@.<5LGJ>M]DY8VR#L5]G.X\ ?3% TBA*'J*1BXR4L.#>$R+_3Z$U$76_@:=^03Y+*Q#UE4TC6Z-=!=-RP'N MX736#?[4BJ=;Y>DS,]I:@1]LX+:O))V-W0U*JR+UL8K42&'UV&%[7+IA36,U M99F$2Y8O^:8 ;Q:<:B2&@MDZM[%U>#A?K;C0)@=WB$L3S$G\CR(;T08+5"*7(L?>+\_T-<212U^B=)RXX4LXR=3% MWM3T:!FJ;S@$)-,<&2B-C93O!L%+...R@-UKSJ3"2G1#_!!UA6_;.).'=\[- M\"D8F;LCU+$]HE1_)INI&U:]U>5QP;S'I;?[<$NEL)OG,./WC4BN-A6C# M?W=#"I$W0WMT]:F+#6SL&JK;=(P;&E$!(4BHXP<,,(,S1IS&\CE4'CJK7@S +U5?[P?U!+ P04 " #K0FY5A3O?9\D$ #)#@ &0 'AL+W=O MDXJ2_?D=*EE^2J-GW @E%27#(G:R&_JHQS M#8]E4:GI(--Z=3H>JR3C)5,CL>(5ODF%+)G&6[D\4KFH0/)T.C@GIQ>!L;<&GW.^5CMS,)',A?AJ;CXMI@/'$.(% M3[1!8'AYX)>\* P0TOC68@ZZ)8WC[GR#?F5CQUCF3/%+47S)%SJ;#J(!+'C* MZD+?BO5OO(W'-WB)*)0=8=W8TG 2:VT*%MG9%#F57-ECVT>=APBYQ4'VCI0 MR[M9R++\R#2;3:18@S36B&8F-E3KC>3RRA3E3DM\FZ.?GOW.,20%'^[9O.#J M>#+6"&I>C9,6X*(!H*\ Q' M*ITI^+5:\,6^_QC)=(SHAM$%[06\XZL1N,X0 MJ$-I#Y[;1>A:/+<_PG_.YTI+%,&_+\780'@O0YB-<:I6+.'3 2I?*1\3P" Y=.\G'/9U?!-5@3^P'!^"/4&(P)_'I(_> ))AB. MP"..&?T01S*D46ROKA/#9\R2FDSK\W-<"J2],Y3D1Z4J,_4XIK!<0C$+K@40](Y,&G M2G-4G@;T:-83\R)?6@@%'M*B0-P 5]Y?K*-%(A^0B1\X0-T8[C*D<(*896LG M>:6W,0"NBG]8.J%9L?_R"$+,Q!$$OLD>'1)[)Q+9I2IC*($5U M*DBE*)]+#$M!32D\#,<6PHV:PL11#TRZGUOC;FA1XXH).<*0VY2\R9M0$YMO MI.#:D?@4[*?*5&JG0/PQR5BU1 5BL(?!0('RR8M >L&@1_ M%'=H=M[3T_VNI_N]O7BKUZ:E7S-=2UNXE_IZ+];+7Y^K&@&Y^460EW5I=RAN MU!5[PA],J*(:>^-S5;(E-N+&@$FCN/9[@>W]H+%O^6_:R=^<2>#5PCS[R).V MY9*V+W_HQ'!LU.W:'8P:[/-R4:=!3"$(XEX[;$1#S_$@"&FO'38X-T2KH-3VPHMY1VP%'OD%G?R"7OEMBO86\?4B_13?3_&U!Z+F M>%%RN;2'* 5VT>:DT3WMSFGGS?%D:]X<\JZ97.;XBZ7@*;HZHQ!;GVP.3LV- M%BM[6)D+C4&PO=V]R:W-H965TYCV8. J\9FMFF:?[^S26@FI7F! M._ON\W<^?S?;*/UD:D0++XV09A[4UK;3,#1YC0TSEZI%23NET@VSY.HJ-*U& M5OBD1H1Q%%V%#>,R2&=^;:73F>JLX!)7&DS7-$QOERC49AZ,@OW" Z]JZQ;" M=-:R"M=H?[0K35XXH!2\06FXDJ"QG >+T729N'@?\)/CQAS8X"K)E'IRSK=B M'D2.$ K,K4-@]'O&&Q3" 1&-OSO,8#C2)1[:>_2OOG:J)6,&;Y3XQ0M;SX/K M HL62?L@]KBSNX2#A.GHC M(=XEQ)YW?Y!G>V290',^"RT=Y1+"? >[[&'C-V _P;V2MC;P1198_)\? M$L6!9[SGN8Q/ JZQO81Q= %Q%,@J^GR":3(P34ZAIVO28=$) M!%7"2G.9\Y8)6+&M:Y$!>MF/J!MPC3Q&_23X<>J/-4*I!.F5RPJL>P-.?TY( M!BQMF@-*[4"I/:#DH@9:P(R+I!9:;#+40Q_AC+M0U1EZ@.9\>JP^'_<>1A=1 M%#EG#%=[,WDU)Q![DP(GWCAV\>&!3!K4E1\&!G+52=LK9E@=YLVBE]EK>#^L M[IFN. E'8$FIT>7'20"Z'P"]8U7K19$ \N,DE ML>;8P7=I-\2/QW;24*#M2^P[WWW?=Q>?DXTV3U@!$'NNI<)94!$UEV&(604U MQU/=@+(GA38U)VN:,L3& ,]]4BW#.(K.PYH+%:2)]RU,FNB6I%"P, S;NN;F M90Y2;V;!*-@Z'D59D7.$:=+P$I9 GYN%L58XH.2B!H5"*V:@F 77H\OYQ,7[ M@"\"-KBS9ZZ2E=9/SOB8SX+("0()&3D$;I<>)H8O6'&15LTM_&E^FPK3BCW4Y9D M[*FP>93> F9&-+Y#NF#S%FT (GMS"\2%Q+=)2);&!8=9#SGO(.,#D._8O594 M(7NO/HA,51'+."7K\:32^N6,$S(06]'&$8 M#UT8>X;Q 88'4W(E?G+7AA-VHQ5J*7+>W1N5LX4!!$5\VZ8[H;C*!)=L:9U@ M+RDA^W:]0C+VFGW?U[-.P-E^ 6[T+K'A&X&YT]X]_S< M&ULQ=W]3]M('L?Q?\7*G5:[4EMBYY$N(+5XQ@_:[J*R#R>=[@2?WZIE=GW<=C MI_I1/F39Q^J3:'[&3"N!XSWG6%2#YC<'S!Z9,"T'C#==X;#>L#AO@/<_I=_N?ZN@F[^ MR7?UXB=EYOI/4SVN//DI_7.;SM/R MLY.LY\YILDG+9.F\5T6VS6>J<+[W59FDR^('YZ7SV[GO?/_/'XX.2CUQ-?Q@ M5D\2WDSB/3+)H?,N6Y>+PA'KN9J;XP_T =\>M??EJ-]Z5C#>KE\Y@_X+Q^M[ M7LOQG.XQW!T_.MS?9_CHT>%BC^%][]'ATC[\7?+9]J,']M%O-KF>_/$?/;0/ M/U<;ZU]\M/]PMV5XO,_!3]MF-\IH<%O\@YTWV*OX@RQ=7SJGV7JF\G7U>Y'. M59Y4#^.%\^^?]%@G*M6J^$_+@;^]F6C8/E%UDGM=;)*9.N[ILUBA\BO5._GN M'^ZX_V-;]9*83V*"Q"2)!206DEA$8C&$&>TRO&V7H4T_.4V*Q0MGIG]UE&Z< MJV2IUF6QZYUT?:6*(.-=UBU)+\Z\2;C?O7?T<'5W68@9XTAS&B&T6TSC*S-\(=>]E?GB]G- MDJFMQ*U UQ(G,9_$!(E)$@M(++S!1G=+?-!O*W%RUAC"C!(?WY;XV%KB/^OM M^>[1?ENHZB'>T;OR:CVDJWZWK4W+5!5MA6]ENQ8^B?DD)DA,DEA 8N'X0>&_ M=,=3KZ7RQP_. B^]X:@_??"=,72 1EE/;LMZ8BWK=^DZ76U7-Z4]RZ[4.EF7 M;65L9;J6,8GY)"9(3))80&+AY$$9N_W6QV]RUAC"C$*?WA;ZU%KH9WDV4VI> M.!=YMG*JA;B37>R6[N7G%\Y:M1:]E>Q:]"3FDYB8/GBH'+=4@R5D#$@M) M+"*Q&,*,HC^\+?I#:]&?JURO2IQ_54_@7*F\3/5&U#G+U87*<[V*.2^SV<>V MNK>J7>N>Q'P2$R0F22P@L9#$(A*+(&$ MZ+P1JL649M9_DP^[UCSMY+VZ3(M251L'/]6/^:7SRX7>2%2KIC^2/$_69>OS MGW:U

@<3"J"523J!:@6HAJ$:K%E&9V21,+N\-GVU2@L3"J^:@F4$VB6H!J M(:I%J!93FMDY38;LVD/DG[>K#RJOUE3%(M$35!_-LM5*[S"*ZHDJYR++G>M% M.ELXUS?G&RA?AWN\$-'1&M0C58DHS.Z&) MKUU[?BUN'OY57?[ZE/'EW%"=#/9L!C3;1C4?U02JR5I[NAG0Z!K5(E2+*

P\9 M,H0YA&CLY>7%ZZ3*HC/XL!$)H?K>>-",S@1]KZQ(R337D8-DW^T1C!V9""LR&-O M25Z]>A?J>??99&QF.'S\. D%!04P*O>;*]HG0)9-%?W%[4*KAF9F94(Z? MGU]5517[(=5KUZZQO^G2J8]D&0U%"*9IK+0.D;%DQ1409W)HQC.MXW-R*Z0M M2/URY![D\@](92?2+$CU\4H,#DEG#E\8FN8[^*\G+O=^?]?2-N;T&3$S:RPD M)26IM!Z&JJRLA%&Y9?O_ON.[BC M,L&'E/4-/D(A5,*-!_VL1M\K*^^L1K+O\QH2(@TT5)V@H3Y5H$?H!#VBT8&S M(65G0QIY%Z2V;]].GK(I*BK:M&G3U*E3WWWW7;@;KJZNEK$6X_#RRR^KM)XN M4ZO5JGJRLO[^ULV5[1.A2R:+_N+VH%3##QX\"/++ MER_7Z-J<4EP?R3*:^A!L967UT4.V/K$+MF[O< MDA)NJ \.2>_:XS39":&R\K&+ZXE)4S+@'O;V M]G"'S22")<,%@G&0OIPQ8\9 %LZ^JCH=! @*"NK4J1/9<@*4<79VGC!A@J:N MGTO;M6L7&AHJO6T-AK[!1RB$2KCQH)_5Z'MEQ6@130^<#2D[&]+(NR!%E)@Q8X:KJRM\L+6U)N;FY,E9D!&;. MG F:@UFP$Q,2$DB+XN+BF,3^_?MW[=I5NP2=<5,H(R$K*\O.SL[!P8'9AG;B MQ(E0( 1KCN3DR9,A_?OOOZ=HEB &MA>RAX6%021MTZ9-\^;-UZ]?SSY+K[FR M?2)TR6317]P>E&HX>3++S\^OO+RL0Z^3\>UG9$X\B:V]JWM(E_J=# M3[S"YMC_U:V%+5QT-2WMP=LS+L/GI&0UI"^(N-JJ;7Q!X1,;3C5JSIT[UZ5+ M%T='1XB$BQ^655]1J-64)^?GY<"\"+E-65L9.U^D@P-&C1R'] MO??>2TU-);_>)[L5S)\__YEGGBDH*)"KF3*B;_ 1_\) KQL/^EF-1L\K*SZK MT7D=.4CS?2%#0J2!AHJ&BK!!CT"/:'K@;$C9V9!&W@6IZ=.GJ^HWD_?R\DI/ MK_N9!L04\ENP%UYX0<:*C$!,3(RJ?G-[YEU%8*,! 0'$1 X?/DP2;]^^3:8! MVB6(QTV1C)KZ1Y/Z].D# MNW;V<20T)"(.6GGW[B"$,TA_2=.W?JV<0G,+"] M]O;VC/_ M?[MM]_89RDU5[Q/A"Z9+/J+V(."#:^MK87A&;*T;]\>/O3LV?/L MV;/B[YKEU4>"#,,''WP G9.=G0VYX 8";AT@AL"HS.RF3]-8:1TB8\F**R#$ MVS,N-VL>=_G*7WL_25B0BMJ0#5G"W^:^+6[I\NN'?RG,OE6N5E>?/U\* I:V M,;8.L:FI#SC96[K$0PEMW$YLVU%WEYF1469C'TN>V+I75+5ZS@130^<#2D[&]+(NR!%7@U@86'! MWHSMT:-'9('CXO'GSR&\[R2OD8F)BB,QGGWT&APD) M"=K9Q>.F2$;H,8C%VBL4K[_^.B0>.'" (S]UZE1(W[-GCY1&LC"DO34U-1#Z M;]VZ%1T=#9?;W-R<>;$%O>:*]XG0)3-'EY>4K5Z[LW+DS,V:W M;=LV*BJ*-Q +Z:.OC#AD9\&Q8\>20YK&2NL0&4M67 %>8N.*+6QB5GUTDTF1 ML"#U7-]$R'(F4?=F3W/_I^Y-?/\][@(GO::FMJBHZO'COS8O#QR>YNV7#(=J M=77G;J=?+DY.1DN)\X=NR8M[%Q6A5Z]>('_Z]&F=DAP'88 X7%14Q'@NN.& 0/@$&YN.G;LZ.+B,F'" MA';MVKFZNIK(,U-Z!1^A$"KAQH-^5J/OE=5KOB1T'1FD^3Z](35V8 IQ]$E* M2DIX$PVL" T5#=68U-;6/5S,_BLIJ>9-5$I#] CT"*-A-'? V9""LR&-O M2 MY$UMO7OWYJ1/FC0)TK=NW2IC748 3/"33SXA*S+FYN:#!P^&,.'KZPN'&1D9 M1 ;B7>O6K?4*P>(9P1](#)TQ8P;G%/DR07N1E2Q&ZO55/"\&MI)](OXUCF3]Q0L7R6AD8X#1NFO7KG/GSFW1H@44$A$10:^/7C(Z@;L3 M5?WS>N20IK'2.D3&DA570!L8L+OV.-W]V=-Y=RH+[U61OX\^OFEA$_/>PJOP MN;14]VO7SB3>!_D^7CK>5DNXDOD0A-W<^==D"7N^N6-I&Y-<_\.]%:MN6-G% M7KI<]W1Z]JUR.\>X^0NR1/*:+&03QY=>>HF=6%Q<#'YM8V-#\T02!%L5]?:N M' ?A9??NW69F9DE)2?!YV;)E$-+)%G5P7VYM;3UOWCR:BHR&SN"C$0ZA$FX\ MZ.<>^EY9O68U.J^C!-_7RY :.]75U:HG24A(X$V4JT8T5%[04.6ENKJ6\W/X MDZ=*>!.5UA0]@A_T"!DQOCO@;,B0DB7/6>1.G?__GTK*RNA_6)%HIM01BA_U*A1JOHG-LGVM&PV M;MP(IQ8M6L1)]_+R@O1KUZY):YTVTMK+!IP'5+IW[QZ]YJ;0)T*7S!#]=19N M"@TG,+^:_O///QT='1T<'-CUBNM#+T/#@P\9?];[XCW/] MGT]BS@X=<=9GD. S\*8,V8./_#B.#=F@E/G)LPC@,B 9%15%4QW'0;11J]5M MV[8-#P\GA\.'#^_;MR]S-B @P-O;FZ8BHR$>? CB;T'5Z\:#?NZA[Y75:U:C M\SI*\'V]#*FQ T:R[TG@KH,W4:X:T5!Y04.5%["I_0?RV7_WBJIX$Y76%#V" M'_0(&3&^.^!LR)"2)<]9Y%R0RLG),3,S:]>N'2<]*"A(Q;?!5:-CUZY=T)!) MDR:1PV^__18.A7:V$XENO!DK*RO)J^Z@?-ZG;%)34^$L\S)O0D%!@86%A9N; MFR$6+X1>[66HKJZVL;$!27 D>LU-H4^$+IED_6D*-X6&$]C;^$')4/ZC1X\H M]:&4H>3$B1-03K=NW<@A36.E=8B,)2NN@#:/']?.FY_%^0L8EF9A$^,[. 4^ M[_U>QPZ+964U3LZ_VSK$YA=0[>Z4<+($"N_9^XR0 %3JXGJ"N6\8X),\=,3? MC^6/?>U"MYZ-\F%U\HW0A@T;..GDCD3[M_0KU^_@( YFQP<'#GSIUI*C(:(L&'02B$2KCQH)][Z'ME]9K5 MZ+R.^OJ^OH:$Z L:*B]HJ$\MZ!&\H$V]=>L6.!ZGG*5+ MEX)* P<.U$MS4^@3D4LF07_*PI5M^-FS9R%VD,],"+YZ]6JS9LVZ=^].KP^E MSL //_RP:M6JM+0T<@AW)!P34JO5 P8,4#WYHVN:QM+(<&J7L61*L<\__QP4 MR,O+:P@%:.#=0VK+ESFKU]S,N\/UY9W_R@/AD']R]X0"JB]<*+5N%DOV-2= R1Y=3C'#DV?_Q.$C&]E6@X0=.W; Y>C7KQ\X M I.8E94%?@0WW+=OWR8IVE>?\/777T/V,6/&:)=,Z2!LTM/38> G^YH3H&1W M=W?F/@#,:>C0H?JW4F9H@@\;D?BL[XV'2%&<$$%Y97663'D=I<4'!A%#0B2# MAHJ&BK!!CT"/:'K@;$CQV9#,"U(9&1F.CHY65E90][Y]^]:M6^?L[ Q*K%V[ M5MZ*C$!@8.#X\>.A"5]^^>6L6;.@7= 0^$S.@LTY.3D%!05QO7'SQXD&Q9 M[^'A45QS?'U]%R]>#"&O4Z=.TZ=/)R[,/-),HP^ES@"D@.077WQ!#B,C(UNU M:A46%@8E;-FR9?[\^2XN+B#0I4N7HJ(BO1I+(\.I7<:2*<6@79#(?CF+C K0 MP+L@U?W9TY#(>3L>X!^0"NF_'.'YP4O4ANPV;B?"W[[\\;H_O]B:LR#BJFO[ M!!"&HHKX'IRNK=4,"4SS&YS"_G;DP \%D.5_/[U5554;_>^ZQ2_XKV^+3(%' MCQZ1W??Z]NT+9GS@P('5JU>#84,*\[LY#=_5)\"MCTK@EWV4#L)06UL[>/!@ M'Q\?]M=0^_?OARR;-FV"@+-SYTZ5P6]EE06:X*.AB\^4-QXT17%"!.65U5DR MY764%A\81 P)D0P:*AHJP@8] CVBZ8&S(<5G0S(O2 ')RGIZJ_]"R9..--\S-S9F&].C1@_V0YZ^__@J).W;LX.1:LF2)BH^.'3N*9(R( MB.#-!8P<.9(M>>C0H?;MVS-G8>XAU^Y1$MH+7MJ[=V^VMF9F9D.'#N5]&:J( MYLKVB/'CVZ:]>NMK:V8 !PW4-#0S,S,_72AUYG M, ](C(^/)X=PE^#N[LZ6M[&QF3QYLO9;P&@:JU.&4[N,)5.*\2Y)R*B 3N@7 MI,@.Y>X>)VMJ>)ZP_>%@@4>74^P=J9HUCPL-NR3TFKSH?^=9V<6FI7'7O&:^ M>P7RPBGX/SDT@WD37Z,C)R=GS)@Q[! *MS+OO_\^^^M9WJM/-JUT+I2=IK$B,D*U&UZR!+&&4\"8Y.95I*2H8V*+T](>E)>+ MK7$D)ZO/)/('A^Q;Y;%QQ=>N>:(R4E)26#*6# !# MA5X:G9V=#8.RC*^_D!&Y@H^!-QXB(4*6*TM_'3F8H.\_G:"ABH.&^K2!'B$. M>D1C!&=#BLR&&FI!JLD3$! P=NQ88V94E@95NY'V"4/3,(93ITXU= B.CX]7 MJ51"$^:&1MG:$001P@C!AP8,$8@X:*@(P@8] FEZX&Q($7!!"D&0.I*3DT>- M&M6@55R_?OW(D2,-6H7)UHX@B!!&"#XT8(A Q$%#11 VZ!%(TP-G0XJ "U(( M@B (@B (@B (@B"(4<$%*01!$ 1!$ 1!$ 1!$,2HX((4@B (@B (@B (@B ( M8E1P00I!$ 1!$ 1!$ 1!$ 0Q*K@@A2 (@B (@B (@B (@A@57)!"$ 1!$ 1! M$ 1!$ 1!C HN2"$(@B#_S]Z9@$5Q; N854!!C"@HBN)NU(!H"/ 4 NXW"Z*\ M7+V)&T&,1./RC.)RXQZC8M1G$A/CQKW1J%%C8HSZ$H$@+BRBHG$!MZ" @*. M(+O,.U"YG;:GNZ>ZIV>&P?-_?'S3U:>J3U6?/C,V7*%&A5V2H9K+ZU MM;50[*Q9LX8-&^953VAHZ.[=NS5ONO[:A%YS36BTDJ&YOJLLN[Z\G#U[=L" M ;RG:/2AOTT<5JQ8H1DN%BQ8P!&CJ:R\!E&P9*,K($Y^0=6,61D?S,PX\G.! MB%AJJ@IDA/Z>/JTE8BM7W=$\N^BCFYS2DE-4(:'I?5].?FOLI",G+,PP +%EBU;IF!]%40D^*BI0VA.3L[BQ8N)CPP9,F3>O'F7+U]F MSLH>GR@8C:5:"*, 7-3;V[M?OW[OO/-.0D("KYBRW0'""QJJ"&BHSR'H$2*@ M1Y@H.!LRRFQ(R06I;[[YQDP %Q>7VMI:!:^E"/[^_FPEQXP9HRFC4JGZ]NT+ M9]W+%BW@ ML[FY^:I5J^2I9+#ZEI>7DS)!OD>/'FW:M"&'@PZZ6SO +LHC)O/&GF&#\@X-RZ]5G]7DENT>JW[)P*ML"" M13=;.B<\R*N46I>&1DQ,C*6E)=R7[MV[@]<[.SL3,[YV[9I0%LH>D\9!,C,S M;6UM_?S\HJ.CP53 0K*SL]D"45%1CHZ.#QX\T$?==4=D_$<90H\>/=J\>7,0 M@. #(0@J"Y\7+5K$",@;GR@8C658"+!KURYK:VNX(ES]Y9=?;M*D"7Q>MVX= M1TSQ[@#A!0U5"#34YQ/T""'0(TP7G T993:DY()4145%@0:@ >@Q;]X\!2^D M%*&AH6^]]=::-6N6+%DB%"XC(B+@U)0I4\@R/-3(P\,#4@X?/LR1G#ES)MA< M;FXN?>& MT MB0T(2M.Z(%51\;3@817G;\:L#,@X?^%?#T#U>NELT^;Q'+'"PBIV4>$15ULZ M)Y24U%G%@[Q*D)\])Y,Y>^WZ$SN'^,^^N$=?BX8)]+[-FC4#_]VW;Q])J:RL MA/L%]VC8L&%"N2A[3!H'"0L+@W%\24G= V@/'CP >8@GS%D8-\-H>-.F30I7 M6PG$@X^:+H1>OGP9J@RSFOW[]S-?F$/BZ=.G&1EYXQ.EHK$\"X$NU::>8\>. MD93,S$QH*R@G-365+:E@=X#P@H:*AHJP08] CVA\X&S(B+,A_>XA!??#U=45 ME&C@O\;\Z:>?>,/EPXDZ!70+)RF3:1J+H16K21I+CNCPGM[!P0$,(<0A#T]/7F=U+AH#3YL1$)H4% 0G#ITZ)"DJ].,3Y2*QO(LY*./ M/H)+A4E430:WT93IPX 3+!P<'T"E 6SFD329J+H/N"E&F9 9"1D0'E^/GY M5555L1]2O7GS)ON;+JWZR)914X1@FLK*:Q %2S:Z N),#+OR0NN$[)P*>0M2 M/Q]]"+G\ \^Q$VD6I/IX)H6$IC.'KPY*\QWXY]>#^[Y[8&4;>^:LF)F9"LG) MR9K?EU965D*OW+)E2_IR>'M,F@6I%U]\D1UIH==_Y957R.>]>_?"B(K]A7,# M06KP$0JA-V[<@'1H :D*R!Z?R(C&\BPD)"0$G3Y^^=>M63L"BJ:R\!E&P9*,K(,*QXW7+25]NJ=M42-Z"5.C? M+T&NG?_*92?V>NFLK7W/)F^'-X> M4ZN# ,'!P9TZ=2*[:8 R3DY.X\:-4]>U MS,Q,>@40V:"AHJ$B;- CT",:'S@;,NYL2*W7!:F\O#QH67M[^]+24OU=11&$ MPN7X\>,A'>(C)WWBQ(F0_MUWWS$I_?KUZ]JUJZ3"M694U__JV,[.#MJ0V8R6 M7B41]%??:=.FA8>'0V_AXN+2O'GSM6O72E) O'""9IM(TEP$W1>D3,L,U/]Y M,LO/SZ^\O)P^!//> ADR!,UM_!P='7_XX0=&@*:R\AI$P9*-KH 0*E5UQ\ZG M H+2R*J0C 6IO/Q*6_LX1Z??2DN?>119'CDY.0(E29[?"([&LNP$.A/H008 MGK(3$Q,3207CX^,E*8#( PT5#15A@QZ!'M'XP-F0<6=#:KTN2$5'1YM1/*+6 M$! *EZ&AH9#^XX\_&]>_?(9$!2X5HS0K#KTZB[S6M'G\M>M_[OTD8T%JW?HLR!+Q'O>%,HN7WCKR36[76CS"M72FV:Q9$GMAX65JU< M=6?2NU>6+K]]_X$)OVNOJJIJTZ9-Y U!A-Z]>Q\]>I2^!*$>4ZN#,-G)U5NU M:O7UUU]#RN^__VYE9;5Y\V9U_:_Z5ZQ8,6'"A,6+%]^_?U_GZBJ U. C%$*G M3IUJ5O\6&T]/S_3TNM^'PF2&_&("^B"ATN2-3W2)QC(L)#8VUJS^)3O,.Q-A MK!P8&$BR'SER1)("B#S04-%0$3;H$>@1C0^<#1EW-J36ZX)4KUZ]X-IGSIS1 MWR640BA3*D[]Z]FQQ^_OGG<)B8F*CF0V0E0B1C65D9 M1&3-=0I*E<317WUK:FH@=M^]>S;BZ+@@ M97)F0(!N/'DT.:2HKKT$4 M+-GH"O 2%U]D:1.[XN,[3(J,!:F7^B9!EK-)VC=[FO4_=6_B^^\QESCI-36U MA8553Y_^N7EYT) T;[\4.%2IJCMW.]VV?>*$25]O;TA1>@I44WH>TR.@S! ^"TL+&0\%]RP?__^< B# MFXX=.SH[.X\;-ZY=NW9MV[9M(,],20H^0B&4O&[)TM*2O<$M1"&RZRV,*7DO M+6-\HDLTEFTAY,M&)R>GB(B(V;-GDSTFR!ML8+V7_%Q=6\B<;2$#T"/<)@&,P=<#9DQ-F06G\+4A LS&1M M5F<4Q-?O-=JTO0VIJ M*N1RYSI_N*9W/N5!0^KR-_'G]RQM(G] M<-X-^%Q2HOVU:V>3'H%\'T\M;ZLE7,]X L*N;OQKLH3=W]ZWLHU-J?_AWK(5 MMZWMXJY>JWOP/NMNN9U#_)RYF307:FB031Q?>^TU=F)141'X-8Q!:9Y(DM1C M@45)=76WV+(F)B;R)2ET1#57HNFBH"E)=7%PX77KUNFI?&41"I<;-FR ]/GSYW/2/3T] M(?WFS9OP^=&C1];6UB*[Q@H5+I2QHJ)BQ(@19O6/I))-:J6JI!6]UI<->!%D M?/CP(:4"\MJ$4G.MZ+(@98IFP('YU?0??_SAX.!@;V_/OJ[66T I0\/CQX^A MD*9-FY)#FLK*:Q %2S:Z IIH=MBY)_7'?:W"_U>26;.#AIZWF= JD#6!@W9,(+\.(X-V7N5>3Y? M!$D])L=!-%&I5&W:M(F(B""'0X8,Z=NW+W,V,##0V]N;YD(&0SSX$,1?#AL0 M$,!)GSU[-J3#E$#SJ AJH[<.L.',QC_STLK.)--+:FZ!'H$7K'\.Z LR%=2I9M MU7I9D"HM+87[!]/LO+P\?92O.$+A\MRYKJ2HQLSYX] M(,/98I:F<-Z,$+G(VQDF3)C ^ZP-C4I:T6M]&2 $V]C8@#!X%*4"\MJ$4G.M MZ+(@98IFP(&]C1^4#.67E951ZD,I0\G)DR>AG&[=NI%#FLK*:Q %2S:Z IH\ M?5H[>TXFYR]P<)JE3:SOP%3XO.\[+3LLEI;6.#K]9FL?EY=/M;M3XJEB*+QG M[[-" G!1Y[8GF7%#?Y^404/_>BQ_]%N7NO4T@9]X:T*^$5J_?CTGG8Q(-']+ MST%JC\EQ$$UFSISIY.3$S,.]O+P" P.9LR$A(9T[=Z:YD,$0"3X,0B$T.[JL MHD0 '__241!5#O;W-R\7;MVG/3@X& SOITUI;:V(M%81PMA\\TWWQ!E)"F M* (:*HTF!#34YP'T"!I-".@1I@+.AG0I6;95ZV5!:L>.':#-J%&C]%&X/A!9 MB2"[D<7%Q3$I<^?.92_^C1T[UL[.[LF3)U(+U\Q8554U677Z970':;T&BN%5T6I$S1#(#SY\]#[""?F1!\ MX\:-IDV;=N_>G5X?^MOT_???KUBQ(BTMC1S"B(1C.2J5JG___F;/_NB:IK(T M,IRK*U@RI=@77WP!"N3FYNI# 1IX]Y#:_%7VRE5WCIT_&1? MZ=>LI4Z; AZ^^^FK)DB5DSS];6UOV]@WZ:Q-]-XL,S?5=9=GU M94.>S_+U]5VX<"&$O$Z=.DV=.M7!P<':VIKQ7QI]Z&\3I(#DEU]^20ZCHZ-; MM6H5'AX.)6S>O'G.G#G.SLX@T*5+E\+"0DF5I9'A7%W!DBG%H%Z0R'X_FH(* MT,"[(-7]Q3.0R'D['N ?> [2?S[*\X.7=>NS7%Q/1KQW[9,U?WRY)7MNU(VV M[1-!&(HJY'MPNK96'1"4YC' M_374@0,'(,O&C1LAX.S>><=J!%TK%!EJ"8(P&>.V@J&"(0#&BH: M*L(&/0(]HO&!LR&CSX:47Y B6W"YNKJ*+PTV!!8M6F3&1\>.'=EBAP\?;M^^ M/7,6AOO,;R!_^>472-F^?;O4PGDS1D5%\68!A@\?3JF24>H+[MJ[=V]VF>;F MYH,&#>),O?3:)GIM%AF:&Z#*\NK+YO'CQS$Q,2-'CNS:M:NMK:V%A46/'CW" MPL(R,C(DZ4.O,U@%)"8D))!#Z-W=W-S8\C8V-A,G3M1\"QA-9;7*<*ZN8,F4 M8KQ+$@HJH!7Z!2FR0[F;^ZF:&IXG;+\_E._>Y31[1ZJFS>/#PJ\*O28OYM^Y MUG9Q:6G<-:]I'UR'O' *_D\,N\*\B<_DR,[.'C5J%'@05&MXQ-.B% P&LNSD'_\XQ_L+-!$0C\242I$(!S04-%0$3;H$>@1 MC0^<#2E5,J68(1:D&B4P?+]X\6)\?/SMV[?9Z>^__SY8K8RMLF1GU*J2(LBK M+[@-3(1.G#B1E)3TZ)'VE\1ST+U-U'IN%B$:AQDD)B8ROYK6$Y65E79V=H,' M#^:DY^3DP* $+ ?LI[R\7"@[365%9(2NKGO),L3TIX AR*/"5EWR^/BBV[>XFX\88H4%Q>?.7,&+/G\^?.:OV*6#:6# M ,G)R4+OP\[*RHJ-C6V8(UVE@D]F9B;4$5J)/56@1R1$T$#CH3(LI*BH"&YK M7%P MU3;1-E$W%C,X??JTOD-P0D*"F9F9T(19WQCWZ@B""&& X$,#A@A$'#14!&&# M'H$T/G V9!1P00I!D#I24E)&C!BAUTOKU$@[TZ@B!"&"#XT( A M A$'#15!V*!'((T/G T9!5R00A $01 $01 $01 $00P*+D@A"((@"((@"((@ M"((@!@47I! $01 $01 $01 $01"#@@M2"((@"((@"((@"((@B$'!!2D$01 $ M01 $01 $01#$H.""%((@"((@"((@"((@"&)0<$$*01 $01 $01 $01 $,2BX M((4@"((@"((@"((@"((8%%R00A $01 $01 $01 $00P*+D@A"((@"((@"((@ M"((@!@47I! $J:.TM/3Z]>O&U@)!D.<.##Z(28"&BB!LT".0Q@=:M5%0?D'J MPH4+D9&1OKZ^??KT"0H*6KIT:4%!@>)748I;MV[MV[=O_OSYTZ9-V[%CAVP9 MH+JZ>L:,&3$Q,;IDO'3I$K182$B(EY>7CX_/E"E34E)2-+.4E96M6;,F,##0 MT],S.#CXP($#QJUO;6TM9)DU:]:P8<.\Z@D-#=V]>_?3IT_E:2ZC3>@+EU%E M>AU,P@QX.7OV[( ! WA/T>A#WT0<5JQ8,4V#!0L6<,1H*BNO010LV>@*B)-? M4#5C5L8',S.._"P6DU-352 C]/?T:2T16[GJCN;911_=Y)26G*(*"4WO^W+R M6V,O7;YEE&=AH;4O@\<1-/R&9C@2>D@24E)8!@>'AX0 M>\$9.6=A@ 6*+5NV3,'Z*HA(\%%3A]"?,N7[XLKR@. M-'=6:\F4]U$3K;Y/:4B([J"ABH"&^AR"'B$">H2)@K,AH\R&%%Z0@NFTI:6E MF9E9]^[=_?W]G9V=X;.+B\NU:]>4O9 B@(9F+,:,&2-/AA 7%P<"6[9LD9UQ M\^;-1-C>WKYGSYXM6K2 S^;FYJM6K6++JU2JOGW[PBDW-[> @ '!P?X/'WZ M="/6M[R\G,B#,CUZ]&C3I@TY'#QX,)R2H;G4-M%KL]#KH#8%,Q!"* 33Z".I MB3B P9AI $%#:F7E-8B")1M= :V,>?NRI4TL_'VTY):(V*YO[Q,QS3]7M\3: M/]>CU+U>.LLKP"XJ\\:39H[Q P+.K5N?U>^5Y!:M?LO.J6 ++%ATLZ5SPH.\ M2JEU:6C(Z/N^^>8;3;=Z\.0A \($0!)6%SXL6+9)1% >:.TM3 M,LU]U(3&]RD-"=$=-%0AT%"?3] CA$"/,%UP-F24V9"2"U*@0;-FS:#=]^W; M1U(J*RNG3)D">@P;-DS!"RE%:&CH6V^]M6;-FB5+E@A%(AH9PLR9,Z'NN;FY MLC-^]MEG;[_]=D)"0DU-#3FU:]L&):Q>O5J&YE+;1*_-0J^#VA3, M0)/CQX^#8ITZ=;*RLH*[-GSX\.7+ES]Z](B^^I*:B .$8!L;FX)G*2PL9,O0 M5%9>@RA8LM$5$.?0#_F6-K$!06E:%Z0J*IX6/*SB_,V8E0$9YR_\ZP&H7B^= M;=H\GB-66%C%+BH\XFI+YX22DCJK>)!7"?*SYV0R9Z]=?V+G$/_9%_?H:]$P MD=?W5514%&@ ?3;DFC=O'B-&XR!A86$PCB\IJ7L [<&#!R /\80Y"^/O)DV: M;-JT2>%J*X%X\%'3A=#+ER]#E6%6LW__?N9;94@\??HT6XP^&C-0WEF:DFGN MHR8TOD]I2(@NH*&**X"&^KR!'B&N 'J$*8*S(2/.AI1'"6%2$H0$2 M)E;P0HKSTT\_:8UQ6F7,(ED04H\8W^?E+^]<8$Y M]!F0&C@XC3D<.N*\EW7C!R8@Z] MO;T# @*80PC"GIZ>O$YJ7+0&'S8B(30H* A.'3ITB/*Z-#T@0>J=%2F9YCYR MD.W[O(:$R 8-51PTU.<-] AQT"-,$9P-&7$VI%9V02HY.5GS"^'*RDK0K&7+ ME@I>2'%T7Z"Y>/$BG.5])$]V1L+V[=M!(#P\G!SNWKT;#B=-FL01VC)HB!--45EZ#*%BRT1409V+8E1=:)V3G5,A; MD/KYZ$/(Y1]XCIU(LR#5QS,I)#2=.7QU4)KOP%3R>=]W#ZQL8\^<%3,S4T&I MON_(D2.:8VB:T?"++[[(1%IU_<\07GGE%?)Y[]Z],*+B?.'<$) :?(1"Z(T; M-R =6H#^TO2A7NJ=5796(]OW>0T)D0<:JE;04)\KT".T@AYA;*"%U(O7KVJ8$;"!Q]\ M +1T='D,"HJ"@XW;-C $8.P"^F4LPZ]UI=045'QYIMO@LRWWWXK57.I;2*I M0,T ^#0H4,@OW3I4K6VS2G%]9$MHZX/P=;6UA]__/&[[[X[ M??ITB!B<@$5367D-HF#)1E= A&/'ZY:3OMQ2MZF0O 6IT+]?@EP[_Y7+3NSU MTEE;^[A5J^],GG)UQJR,;3MRBHNK.1E#0M.[]CA#=D*HK'SJW/;DA$E7X'-) M24V'3J?"(P0-WK10JN\;-6H49.'LJZK508#@X.!.G3J1+2= &2ZFFN- M6HO21.J=%9_5:+V/'&3[/J\A(?) 0T5#1=B@1Z!'-#YP-F32%ET7Z#IUZ]?UZY=EGMF,=OSX\5 :A&R.Y,2)$R']N^^^$ZD"I4JZJ#UMVC2X]1!275Q< MFC=OOG;M6N84O>92VT12X2+0=W6\.HAKW@#-0/V?)[/\_/S*R\OI0[!0]:7* M$#2W\7-T=/SAAQ\8 9K*RFL0!4LVN@)"J%35'3N?"@A*(ZM",A:D\O(K;>WC M')U^*RU]YE%DS4W-6SHG_'CXF5?8'/^_NK6P>?-OI*4]?B_R&GQ.3JGK"^9& MW6C5)B&_X)D-ITP:W?N^O+P\&(N RY26EK+3M3H(<.S8,4C_\,,/SYT[1WZ] M3W8KF#-GS@LOO)"?GZ]4-15$:O 1"J%D]!,9&=FV;5OX8&MK2UK)P\,C)R=' M4E&\2+JSXK,:K?>1@SS?%S(D1!YHJ&BH"!OT"/2(Q@?.AHP[&U(KOB!5556U M:=,F\I8$0N_>O8\>/:KL511'QP6:>_?ND'B4'9U M0CJ8G!D M;6UT#U#EO;MV\.'GCU[GC]_7OQ=LT+5ERK#\,]__A,:)RLK"W+! M *&#C!H@%XY-?7/WW;15%9>@RA8LM$5$.*]R&M-F\=?N_[GWD\R%J36K<^" M+!'O7>.D+UYZZ\C/!5EWRU6JZHL72T# RC;6UC[NW+G'G.PMG1.@!!?7DUNW MUXTRKUPIM6D61Y[8>EA8M7+5G4GO7EFZ_/;]!R;\KCW=^[[HZ&@SOH>ZM3H( MDYUDL)^4:8#HN$#S^>>?PZG$Q$3-4[(SEI6504367*<8.W8L)!X\>) C/WGR M9$C?O7NW2!5H5-)1[9J:&N@#[MZ]&Q,3X^KJ:F%AP;SA@E)S&6U"7[@X-,TB MHH/)F0&AO+Q\^?+EG3MW9OKL-FW:K%NWCC<0BU1?DHPX9&?!T:-'DT.:RLIK M$ 5+-KH"O,3%%UG:Q*[X^ Z3(F-!ZJ6^29#E;)+VS9YF_4_=F_C^>\PE3GI- M36UA8=73IW]N7AXT),W;+P4.5:KJSMU.MVV?.&'2E0Z=3K7OF&BBSTPITO?U MZM4+Y,^<.:-5DN,@#!!^"PL+&<\%-^S?OS\.SL[.X\:-:]>N7=NV M;1O(,U.2@H]0""7O)+*TM&3O @M1B&P-"V-*^J(TD7IG)F$,>>I;BXF#=1QPNAH:*A&I+:VKJ'B]E_Q<75O(G&TA ] CW"8!C,'7 V M9,39D%K9!2FRD=5KK[W&3BPJ*FK=NK6-C4T#^5:6%QT7:"#J01V%5E)E9 2O M()$T,C*2NLV;-:M&B!102%15%KX\D&:W Z 1*<'%Q(85M MM83K&4] V-6-?TV6L/O;^U:VL2GU/]Q;MN*VM5W3 MYD(-#=W[/AB#FE%O[\IQ$%YV[=IE;FZ>G)P,GY9,F36;/ MGDUS(8.A-?BHA4/H1Q]]9%;_U3KJ:K-G24Q,Y$U4ZHIHJ+R@H2I+=74MY^?PITX7\R8:6U/T"'[0(Q3$ M\.Z LR%=2I8]9U%R06K:M&EP,?(# 39DD[8C1XXH>"UET66!YM&C1];6UB*[ MQDK-6%%1,6+$"+/ZYS;))K5L-FS8 *?FSY_/2??T](3TFS=OBE1!JTJZJ,T+ M>!$4\O#A0TK-Y;4)9>%:$6\6<1U,T0PX,+^:_N.//QP<'.SM[=G7U7H+*&5H M>/SX,132M&E3CG'E+OK*19C=;[*,/W)1F2J0-&LO]98+#!FZC4 M%=%0>4%#51:PJ0,'\]A_#PNK>!.-K2EZ!#_H$0IB>'? V9 N)LRBY($56 MQ=:O7\]))W=%\_>$#0==%FCV[-D#Z2+[VTG*6%E9^?KKKT/ZA D3>)^U.7?N M')QE7NE-R,_/M[2T='5UI;1[O=:7H;JZVL;&!H3!HR@UE]5E5'J0RE#R9<4-_GY1!0_]Z+'_T6Y>Z]33)A]5U[/M*2TMAQ&-M;9V7ET=S.8Z# M:#)SYDPG)R=F'N[EY148&,B<#0D)Z=RY,\V%#(9(\&$0"J'9V=GFYN;MVK7C MI <'!YOQ[:PI4I0F4N^LI%F-UOLHU?>E&A(B%3147M!0GUO0(WA!CS!I<#:D M2\FRYRQ*+DAMW[X=E("Q;U757^N4F9F939LVA:!S[]X]!:^E++HLT(P=.];. MSN[)DR>Z9X1V&SER) C#J9H:P5_3D W2XN+BF)2Y<^?RKD=*54F>VL#=NW?! M SF2BQ?OEE>LUEMPE-X5H1JC*-#J9H!L#Y\^,&^&SW M[MWI]:&_3=]___V*%2O2TM+((8Q(.):C4JGZ]^]O]NR/KFDJ2R/#N;J")5.* M??'%%Z! ;FZN/A2@@7%=_XK%X1#_\[=$PK(SJFHK'RF MHU6IJKW]4L@[]7@O?>E229.F<61??1+&C*<9]N(A@]EWZ=Y M]PD[=NR [*-&C=(LF=)!V*2GIT/'3_8U)T#);FYNS#@ S&G0H$'2:ZDP-,&' MC4BW-7SX<#BU9\\>)N7JU:M65E806@L*"C3E18KBA BIHQJ1J1?-?907'QA$ M# F1#1HJ&BK"!CT"/:+Q@;,AH\^&E%R0*BLKZ]:M&URR;]^^FS=O/GCPX,J5 M*UNU:@4IS&\'&A3[]NT;4X^_OS\HV:%#!W(X??IT2AFP/$='Q^#@8*F%\V9< MM6J56?T.?Z&AH6.>Y9-//F'$X!Y#O(;L:]>N/73H$-FXWMW=O:BHR%CU!?5: MMVX]9>@_2?C_+\X&7=^BP7UY,1[UW[9,T?7V[)GAMUHVW[1!"&H@KY'IRN MK54'!*7Y#4QE?SMR\/M\R/*_G]VMJJJ-^7?=XA?\EUJCA@!EWZ=Y]PDP]#$3 M^&4?I8,PU-;6#APXT,?'A_TUU($#!R#+QHT;(>#LW+G33,J+./4'3?!1TW5; M5ZY<(1EAT+-___XU:]8X.3F!\.K5J]E7I"F*$R(H[ZS6DBGOH[SXP"!B2(AL MT%#14!$VZ!'H$8T/G T9?3:DY(*4NGZ%;]2H4186%F;_ 6[G@@4+V$O4#8=% MBQ:9\=&Q8T=*F5]^^04^;]^^76KAO!FCHJ)XLP##AP]G2QX^?+A]^_;,69B! MT&P;I+_Z@KOV[MV;+6]N;CYHT"#-J9>(YCJVB?Z:1:L.IF4&;!X_?AP3$S-R MY,BN7;O:VMJ"Y_;HT2,L+"PC(T.2/O0Z@U5 8D)" CF$48*;FQM;WL;&9N+$ MB9IO :.IK%89SM45+)E2C'=)0D$%M$*_($5V*'=S/U53P_.$[?>'\MV[G&;O M2-6T>7Q8^%6AU^3%_#O7VBXN+8V[YC7M@^N0%T[!_XEA5Y@W\9D<-'T?[]TG MFU:ZNKKR?IE&[R"$G3MW@@[,%WT,9$! U!L_?KR.CY$K DWP4=-U6T!*2HJ' MAP=SMF7+EILV;>)UEDQY'V7'![4V0T)D@X:*AHJP08] CVA\ MX&Q(J9(IQ?2^($4H+BX^<^;,B1,GSI\_K_E+KL;$^^^_#U8KXT>_LC,RP(SB MXL6+\?'QMV_?EEV(5,35!K>!B1#<]Z2DI$>/!%\2+Z2Y[FTB4KA>:1QFD)B8 MR/QJ6D] -+"SLQL\># G/2.J6^4"CZ9F9E01V@E>=^!B80(1>XL_7WDT !]__D$ M#54<--3G#?0(<= C3!&<#1EE-J27!:GGA\# P-&C1QLRHW'1J]HFVB;JQF(& MIT^?UG<(3DA(,#,S$YHPZQOC7AU!$"$,$'QHP!"!B(.&BB!LT".0Q@?.AHP" M+D@A"%)'2DK*B!$C]'J)6[=N'3UZ5*^7:+!71Q!$" ,$'QHP1"#BH*$B"!OT M"*3Q@;,AHX +4@B"( B"( B"( B"((A!P04I!$$0!$$0!$$0!$$0Q*#@@A2" M( B"( B"( B"( AB4'!!"D'^G[TS 8OBV!8PJX""&%$4%,7=J %1"? 4 NXW M"Z*\7$U<"6(D&I=G%)?$#6-4B/I,8F+-&C4FQJ@O$0CBPB(J&A=PBPHH M(.((LLN\ Y7;:7MZ>JI[>C8\_\?'-UU==>I4]3FGJVIZJA$$01 $01 $01 $ MT2NX((4@"((@"((@"((@"(+H%5R00A $01 $01 $01 $0?0*+D@A"((@"((@ M"((@"((@>@47I! $01 $01 $01 $01"]@@M2"((@"((@"((@"((@B%[!!2D$ M01 $01 $01 $01!$K^""%((@=926EEZ[=LW06B (\L*!P0@32 M\$"K-@CR+TA=O'AQRI0IWM[>??KT&3MV;%)2DNQ5R,C-FS?W[MT[?_[\:=.F M;=NV334#-&?ITJ4A(2%>7EX^/C[0M+2T-%Y1U=75,V;,B(N+HQ>N6I"RNK*R MLM6K5P<&!GIZ>@8'!^_?O]^P[:VMK06QLV;-&CITJ%<]H:&ANW;M>O;LF5@% M)/>)-MTBC 2=Z4LI)3667C@]9\Z7?3) M#8ZTU#1%2&AF[WZI;X^Y>.E2">=L:6G-?_FG+U]Q2T)SC(WSY\]'1D;Z^OKV MZM4K*"@(W*&P4*B?P4%4+9^!"9Z4#I*2D@*&X>'A ;$7G)%S%@98H-BR9C1HSD9-F[<2$[9V]M#BYHU:P:?H44K5ZY4E9:0 MD !G-VW:1"EZNSL3,SXZM6KZHKLV+%#U?(9^Z_]3T?3.$AV=K:M MK:V?GU],3 R8"EA(3DX..T-45)2CH^.#!P]TT7;M$1C_48:[(T>.-&W:%#) M\($0!(V%SXL6+6(R4/8V!QEORA(L1$D]IM+1[0_A@(:J#C34%Q/T"'6@1Y@N M.!LRR&Q(S@6I6[=NV=1S].A1D@*CY X=.L"52$]/E[$BN0@-#7W[[;=7KUZ] M9,D2WG#YQ1=?O/ONNTE)234U-22%A!C(G)*2PLD\<^9,:&E>7AZE<-6"E-5% M1$1 RI0I4\@W X6%A1X>'I!RZ- A0[6WNKIZ\^;-8 #,V.5,XZ:)G&Q%155L4>$15YH[)Y64U%G%@_Q*R#][ M3C9S]NJUIW8.B5]\=8^^%<8)W'V;-&D"7KQW[UZ24EE9"=<+KM'0H4/5E:JH MJ"A4 >[94&K>O'E,-AH'"0L+@W%\24G= V@/'CR _!!5F+,P;H;1\(8-&V1N MMAP(!Q\E7;B[=.D2-!EF-?OV[6.^,(?$4Z=.,7DH>YN#7#=E:19"/Z;2T>T/ M84!#14-%V*!'H$V,! 'S+/G3N7D^[N[N[CXT,O7+4@374/'SX$/W%R73BQ G( MX^_OKZX*2I5D:2_#_OW[S>H?DJ)70%4XI4JR=(LP]#J+*J44WUA1PC4"#@M" M(/*"'#RGC*)9$%*N&!?G[1_O'F>.?3IGQXX*(,Y M'#+\G)=W*@@7I8P10AYRY'RE!@-9\"-AV^8 ?N3JZ@JBV/L7:'00P,O+"T9. MS*&WMW= 0 !S"$'8T].3UTD-B\;@PT8@W 4%!<&I@PZ7;MVP>&D29,X MV5JU:F5A85%<7$S3!)VVE^'X\>.0)S@X6*P"8OM$*5.W""--9XU=+:&Q],(U MDI65!1+\_/RJJJK8#ZG>N'&#_4V7**U$Y5%2A&":BRO- &24;' %A)D8=OFE MEDDYN172%J1^.?(02OD'GF4GTBQ(]?),"0G-9 Y?&YCA.^"OKP?W?O_ RC;^ M]!DA,S,54E-35;\OK:RLA+MR\^;-Z>4Q+LR#U\LLOLR,MW/5???55 M\GG/GCTPHF)_X6PDB T^ZL+=]>O7(1UZ0*P"O+U-@X2;LC0+H1Q3Z>'V]R*# MAHJ&BK!!CT"/:'C@;,BPLR&EO M2;[SQAIG*$UD*A<*LGNSL;'4%#8ZHB?V' M'WX(F6-B8MB)RY8M@\0K5ZZ(%2Y0D+>ZJ*@H.%RW;ATG&X1+2*><=>BTO82* MBHJWWGH+\GSWW7=B%1#;)TJ9ND48:3IK[&H)C:47KI&#!P^"A*5+ERHU;4Y) MKY6H/,KZ$&QM;?WIIY^^]]Y[TZ=/W[QY,R=@T5Q<:08@HV2#*R# T6-URTE? M;ZK;5$C:@E3H/R]"J>W_RF,G]GCEC*U]PLI5MR=/N3)C5M:6;;G%Q=6<@B&A MF9V[G2:;/%16/G-V.3%ATF7X7%)2TZ[#R? (M69O6L#PU-W='0::,,)F$L&2 MX0)-GCR97L[(D2.A"&?S5XT. @0'!W?HT('LI@'*.#DYC1LW3EG7SR5MVK0) M"PN3WC:=(3;XJ MW6[9L,:O_+KJHJ&C]^O70X1!Y]NS94UW-M48.O+U-@X2; MLC0+H1Q3Z>'V]R*#AHJ&BK!!CT"/:'C@;,BPLR&EO M2TZ9-@\J@*]F)RZ"?V$$?L[.SL[>TYN\/VZ=.G<^?.$H0+%.2M;OSX\2 -0C8G MY\2)$R']^^^_U]@$C2H)*R"L-MA >'@XW"U:M6K5M&G3-6O62%! ;)\H9>H6 M8:3IK+&K)3267KA&R/-9?GY^Y>7E]"%86"OZ/ 35;?P<'1U__/%')@/-Q95F M #)*-K@"ZE HJMMW/!D0E$%6A20L2.475-K:)S@Z_5Y:^MQ3KJJ;FC=W3OKI MT'.OGCGV?W5K8?/F7\_(>/)^Y%7XG)JF@/2Y4==;M$XJ*'QNPRF3YOSY\YTZ M=7)P<( N'#APN#@8'-S\S???!/&H)02\O/S82P"+E-:6LI.U^@@P-&C1R'] MHX\^.GOV+/GU/MFM8,Z<.2^]]%)!08%@1[1\,#9D&%G M0TIY%Z3BX^/-ZC>$9][O ]*"?V$'UZ]>H%.;=LV<). MOW?O'ID,B!4N7)"WNM#04$CYZ:>?.)DAID/Z]NW;A9N@426-"@BKW:1)$\:1 M7GOMM=]^^TVL A+Z1"E3MP@C36?AKI;66$KA--36UL)M%82T;=L6/G3OWOW< MN7,"K]&ET8HR#\/''W\,#;ESYPZ4@AL_W/+A9@\##F;K1YJ+*\T 9)1L< 74 M\7[DU<9-$Z]>^VOO)PD+4K%K[T"1B/>Y+Y19O/3FX5\*[]PM5RBJ+UPH@0Q6 MMO&V]@EGSS[A%&_NG 026KF>V+RU;I1Y^7*I39,$\L36PZ*J%2MO3WKO\M+E MM^X_,.%W[55556W8L(&\(8C0LV?/(T>.T$N(B8DQXWNH6Z.#,,5)[2U:M/CV MVV\AY8\__K"RLMJX<:.R_E?]T='1$R9,6+QX\?W[][5NK@R(#3[JPMW4J5/- MZM]BX^GIF9E9]_M0F,R07TS /4B=-'6]+8PV-V4)%D(YIM+#[>]%!@T5#15A M@QZ!'M'PP-F086=#2GD7I)3_61AS=L:^*>\=$E(?&1I$Q_]Z6TF1<*"U"N]4Z#(F13-FSW-^I^Z-_']]^B+G/2:FMJB MHJIGS_[:O#QH<(:W7QH<*A35';N<S8,6]O;TA1]Y2H*CUZ](#\IT^?UIB3XR ,$'Z+BHH8SP4W M[-NW+QS"X*9]^_;.SL[CQHUKTZ:-BXN+D3PS)2KXJ MWY'5+EI:6[ UN(0J1 M76]A3,E;-7UOLV5*OBE+MA":,94>;G_&"4PACCY/<7$Q;Z*6%:&AHJ'JD]K: MNH>+V7_%Q=6\B8;2$#T"/4)OZ,T=<#9DP-F04O8%*;ALGW_^.7$Y"PN+ 0,& M0-3P]?6%P\N7+\M;EXQHG-B#F9*0%!D9J7H63K5LV5+=2JJ <'4%!:HC7RFH M+K62)4G*+^1UVEZ&]/1TD.#FYB9* 0E]HI2I6X21H+-P*8&"PHVE%"X6N,MV M[MQYUJQ9S9HU [%145$2M*+47!@8G9C5?[E$#FDNKC0#D%&RP150!6[8G;N= M[OKRZ;S[E84/J\C?IY_=MK2)_VC>=?A<4J+Y11-G4AY#_EZ>&MY62[B6]10R MN[KQ+\T3=GUWW\HV/JW^AWO+HF]9VR5/P+MA#$KS1!+<*,VHMW?E. @O.W?N-#D-C\%&J#W?D?48]>_;DI$^8, '2-VW:I"I*5&\3M+PI M2[80FC&5'FY_QDEU=;79\R0G)_,FRE4C&JJZ>M%09:2ZNI;S<_B3IXIY$PVM M*7H$>H3.T;\[X&Q(&\F2K5KF!2F&RLI*LB]=146%G9V=2;]E#YHP?/APL_IG M1,FNL6P>/WYL;6TML&NL.N'J"@I7MV[=.C@U?_Y\3KJGIR>DW[AQ0YT:-"K1 M**"QO6S BT#.PXN!C([O/2[N@P*176;=LGO1_Y5[]!_G._S:BIS=N"0!G+&QL335<1Q$%85"T;IUZXB("'(X>/#@WKU[ M,V<# P.]O;UI*M(;PL&'H"[I$];92CINR]A8B M,*;2P^W/.(%KL>]Y8+#!FRA7C6BH&G5 0]4>N'3[#^2S_QX65?$F&EI3] CT M")VC?W? V9 VDB5;M:X6I!AV[-@!&DR8,$'7%6F#P,0>0@EY70(T@?<1F-V[ M=\-9SA:S-,)Y"VJL[NS9LW"6>:4WH:"@P-+2TM75E=+N==I>!@C!-C8VD!D\ MBE(!:7VBE*E;A!&EL\92Z@K2-)9&N 38V_A!3X+DLK(R>JU$:2[,B1,G0$Z7 M+EW((PT[+):6UC@Z M_6YKGY!?0+6[4_+)8A#>O><9=1F@4F>7$\RXH:]/VL A?S^6/^KMBUVZBW@. MWW@@WPBM7;N6DTY&)*J_I>=06EH*(QYK:^O\_'R:ZC@.HLK,F3.=G)R8>;B7 MEU=@8"!S-B0DI&/'CC05Z0V!X,.@+MSEY.28FYNW:=.&DQX<'&S&M[.FV-Z6 MY::LI86P41U3Z>'VAQ#04&DT(:"AO@B@1]!H0D"/,!5P-J2-9,E6+?."%.*54ER>^_>O0L>R,FY>/%B$-6O7S]Z!23WB5*. M;A&&7F>:4KP%Z1NK43@EY\Z=@]A!/C,A^/KUZXT;-^[:M2N]5O2:__###]'1 MT1D9&>001B07)@^G=ADE4V;[ZJNO0(&\O#Q=*$ # M[QY2&[_)6;'R=MY]K@MO_U<>9 [])W=/*" GMZ*R\KD;K4)1[>V71MZIQUOU MQ8LEC1HGD'W-"2#9O=,IYO;DT2=E\##^;2.,G*U;M\+E\/+R D=@$K.SL\&/ M8,!][]X]DJ)Z]0G;MFV#XB-'CE253.D@;#(S,^'&3_8U)X!D-SD H*"AH[=NSJU:N_^>:; MZ=.G.S@X@ ;P6=Y:Y&+OWKVCZ_'W]P<]V[5K1PY!F2H M]L+9EBU;3IDR!3[ Y5ZR9 G9\\_6UI:]?8/N^D2;;M&FT]1UB,:NUJ:Q&H73 M0Y[2\O7U7;AP(82\#ATZ3)TZ%=S6VMJ:>1291BOZRP0ID//KK[\FAS$Q,2U: MM @/#P<)&S=NG#-GCK.S,V3HU*E345$14XKFXM+DX=0NHV3*;- N2&2_'TU& M!6C@79#J^O)I2.2\'0_P#SP+Z;\@@[V[=O-S..U_?0!!\E7;B#(3XI"(.>??OVP0C$ MR5JJ$"+ENRI(MA'),I:/;'Z)$0T5#19X'/0(]HN&!LR&# MSX9D7I!ZYYUW+"PLS/Y#MV[=1#W0J&<6+5IDQD?[]NU)AJBH*-X,P+!APR## MK[_^"I^W;MTJ5CAO08W5,1PZ=*AMV[;,69B!T/S86'?M!7?MV;,G.[^YN?G M@0,Y4R^=]HGD;M&FT]1UB,:NUJ:Q&H73\^3)D[BXN!$C1G3NW-G6UA:<%WPV M+"PL*RM+E%;TEPFL A*3DI+((=S=W=SR;W\PE%FP8 '[:U7> MJT\VK71U=>7],HW>00C;MV\''9@O^AC(@("H-W[\>"T?(Y<%FN"CI YW:6EI M'AX>S-GFS9MOV+!!M5+AWE:JA @9;\K2+(1^3*6+VQ^B1$-%0T6>!ST"/:+A M@;,AN2139M/Y@I2R_NT#J:FI"0D)V=DF^;XD47SPP0=@M92_9Y:E( /,*"Y< MN)"8F'CKUBW)0L0BK#:X#4R$CA\_GI*2\OBQYI?$BQ).B9Z[Q8 &(#O)RO(CU=$9_P*"/C27FYT!I'6IKB3 I_3+ASMSPA\=&-F]R-)TR1XN+BTZ=/ M@R6?.W=.]5?,DJ%T$ !NONK>AWWGSIWX^'CC'.G*%7Q@U %MA%YB3Q7H$0@1 M--!XJ 0+H1]3&6&(:&"@H0J AOH"@AXA 'J$B8*S(8/,AG2^J7G#)C P<-2H M4?HL:%ATJK8I]DE#,H!3IT[I.@0G)269F9FIFS#K&L/6CB"(.O00?&C $($( M@X:*(&S0(Y"&!\Z&# (N2"$(4D=:6MKPX<-U6L7-FS>/'#FBTRJ,MG8$0=2A MA^!# X8(1!@T5 1A@QZ!-#QP-F00<$$*01 $01 $01 $01 $T2NX((4@"((@ M"((@"((@"(+H%5R00A $01 $01 $01 $0?0*+D@A"((@"((@"((@"((@>@47 MI! $01 $01 $01 $01"]@@M2"((@"((@"((@"((@B%[!!2D$01 $01 $01 $ M01!$K^""%((@"((@"((@"((@"*)7<$$*01 $01 $01 $01 $T2NX((4@"((@ M"((@"((@"(+H%5R00A"DCM+2TFO7KAE:"P1!7C@P^" F 1HJ@K!!CT :'FC5 M!D&&!:F;-V_NW;MW_OSYTZ9-V[9M&V^>LK*RU:M7!P8&>GIZ!@<'[]^_7_MZ M]0!-TX#JZNH9,V;$Q<6)*L4I>/'BQ:5+EX:$A'AY>?GX^$R9,B4M+4VR2M(0 MV][:VEK(/VO6K*%#AWK5$QH:NFO7KF?/GFDO7&D#,F3/]^_?G M/46C%7U'<8B.CIZFPH(%"SC9:&*(M#@CHV2#*R!,06'5C%E9'\[,.OQ+H4"V M]'0%Y%'W]^Q9+S=+_7M,1@4%!8$[%!8*]3,XB*KE,S!1E-)!4E)2 MP# \/#P@"(,SYN;F+%R\F/C)X\.!Y\^9= MNG2).4O9VZI01C8:#Q5K(8P"4*FWMW>?/GW&CAV;E)3$F\U$1UFF!1JJ &BH M+R#H$0*@1Y@H.!LRR&Q(VP4I?W]_,Q:C1X]6S:-0*'KW[@UGW=S< @("'!P< MX//TZ=.UK%K7T#2-D)"0 !DV;=HDJA2[X,:-&TE^>WO[[MV[-VO6##Z;FYNO M7+E2FDH2D-#>\O)RDAFN:;=NW5JW;DT.!PT:!*>T%&X,?4*I T=SL5H929/5 MA6 :K41U% >P'#,56K5JQ2I4T\_'VRY*9 MIW? MW2?95/]/! %VW7'H'Q M'V6X.W+D2-.F32$#!!\(0=!8^+QHT2(F V5O*L%"@)T[=UI;6T.- M4'N_?OT:-6H$GV-C8SG93'2497*@H:H##?7%!#U"'>@1I@O.A@PR&])V02HT M-/3MM]]>O7KUDB5+U$6;- MFV_=^OOIALS,S"Y=ND#Q5:M6:2G<&/J$4@>.YF*U,GB3CQT[!D(Z=.A@964% MEV_8L&'+ER]__/@Q?2>(ZB@.$()M;&P*GZ>HJ(B=AR:&2(LS,DHVN +"'/RQ MP-(F/B H0^."5$7%L\*'59R_&;.RH.#\A7\_ -7CE3.-FR9RLA455;%%A4=< M:>Z<5%)29Q4/\BLA_^PYV>VCDD?O'5/?I6&"=P]VW2I EX\=Z]>TE* M964E7"^X1D.'#E57JJ*BHE %N&=#J7GSYC'9:!PD+"P,QO$E)74/H#UX\ #R M0U1ASL*X&4;#&S9LD+G9[2I4O09)C5[-NWC_G"'!)/G3K%Y*'L M;0Z4D4VCATJS$+BWVM1S].A1DI*=G0U]!7+2T]/9.4UTE&5"H*&BH2)LT"/0 M(QH>.!LRX&Q(MCVD?O[Y9]Z(\_#A0[BN3DY.[$=F3IPX 9G]_?WEJEVGJ&L: M@[N[NX^/C]A2[(*,X;*!&05(F#MWK@25M$%:>QGV[]]O5O^0E);"C:%/1.E@ MHF8P8\8,$ *1%^2XN;E!!/'U]86[)O/(-(U68C5G0T*P0 ::&"(MSL@HV> * M"//H476;=LDAH9GK-]S5N""E2DU-K9O[22AX+>LIDT@6I(0+]O5)^\>;YYE# MG_[I@8,RF,,AP\]Y>:>"<%'*&"'D(4?.5VHPD 4_$K9M#N!'KJZN((J]?X%& M!P&\O+Q@Y,0<>GM[!P0$,(<0C3T]/7F=U+!H##YL!,)=4% 0G#IX\*"HVGE[ M6S6/:B(GLM%XJ#0+^>233Z 4]!([$69ND @S/2:E 8RRC!PT5#14A UZ!'I$ MPP-G0P:<#2GUL""U:] M>NLMR/#==]_)+EQIN#[1J(.)FL'!@P=!PM*E2Y6:-J>DUTI4'F5]"+:VMO[T MTT_?>^^]Z=.G;]Z\F1.P:&*(M#@CHV2#*R# T6-URTE?;ZK;5$C:@E3H/R]" MJ>W_RF,G]GCEC*U]PLI5MR=/N3)C5M:6;;G%Q=6<@B&AF9V[G2:;/%16/G-V M.3%ATF7X7%)2TZ[#R? (M69O6L#PU-W='0::,,)F$L&2X0)-GCR97L[(D2.A M"&?S5XT. @0'!W?HT('LI@'*.#DYC1LW3EG7SR5MVK0)"PN3WC:=(3;XJ MW M6[9L(=]%%Q45K5^_'CH<(L^>/7NJJ[G6R(&WMVG@1#8:#Y5F(6^\\8:9RE/N M"H7"K)[L[&QZ!1#)H*&BH2)LT"/0(QH>.!LR[&Q(J8<%J?'CQT,ZA!A.^L2) M$R']^^^_ETL!W2$\[>_3IT_GSIW%EA(H2(" 96=G9V]OS[L-K0$7I'C5GC9M M6GAX.-PD6K5JU;1ITS5KUL@HG,& ?:)1!Q,U _)\EI^?7WEY.7T(%M:*/@]! M=1L_1T?''W_\DY;\>I_L5C!GSIR77GJIH*! KF;*B-C@ M(_RE5V1DI(N+"WRPM;4EO>3AX9&;FZM.FKK>UHAJ9*/T4 D6 C=6D ##4W9B M.!LR[&Q(J8<%J=#04$C_Z:>?..D0 M@R!]^_;M_7J!1FV;-DB5B7MD=#>)DV: M,/[SVFNO_?;;;S(*)QBV3X1U,%TSJ*VMA=LJ"&G;MBU\Z-Z]^[ESYP1>HTNC M%64>AH\__A@:^4&;QTIN'?RF\<[=;ERZ4V31+($UL/BZI6K+P]Z;W+2Y??NO_ A-^U M5U55M6'#!O*&($+/GCV/'#E"+R$F)L:,[Z%NC0["%">UMVC1XMMOOX64/_[X MP\K*:N/&C+%]^_?U[JY,B V^*@+=U.G3C6K?XN-IZ=G M9F;=[T-A,D-^,0$W(W72U/6V,+R1C=)#)5A(?'R\6?U+=IAW)L)8.3 PD!0_ M?/BP* 40::"AHJ$B;- CT",:'C@;,NQL2*F'!:DQ8\9 ^H$#!SCIDR=/AO1= MNW;)I8#N$)CV?_GEEW J.3E95"GA@F5E91"+!=8I- K7$@GMK:FI@9!]]^[= MN+@X5U=7"PL+YH44V@M7&D&?".M@TF8 M\GERY=W[-B1N=>V;MTZ-C:6-Q#3 M:$631QBRL^"H4:/((4T,D19G9)1L< 5X24A\9&D3'_WI;29%PH+4*[U3H,B9 M%,V;//BXF(D MSTR)"C[JPAUYW9*EI25[@UN(0F376QA3\E9-W]MLF;R1C<9#)5L(^;+1R@1^@-O;D#SH8,.!M2ZF%!BBR!JRX-DB4T45\@&PJ!:3_$J98M M6XH*P<(%P1]([(N,C)2FDO9(:R]#>GHZ%'=S7 M3^?=KRQ\6$7^/OWLMJ5-_$?SKL/GDA+-KUT[D_(8\O?RU/"V6L*UK*>0V=6- M9X&58==W]ZULX]/J?[BW+/J6M5W"E:MU#][?N5MNYY X9VXV347&!MG$\?77 M7VGM7CH/PLG/G3G-S\]345/B\9,D2"PL+LE$= MC*<;-6H$XV.:BO2&QN"C5!_NR/N,>O;LR4F?,&$"I&_:M$E5E*C>)@A$-AH/ ME6PA<'?X_///R30&+N* 0- >5]?7SB\?/DRO0(-DNKJ:K/G24Y.YDV4JT8T M5'7UHJ'*2'5U+>?G\"=/%?,F&EI3] CT")VC?W? V9 VDB5;MGI"^HT;-^120'>H:]KCQX^MK:W5[1*I 'LCY^;H[&G,J MZRY<#61V>.EW=1D4BNHV[9+?C_RKWJ'_.-_GU53F[, AYWSZIZLI:M20#2/( MC^/8D+U7F>?S!0"7@9RQL;$TU7$<1!6%0M&Z=>N(B AR.'CPX-Z]>S-G P,# MO;V]:2K2&\+!AR#\)M^ @ !.^NS9LR$=I@2JU8GJ;:6FR$;CH=I;2&5E)=GK M%Y2QL[-COZJI 8RRI '78M_SP*B#-U&N&M%0->J AJH]<.GV'\AG_STLJN)- M-+2FZ!'H$3I'_^Z LR%M)$NV:ITO2)T]>Q;2F5=0$PH*"BPM+5U=7;6Y3GI# M7=-V[]X-Z9S-93664E<08A9Y+\.$"1.$'T$2%JX]TMK+ )'7QL8&JU$:2[,B1,G0$Z7+EW((4T,D19G9)1L< 54 M>?:L=O:<;,Y?X* ,2YMXWP'I\'GO]QIV6"PMK7%T^MW6/B&_@&IWI^23Q2"\ M>\\SZC) I.'6DJ MTAL"P8=!7;C+R*B6%L)FQXX=1!E1 M"B"R@(9*HPD!#?5% #V"1A,">H2I@+,A;21+MFJ=+T@!9$.OA(0$)F7NW+F\ MZV?&B<#V6'9V=D^?/A55BK=@5575B!$C(#^<8M;.):@D"_3MO7OW+C@>)]OB MQ8NA>+]^_;04;@Q]0J.#29O!N7/G(':0STP(OG[]>N/&C;MV[4JO%;WF/_SP M0W1T=$9&!CF$$0G'A!0*1=^^?_]$U30RAR<.I74;)E-F^^NHK4" O+T\7 M"M# NX?4QF]R5JR\G7>?Z\O;_Y4'F4/_R=T3"LC)K:BL?.Y&JU!4>_NED7?J M\59]\6))H\8)9%]S DAV[W2*N3UY]$D9/(Q_VP@C9^O6K7 YO+R\P!&8Q.SL M;/ C&'#?NW>/I*A>?<*V;=N@^,B1(U4E4SH(F\S,3+CQDWW-"2#9S M.0T<.%!\*V6&)OBP$0AWPX8-@U.[=^]F4JY5*B&" M,K)I]%#)%L*I].;-FRXN+HT:-6)^]$&I "(9-%0T5(0->@1Z1,,#9T,&GPUI MNR"U=^_>T?7X^_M#9>W:M2.'TZ=/9_* 3A!?'!T=UZQ9<_#@0;+1NKN[^Z-' MC[2L7:<(-PUL#EH4'!PLJI2Z@BM7KC2KW]LO-#1T]/-\]MEG],+UW%[0K67+ MEE.F3($/WWSSS9(E2\A6?[:VMIQ=&R0(-X8^T:B#J9L!>4K+U]=WX<*%$/(Z M=.@P=>I4!P<':VMKYE%D&JTH-0<@!7)^_?77Y# F)J9%BQ;AX>$@8>/&C7/F MS'%V=H8,G3IU*BHJ8DK1Q!":/)S:991,F0W:!8GL]Z/)J -O M275\^#8F< MM^,!_H%G(?V7(SP_>(E=>Z>5ZXF(]Z]^MOK/KS?ES(VZ[M(V&3*#J"*^!Z=K M:Y4!01E^ ]+9WXX<^*$ BOSO%W>KJFKC_EVW^ 7_Q;;(&"@K*R-;1?3NW1O, M^,"! RM6K ##AA3F=W-*OJM/@*&/F9J'_RD=A*&VMG; @ $^/C[LKZ'V[]\/ M1=:O7P]A9_OV[6;&\?H>FN"CI MW,,0G!6'0LV_?OM6K5SLY.4'F5:M6J=8K MT-M*E1!!&=DT>JAD"PD*"AH[=BRT".ZPT&1H)F2 SQRU372491*@H:*A(FS0 M(] C&AXX&S+X;$C;!:E%BQ:9\=&^?7MVMD.'#K5MVY8Y"R-FX_]QK'#3?OWU M5_B\=>M64:74%8R*BN(M!0P;-HQ>N)[;"U[:LV=/=F9S<_.! P>JSK@D"#>& M/M&H@ZF;P9,G3^+BXD:,&-&Y"!S'7"(8R"Q8L8'^MRGOUR::5KJZNO%^FT3L( M8?OV[: #\T4? QD0$/7&CQ^OY6/DLD 3?)34X2XM+& %?N' A,3'QUJU;>JM4=WSPP0=@KY2_9):EH&$14!N\!>8_ MQX\?3TE)>?Q8\[OA10DW5":QQI:8K_ M9^],P*(XM@7,*J @1A001<%]BXB*P!,0=V\61'FY^A(W@AB)QB5&49.X88R* MU_A,8F)"0FU<=%U]VZS9WX0E#I+R\_,*%"V#)&1D9 M_->9U8;208#DY&1%W\/.SH0(Z!$&"HZ&=#(:TMZ$5 O#W]]_ MRI0IVLRH6YI5;0/M$WG+,H/SY\\W=PA.2$@P,C)2-&!N;G1;.X(@BM!"\*$! M0P0B#AHJ@K!!CT!:'C@:T@DX(84@2!,I*2D3)TYLUBINW[X=$Q/3K%7H;>T( M@BA""\&'!@P1B#AHJ C"!CT":7G@:$@GX(04@B (@B (@B (@B (HE5P0@I! M$ 1!$ 1!$ 1!$ 31*C@AA2 (@B (@B (@B (@F@5G)!"$ 1!$ 1!$ 1!$ 1! MM I.2"$(@B (@B (@B (@B!:!2>D$ 1!$ 1!$ 1!$ 1!$*V"$U((@B (@B ( M@B (@B"(5L$)*01!$ 1!$ 1!$ 1!$$2KX(04@B (@B (@B (@B (HE5P0@I! M$ 1!$ 1!$ 1!$ 31*C@AA2!($Y65E3=OWM2U%@B"O'!@\$$, C14!&&#'H&T M/-"J=8($$U*W;]\^=.C0BA4KYL^?OV_?/K5E](TK5ZZL7;LV,##0W=W=T]-S M[MRY*2DI@I+U]?4+%RZ,CHXFN_2-96>DK*[Y>E*]]M+GNG3I4EA8F)>7U\"! M T>-&@6YBHN+)2F\^?JDL;$12EZ\>/'X\>/=GQ$4%'3@P(&G3Y^*:ZZ25GK2 MY(L7+XX8,4+P$(U6]); (2(B8CZ/E2M7 M8!ML&9E,-GCP8$AW=G;V\_.#TP';<(%758:/A"7K7 &E3'WSJJE%+/Q]O.:V MB-C^[QX0,?Z?DW-BXU_S4?+^+U\4%& 7E9WSI(UM_ B_M*W;'V]K:/GSXL#G:KCDB]W\TX8ZFBRB+XJ/4^VBB'^6Y M%N>--]X@63[\\$-5E40D 0V51A,TU!<'] @:3= C# L<#>ED-*3IA%104!!X MVN;-F]>L6:,H3-#(Z!N??_[YFV^^F9"0T-#00%+V[]]O;FX.^B/U MMD_DSYY=VKU[]YT[_WE\(S,SLU>O7E#1IDV;%&FNJE8Z;_+ITZ>A$%=75S,S M,VC=A D3UJ]?_^C1(W*41BN5[(<#A& +"XOBYRDM+67+A(:&0E%@,^3W*! 8 M-&@0I!P_?EPE&3X2EJQS!<0Y]E.1J46LWZATI1-2-35/BTOJ.'\+%V=!QA6K M_O, 5/^7+[9N&\\1*RVM8Q<5$GJ]O7U"146353PLK 7Y)4NSF:,W;CZQLHG_ M_,M[]*W03U0*<0PU-37%/.":#;F6+U_.B-$X2'!PL*VM;45%TP-H#Q\^!'F( M*LS1&S=NM&K5:L>.'1(W6PK$@X^<+MS1=!%E47R4>A]-]*,\UR(@1Z1,L#1T,Z' U)MH;4B1,GE(8)&AD]@;$D-G"+ M#_HO6[:,D^[BXN+IZ<&IN7KU*A&@T4I5 MS=F0$"PB4%)2 M<&.SL[]E-I9\^>A<)]?7WI99JU9)TK($Y967WGKHF!09G; M=^0IG9#BT]#0Z.QR#C+>S'K"))()*?&,0SU3_O;:)6;7'AY^?'[$*P:T64E94Y.CH&! 1\]MEG_%&-)"$" M$0$-%0T588,>@1[1\L#1D Y'0W*S8GW<'!P<3$ MI+R\G%*F64O6N0+BS J^]E+'A/S[->I-2/T24P*Y?/W3V(DT$U(#W9("@S*9 MW9&CT[U\4LGVH1\>FEG&7K@H9F:& GV($^?DR9/\B2V:6_9^_?JQ(Q)<]8>!H2+>C(3E.2*G$>^^]!_I'1D:R$]>M6P>)UZ]? MYP@K;:RBC.+5418N"2JU5R07#,Q<7%S:M&F3DY/#).[>O1O$YLR9HV'A#-KI MDYJ:FM=??QTJ^NZ[[]CI!FH&QXX=@Q+6KETK5[8X);U6*LG(GX5@'0SEP.>=DA/$_I).1-HT,'PE+UKD"(IPZW32=]-6N MID6%U)N0"OK[%<@5]<\"=F+_ER]:6L=MW'1WSMSK"Q=G[=EWO[R\GI,Q,"BS M9Y\+9)F%VMJG]IW.SIQ]#;8K*AJZNIX+"55H]H8%?8@39_+DR9"%LV*K4@Y_2Z"=XK@6)B8D!R9T[=\*VX*A&\Q"!B("&BH:*L$&/0(]H>>!H2+>C(3E. M2-&3G9UM965E;6W-61=VR) A/7OVY,LK;:RBC.+541:N.:JV5SS7I4N7>O3H M86-C$Q(2LFK5*A@^&1L;O_;::S*93//""WM[5U=7T(5A<*WH9 G\9/UM;VY]^^HD1F#%C!B0>/'B0DW'6 MK%F0_L,//U#*\)&P9)TKH B9K+Y;]W-^H]+)K) :$U*%1;66UG&V=K]75C[W M*#)_4?/V]@D_'W_NNW*G_Z]I+FSYBIST],?OA-V [>24)I=?%I[3P3&AJ/BY M!:<,&LH0)T)A82'^ M]-)+145%4C530E0-/N*C&J5=1%D4!_6\3VGT4W2N^8#]=.G2Q.AG0[&I+CA!0E$%D&#AP(RN_9LX>=?N_>/3(, MX&<1;ZQ(1I'J* O7'#7:*Y(+J*NKV[%C![@6XV8#!@R(B8F1I'!"L_9)FS9M M&,U'CASYVV^_L8\:KAG E1+&S% (7#AAHV_?OAD9&>(?LE6J%:4,PTHO7ZX M 3/+6$OKN+2TQYSL[>T3H 0'I[.[]]Z'E&O7*BW:Q)$GMDI*ZS9LO#O[[6MK MU]]Y\-" O[5'$^+$B8R,-!)ZJ%NI@S#92>T=.G3XYIMO(.6//_XP,S,C/\^6 ME)1$1$3,G#ES]>K5#QX\T+BY$J!J\!$)=Y1=1%,4!S6\CR;Z*3K7?$)#0RTL M+)AO-0J.:C0,$8@X:*AHJ @;] CTB)8'CH9T.QJ2XX04#55552-'CA2<./CB MBR\@/3$QD9]+O+$B&46JHRQ<0]1KKT@N<.EQX\;!H5FS9J6DI("SG3Y]VL/# M U+8CQKIO7K^_>O3LS MD'9T=-RZ=:M@(*;1BD9&'+*RX)0I4\CNM&G38/?(D2,J[]SK?J4OBS-G7NKJ>Z](MT4"?F:(,<>+T M[]\?Y"]C M(3E.2"D%#)2,-,+"POA'X5#'CAW5",&*,HI71UFX)JC77O%<9(6S5UYYA9U8 M5E8&15E86# _U^MMGW!(34V%BIR=G9F4EF$&,(3NV;/GXL6+V[5K!\6&AX>K MH16EYN+8%,PY.'4&AD^$A8LLX5X ,7[)Y]+O3N M=Z'@06UQ21WY^^33NZ86L1\LSX'MB@KEGUV[F/0(Y >Z*?E:+>%FUA,0=G(6 MF&!E./#= S/+V)1G+^ZMB[AC;A5W_4;3H^^Y>=56-O%+EV735*1O4(8X$> & M%TKHUZ\?374^CC'Z4Y[JQL='5U;5'CQX%!07,%Z W;-@ >=]__WW8 MKJBH4$/)ED1]?;W1\R0F)@HF2E4C&BH?-%3)J:]OY+P.?^Y\N6"BKC5%CQ M/4):M.\..!K2I&2UK1HGI,2HJ:F9.'&BT;/G,\EKP&P>/7ID;FZN:+U8D<8J MRBA>'67AFJ!>>Y6J/7_^?*-_+^S'ABP->/+D24T*9]"F=4%T@+I*2DKD+<@, MF+>F__SS3QL;&VMK:W;M-%K1:R[.X\>/H9#6K5N37?++THH5*SAB;FYND'[K MUBU*&3X2EJQS!?CP+]B'Q !B3_\5FN4DEYTXEK &&;EWY7)""3U7?N MFOA.V%_UCO_;I2'#DYFCH\=E>(X0?E!?SZ$)<>* RX#DUJU;::KC. @?F4SF MZ.@8&AI*=L>.'3MX\&#FJ+^_OX>'!TU%6D,\^!!4"G?B741?%+WWT4<_RG/- MGUCAP+PVHG:(,'2@GW]\'K@H"R9*52,:*A\T5,F!TW+X2"'[KZ2T3C!1UYJB M1PB 'B$MVG<'' UI4K+:5HT34@JIK:U]]=570>&9,V<*/OSR_???PU%%R^^) M-%8PH]+J* M7&_7:2Z,VF2[=MFT;)YVX*WG15#_[1!"XV%A86$!=$"GD+<@, MV,OX#1\^'$JNJJJBUTHES<4Y>_8LE-.K5R^RFY:6!KO,9^P)145%IJ:F3DY. M)-;3R/"1L&2=*\#GZ=/&)4NS.7_^8])-+6*]?%)A^] /2E98K*QLL+7[W=(Z MKK"(:G6GQ'/E4'C? 1<5"4"E]IW.,O<-0SU31H_+8(Y.>>-*K[[*7UC30VA" MG B5E95PQV-N;EY86$A3'<=!^"Q:M,C.SHX9A[N[N_O[^S-' P,#NW?O3E.1 MUA )/@PJA3OQ+J(OBM+[Z*,?_;F&" M1T4:R\](4QUEX>JA7GLIU=Z[=R_(P* (Y)G$[.SLUJU;&QL;W[MW3Y/"&9K# MNO+R\B"RJWH-3]Z M]&A$1$1Z>CK9S<_/Y_2P3"8;.G2HT?,O79-% >/BXIB49;@:60XM4M8 M,J78EU]^"0H4%!0TAP(T"*XAM?/K_ T;[Q8\X)IZU#\+0#CH[]PUH8#\^S6U MM<]=:&6R>@_O%/)-/<&JKURI:-4ZCJQK3H"277J<9RY/@X8DC9V0(9A7SZ$) M<7*ALT_8MV\?9)\\>3*_9$H'89.9F0D7?K*N.0%*=G9V9NX#P)Q&CQZM>BLE MAB;XL%$4[M3H(I'(J4:(4"ENBYQKN6(+81!2E$OWL$P JZMBQX]RYAF0)[2\O+R6K5J%80\5U?7>?/FV=C8F)N;,^\9T6A%J3D *2#YU5=?D=W( MR$BPA)"0$"@!;&/ITJ7V]O8@T*-'C]+24B87Q#4S,S/HL2U;MAP[=HQ\K,'% MQ:6LK$PE&4[M$I9,*0;M@D3V%V0D5( &P0FIWOTN0"+GZWB KW\:I/\2(_#" MR]9MN0Y.9T/?N?'IYC^_VI6_+#RG4Y=$$(:B2H4>G&YLE/N-2O?V267_.G+D M:!%D^=_/\^KJ&J/_U33Y!?]5;9$^H#3$$?AGGP"W/D8*WNRC=!"&QL9&'Q\? M3T]/]L]0AP\?ABS;MV^'L!,5%66D'Y_OH0D^E\-*3IA!1XEY$0W;IU4TE& MWP@/#Q?4&9@P80((_/KKK["]=^]>3D:EC17,J+0ZRL*UW%Y*M>7/IGXG3YYL M8F+""("?KURYDCQ0H)]] D 8&C!@ +M88V/CT:-',RYDZ&;P^/'CZ.CH29,F M]>S9T]+2$DY0GSY]@H.#L[*R5-**WA*@]R Q(2&![,+0W=G9F2UO86$Q:]8L M_E? CA\_WJ5+%T8,1MW\5Y&5RG!JE[!D2C'!NQ8)%5 *_8046:'5<0X/ M$[9'CQ6Y]#C/7I&J==OXX)#KBCZ3%_VO G.KN/1T[IS7_/=N0EXX!/]G!5]C MOL1G<(B'.(+@V2>+5CHY.0G^F$;O((2HJ"C0@?FACX'<$!#U9LR8H>%CY)) M$WSD%.&.OHMH(J<:(8(^^HF?:[D&HQJE2B)J@X;*!PWU108]@@]ZA*&#HR&I M2J84DWY"ZH7EW7??!7NE7/)#DHRZ11*UR\O++URX<.;,F8R,#/:CB7K>)Q . M8( ':BDI$ /0S]7 M5U1DB*[F/1(\%!N7G5KU(PBB""T$ M'QHP1"#BH*$B"!OT"*3E@:,AG8 34@B"-)&2DC)QXL1FK>+V[=LQ,3'-6H7> MUHX@B"*T$'QHP!"!B(.&BB!LT".0E@>.AG0"3D@A"((@"((@"((@"((@6@4G MI! $01 $01 $01 $01"M@A-2"((@"((@"((@"((@B%;!"2D$01 $01 $01 $ M01!$J^"$%((@"((@"((@"((@"*)5<$(*01 $01 $01 $01 $T2HX(84@"((@ M"((@"((@"()H%9R00A $01 $01 $01 $0;0*3D@A"((@"((@"((@"((@6@4G MI! $01 $01 $01 $01"M@A-2"((T45E9>?/F35UK@2#("P<&'\0@0$-%$#;H M$4C+ ZU:)T@P(77[]NU#APZM6+%B_OSY^_;MXPM M<^?.34E)T;S>9J6QL1$:M7CQXO'CQ[L_(R@HZ,"! T^?/N4+U]?7+URX,#HZ MFNPJ[1#!C)2]1%^X2JC77I5R46JN/WW"IZBH:,&"!5#+B1,GQ#5722L]:?+% MBQ='C!@A>(A&*[7=/"(B8CZ/E2M7LD M;*^$B 0?.76XNW___NK5JXF/C!T[=OGRY5>O7F6.4O8V'\K(1N.AJEH(HP!4 MZN'A,63(D+?>>BLA(4%03)(0@8B#ABH"&NH+"'J$".@1!@J.AG0R&M)T0LK7 MU]>(Q=2I4SD".W?N)(>LK:W[]NW;KET[V#8V-MZX<:.&53@UUY\^X?/& M&V^06C[\\$,1S5752D^:K"@$TVBEB9N#Y1CQ<'!P8,O(9++!@P=#NK.SLY^? M']@;;"]8L$!5&3X2EJQS!90R]T#$^'].SHF-?\U' MR?N_?%%0@%U4=LZ3-K;Q(_S2MF[+'3(\N5V'W_/OU[ %5GYXJ[U]PL/"6E7; MHF]$1T>;FIK">>G=NS=XJ+V]/3'C&S=N*,KR[;??\BV?L?_&?WWM'1D:"J8"%Y.?GLP7"P\-M;6T?/GS8'&W7')'[/\IP%Q,3T[9M6Q" MX ,A"!K+"=24O*@:%@+LW[_?W-P<:H3:APT;UJI5*]C>NG4K1TRJ M$(&(@X:J"#34%Q/T"$6@1Q@N.!K2R6A(TPFIH* @&*5OWKQYS9HU@A'G\\\_ M?_/--Q,2$AH:&D@*\5(03DI*TK#VYJ.^OG[W[MUW[OSG=_O,S,Q>O7J!VILV M;>((+UJT"*RMH*! 3M$A@ADI>TFEPK707OI<])KK3Y]P.'KT*)3OX^-CI&!" MRG#-X/3ITU"(JZNKF9D9G+X)$R:L7[_^T:-'Y"B-5IJX.81@"PN+XN@^K]\L77;>(Y8:6D=NZB0T.OM[1,J*IJLXF%A M+<@O69K-'+UQ\XF53?SG7]ZC;X5^ E??-FW:@!< U&W(M7[Z<$:-QD.#@8+B/KZAH>@#MX<.'( ]1A3D*]\UP-[QC MQPZ)FRT%XL%'3A?NKEZ]"DV&4?/GV=D*'N; V5D4^JAZED( M7%LMGG'JU"F2DIV=#7T%Y:2FIK(E)0D1B AHJ&BH"!OT"/2(E@>.AG0X&I)L M#:D3)TX(1ASFE+"!>V407K9LF52U:X?#AP\;/7O\AY/NXN+BZ>G)2534(8(9 M5>TEFL(U1Z7V*LU%4*JY?O9)65F9HZ-C0$# 9Y]]IFA"RD#-8.'"A5 (1%XH MQ]G9&2*(EY<77#691Z9IM-+$S4D(%A$H*2F!:X.=G1W[L;NS9\]"X;Z^OO0R MS5JRSA40IZRLOG/7Q,"@S.T[\I1.2/%I:&AT=CD'&6]F/6$2R824>,:AGBE_ M>^T2L^LY(M5_3#JS.VYBAKM',A2NDC)Z"'G(D?.3&MS(@A^)VS8'\",G)R'.B=GU\/#P\_-C=B$:N[FY"3JI;E$:?-B(A+M1HT;!H6/' MCJE4NV!O\V7XB9S(1N.AZEG(QQ]_#+F@E]B),'*#1!CI,2F2A A$!#14-%2$ M#7H$>D3+ T=#.AP-R;4P(27(WKU[03@D)$2JVK7#F3-G0.V @ !VXN7+ER&1 M_S">T@Y1E)%!I)>T,R&E4GO%OJZM@/J=ZZ=8O]2Y=*6JDD(Z<(P0<.'(!R9L^>S4EW<' P,3$I+R^G ME&G6DG6N@#BS@J^]U#$A_WZ->A-2O\240"Y?_S1V(LV$U$"WI,"@3&9WY.AT M+Y^_?AX\],-#,\O8"Q?%S,Q02$Y.YO]>6EM;"U?E]NW;TY=S\N1)_KTOS814 MOW[]V"$7KOK#AP\GVP?WUUT'M[[[[CIV^;MTZ2+Q^_3I'7FF' M*,K((-)+6IB04K6]XKD8Q#77SSZ)B8F!DG?NW G;BB:D#-0,CAT[!B6L7;M6 MKFQQ2GJM5)*1/PO!YN;FGWSRR=MOO[U@P8+=NW=S E9X>#B4 SW/R0BW")!. M1MHT,GPD+%GG"HAPZG33=-)7NYH6%5)O0BKH[U<@5]0_"]B)_5^^:&D=MW'3 MW3ESKR]:<(?-)((EPPF:,V<.?3F3)T^&+)S%7Y4Z"! 0$.#JZDI6 MTP!E[.SLID^?+F_JYXK.G3L'!P>KW[9F0]7@HRC<[=FSA_P675I:NGW[=NAP MB#P'#QZLK^=:(P?!WJ:!$]EH/%0]"WGUU5>->$^YRV0RHV=D9V?3*X"H#1HJ M&BK"!CT"/:+E@:,AW8Z&Y#J9D )7M+*RLK:VUML%5MG,GS\_)"0$PI^#@T/; MMFVW;-G"$1@R9$C/GCWY&95VB**,!/%>:K[)%_7:JS07I>9ZV"=P">G2I8N/ MCP\9["F:D#)0,R#/9WE[>U=75].'8!H7IG=S_C)^MK:V/_WT$R,P8\8,2(3; M%$[&6;-F0?H//_Q *<-'PI)UKH B9++Z;MW/^8U*)[-":DQ(%1;56EK'V=K] M7EGYW*/(_$7-V]LG_'S\N4_/G/Z_IKFPY2MRTM,?OQ-V [:34V20OBP\IX-C M0E'QY^L5K!TZ=*77GJIJ*A(JF9*B*K!1U&X M(W<_86%AG3IU@@U+2TO22X,&#;I__[ZBTA3UME+XD8W20]6P$+BP0@EP>\I. M3$Q,) V,CX]720%$/=!0T5 1-N@1Z!$M#QP-Z78T)-?^A!0X\,"! T%RSYX] M4E7=K+1ITX:QC)$C1_[VVV_LH_?NW2/# 'Y&\0X1R2BGZ*7FFY!2K[WBN2@U MU\\^@=&=A84%\S4-P0DIPS6#QL9&N*Q"(5VZ=(&-OGW[9F1DB'Q&ET8K2AF& MCS[Z"!J2FYL+N>#"#Y=\N-C##0>S]&-04! 4]?///W,RPGT,I$=%15'*\)&P M9)TKH(AWPFZT;AM_X^9?:S^I,2&U=5LN9 E]A_M!F=5K;Y_\I3@WKUHFJ[]\ MN0($S"QC+:WCTM(><[*WMT^ $ARVW27>>U:I46;./+$5DEIW8:-=V>_ M?6WM^CL/'AKPM_;JZNIV[-A!OA!$&#!@0$Q,#'T)D9&11D(/=2MU$"8[J;U# MAP[??/,-I/SQQQ]F9F;DTN7KWZP8,'&C=7 E0-/HK"W;QY M\XR>?<7&S@1[1\L#1D&Y'0W(M3TA5555!E!$9 M@>LA#0T-$(SR\O*BHZ.=G)Q,3$R83RT 7WSQ!30G,3&1GU&\0T0RTO12\TU( MJ==>\5R4FNMAGY"+ROKUZYD4P0DI@S8#N$Q" [MW[\Y<:QT=';=NW2H8B&FT MTMS-RZWRG+HDS9U_KZGJN2[=$ WUF"IQEW+AQ<#IFS9J5DI("]Q.G M3Y_V\/" %)''13GT[]\?Y"].*H5@\8R4O:2=1/0H*"I@/<&[8L %J>?_]]V&;?&1=1'.E6NE5D^$JV[-GS\6+%[=K MUPZ*#0\/5T,K2=P<[DZ,GOVX1';)SVC\GQ?(-#SYG8I&AH^$)>M< 3YPP>[9 MYT+O?A<*'M06E]21OT\^O6MJ$?O!\AS8KJA0_MFUBTF/0'Z@FY*OU1)N9CT! M82=G@0E6A@/?/3"SC$UY]N+>NH@[YE9QUV\T/7B?FU=M91._=%DV347Z!EG$ M\9577F$GEI65@7?#/2C-$TEP>VU$O;PKQT$$V;]_O[&Q<7)R,FRO6;/&Q,2$ M+%0']].M6K6"^V.:BK2&TN C5QSNR/>,!@P8P$F?.7,FI._:M8M?E$J]31") M;#0>JK:%P-7A'__X!QG&P$GT\?$!Y;V\O&#WVK5K] JT2.KKZXV>)S$Q43!1 MJAK14!75BX8J(?7UC9S7X<^=+Q=,U+6FZ!'H$TLZ$E%R5 M]BK*Q4&1YGK8)_S[6@[DF>$68P;,6]-__OFGC8V-M;4UNW8:K:1R\\>/'T,A MK5NW)KODJ;05*U9PQ-S/R_ Q(6NO,L_GBP N Y);MVZEJ8[C('QD,IFCHV-H:"C9'3MV[.#!@YFC M_O[^'AX>-!5I#?'@0U 4[LB P<_/CY.^9,D22(2+P[,G#E3_.$:/0=BBH6% M!30$3 1VO__^>]CF+"[+(-(A@AE5ZB7M3$BIU%Y%N3@HTEP/^P1J7,0#KIU0 MR_#APV&;K-G68LR O8P?-!!*KJJJHM=*0C<_>_8LE-.K5R^RFY:61OJ<+5-4 M5&1J:NKDY$1B/8T,'PE+UKD"?)X^;5RR-)OSYS\FW=0BULLG%;8/_:!DA<7* MR@9;N]\MK>,*BZA6=TH\5PZ%]QUP49$ 5&K?Z2QSWS#4,V7TN/\\EC_EC2N] M^JKP'+[^0'X1VK9M&R>=W)'PWZ7G4%E9"7<\YN;FA86%--5Q'(0/1"<[.SMF M'.[N[N[O[\\<#0P,[-Z].TU%6D,D^# H"G?Y^?G&QL:=.W?FI <$!!@)K:RI M:F\KC6PT'JJAA;#Y]MMOB3(J*8!( AHJC28$--07 ?0(&DT(Z!&& HZ&-"E9 M;:MN]@FINKJZ29,FP:%ITZ8QL\+Z3UY>'I@4)W'UZM70D&'#AI%=:)&5E=63 M)T\$2Q"9+.!G5+67))]\4:^]-+DH-=?#/A&$OX:409M!1D8&Q ZRS83@G)R< MUJU;]^[=FUXK>LV/'CT:$1&1GIY.=N&.A&-",IELZ-"A1L^_=$T6!8R+BV-2 MEBU;QIF#IY'AU"YAR91B7W[Y)2A04%#0' K0(+B&U,ZO\S=LO%OP@.O+4?\L M .&@OW/7A +R[]?4UCYWH97)ZCV\4\@W]02KOG*EHE7K.+*N.0%*=NEQGKD\ M#1J2-':"\+(1>L[>O7OA=+B[NX,C,(G9V=G@1W##?>_>/9+"/_N$??OV0?;) MDR?S2Z9T$#:9F9EPX2?KFA.@9&=G9^8^ ,QI].C1JK=28FB"#QN1<#=AP@0X M]/WWWS,IUZ]?-S,S@P!;7%S,$1;I;3DO1%!&-J4>JK:%<"J]??MVITZ=6K5J MQ;ST0:D HC9HJ&BH"!OT"/2(E@>.AG0^&M)T0NK0H4-3G^'KZPN5=>W:E>PN M6+" "&S MTO+R\EJU:A6$/%=7UWGSYMG8V)B;FS./(M-H1>_FD *27WWU%=F-C(SLT*%# M2$@(E+!SY\ZE2Y?:V]N#0(\>/4I+2YE<$-?@'@5Z;,N6+<>.'2,?:W!Q<2DK M*U-)AE.[A"53BD&[()']?30)%:!!<$*J=[\+D,CY.A[@ZY\&Z;_$"+SPLG5; MKH/3V=!W;GRZ^<^O=N4O"\_IU"41A*&H4J$'IQL;Y7ZCTKU]4MF_CAPY6@19 M_O?SO+JZQNA_-4U^P7]56Z0/5%55D:4B!@\>#&9\Y,B1#1LV@&%#"O/>G%SH M[!/@UL=(P>%",K(IM1#U;:04:-& MO?766] BN,)"DZ&9( #;'+4E#!$(!S14-%2$#7H$>D3+ T=#.A\-:3HA!2-S M(R&Z=>M&!,+#PP4%@ D3)FA8>_,!]C=@P "VML;&QJ-'CV;Z[M=??X7$O7OW M,+VZ+$B MEQ[GV2M2M6X;'QQR7=%G\J+_56!N%9>>SIWSFO_>3<@+A^#_K.!KS)?X#([\ M_/S)DR>#!S'G"&YE5JY MA?S/__P/.PMTD:*71*0*$0@'-%0T5(0->@1Z1,L#1T-2E4PI)OV$5,L&[ #N M[,^<.9.4E/3HT7-?/7_WW7?!7BG?9)8DHQ90K[TBN2C1YSX1IR6906)B(O/6 M=#-16UMK9?7_[)T)7%75UL!!0$ 93)1)47!.#41#X!,(G%\#H7P^_95CB,F3 M3#/%M)PS%3.?E65.O)=FYE1JZ/<*"'%@$!7-":=00)F]@DP7N-_"W3L=SW3W MG>_%]?_QXW?N/FOOO?8^:ZVS][[G[F,[;-@P3GI!00$,2L"$P)!J:FK$LL,L M^L*%"RDI*;=OWU9#1JQVS4M60TQW"NB3@L+:K"Q94G)Y=O:CFAJI-8[,3-F9 M=.'@D'>W)CFE_.8M[L83IDA%1<7ITZ?!DL^=.\?_.;/:4#H(D)&1(?8^[+R\ MO*2D).,JH:%E)>7PV5-3DZ&UFFN *() M:*@2H*$^@Z!'2( >8:+@;,@@LR%+6K5N)B8DZK<)H:T<01 P]!!\:,$0@TJ"A(@@;] BD MY8&S(8. "U((@B (@B (@B (@B"(7L$%*01!$ 1!$ 1!$ 1!$$2OX((4@B ( M@B (@B (@B (HE=P00I!$ 1!$ 1!$ 1!$ 31*[@@A2 (@B (@B (@B (@N@5 M7)!"$ 1!$ 1!$ 1!$ 1!] HN2"$(@B (@B (@B (@B!Z!1>D$ 1!$ 1!$ 1! M$ 1!$+V""U((@B (@B (@B (@B"(7L$%*01!$ 1!$ 1!$ 1!$$2OX((4@B#- M5%557;MVS=!:( CRS('!!S$)T% 1A UZ!-+R0*LV"%I8D+IUZ];>O7L7+EPX M:]:L'3MV<,XV-37!V3ESYHP<.=+W"9&1D;MW[VYL;-2\:KU17%P<&QL+#3QR MY C_K%PNGSU[=D)" ODHW2%B&2]>O+ALV;*(B CH(G]__QDS9F1F9O*ST!>N M"93M5>GB5E=7KUV[-C0TU,?')SP\?/_^_8)5&UN?K%RYPYU]]Y]_K1GTLD MQ+*R9" C]M?8V$3$5JV^PS\J0W;/ !__TE$052[^*.;G-(R,F41D3D#7LP8 M-^'BI4N5G+-550W_$YRU8M5M-9IC;)P_?SXF)B8@(*!___YA86'@#B4E4OT, M#L*W? 8FBE(Z2'IZ.AB&M[[6(1/!14(>[@H*" M)4N6$!\9/GSX@@4++EVZI%Y1'&BNK-*2Z6\E')3Z/J4A(9J#ABH!&NHS"'J$ M!.@1)@K.A@PR&])T02HX.-B,Q?CQXSD"-34UY)2]O7WOWKU=75W)QV'#AL$I M#6O7&^/&C2-J+UZ\F'\V.3D93FW9LD5!T2&"&3=OWDSD[>SL^O3ITZY=.S@V M-S=?O7HU6UZEPC6!LKWT%U7AXA(2$@#P+B(J&YJEH929/%0C"-5I2:"T+3PS3V0V]C.BK9X HH9?P;ERRLD^#OHZ6W M),1V?7>?B/'_W#W2FOY&,H "[J-P;C]LZI@P).;M^0][ P1GM.OR6 M7U#+%OA@\E5Z]>X*'.SL[$C*]>O2J6Y=MO MO^5;/F/_3?_M:!H'R8+C@;,LAL2-,%JN75965E!">GHZ(Z]2X6I#WU[ZBQL='0V),V;, M($O^)24EWM[>D'+X\&&QPHVD3R! 6%M;ESQ-65D97])TS>#X\>-0B)>7EZ6E M)5R^4:-&K5BQXN'#A^0LC5:4F@M"T\,T]D-O8SHJV> *2'/HQV(+ZZ20L&RE M"U*UM8TEI?6@"J[PMGVCBD<,3*RNK9145%7VGOG%I9V6P5 M#XKJ0'[NO%SF[-5KCVWM4S[_\AY]*XP3N/NV;=L6O'COWKTDI:ZN#JX77*.1 M(T>*Y:JMK2WA ?=LR+5@P0)&C,9!IDV;!N/XRLKF!] >/'@ \A!5F+,P_F[= MNO6F39NTW&QM(!U\%'3A[M*E2]!DF-7LV[>/^589$D^=.L464R-R4EY9FI+I M;R5L:'R?TI 034!#E58 #?59 SU"6@'T"%,$9T,&G UI;0^I(T>.T,^-]^_? M;_;D.1IMU:X[RLO+75U=P\/#/_OL,[$%&D]/3W]_?TXB38!O[%+2TM!=]VJ4M:1&3.QDUWE2Y(\6EH:/+P/ D9KUU_S"22!2GIC(/\,__VZGGFH_^0 MK-!AVA# C]S=W:$H]OX%-"'( MU]<71D[,1S\_OY"0$.8C1&,?'Q]!)S4L2H,/&XEP%Q86!J<.'3I$62]]Y%3U MRDJ43'\K85#;]P4-"5$;-%1IT%"?-= CI$&/,$5P-F3 V9#"4 M2O_[Z*PB' MAX=KJW;=,6G2) <'A_S\?+$%F@L7+D Z_V$\I1TBEI%A^_;M(! 5%<4_I;L% M*;7;R\"_N+MW[X:4J5.GIK$?>AO346-HDG3XC96:F0D9& M!O]AJ+JZ.K@KMV_?GKZ/\L?0-"'H^>>?9X=MVG5$8F(BZ+EY\V8X%EN@6;Y\ M.:1?N7*%DZZT0\0R,KSSSCL@$!\?SS^EH\473=I+$+RX<7%QD (%BHV-W;IUJZ [F:@9'#IT"$I8MFR90MGFE/1: MJ22CH.AA&ONAMS$=E6QP!20X=KQY.>FK+_"MF)?5\X M8V.7O'K-G>DSKLR>I\E."'5UC)$17,_5W;JU&G:M&GJMTUGJ!I\Q,+=MFW;('WV[-EE M964;-VZ$#H?(\_WWW\OE7&M46A0?5:^L]*R&YE;"1FW?%S0D1#W04-%0$3;H M$>@1+0^<#1EV-J30YX+4K%FSHJ*BP-E<7%P<'!S6K5NGK:IUA$PFZ]RY/'OSL2CM$+",A-S?7UM;6SLY.Z8L[:=(D M* IN,YQ<4Z9,@?0??OA!NG &_?>)0FB3.4='QQ]__)$C9J)F0)[/"@P,K*FI MH0_!TEK1RQ"4]C"-_=#;&!LMEFQP!<20R>1=NYT,"'FYN;O[JJZ]"7*4LH:BH",8B MX#)5557L=)H0=.S8,4A___WWSYX]2WZ]3W8KF#=OWG///5=<7*RM9FH158./ M6+@CHY^8F!@W-SU=4%"@4E&"J'1EI6J! MAHJ&BK!!CT"/:'G@;,BPLR&%/A>DVK9MRW3Q2R^]],LOOVBK:AT!PWIK:VOF M=0R""S3W[MTCTP!^=ND.D+(VU+]_?Q#8MFV;H( N%E\T::_TQ8V,C(3T MGW[ZB9,+[D.0OG/G3NG""0;I$^###S^$DO/R\D !N+W!C0UN:7#/R,K*8F1, MUPR:FIK@]@R%=.[<&0[Z].ES[MPYZ7?-*M6*4H9!:0_3V ^EC7'08LD&5T", MMV.NMG%(N7KMS[V?U%B06K\A#[)$O\U]6]R29;>._ER2=[=&)I-?N% ) I8V M239VR6?//N)D;^^<"B6XN)_8NKUYE'GYFOG5YV8K; M]Q^8\+OVZNOK-VW:1-X01.C7KU]B8B)]"?'Q\69"#W73A""2G=3>H4.';[[Y M!E)^__UW2TM+\L1K:6GIRI4K)T^>O&3)DOOW[VO<7"V@:O 1"W_(6 M&Q\?GYRKXO9DB(>J"AHJ$B;- C MT"-:'C@;,NQL2*'/!:F&A@:(#G?OWDU(2'!W=V_5JA7S[@,C)"DI"9JS8L4* M)D5P@>:++[Z Q+2T-%X!2CI$(F-U=37$8HEU"J6%JX&&[96^N!,F3(!O5NZ<(6!^D0,LN_=V+%CF123-H.:FAJX[MVZ=6/NV:ZNKNO7 MKQ<,Q#1:T8W\?WO^(N<](:&IK*R^L;&/S[1>8"1]E,GFWGJ?<.J=- MGGJYB]?)SEW33/29*7"6$2-&P.68,F5*9F8FC">.'S_NY^<'*?3/ O?MVQ?D M3Y\^K522'X(($(?+RLH8SP4W'#1H$'R$P4W7KEV=G9TG3IS8J5,G-SIJ*@03-2P(C14-%1]TM34_' Q^Z^B0BZ8:"@-T2/0(_2&WMP!9T,&G TI M#+6I>596%@A[>'AHJW;M @,:+R^O[MV[%Q86,F]>7+5J%>C\WGOOP3%YNS8 M\:YCQXXJA6#IC. /)(;&Q,1(:*C=Q1>MM)>!?W')UR#\Y6&RC,I\7V%4?2(! MW#NA(A<7%R:E99@!W*U[].@Q9\Z<=NW:0;%Q<7%J:$6IN32<'J:Q'TH;XZ#% MD@VN !^X8??H?;K7\Z<+[]>5E-:3OX\_N6-AG?3^@AMP7%FI_+5K9](?@GQ_ M'R5OJR57=K;.U3 MYLW/I:G(V"";.+[\\LOLQ/+R28 QJ1KV]*S\$\=FU:Y>YN7E& M1@8<+UVZM%6K5F2C.AB7MV[=>N[ M#.E;MFRA+XJ/JE=6I9BL]#JJX?LJ&9*I(Y?+S9XF+2U-,%%;-:*A"H*&JEWD M\B;.S^%/GJH03#2TIN@1PJ!':!']NP/.AC0I6>TYBV$6I!1/MEL'^=+24FTI MH$7X QH.Y(G*AP\?6EE9B>T7*]$A8AEK:VM'CQY-RB<;.8FAW94(K;27#>?B MDH>M%BY#1HT=049LV;SL[.W;M-%K1:RX-IX=I[(=&AH\62S:X GSX-VS.'_]7>'Q !B0__2Q/J:2B M^<(U@+#]<[^)"D7\[/W!P!G-VZ(AS_D-$GX$W9F;-FF7V MW]=!L"$;E!X]>E1I"> R(+E^_7J:ZC@.PD^EI;"FB1QL;&=WE T 2%!P\>#,=D MLZX]>_9 BMC.=A(=(IBQKJ[NE5=>@?3)DR=+/X(D7;@::*6]#/R+>_;L65(4 M6ZRXN-C"PL+=W9WXJK'UB00G3IR BGKV[$D^MA@S8&_C!Q<+2JZNKJ;72B7- MI>'T,(W]T,CPT6+)!E> 3V-CT]QYN9R_T&'9%M9) 4%9<+SW!R4[+%95-3@Z M_69CEUQ43+6[4]K)"BB\3[\S8@)0J;/;"6;<,,@_<^B(OQ[+'SON8L\^)OFP M.OE&:,. QT,B+A_Y:>0U55%8QXK*RLBHJ*:*KC. @?"-I.3D[,/-S7US'AYL)[:PI410?5:^L M2C%9Z754U?=5-21$5=!0!4%#?69!CQ $/<*DP=F0)B6K/6?1^8+4W;MWX=IP M$ISUU"-LT_@?LEIH$PF&S1HD!GK)\$F M;0;GSIV#V$&.F1!\X\:--FW:].K5BUXK>LT/'CRX@0&%AH2X4H$%P#ZG-7^>O6GVG\#[7EW?^JQ"$(__.W1,* MR"^HK:M[ZD8KD\G] C/)._4$J[YXL;)UFV2RKSD!2O;L?HJY/7D/3!\^2F#; M".-G^_;M<#E\?7W!$9C$W-Q<\",8<-^[=X^D\*\^8<>.'9!]S)@Q_)(I'81- M3DX.W/C)ON8$*-G#PX,9!X Y#1TZ5/56:AF:X,-&(MR-&C4*3NW9LX=)N7+E MBJ6E)038DI(2OKQ$49P007EEE99,>1W5BP\,$H:$J T:*AHJP@8] CVBY8&S M(8//AC1=D-J[=^_X)P0'!T-E7;IT(1]C8V.)P">??-*Q8\<9,V; P==??[UT MZ5*RJYR-C8T6?]BO!S@+-&!SCHZ.X>'A'#&E'2*8?/F>?/F.3L[0RW=NW8 I(#D5U]]1=G#!&G[H9?AU*[%DBG%H%V0R'XYBQ85H$%P M0:K7\Z#FC'J )/@JZ<'?Y\F62$08]^_;M6[MV MK9.3$PBO6;.&72--49P007EEE99,>1W5BP\,$H:$J T:*AHJP@8] CVBY8&S M(8//AC1=D%J\>+&9$%V[=B4"<"'[]>O'/F5N;CYTZ%")]V4:)YP%FO_\YS_P M?_WU'CUZV-C8M&K5JG?OWM.F M3;M^_;I*6E%J#H!Y0&)J:BIE#S-(V ^]#*=V+99,*2:X)*%%!91"OR!%=BCW M\#S9T"#PA.W!0\6>W4^Q=Z1JXY R+>J*V&OR$OY=:&6;G)W-7?.:]9-_&9'/GY^6/&C $/8JX1#&4^^. #]M>S@E>?;%KI[NXN^&4:O8,0 M=N[<"3HP7_0QD $!46_2I$D:/D:N%6B"CX(ZW&5F9GI[>S-GV[=OOVG3)DZ- M-$7Q0P3-E55:,N5U5#L^*)09$J(V:*AHJ @;] CTB)8'SH:T53*EF/87I"B! M#H4A\J^__IJ>GO[PH?+7AQL___C'/\!>U?BYK]H9#8N$VO07%V9!%RY<2$E) MN7W[-F7AQD!!00'<,J&!T,R:FAKVJ99D!FEI:XFX\88I45%21@A+[_;(*&*@T:ZK,&>H0TZ!&F M",Z&##(;TM."5,LC-#1T[-BQ^LQH6'2JMHGVB:)EF<&I4Z=T'8)34U/-S,S$ M)LRZQK"U(P@BAAZ"#PT8(A!IT% 1A UZ!-+RP-F00< %*01!FLG,S!P]>K1. MJ[AUZU9B8J).JS#:VA$$$4,/P8<&#!&(-&BH",(&/0)I>>!LR"#@@A2"( B" M( B"( B"( BB5W!!"D$0!$$0!$$0!$$0!-$KN""%( B"( B"( B"( B"Z!5< MD$(0!$$0!$$0!$$0!$'T"BY((0B"( B"( B"( B"('H%%Z00!$$0!$$0!$$0 M!$$0O8(+4@B"( B"( B"( B"((A>P04I!$$0!$$0!$$0!$$01*_@@A2"( B" M( B"( B"( BB5W!!"D$0!$$0!$$0!$$0!-$KN""%($@S5555UZY=,[06"((\ M@;0\T*H-@A86I&[=NK5W[]Z%"Q?.FC5KQXX=TL+%Q<6Q ML;$@>>3($.##S[@2\KE\MFS9RW=C M8Z/:FAM5GS 4%!0L6;(D-#34Q\=G^/#A"Q8LN'3IDH3F*FEE)$T^<^;,D"%# M!$_1:$6I.1]*PZNNKEZ[=BVY!.'AX?OW[^<712.C7B[*D@VN@#3%)?6SYUQ_ MY]WK1W\ND1#+RI*!C-A?8V,3$5NU^@[_[.*/;G)*R\B4143F#'@Q8]R$BYE@&-[>WA"$P1DY9V& !8HM7[YJJJ%, I I7Y^?@,'#GSSS3=34U,%Q;02(A!IT% E0$-]!D&/D ]PD3! MV9!!9D.:+D@%!P>;L1@_?KRT_+AQXXCDXL6+-:Q:U_3NW=N,AXN+"U\R.3D9 M3FW9LD6A8HSL^O3ITZY=.S@V-S=?O7HU6U[5WM9U>VMJ:HB8 MO;T]9'=U=24?APT;!J?4T]RH^H20F)CHX. A8,.H(FCHZ.@ 9NZ&8B%8!JM M*#47A,;P9#+9@ $#(-W#PR,D) 3L#8YC8V-5E>&CQ9(-KH!2QK]QR<(Z"?X^ M6GI+0FS7=_>)&/_/W2.MZ<_U*$7?%\X("K"+RKWQN*UCRI"0L^LWY TH%'NKL[$S,^.K5JV)9 MOOWV6[[E,_;?]-^.IG&0W-Q<&QN;P,# ^/AX,!6PD/S\?+9 7%PHZ8MD($(@T:JAAHJ,\FZ!%BH$>8+C@;,LAL2-,%JCHCKU+A>FBO7"[?NG7K[=M_/=V0DY/3LV=/T&W- MFC7L+/2:&U6? )W-Z0^<6EG9;!4/BNI ?NZ\7.;LU6N/;>U3/O_R'GTKC!.X M^[9MVQ:\>._>O22EKJX.KA=$!]VS(M6#! D:,QD&F39L& MX_C*RN8'T!X\> #R$%68LS!NAM'PIDV;M-QL;2 =?!1TX8XF2E/V-@?*R*;4 M0]6S$+BW6C_AV+%C)"4W-Q?Z"LK)RLIB2VHE1" 2H*&BH2)LT"/0(UH>.!LR MX&Q(:WM('3ER1'IN7%Y>[NKJ&AX>_MEGGYG0@A2-I*>GI[^_/R=1:8>P,S*& MRP9F%%#"_/GS^:=H"E<5#=O+L'__?K,G#TD)GE6JN5'U"1 6%@;%'CIT2*FD MB9K![-FSH1"(O%".AX<'1)" @ "X:S*/3--HI:KF;)0:7FEI*=P;G)RRT7BH>A;RT4J:2) MFL'UZ]>AA,# P/KZ>O9#JC=OWF1_TZ625BK)*"@,;_?NW5#.U*E3.>DN+BZM M6K6JJ*B@E-%IR0970)HITRX_US$UOZ!6O06IGQ-+(5=PZ%EV(LV"5'^?](C( M'.;C2T.S X+^_'IP[P\/+&V23I^1,C-3(2,C@_]]:5U='=R5V[=O3U_.T:-' M^6-?FL@,,8H=>!LR+"S M(87>%J02$Q/A[.;-F^'8A!:DK*RL/O[XX[?>>BLV-G;KUJV"_;A\^7)HSI4K M5SCI2A<+Q#(RO//..R 0'Q_//Z6C!2E-VDNHK:U][;770."[[[X3%)#6W-CZ M9-NV;>1;CK*RLHT;-TZ?/AT4@ F>7"ZGU-S(S>#0H4-0PK)ERQ3*-J>DUTHE M&06%X<7%Q4$Y$#+)1M< 0F.'6]>3OIJ2_.F0NHM2$7^ M_2+DVOFO0G9BWQ?.V-@EKUYS9_J,*[/G7-^VHZ"B@NL7$9$Y/7J?)IL\U-4U M.KN=F#SU,AQ75C9T\3H9%2UJ]J8%#$\]/3UAH DC;"81+!DN$ 0-^G+&C!D# M63B;O])$YO#P<"\O+[*;!BCCY.0T<>)$17,_5W;JU&G:M&GJMTUGJ!I\Q,(= M?93F(-C;-' B&XV'JF93&;VA-S<7'H%$+5!0T5#1=B@1Z!' MM#QP-F38V9!"/PM2X(2=.W<."@HBPV436I R>QI'1\/7KP MLRM=+!#+2(" 96MK:V=G)[@-K8X6I-1N[ZQ9LZ*BHN FX>+BXN#@L&[=.K%: MI#4WMCXA?A43$^/FY@8'-C8VI&>\O;T+"@IH-#=R,R#/9P4&!M;4U-"'8&FM MZ&4(2@UOTJ1)D C#%$[&*5.F0/H//_Q *<-'BR4;7 $Q9#)YUVXG0\*RR:J0 M&@M21<5U-G;)CDZ_554]]2@R?U/S]LZI/QU^ZM4SQ_^O>2ULP<(;V=F/WHZY M"L<9F3)(GQ]WHX-K:G')4QM.F33GSY_OWKV[O;T]1,)%BQ:%AX>;FYN_^NJK M/4M^O4]V*Y@W;]YSSSU7 M7%RLK69J$56#CUBXHX_2;,1Z6RG\R$;IH6I8"-Q8H008GK(3T]+22 -34E)4 M4@!1#S14-%2$#7H$>D3+ V=#AIT-*?2S( 7C8VMK:^9]!*:R(/7AAQ]"H_+R M\B#H0#R"2 0Q".(@>T>Z>_?ND6D /[OT8H%$1L63);S^_?N#P+9MVP0%=+'X MHDE[V[9MR_C/2R^]],LOOXC5(J&Y$?;)S)DSS9Z\'\''QRW[#TSX77OU]?6;-FTB;P@B].O7+S$QD;Z$ M^/AX,Z&'NFDB,\E.:N_0H<,WWWP#*;___KNEI25Y,+FTM'3ERI63)T]>LF3) M_?OW-6ZN%E U^(B%.\HHS4&LMZ41C&R4'JJ&A20E)9D]>/'E5) 40]T%#14!$VZ!'H$2T/G T9=C:DT,."%''+%2M6,"FFLB#%AVQX M-G;L6";EBR^^@)2TM#2^L/1B@43&ZNIJB,42ZQ1*"]<6].UM:&B D'WW[MV$ MA 1W=_=6K5HQ+Z3@(*&Y$?8)>9&'A84%>^M$4(;LIPC12JGFQF\&<)L$]^S6 MK1MSKW5U=5V_?KU@(*;1BD9&&H[A39@P 3X>.'" (S9]^G1(W[U[-Z4,'RV6 M;' %!$E.*;>P3EKY\1TF18T%J1<&I$.6,^G*-WN:\U[SF_C^=_Q%3GI#0U-9 M67UCXY^;EX<-S_8+S(2/,IF\6\]3;IW3)D^]W,7K9.>N:2;ZS!0XRX@1(^!R M3)DR)3,S$\83QX\?]_/S@Q2)QT4Y].W;%^1/GSZM5)(?F0D0A\O*RAC/!3<< M-&@0?(3!3=>N79V=G2=.G-BI4R69*I> C%NXHHS0'^MYFERD8V6@\ M5&T+(5\V.CDY14='SYT[E^PQ05YE"X,K>@5:)#"%./8T%145@HD:5H2&BH:J M3YJ:FA\N9O]55,@%$PVE(7H$>H3>T)L[X&S(@+,AA:X7I&!DX.7EU;U[]\+" M0N85AJM6K0+)]]Y[#X[):ZI-!0B:9D_6O)D4B%,=.W94*01+9P1_(+$O)B9& M0A/]+$BIU%Z&K*PLR.7AX2%X5D)S(^P3\J:,?OWZ<=(G3YX,Z5NV;)'67*E6 M1M5DN,OVZ-%CSIPY[=JU@V+CXN+4T(I2^1N-_O4"6X'>\I6WK6R3KUQM?O ^[VZ-K7W* MO/FY-!49&V03QY=??IF=6%Y>#MX-8U":)Y)@>&U&O;TK/S+SV;5KE[FY>49& M!APO7;JT5:M69*,Z&$^W;MT:QLD-I<%'(1[N**,T&Y5ZFR 1V6@\5&T+ M@;O#IY]^2J8Q@5:)'*YW.QITM+2!!.U52,:JEB] M:*A:1"YOXOP<_N2I"L%$0VN*'H$>H7/T[PXX&]*D9+6M6K<+4OR1 0=5G[HT M+(\>/0*=V[1I0SX^?/C0RLI*;+]8B<4"L8RUM;6C1X\FW4+VVQ)#/PM2*K67 M#3@/9"PM+>6?$M/<./N$W(K8+U GP'0.TN%F(Z&Y4JV,KWM[ M.SL[=NTT6M%K+@W'\,@SE0L7+N2(^?CX0/K-FS;F(!,)N_4)>WMF#_K'?FW\P,'9S!GAXXX MYS\D2R2K44,VC" _CF-#]EYEGL^7 %P&)->O7T]3'<=!^,AD,E=7U^CH:/)Q M^/#A P8,8,Z&AH;Z^?G15*0WI(,/02S!:['L:&'4()FJK1C14I3J@H6H.7+K]!XK8?Z5E]8*) MAM84/0(]0N?HWQUP-J1)R6I;M6X7I!H;&]_E =$') ;+T(TC2A6L1E=K+ )'7VMH: M),&1^&?%-#?./LG/SS[:U&#-@;^,'[@DE5U=7TVNE MDN;2< SO[-FS)&*P98J+BRTL+-S=W4FLIY'AH\62#:X G\;&IKGSW$\RX M89!_YM 1?SV6/W;[NOK&QH:RIR-B(CHUJT;345Z0R+X,(B%.YHHS4;5 MWE8:V6@\5$,+8?/MM]\29512 -$*:*@TFA#04)\%T"-H-"&@1Y@*.!O2I&2U MK5H?FYIS,(D]I"!0@DFQ4V0RV:!!@\Q8OP6=,&&"K:WMX\>/!4N0Z!!^QOKZ M^M=??QWDX12S=BZ!UA=?U&OOW;MW.;F )4N60*X77WQ1)* M7O.#!P^N7+DR.SN;?*0Q/(!L"IB7=_ZK$(0C_\[=$PK(+ZBMJWOJ1BN3R?T" M,\D[]02KOGBQLG6;9+*O.0%*]NQ^BKD]>0],'SY*>-L((V?[]NUP.7Q]?<$1 MF,3EO!"Q&4D4VIAZIM(9Q*;]VZY>;F MUKIU:^9''Y0*(&J#AHJ&BK!!CT"/:'G@;,C@LR%-%Z3V[MT[_@G!P<%069=Z\><[.SJ!V]^[=R\K*%$]L MSM'1,3P\G)-1:8<(9H1:S)[L[1<9&3G^:3[YY!/ZPO7<7M"M8\>.,V;,@(.O MO_YZZ=*E9*L_&QL;SJX-TIH;9Y\0X.9A;V]O964%[K1OW[ZU:]4HK("!@T:)%$/*\O+QFSIQ)VLL\BDRC%:7F *2 Y%=??44^ M*C4\ L0U&*- CZU;M^[0H4/D90V>GI[EY>4JR7!JUV+)E&+0+DADOQ]-BPK0 M(+@@U>OYTY#(>3L>$!QZ%M)_3A3XPBW[[ZR=H_OMJ2/S_NAEOG M-!"&HLJ$'IQN:E*$A&4'!F6QOQTY<+ 8LOSS\[OU]4T)_VY>_(+_JK;(&*BN MKB9;10P8, #,^,"! ZM6K0+#AA3F=W,*H:M/@*&/F/&C1!V=N[<:68?/--:!'<8:')T$P0@&..VEH,$0@'-%0T5(0->@1Z1,L#9T,&GPUI MNB"U>/%B,R&Z=NTJEL4D%J0@Z'AX>+!;9&UM/67*_[-W)G!55=T"9Q10$!,% M05&<30U$0^ I!LY? Z*\/GWE1(A)FMHSQ:&<,Q53GY5E3GQ?6IF:9::^$@AQ M8%31', I%%! P"O(=)'[%NS>Z7BFN^^]YTZX_C]^_.[99^V]USYGK;6'>^X^ M4YB7$_WZZZ^0N'/G3DY&M1=$,&-,3(Q@+F#4J%'TA1NXO>"E??KT8>>RM+0< M.G0H?\8EK;EI7A.&M+0T;V]OIN36K5MOV;)%XK+0:&4B37[TZ%%<7-R8,6.Z M=>MF;V]O9675LV?/B(B([.QLC;2BU!P \X#$I*0D*%"/K(IM9#M;.0__JO_V)G@4LD]B,1N4($P@$- M%0T588,>@1[1],#9D%PE4XK)OR#5M,G/SX=8>>+$"1C?5U55L4^]\\X[8*^4 MOV26):,!T*Z]X"T@#[E24E(>/E3_;G@^IGQ-&')RP>Z$FI(9)"AYV;FPL1S#1'NG(%'\$H38]$B*"!QD.UL)#2 MTE*XK0D)"= ZW15 = $-50(TU&<0] @)T"/,%)P-&64VA M26A(<'#QNW#A# M9C0N>E7;3*^)JFF9P>G3I_4=@I.2DBPL+,0FS/K&N+4C""*& 8(/#1@B$&G0 M4!&$#7H$TO3 V9!1P 4I!$$:2$M+&SUZM%ZKN'GSYM&C1_5:AEI?&ST!>N'1JUM[Z^'I29.W?NR)$C?1L)#P_?NW?ODR=/^"575E:N M6[>.E!P:&GK@P %!!4SJFD!U?--EX#33W,W@[-FS@P8-$CQ%HQ6EYGPHXP.- M_5#:F/Y*-KH"TA05U\Z>F_WNG.PCOQ1+B*6G*T!&[._)DWHBMGK-;?[9)1_> MX)26FJ8("\_J]V+JZQ,N7KI4SCE;45'W'T'I*U??TJ(YIL;Y\^>CHZ,# @+Z M]NT;$A("[E!<+'6=*<,+I8.DI*2 87A[>T,0!F?DG(4!%BBV8L4*&=LK(Q+! M1T4=[F@Z+^TB)\V=U=] 2*WO:]1/(;J ABH!&NHS"'J$!.@19@K.AHPR&])U M02HH*,B"Q?CQX_DR/7OVM.#AYN:F8]4&X.C1HRU;M@1M6[5JU:M7+V=G9_B\ M9,D2CEA"0@*D;]NV345W0?@9MV[=2N0='1VA(J@./EM:6JY9LX8MKU'A!FAO M5545T<3)R0GNO'YSR]/0<,F0(R,/G6;-FF?@U M^?KKK_FFRQAP?7V]H.:::F4B318+P31:46HN"$U\H+$?>AO34\E&5T MX]^X M9&T7#W\?+KLI(;;GFWM$C/_GX9G,6'WO%\X*"K"+RKG^N(5SXJ A&1LVYO8? MF-JJS>]Y^=5L@45+;K1V3;I?6*-I6TR-N+@X:VMKN"\]>O0 #W5U=25F?/7J M5;$LE.&%QD%RT# P-C8V/!5,!"\O+RV (Q,3$0S^_?OZ^/MNN.Q/B/ M,MS1=%[:14Z:.ZN_@1"-[VO43R&Z@(8J!AKJLPEZA!CH$>8+SH:,,AO2=4$J M/#S\]==?7[=NW;)ERR22C:Z -(=^++*VBQ\2DJEV0:JZ M^DGQ@UK.W^RYV9!QX>*_'X#J_<+9YBT3.6(E);7LHB*CKK1V32HO;["*^X4U M(/_>O!SF[-5KCQV<$C_]_"Y]*TP3Z'U;M&@!7KQOWSZ24E-3 _<+[M'(D2/% M7G# VCW[]\'>8@JS%D8?S=KUFS+EBTR-UL.I(./BB[< M479>6D1.RCNKOX$0C>]KU$\AVH&&*JT &NJS!GJ$M +H$>8(SH:,.!N2;0^I MGW_^6=J9Y:K(8(2$A$"+#ATZI%;2R\O+W]^?DRAQ0?@9&<-E S,**&'^_/G\ M4S2%:XJ.[64X<." 1>-#4DS*@PT M\O#P@(KX/S V4S.8/7LV% *1%\KQ]/2$"!(0$ "].//(-(U6FFK.1FU\H+$? MC6Q,'R4;70%I2DN5[3LFAX5G;=YR1^V"%)^ZNGI/KU.0\5KV8R:1+$A)9QS@ MG_:/5\\SA_Z#TH.'93*'(T:?\_5+A<(U4L8$(0\Y*'I M0'U]?6'DQ!SZ^?D-&3*$.81H[./C(^BDQD5M\&$C$>[H.R^U17'0],[*.Q#2 MVOO0G.>??UZMY(4+ M%T"2_S">VK@IEI%AY\Z=(! 9&57:[<@]SCSYR5,C-S(34UE?\P5$U-#?3* MK5NWIB]',+S0=* 0NMDA%WK]@0,'DL_???<=C*CX#[H:'4V#CUBXH^^\U!;% M1],[*^] 2&O?%^NG$"U 0U4+&NHS!7J$6M CS Z<#1EW-J0RV(*4K:WM1Q]] M]-9;;\V:-6O[]NV4DR@CLF/'#FC.[-FS2TI*-F_>/&W:M'???1=&]DJEDB.Y M8L4*D+QRY0HG76W<%,O( #6"0&QL+/^4[(LONK>74%U=_=IKKX' -]]\PR3& MQ,1 RJ9-FSC"T%5 .GNF9%+71)"Q8\="+?R-#\W4# X=.@0E+%^^7*5NUITZ_,GIN]8U=^61DW7(2%9W7K>8;LA%!3\\35_>3DJ9?AO(!AKI>75XL6+6"$S22")<,-@EA*7XY@>*'I0$-#0SMW[DRV MG !E7%Q<)DZ/B(C0OFUZ0]/@(Q;NZ#LOM47QT?3.RCL0TMKW MQ?HI1 O04-%0$3;H$>@130^<#1EW-J0RV(*4Q=,X.SO_^../(A(L7+PX-#;6TM'SUU5<5"@5E"6+AA:8#/7;L&*2___[[&1D9Y-?[ M9+>">?/F/??<EIZ?+5;OL MS)@QPZ)Q8WP?'Y^LK(:?G$!\# L+@\277GJ)$;M[]RZ9!O!+D(Z;$AE5C;]S M[MNW+PCLV+%#4$#VQ1<=V]NB10O&?T#^M]]^8Y\-#P^'])]^^HF3"_HA2-^] M>[=TX03#7Q,^L;&Q%D)/79JO&=37UT/W#(5TZ- !/O3JU>O?ERA5V+ M!/+$UH.2VM5K;D]]Z_+RE;?NW3?C=^W5UM9NV;*%O"&(T*=/GZ-'C]*7(!9> M*#M0R$YJ;].FS5=??04I?_SQAXV-S=:M6U6-O^I?M6K5Y,F3ERY=>N_>/9V; M*P.:!A^Q<$?9>=$4)8A&=U;>@9!VOB]F2(AVH*&BH2)LT"/0(YH>.!LR[FQ( M99@%*3YDY[!QX\;)5;OLD-<<6%M;LS>6JZRL)+O-@9F2E,\^^PP.DY.3^25( M7Q")C% +Q&*)=0JUA6N!CNVMJZN#T'_GSIVXN#C(8F5EQ;S8 I@P80+D.GCP M("?7M&G3('WOWKW2A:N,=$WX].[=&ZHX<^8,)]VLS:"JJFKERI5=NG1A^NQV M[=IMV+!!,!#3:$4C(PTG/M#8#Z6-<9"Q9*,K($A"8JFU7?RJCVXS*5HL2+W0 M+P6RG$U1O]G3W/]N>!/??XZ_R$FOJZLO*:E]\N2OS/'C_OY^4$*YW%1 M"<3""Q^Q#A3B<$E)">.YX(8#!@R 0QC<=.K4R=75=>+$B>W;MW=W=S>19Z8T M"CYBX8ZR\Z(IBH^F=U;>@9!VOD]O2.8.3"&./4U969E@HHX5H:&BH1J2^OJ& MAXO9?V5E2L%$8VF('H$>83 ,Y@XX&S+B;$AEK 4IB#X@[.;F)E?MLO/AAQ]: M-*ZF<](G3YX,Z=NV;2.'$._:MFVK40B6S@C^0&)H='2TA'JR+[[HWEZ&]/1T MR.+IZ;.G=NJ52LH M-B8F1@NM*#67AA,?:.R'TL8XR%BRT17@ QUVMYYG>CQ_IN!>3?O+WT<>W MK>WBWU]P'3Z7EZM_[=K9E(<@W]='S=MJ"=>R'X.PAZ? BO#WF_NV=C'IS7^ M<&_%JENV#@E7KC8\G9Y[I\K!*7'>_!R:BDP-LHGCRR^_S$XL+2T%[[:SLZ-Y M(DDBO/"AZ4#W[-EC:6F9FIH*GY;-FS=Y[[SV:B@R&VN"C M$@]WE)T735%\-+VS\@Z$M/!]C0S)W%$JE19/DYR<+)@H5XUHJ(*@HLQAG0>K1HT<@W+QY<[EJEQT2 MR]AOSB; .![2/_GD$_C\\.%#6UM;L?UB)2Z(6,;JZNK1HT=;-#ZQ2;:G%4/V MQ1?=V\L&G =R/7CP@!QNVK0)#A.'%%;@EAX$41M!ZI0*-JU:Q<5%44. MAP\?WJ]?/^9L<'"PGY\?344&0SKX$,3"'4WG15D4'TWOK+P#(2U\7R-#,G? M2/8_#8PZ!!/EJA$-51 T5'D!FSIPL)#]]Z"D5C#1V)JB1PB#'B$CAG<'G WI M4K+6VWW\)G ML9WM)"Z(8,::FII77GD%TB=/GBS]"))TX=JA>WL9E$JEG9T=2((CD92,C PX M9%Y#3B@J*K*VMO;P\""^:H+7A$U%106$)%M;V\+"0LZI)F,&[&W\X&9!R965 ME?1:::2Y-)SX0&,_-#)\9"S9Z KP>?*D_KUY.9R_X&&9UG;Q 8/3X?.^[]7L ML%A14>?L\KN]8T)A$=7N3LFGRJ#P7GW.B@E I:[N)YEQPP#_M*$C_GXL?]SK M%[OW,LN'U)#5AP@3X_/CQ8\'L$M&-G[&VMG;,F#$@#Z?JZM3_ MCD8?BR]:M/?.G3NM!K1:_Y#S_\L&K5JLS, M3')(&1_4V@^E#*=V&4NF%/O\\\]!@8*" GTH0(/@'E);O\Q;O>9VP3VN+^_^ M5P$(A_^3NR<4D)=?75/S5$>K4"C] M/(._4$J[YXL;Q9\P2RKSD!2O;J>IKI MGKS[IPP?);!MA.FS<^=.N!V^OK[@"$QB3DX.^!$,N._>O4M2^'>?(!%>M.A ML[*RH.,G^YH3H&1/3T]F' #F-'3H4,U;*3,TP8>-1+A3VWG1%\4)$91W5FW) ME/=1N_C (&%(B-:@H:*A(FS0(] CFAXX&S+Z;$C7!:E]^_:-;R0H* @JZ]BQ M(SF<-6L6$8B-C6W3IDUD9.2:-6NV;MTZ;]X\5U=7D.S:M6M)28F.M>N5RYJ&FW.V=DY-#24DTOM!1',"!?'HG%O MO_#P\/%/\_'''],7;N#V@FYMV[:=/GTZ?/CRRR^7+5M&M@RTM[?G[-H =@E] M#)2P?OWZ0X<.D9T[ M=YXQ8P8Q Z:Q-%I1:@Y "DA^\<47Y) R/DC;#[T,IW892Z84@W9!(OOE+#(J M0(/@@E2/Y\] (N?M>$!0< :D_W)4X -20D,W!P.OO;D8,_%$&6__GT3FUM?=R_&Q:_X+^F+3(% M*BLKNW?O#C>E7[]^8,8'#QY%%IWH'6U]O=N"XN6,!H F^*CHPIUTYZ5149P007EGY1H( M:1@1Z1-,#9T-&GPWINB"U9,D2"R$Z=>I$!" *>'IZ MLD_9V=E-F3+%1-[R(TU:6IJWMS>C>>O6K;=LV4)._?KKKY"R<^=.3A:U%T0P M8TQ,C& N8-2H4?2%&[B]X*5]^O1A:V)I:3ETZ%#!EZ$>/GRX0X<.C"3,FIB? MDIKR-5']_ZYR'AX>_-5N#1X\>Q<7%C1DSIENW;O;V]E965CU[]HR(B,C. MSM9(*TK- 3 /2$Q*2B*']/%!PG[H93BURU@RI9C@DH2,"JB%?D&*[%#NZ76J MKD[@"=L?#A5Y=3W-WI&J>Q-PC&,HL6K2(_?6LX-V7""\JS3O0W;MW@P[,%WT, M9$! U)LT:9*.CY'+ DWP45&'.XG.2Z.B^"&"YL[*-1#2.CZHU!D2HC5HJ&BH M"!OT"/2(I@?.AN0JF5),_@4I2O+S\R'HG#AQ @;*5555AJE4+G)RY&T^8(V5E96?. MG %+/G?N'/_GS%I#WX&FIJ:*O30Z-S<7 KMVZYCZ1J[@(]AYT2,1(F2YLUH/ MA$S0]Y]-T%"E04-]UD"/D 8]PAS!V9!19D,&6I!J>@0'!X\;-\Z0&8V+7M4V MTVNB:EIFK=?3H4;U68;*U(P@BA@&"#PT8(A!I MT% 1A UZ!-+TP-F04< %*01!$ 1!$ 1!$ 1!$,2@X((4@B (@B (@B (@B ( M8E!P00I!$ 1!$ 1!$ 1!$ 0Q*+@@A2 (@B (@B (@B (@A@47)!"$ 1!$ 1! M$ 1!$ 1!# HN2"$(@B (@B (@B (@B &!1>D$ 1!$ 1!$ 1!$ 1!$(.""U(( M@B (@B (@B (@B"(0<$%*01!$ 1!$ 1!$ 1!$,2@X((4@B (@B (@B (@B ( M8E!P00I!D 8J*BJN7;MF;"T0!'GFP."#F 5HJ C"!CT":7J@51L%&1:D;MZ\ MN6_?OH4+%\Z<.7/7KEUB8OGY^4N7+@T.#O;Q\1D^?/B"!0LN7;JD>^UZ(BTM M;:8X3YX\80LKE+%YKH" M9,3^GCRI)V*KU]SFGUWRX0U.::EIBK#PK'XOIKX^X>*E2^6WMX0A,$9.6=A@ 6*K5BQ0L;VRHA$\%') M-,;0J(]C0QG9:#Q44PMA%(!*_?S\^O?O_^:;;R8E)0F*R1(B$&G04"5 0WT& M08^0 #W"3,'9D%%F0[HN2 4%!5FP&#]^O*#8T:-'6[9L"0*M6K7JU:N7L[,S M?%ZR9(F.M>N/K[_^VD($-S>W^OIZMG!"0@*D;]NV345]03@9MV[=2N0='1WA M^L!5@L^6EI9KUJQARVM4N ':6U55162O2JFN:9:F4B3Q4(PC5:4F@L"EB-H=6P9 MA4+1KU\_2/?T]!PR9 C8&WR>-6N6IC)\9"S9Z JH9?P;EZSMXN'OPV4W)<3V M?'./B/'_/#R3F6#0^X6S@@+LHG*N/V[AG#AH2,:&C;G]!Z:V:O-[7GXU6V#1 MDANM79/N%]9HVA93@SY0,%!&71H'RW#PP,C(V-!5,!"\G+RV,+Q,3$ M0+=[__Y]?;1==R3&?W*-,33JXQ@H(QN-AVIA(<">/7ML;6VA1JC]Q1=?;-:L M&7S>L&$#1TRN$(%(@X8J!AKJLPEZA!CH$>8+SH:,,AO2=4$J/#S\]==?7[=N MW;)ER\0BSJ5+E^SL["#B[-^_GUG,AL33IT_K6+O^J*ZN+N8!5Q/:N&#! H[P MG#ESP-H*"@I4=!>$G_'33S]]XXTWDI*2ZNKJR"D2RZ"$E)041EZCP@W07J52 MN7W[]ENW_GZZ(2LKJWOW[I!K[=JU["STFIO.-5$U.E6+%BU GWW[]I&4FIJ: MZ=.G0T4C1XX4TUQ3K8S>Y./'CT,AG3MWMK&Q@=LW:M2HE2M7/GSXD)RET8I2 M24D)6R8J*@J*@BM/ @@(>'M[0\KAPX=O]MQLR+AP\=\/0/5^X6SSEHD#G/VZK7'#DZ)GWY^E[X5IHE&@8*!,NK2.$A$1 2, MX\O+&QY NW__/LA#5&'.PK@91L-;MFR1N=ER(!U\5/*-,33JXQ@H(YM:#]7. M0J!OM6ODV+%C)"4G)P>N%923GI[.EI0E1" 2H*&BH2)LT"/0(YH>.!LRXFQ( MMCVD?O[Y9[&($Q(2 J<.'3HD5UU& 6S+P\,#&L+_9:F7EY>_OS\G4>*"\#,R MALL&9A10POSY\_FG: K7$4W;RW#@P &+QH>D!,^JU=RDK@EY=HFS4@[]$W0J M$#4XPF9J!K-GSX9"(/)".9Z>GA!! @("H(',(],T6FFJ.1L2@B4$'CQX 'V# MBXL+^[&[DR=/0N%!04'T,GHMV>@*2%-:JFS?,3DL/&OSECMJ%Z3XU-75>WJ= M@HS7LA\SB61!2CKC /^T?[QZGCGT'Y0>/"R3.1PQ^IRO7RH4KI$R)HA&@4(" MP:BKUD$ 7U]?&#DQAWY^?D.&#&$.(1K[^/@(.JEQ41M\V,@^QI#HX]@R_$1. M9*/Q4.TLY,,//X1<<)78B3!S@T28Z3$ILH0(1 (T5#14A UZ!'I$TP-G0T:< M#:D,L"!U_?IU2'_^^>?EJLA8'#ERA!^5@ L7+D Z_V$\M8L%8AD9=N[<"0*1 MD9'\4P98D-*TO0PG3IP @=#04,&STIJ;VC5)34WE?PU24U,#SM:Z=6MVHIF: M079V-I00&!A86UO+?DCUQHT;[&^Z--)*(QD510C>NW4E&S>O'G:M&GO MOOLN#)&52J5<51N&L6/'0D/XV_*M6+$"TJ]%I[5K><9LLE#33 MDZ=>AL_EY74=.Y^*C!(U>_."/E!((QAUU3H($!H:VKES9[*;!BCCXN(R<>)$ M5<-U+F_?OGU$1(3V;=,;F@8?V<<88GV<6CB1C<9#M;.05UYYQ8+WE+M"H;!H M)"@130^<#1EW-J0RP((4T2PZ.MK=W1T^V-O;$X?T M]O;.S\^7JW9]4UA8"%;BZ.A845'!.=6_?_]NW;KQLZA=+!#+2(" Y>#@ #4* M;D.K[P4I3=L[<^;,R,A(Z"3S4Y=20D$RR*J3% M@E1A48V]8X*SR^\5%4\]BLS?U+RU:])/AY]Z]9'W.]3;NDHN*G-IPR:R@#A01B45>M@P#'CAV#]/???S\C(X/\>I_L M5C!OWKSGGGNNJ*A(KF;*B*;!1]XQAD0?)PT_LE%ZJ!86 ATKE ##4W9BY=, _A9I!<+)#*J&M?1^_;M"P([ M=NP0%-#W@I2F[6W1H@7C/W!;?_OM-[&2)30WS6M26UN[9 M/4JIN8F;07U]/72K4$B'#AW@0Z]>O3%@M2&S;F0I:HM[DOE%FZ_.:17XIS[U0I%,H+%\I!P,8^WMXQ(2/C M$2=[:]7K[QU[[X9OVN/ M)E!((Q9UU3H(DYW4WJ9-FZ^^^@I2_OCC#QL;FZU;MZH:?]6_:M6JR9,G+UVZ M]-Z]>SHW5P8T#3[RCC'$KK8T@I&-TD.UL)#X^'B+QI?L,.],A+%R<' PR7[D MR!&-%$"T PT5#15A@QZ!'M'TP-F0<6=#*@,L2)%7(5A;6[,WGZNLK"0[TL'] MEDL!O=*[=V_0]LR9,YSTSS[[#-*3DY/Y6:07"R0RPL6!6"RQ3J&V<-W1M+UU M=740LN_/,@1FS9M&J3OW;N74H:/C"4;70%!$A)+K>WB5WUTFTG18D'JA7XI MD.5LBOK-GN;^=\.;^/YS_$5.>EU=?4E)[9,G?VU>'C(\TR\P#0X5"F67[J?= M.R1/GGJY8^=3'3HEF^DS4Y2!0AJQJ,N'XR ,$(=+2DH8SP4W'#!@ !S"X*93 MITZNKJX3)TYLW[Z]N[N[B3PSI5'PD7>,07^UV64*1C8:#]7:0LB7C2XN+E%1 M4>^]]Q[98X*\RA;F//0*-$E@"G'L:[.]_/++[,32TE+0$[H6YD&#IF$&T,MVZ]9M[MRYK5JU@F)C8F*TT(I2 M7J7[MV-N4AR/?U4?.V6L*U[,<@[.$IL,#*L/>; M>S;V\6F-/]Q;L>J6K4/"E:L-#][GWJER<$J<-S^'IB)3@S)02" 1=?EP'$20 M/7OV6%I:IJ:FPN=ERY9965F1C>I@/-VL63,8']-49##4!A^5K&,,C:XV02*R MT7BHUA8"O<,GGWQ"IC%P$P@1ZA=PSO#C@;TJ5DK:U:[PM2Q)G9 MKZ FP( 8TL%=Y5) ?T1&1H*J&S9LX*0_?/C0UM96;+]8B<4"L8S5U=6C1X^V M:'P8E6Q/*X9>%Z2T:R\;>??SHY.3DZ.K)KI]&*7G-I'CUZ!(4T;]Z<'&[:M D.%RY?4M]]^"TW@;"[+(+%8()@18A9Y+\/DR9.E'T&2+EQ'M&XO M T1>.SL[D 1'XI\5T]PTKPE9Z-VX<2,GG00:\A/9)F,&[&W\!@X<""575E;2 M:Z61YM*O3LYS,C(@$/F-?:$HJ(B:VMK#P\/$NMI9/C(6++1%>#S MY$G]>_-R.'_!PS*M[>(#!J?#YWW?J]EAL:*BSMGE=WO'A,(BJMV=DD^50>&] M^IP5$X!*7=U/,N.& ?YI0T?\_5C^N-'/K1NW?O"FI.J94I-/G@U_^&''U:M6I69F4D.843",2&%0C%@P "+IW]T338%3$A(8%+FSY_/ M68.GD>'4+F/)E&*??_XY*%!04* /!6@0W$-JZY=YJ]?<+KC']>7=_RH X?!_ M$ O+RJVMJGNIH%0JE7V :>:>>8-47+Y8W:YY ]C4G0,E>74\SW9-W_Y3A MH\QC5T$.-(%")73W"1)1E])!V&1E94''3_8U)T#)GIZ>S#@ S&GHT*&:MU)F M:((/&[G&&!)76\4+$9213:V':FTAG$IOWKSI[N[>K%DSYDN!LR.BS(5T7I/;MVS>^D:"@(*BL8\>.Y'#6K%F,#+B?DY.3K:TM M*+1___YUZ]:YN+B \-JU:W6LW0" 45H(/98)-N?L[!P:&LI)5WM!!#.N6;/& MHG%OO_#P\/%/\_'''],7;N#V@FYMV[:=/GTZ?/CRRR^7+5M&MOJSM[?G[-H@ MK;G)7I/*RDKR"_!^_?IMW;KUX,&#JU>O;M.F#:20G\.8NQF0I[0" @(6+UX, M(:]SY\XS9LP@WLK8 (U6E)H#D *27WSQ!3F,C8V%ZQD9&0DEP!6>-V^>JZLK M"'3MVK6DI(3)!7$-QBAPQ=:O7W_HT"'RL@8O+Z_2TE*-9#BURU@RI1BT"Q+9 M[T>340$:!!>D>CQ_!A(Y;\<#@H(S(/V7HP(_>-FP,=?-XV34VU<_7O?G%]OR MYL=<=^^0#,)05(G0@]/U]:HA(9F!@]/9WXX<_*$(LOS/IW=J:^OC_MVP^ 7_ M-6V1*: V4!#X=Y\@%G55U ["4%]?/WCP8']_?_;74 <.'( LFS=OAK"S>_=N M"]-X?0]-\%'I88PA<;55O!!!&=G4>JC6%A(2$O+FFV]"BZ"'A29#,_^/O3,! MJZKJ&C_S(" FAH*B.)L:."'P*03.;P.B?+U6CH18I#E\IFB^.6>9E/VM+'/B M?=74U"PS]2N!$ <&4=$<0-%00 $!KR"SW&_![G\ZGNGN>^ZY [A^#P_//?NL MO??:^ZRU]MG[GKL/",!GCMH*A@B$ QHJ&BK"!CT"/:+Y@;,AH\^&=%V06K)D MB9D0G3IU8HNEIJ9Z>7DQ9UNW;KUAPP8=JS8 9#LQ=W=W_C+GK[_^"J>V;MW* M2=?8(8(9HZ.C!7,!HT>/IB_/GP8&QL[=NS8;MVZV=G903-[]NP9'AZ> MF9FIE5:4F@-@'I"8F)A(#F%T]_#P8,O;VMI.G3J5_Q:P0X<.=>C0@1??_ MI\@:93BU*U@RI9C@DH2""FB$?D&*[%#NX7FRKD[@"=L?#A9Z=CW%WI&J1(NFIM M'(2P??MVT('YHH^!W! 0]29/GJSC8^2*0!-\U$K?8TCWMIH7(N@CFT8/E6D3S V=#2I5,*:;\@I169&5EQ<7! MM.J\)-A-+2 MTM.G3T,;SYT[QWZHLCF905)2$O.K:3T!76=O;S]\^'!.>EY>'MR40/>"(556 M5HIEAUGTA0L7$A(2;MZ\*4-&K';=2Y8AIC\%#$E>?E5:FBHNOB0]_6%EI=0: M1VJJZDRR<'#(N5T9GU!R(YN[\4131"Q0Z BE@P I*2EB[\/.RU6ZB?:)N7F9PZM0I?8?@Q,1$,S,SL0FS MOC%N[0B"B&& X$,#A@A$&C14!&&#'H$T/W V9!1P00I!D 924U/'C!FCURJR ML[./'#FBURI,MG8$0<0P0/"A 4,$(@T:*H*P08] FA\X&S(*N""%( B"( B" M( B"( B"&!1_-&M6_D;"P ML%V[=@E>5DK-3:U/B!I0M8^/SX ! R9.G)B8F*A1+%'+&*BHJU:]<&!05Y>WN'A(3LW[^?7Q2-C+Q &I[245%5H M6$:_02FOOG;QTJ4RSMGR\KK_"DA;N?JFC.:8&I3QDX%R<*1TD.3D9# ,+R\O M",+@C)RS<(,%BJU8L4+!]BJ(1/!14X>[O+R\I4N7$A\9,6+$PH4++UVZQ)R5 M?2M"&=EH/%1;"V$4H!F % D1B#1HJ!*@H3Z%H$=(@![11,'9D%%F0[HN2 4$ M!)BQF#!A D=@QXX=9B*T;=NVOKY>1P7T1VQLK*6E)>C9HTK5 MJQS)^/AX.+5ITR8U18<(9MRX<2.1=W1T[-6K5ZM6K>"SN;GYFC5KV/):%6Z M]E965A)-G)R<>O;LV:Y=.W(X?/AP."5/0;6V;3$UZ.,G ^7@ M2.,@65E9=G9V_O[^Z]:M U,!"\G-S64+1$='.SL[W[MW3Q]MUQV)^S_*<'?D MR)&6+5N" 0?"$'06/B\9,D21D#>K0AE9*/Q4!D6HJ8>@)0*$8@T:*ABH*$^ MG:!'B($>T73!V9!19D.Z+DB%A86]^NJK:]>N7;9LF6#$J:JJ*N(!:H'PPH4+ M=:Q=?T!O.C@X@ WMW;N7I%175\^8,0/4'C5J%$=XSIPY()F?GZ^FZ!#!C%]\ M\<4;;[R1F)A85U='3I%8!B4D)R;-OY]NR,C(Z-Z] M.^3Z^../V5GH-3>=/@&@:;:-'#UZE*3 Q*]SY\Z@85I:FICFVFIE]"8?.W8, M"H%V65E9P>4;/7KTRI4K'SQX0,[2:$6IN2 0@J&'.2&BN+B8+1,9&0E%@4&2 M;\- P,O+"U(.'3JDE0P?!4LVN@+2'/RQT-(V+C X7>."5%75XZ+[-9R_V7,S M(>.B]_]^ *KW\V=:M$S@B!47U["+BHB\TMHUL:RLP2KN%52#_+SY6 MV3LE?/'5'?I6F"9:Q4\&RL&1QD'"P\/A/KZLK.$!M'OW[H$\1!7F+-PWP]WP MA@T;%&ZV$D@''S5=N+MTZ1(T&68U^_;M8[XPA\13ITXQ,O)N12@CFT8/E6@1[1_,#9D!%G0XKM(?7SSS]3SHWA(KF[NX.P*?]$ MDSRTPEDBA< $T03,A2/LZ>GIZ^O+2:3I$"8C8[AL8$8!)2Q8L(!_BKZW*=&] MO0S[]^\W:WQ(2O"L1LU-IT^ #S[X ,JPLZJ7'1&'S82(2[X.!@.'7PX$&M:J>Y%:&);#0>*L]" M* <@14($(@$:*AHJP@8] CVB^8&S(2/.AM1&69 Z?/@PW[U-C924%/[Z=W5U M-?1RZ]:MV8D7+EP 2?[#>!H[1"PCP]:M6T$@(B*"?TKQQ1?=V\MP_/AQ$ @) M"1$\*ZVY2?4)$!H:"F7"*,).+"@H@$0'!P=VW&FB9I"9F0DE^/O[U]34L!]2 MO7'C!ON;+JVTTDI&31&"=^W:!>5,FS:-D]ZV;5L+"XO2TE)*&;V6;'0%I)D: M?OF99Q-S\ZKD+4C]&''[[YYINS9LT"J^,$K.CH:"AG_?KUG(QPBP#I9*9-(\-'P9*-KH $ M1X\U+"=]O:EA4R%Y"U)A_[P(N;;_.Y^=V/OY,W:.\6L^OC5]QI79_;4UG*MD8/L6Q%.9*/Q4'D60CD Z1XB$ G04-%0 M$3;H$>@1S0^<#1EW-J0V_()404$!=+>CHV-Y>;E25>N)\^?/=^W:UAUS_+W]Z^LK*0/P=):TF+# MJ28-9?R40&QPU.@@P-&C1R']O??>.WOV+/GU/MFM8/[\^<\\\TQA8:%2S500 M;8./6+@C=S]145%N;F[PP<[.CO22EY=77EZ>6&FR;T7XD8W20V58".4 I&.( M0*1!0T5#1=B@1Z!'-#]P-F3,[#IA75D&H"@H*(BT]?/BP1LU-W SJZ^MA M6(5".G3H !]Z]>IU[MPYB=?HTFA%*VG"7>?ERN:U#/'EBZWYQS>HUMZ:]>7GYRIMW[S7A=^W1Q$]IQ 9'C0[" M9">UMVG3YMMOOX64/_[XP\K*:N/&C>K&7_6O6K5JRI0I2YO7N#V.G3IY6J5T^ %8X<.1)4 MG3IU:FIJ*MC'L6/'?'Q\((7]^,^77WX)*4E)2?P2I#M$(F-%107$8HEU"HV% MRT#']M;5U4'(OGW[=FQLK+N[NX6%!?-""GK-3:U/"&2MU\7%)3(R>0G MON1-@C#D:-3<],T ALF5*U=VZ=*%&6O;M6L7$Q,C&(AIM**1D8;L+#A^_'AR M^-IKK\'A@0,'.&+3IT^']%V[=E'*\%&P9*,K($A\0HFE;=RJ#V\Q*3(6I)[O MEPQ9SB1KWNQI[O\TO(GOOR=F=(J^(B%._*Z)4M+2_8&MQ"%R*ZW<$\I6+6, M6Q&QR$;CH;(MA&8 TB5$-&E@"G'T24I+2P43=:P(#14-U9#4US<\7,S^*RVM M%4PTEH;H$>@1!L-@[H"S(2/.AM0&7I"""&(F:P<[PT,VY7KQQ1?9B24E)<\^ M^RS$%.8;9HA3D*)5");."/Y 8E]45)2$>HHOONC>7H:TM#0HRL/#0UO-3:U/ M"*#/IY]^2D81"PN+H4.'@AG[^?G!X>7+EZ4UUZB523491MENW;K-G3NW5:M6 M4&QT=+0,K2@UEP;N3LP:OUPBA^1K-/[7"V09GGQ/12/#1\&2C:X 'QBPN_4\ MW>.YT_EWJXONUY"_#S^Z96D;]]["Z_"YK$SS:]?.)#\ ^;[>&MY62[B6^0B$ MW3T$%E@9=GUWU\HN+K7QAWLK5MVTMH^_=FR91"[R$9U<#]M8V,#]\?G\"=/E0HF&EM3] CT"+UC>'? V9 N)D'[CQ@U*&3X*EFQT!?CP!VS.'_]7>'Q !B0_79^C45+=<.'J0-CIF=_% M!%2JVO8=D]Z*^JO>4?\X/V!P"G-VV,ASOD/21+*:-#3Q4QJM!D>.@_!1J53M MVK6+C(PDAR-&C.C7KQ]S-B@HR,?'AZ8B@R$=? ABX8Y,& (# SGI\^;-@W28 M$O"KT_961#JRT7BH[A8B-@!1*M L@6NQ[TG@KD,P4:D:T5 UZH"&JCMPZ?8? M*&#_W2^N$4PTMJ;H$>@1>L?P[H"S(5U*EFW5AEN0*B\OAXL*,_""@@*E*M4? M9(7OL\\^XZ03"R._C=R]>S=\YFPNRR#1(8(9(6:1]S),F3)%^A$DZ<+EH7M[ M&2#RVMK:@B0X$KWF)M@G8NS8L8.H1 Z;C1FPM_$;/'@PE%Q144&OE5::2W/B MQ DHIWOW[N3P[-FS<,B\QIY06%AH:6GI[NY.8CV-#!\%2S:Z GP>/ZZ?-S^+ M\QT$<]\PT#=UV,B_'\L?_^K%[KU,_=?<@M#$3PFT'1PY#L)GSIPY+BXNS#R\ M?__^04%!S-G0T- N7;K05&0P)((/@UBXR\W--3/CXYF4!0L6<-;@:60X MM2M8,J785U]]!0KDY^?K0P$:!/>0VOA-[NHUM_+O'LQ] )C3L&'#M&^EPM $'S82 MX6[TZ-%P:O?NW4S*E2M7K*RL(, 6%15QA*5O13@A@C*R:?10V1:B<0"B5 "1 M#1HJ&BK"!CT"/:+Y@;,AH\^&=%V0VKMW[X1& @("H+*.'3N2PUFS9G$DX>J: MT3W?: I45%20G_[VZ]=OX\:-!PX<6+UZ=9LV;2"%_ X";,[9V3DD)(2346.' M"&9/>?F%A81.>Y*.//J(OW,#M!=V>??;9&3-FP(=OOOEFV;)E9*L_ M.SL[SJX-TIJ;9I\0@H.#)TZ0U[ESY[???AO::&UMS;@JC5:4F@.0 I)??_TU.5RW;AV8641$!)0 AC=_ M_GQ75U<0Z-JU:W%Q,9,+XAKV:FOK8 M_S0L?L%_;5MD"FB,GP3^U2=(#(Z4#L)07U\_=.A07U]?]M=0^_?OARR??_XY MA)WMV[>;F<;K>VB"CYHNW,$M/LD(-SW[]NV#<.WBX@+"'W_\,;]>Z5L13HB@ MC&P:/52VA4@/0/0*(+)!0T5#1=B@1Z!'-#]P-F3TV9"N"U)+EBPQ$Z)3ITYL M,;(OE[N[.\US'R9";F[NN''C+"PLF$:!:2Y>O)@LD__ZZZ^0LG7K5DXNC1TB MF#$Z.EHP%S!Z]&CZP@W<7O#2/GWZL#4Q-S[&=TF[H9/'SX,#8V=NS8L=VZ=;.SLX.60@/#P\,S,S.UTHI2;'E;6]NI4Z?RWP)VZ-"A#ATZ,&(PZ^;_%%FC#*=V!4NF%!-< MDE!0 8W0+TB1'Y,F3=7R,7!%H@H^:.MREIJ9Z>7DQ9UNW;KUAPP9^I1IO13@A@CZR:?10 M>18B/0!II0 B#S14-%2$#7H$>D3S V=#2I5,*:;\@E2SI[2T]/3IT\>/'S]W M[AS[:;IWWGD'[%7&?EBR,QH&&>T%;X'Y#V1)3DY^\$#SN^'YF'B?E)24I*2D MQ,?'9V5Q7P'6G,P@*2F)^=6TG@"+LK>W'SY\."<]+R\/;DK A,"0*BLKQ;+# M+/K"A0L)"0DW;]Z4(2-6N^XERQ#3GP*&)"^_*BU-%1=?DI[^L+)2:HTC-55U M)EDX..3/-V1&XZ)7M9MHGZB;EQF<.G5*WR$X,3'1S,Q,;,*L;XQ;.X(@ M8A@@^-" (0*1!@T50=B@1R#-#YP-&05?NW:-6-K@2#(4P<&'Z1)@(:* M(&S0(Y#F!UJU45!@02H[.WOOWKV+%BV:.7/FMFW;!&7.GS\?%17EY^?7MV_? MX.#@Y*,&3-\?'P&#!@P<>+$Q,1$0;':VMK9LV?'QL:2 M0YH.X6>$NJ!;0D-#^_?O[^OK"_6FIJ;RL] 7+@-MVUM?7P_*S)T[=]2H4?T; M"0L+V[5KU^/'C_FY*BHJUJY=&Q04Y.WM'1(2LG__?NG"U0;L$YH29.BOE7I& M-X8S9\X,&3)$\!2-/I0Z\UFU:M5,'HL7+^:(T?0_Y3727\E&5T":PJ*:V7,S MWYV3>?@7J?";EJ8"&;&_QX_KB=CJ-;?X9Y=\<(-36DJJ*C0LH]^@E%=?NWCI M4AGG;'EYW7\%I*UVM+2$LSUZ] !Y5U=7^-RV;=NK5Z_J6+M>V;ESI[6UM;FY>:]>O08-&F1C M8P.?8V)B^)+Q\?'0HDV;-JGI.H2?<>/&C43>T=$1JFO5JA5\ANK6K%G#EM>J M< .TM[*RDFCBY.34LV?/=NW:D;WW+PJML#B)3=:NR;>*ZC6MBVFAHQA;L>.'7S+9^R__O]W-(V# M9&5EV=G9^?O[KUNW#DP%+"0W-YSL?._>/7VT77;*TI1,H08 MZ!%-%YP-&64VI.N"5%A8V*NOOKIV[=IERY8).C.HY>#@ !=C[]Z])*6ZNGK& MC!D@/&K4*!UKUQ\W;]ZT;>3HT:,D!>[X.W?N# U)2TOC",^9,P?2\_/SU10= M(ICQBR^^>..--Q(3$^OJZL@ILCP$)20G)S/R6A5N@/;6UM9NWKP9\C*G,C(R MNG?O#KI]_/''["R1D9&0"->=+/D7%15Y>7E!RJ%#A\0*-UB?T)0@0W]MU3.B M,1P[=@RRP^6VLK*"RS=Z].B5*U<^>/" G*71AU)G02 $@^$5/4EQ<3%;AJ;_ MZ:^1GDHVN@+2'/RQT-(V+C X7>."5%75XZ+[-9R_V7,S(>.B]_]^ *KW\V=: MM$S@B!47U["+BHB\TMHUL:RLP2KN%52#_+SY6V3LE?/'5'?I6F";R MAKFJJJHB'C!F0ZZ%"Q#O?Q964-#Z#=NW,&?A_MO&QF;# MA@T*-UL)I(./FB[07;IT"9H,LYI]^_8QWRI#XJE3I]AB,F(FY96E*9GF.O*A M\7U*0T)T 0U56@$TU*<-] AI!= CFB(X&S+B;$BQ/:1^_OEG06"##T#MV;-GLQ,A8D(B!"^.L*>GIZ^O+R=1K$,$,S*&RP9F M%%#"@@4+^*=H"M<*W=O+L'__?K/&AZ28E/OW[X-ON[BXL!^;.G'B!(@%! 2( M%6[X/A$K09[^VJIGK(;#18?L$'FA! \/#X@@?GY^X)[,(],T^FBK,QL2@B4$ M:/I?JVNDCY*-KH T)26U[3LFA89E?+[AML8%*3YU=?4>GB1@VS?%S0D1#9HJ-*@H3YMH$=(@Q[1%,'9D!%G0VH#+$BEI*3P MOR6NKJX&=5NW;JU4[8H3&AH*:N_;MX^=6%!0 (D.#@YL@[MPX0(D\A_&TQ@W MQ3(R;-VZ%00B(B+XIQ1?D-*]O0S'CQ\'@9"0$"9EUZY=D#)MVC2.9-NV;2TL M+$I+2^D+UVN?B)6@B/[2ZAFKX9F9F9#7W]^_IJ:&_9#JC1LWV-]T::6/5C)J MBA!,T__TUTA/)1M= 6FFAE]^YMG$W+PJ>0M2OQRY#[D"@LZR$VD6I/IZ)X>& M93"'+PQ+]QOZUQ.7>[^_9V47=_J,E)DU%90:Y@X?/LR_AZ:Y&W[NN>?8(1=& M_<&#!Y//>_;L@3LJSA?.IH"VP4665G-;)]7]"0 M$'F@H6H$#?6I CU"(^@130Z<#1EW-J0VP((4^+^GIZ>#@P.$'B9Q\^;-(#Q] M^G2E:E>>04$OOON.R8Q.CH:4M:O7\\1AJ$"TMDS)>/V MB5@)BN@OK9ZQ&G[PX$'(NWSY$ZNK'KFXGIDR[#)_+RNHZ M=CX9$2EJ\$T+I8:Y<>/&01;.OJH:'00("0GIW+DSV7("E'%Q<9DT:9*ZH9_+ MVK=O'QX>+K]M>D/;X",6Z+9LV6+6^'AO<7'QYY]_#AT.D6?/GCVUM5QKU%@4 M'VVOK/2L1N-UY"#;]P4-"9$'&BH:*L(&/0(]HOF!LR'CSH;4$SB^YJ!KUZY.3DX1$1'OO_\^W#J;FYN__/++*I5*J=H59^;,F= < M, MV8E)2$EF@24A(8!('#!C0K5LW?@D:XZ981D)65I:]O;VCHZ/@-K2*+TCI MV%[(#A<7(FG;MFU;MFSYR2>?L,].GCP9"H%AAI-KZM2ID/[]]]]+%\Z@[SX1 M*T$1_:75,U;#R9-9_O[^E965]"%86A]Z&0)_&S]G9^V'"J2:/[,%=04 #W M(N RY>7E['2-#@(7FY@8?[.SL2"]Y>7GEY>5I590@6EU9Z5F-QNO(09[OBQD2(@\T M5#14A UZ!'I$\P-G0\:=#:D-LR!54U.S8<,&\NH$0I\^?8X<.:)4U?H@+B[. MK'%S>^9=16"C04%!1/_#AP^3Q#MW[I!I +\$Z;@ID5'=^&A2W[Y]06#+EBV" M HHO2.G87@<'!^;BOO#""[_]]AO[;%A8&*3_]--/G%PP#D'Z]NW;I0LG&*!/ MQ$I01'\)]8S8\/KZ>AB>(7N'#AW@0Z]>OX:8!1F=E-GZ;_*:\1!P5+-KH"8KP5=;5%RX2KU_[:^TG&@E3, M9SF0)?*MJYSTIW-R\M7WKQ[KPF_:T_W86[=NG5F0@]U M:W00)CNIO4V;-M]^^RVD_/'''U965ALW;E0W_JI_U:I54Z9,6;ITZ=V[=W5N MK@)H&WS$ MW;;[]MUO@6&V]O[XR,AM^'PF2&_ @=!B.MBA)$JRLK43+E=60C MS_?%# F1!QHJ&BK"!CT"/:+Y@;,AX\Z&U 98D(++.7+D2#@U=>K4U-14Z.AC MQX[Y^/A "N/_+:3O$(N+BZ.R'SYY9=PF)24Q,\N M'3-6?7B+29&Q M(/5\OV3(]KJZ^N+CF\>._-B\/'I'NXY\*ARI5 M;9?NI]PZ)$V9=KECYY,=.B4UT6>F%!GF>O?N#?*G3Y_6*,EQ$ :(P\7%Q8SG M@AL.'#@0#N'FIE.G3JZNKI,F36K?OKV;FYN)/#.E5? 1"W3DG426EI;L76 A M"I&M8>&>DKXH/MI>6:VBL=AU9)#G^_2&U-2!*<31)RDM+15,U+$B-%0T5$-2 M7]_P<#'[K[2T5C#16!JB1Z!'& R#N0/.AHPX&U(;8$&*[&[UXHLOLA-+2DJ> M??996UM;$_FJ5A PP4\__92LR%A86 P=.A3"A)^?'QQ>OGR9R$"\@X9H%8*E M,X(_D!@:%14EH9L^%J1T;"]#6EH:9/'P\&!2R-<@_.5ALHS*?%]A]#Z1_AI' MMOX:U3-ZPPDP6G?KUFWNW+FM6K6" J.CHV7H0ZFS-'!W8M;XO!XYI.E_RFO$ M0<&2C:X 'QBPN_4\W>.YT_EWJXONUY"_#S^Z96D;]]["Z_"YK$SS:]?.)#\ M^;[>&MY62[B6^0B$W3V$UV0)N[Z[:V47E]KXP[T5JVY:V\=?N=KP='K.[4I[ MIX3Y"[(D\IHLN@]S$&S-J+=WY3B((#MW[C0W-T])28'/RY8M@Y!.MJB#^W(; M&YMY\^;15&0P- 8?M7B@(Z^([=.G#R=]RI0ID+YITR;ZHOAH>V6UBL8:KZ,, MW]?*D)HZM;6U9D^2E)0DF*A4C6BH@J"A*DMM;3WGY_ G3Y4*)AI;4_0(8= C M%,3P[H"S(5U*ECUGT?N"%-FW9]XZ M]^#! VMK:[']8B6BFUA&*'_,F#%FC4]LDNUIQ=#'@A2#O/:R >[?OT\. MUZ]?#X>+%BWBB'E[>T/ZC1LW) HW9)^(E:"+_AH+-X6&$YA?3?_YYY].3DZ. MCH[L>FGTH==9FH1PQ(@1_?KU8\X&!07Y^/C05&0P MI(,/0?I+K\# 0$[ZO'GS(/W33S_E5TT_4,#^NU]<(YAH;$W1(X1!CU 0P[L#SH9T*5GV MG$7O"U)DJ>RSSS[CI)-+Q?^1H2FS8\<.T'G*E"GD=0?E2S^")%VX@FC57H;:VEI;6UN0!$($E-.]>W=R2-/_ M-#)\%"S9Z KP>?RX?M[\+,Y?T/!T2]LXOZ%I\'GO]QIV6"POKW-V^=W.,;Z@ MD&IWIZ23I5!XKSYGQ 2@4E>W$\Q]PT#?U&$C_WXL?_RK%[OW:I(/J^LXS)67 ME\,=C[6U=4%! 4UU' ?A,V?.'!<7%V8>WK]__Z"@(.9L:&AHERY=:"HR&!+! MAT$LT.7FYIJ;F[=OWYZ3'A(28B:TLZ9$47RTO;):16.-UU%;W]?6D!!M04,5 M! WUJ04]0A#TB"8-SH9T*5GVG$7O"U);MVZ%=+@AKJGY>_$R*RNK18L6$(GN MW+FCE **0QX+8LC.SG9S<[.QL6%^O_;::Z_9V]L_>O1(,+M$=.-GA,X9.W8L MR,,I3KW:%BX;&>V]??LV.!ZGG*5+EX)N@P8-8B>23=WBX^.9E 4+%K#74$VA M3R1*D*$_9>'&;?BY<^<@=I#/3 B^?OTZN&>/'CWH]:'7^8CHY MA#L2C@FI5*J! P>:/?FC:XW]3RG#J5W!DBG%OOKJ*U @/S]?'PK0(+B'U,9O MON95_E^O+V_^=#\)A_^3N"07DYE555S\QT*I4M3[^J>2=>H)57[Q89M,B MGNQK3H"2/;N>8H8GKP')(T8+;!MA^E .<_RK3]BV;1MD'S=N'+]D2@=ADY&1 M 0,_V=>< "5[>'@P]P%@3L.&#=.^E0I#$WS82 2ZT:-'PZG=NWN7+&R MLH+06E14Q)>7*(H3(K2]@9&8>M%<1WGQ@4'"D!#9H*&BH2)LT"/0(YH?.!LR M^FQ(UP6IO7OW3F@D(" *NO8L2,YG#5K%A&HJ*@@VQ+UZ]=OX\:-!PX<6+UZ M=9LV;2"%^4&!:1(<'#QQXL2U:]=^\\TWT!PG)R?0&3Z3LV!SSL[.(2$AG%P: M.T0PXYHU:\P:]_8+"_L_]LX%KHIJ:^" (B"@)@J"HJCX* U\$?"I!+YO#T+Y MNEJI2(A)FNDUQ.,V;,@ \@N7SY)C0:9-A/H]SDSD#NS_+S\UNR9 FDO.[=N\^<.1-.O;6U-7-+,XT]E#8# M4 *2GW[Z*?D:$Q,#V2 B(@(T0'Z8/W^^L[,S"/3LV;.DI(2R_>EE.'M743.E M&!P7%+)?SJ*B 30(3DCU?C(5"CEOQP.&!YZ&\N\/"SSP$OM1OHO;\<@W+GVP M[I=/MQ0LB+[BVB4%A$%5B="-T_7UVH"@+/]AF>Q?1PY\?1>J_-_'-VMJZN/^ MW3#Y!?^E'E%3@/(RQS_[!.CZ6.AXLH\R0!CJZ^N'#1OFZ^O+_AEJ__[]4&7C MQHV0<';LV&%!\7)&(T"3?+1TB2XG)X=4A$[/OGW[X"KFY.0$PFO7KF7OD485 M)T50GEF]FBG/H[S\P"#B2(ALT%'141$V&!$8$N5&/EZ(TG[]^K$ML;2T'#%BA.#+4 \>/-BE M2Q=&$D9-S*.DIFT32@U2[:=1;G)G>/#@05Q3IZ6EK:PL. .<]/#P\ M-S=7DCV4-@/@'E"8G)Q,OD(OP=W=G2UO8V,3%A;&?PN82/O3RW#VKJ)F2C'! M*0D5#= +_8046:'-$79W ';9?Q]_UZ'F2O2)5ZS9)X1$7=;TF+^[?MZSM M$K.RN'->L]ZZ#'5A$_P/"\]AWL1G=M!S8L0-L M8'[H8R = F+>E"E3%-Y&K@HTR4=+G>@R,C*\O+R8K>W;M]^T:1-GCS2J^"F" MYLSJU4QY'F7G!ZT^1T)D@XZ*CHJPP8C B&A^X&A(+XRX\88X8Z#)'&2 )'!=+XW.S\]/ M2$B0-X]I:-1*/G#E@F.$5I+W,,NHMKUZX=/GS8H+MHLGM'$$071D@^-&"*0,1!1T40-A@12/,#1T,F 2>D M$ 1!$ 1!$ 1!$ 1!$*."$U((@B (@B (@B (@B"(4<$)*01!$ 1!$ 1!$ 1! M$,2HX(04@B (@B (@B (@B (8E1P0@I!$ 1!$ 1!$ 1!$ 0Q*C@AA2 (@B ( M@B (@B (@A@5G)!"$ 1!$ 1!$ 1!$ 1!C I.2"$(@B (@B (@B (@B!&!2>D M$ 1!$ 1!$ 1!$ 1!$*."$U((@B (@B (@B (@B"(4<$)*01!&JBHJ+A\^;*I MK4 0Y$\')A_$+$!'11 V&!%(\P.]VB2H,"%U[=JUO7OW+EJT:-:L69]__KF@ MS/GSYV?,F.'CXS-HT*#77GLM.3E9^7Y5@<;XAP\?KENW+C PT-O;.S@X>/_^ M_8)BM;6U<^;,B8N+DZ2<4Q$::L6*%2$A(0,'#O3U]85&R\C(D&>V,8^WOKX> MU,Z=.W?,F#$#&PD-#=VU:]>C1X_D62ZC3>B5RZLHPW+9%0WM!H*<.G5JZ-"A M@IMH[*$_31Q6KUX]B\?BQ8LY8C1N2>FZAM-L<@/$N5M<,V=N[EMOYQ[ZOEA$ M+#-3 S*Z_AX]JB=B[ZVYP=^Z]-VK'&WI&9J0T.P!0])?GG3^PH5RSM:*BKK_ M&9ZYZKWK,@ZGJ7'V[-FHJ"@_/[_^_?L'!05!.!07B[4S! C?\QF8Y$D9(&EI M:> 87EY>D'LA&#E;H8,%AJU2CI4YTA86%RY8M(S$R:M2HA0L7 M7KAP@=E*V=I\*#,;381*]1#& )KNDRHI A$''54$=-0_(1@1(F!$F"DX&C+) M:$CIA-3PX<,M6$R<.)$OLW/G3FMK:TM+R[Y]^PX9,J15JU;P.38V5N&NE4-C MO$:C&3!@ &QU=WKL./Q445K$%%B^]VMXY^4Y1M=1C:6K$Q<6U:-$"SDOOWKTA-IV=G8D;7[IT M25>5+[[X@N_YC/_7_]'0- &2EY=G:VOK[^\?$Q,#K@(>4E!0P!:(CHYNV[;M MG3MW#''LRA'I_U$FNL.'#[=ITP8$(/E "H*#A<]+ERYE!"A;FP-E9J.)4!D> MHJ7N/JF5(A!QT%%U@8[ZYP0C0A<8$>8+CH9,,AI2.B$5&AKZ\LLOKUNW;OGR MY8(9Y_KUZS:-'#ERA)1 U[E[]^YP>C(S,Q7N72%ZC07%Y0.:?BQQ]__.JKKR8G)]?5U9%-)*-!];2T M-$EF&_EX:VMKMV[="N>:V9J=G=VK5R^HN';M6AF62VT30S>+#,L-?&LC1T[=M6J5??OWR=;:>RA/TU\( 5#?BA^G)*2$K8,C5O2 MNZZ!-)O< ''BO[G;PB8A("A+[X145=6CXGLUG+\Y_?N)275U=5PON MJJJJ8AYPS89:"Q7E#3>@W;ES!^0AGS!;H=\,O>%-FS:I?-AJ()Y\M'2)[L*%"W#(,*K9MV\? M\X,Y%)X\>9*1H6QM#I2936^$RO,0^NZ3*BD"$0$=%1T588,1@1'1_,#1D E' M0ZJM(?7==]\)9IQWWWT7RN?,F<,NA-0#A9"JU-J[0G09?^_>/7!*)RF5\RLR[LL&QA50?<&"!3(TZ\*@Q\NP?_]^B\:; MI&18+KM-:)3K@J8BO>6R*QK-#0@0FU =,B]H<'=WAPSBY^<'5TWFEFD:>V2< M)@:2@D4$:-Q2DNL:0K/)#1"GM+2V<]>4D-#LC9MNZIV0XE-75^_N<0(J7L[] MC2DD$U+B%0?[9OSEA;/,5]^AF8$CLYBOH\>=&>B3#LHE&=,$(;0AE]TF5%(&(@(Z*CHJPP8C MB&A^X&C(A*,AK1$FI$)"0J E=UT":36Z .&'A.4]T3"XHK)(W(?7]X7M0:WC@:78AS814?^^TD-!L MYNNS([+\AOW^\^#>K^ZTM$U(/27F9N9">GHZ__?2ZNIJN"JW;]^>7L^A0X?X M?5^:":DGGWR2G6GAJO_,,\^0SWOV[($>%?L'YR:"U.2C*]%=N7(%RJ$%I!H@ MV-HT<#(;383*\Q#*[I,J*0+1!3HJ.BK"!B,"(Z+Y@:,ATXZ&M$:8D'K^^>+=I:30:BT;R\O*T30!=QD='1T/YA@T;..60FZ")%>N=Z* MA+?>>@L$8F)BI&H6P:#'2ZBJJGKQQ1=!9O?NW5(M5](F>I6+H'Q"RKS< (B/ MCX>Z*U:LT.I;G)+>'DDRVL84;&UM_?[[[[_^^NNS9\_>NG4K)V'1N"6]ZQI( ML\D-$.'(T8;II$^W-"PJ)&]"*O2OYZ'6CG_=8A<^]?0I6X?$-6MO3)]Q<<[< MW&V?%Y:5U7(JAH1F>_9))8L\5%<_$!'4WH83.%X,EP@J9/GTZO9_SX\5"%L_BKW@ !@H.#NW?O3E;3 &.'A\L_-H,A-?GH2G3;MFVS:/PMNJ2D9./&C=#@D'GV[-E3 M6\OU1@Z"K4T#)[/11*@\#Z'L/BE/$8@(Z*CHJ @;C B,B.8'CH9,.QK2&F%" M:M:L65 .[GI*4ZZVH;7SJV,[.SL'!07 Q6M5G7I0?+YSNB(@(N%JXN+BT:=-F_?KU MD@P05TX0;Q.]RD50/B%E7FZ@_>/.+']__\K*2OH4K/<44,H0^,OXM6W;]IMO MOF$$:-R2WG79J*C9Y ;H0J.I[=;C1$!0%ID5DC$A572WVM8AL:W33Q45C]W0 MRE_4O+US\K<''WOUS-'_-,R%+5QT)2OKP1M1E^!S>H8&RA=$7^G0*?EN\6,+ M3IDU9\^>[=FSIZ.C(R3 )4N6! <'6UI:OO#""] 'I=105%0$?1$(F8J*"G:Y MW@ !CAPY N7OO//.Z=.GR=/[9+6"^?/G/_'$$W?OWE7K,%5$:O(1_QTE*BK* MU=45/MC:VI)6\O+R*BPLU*5-5VOKA9_9*"-4AH=0=I\4I@A$''14=%2$#48$ M1D3S T=#IAT-:8TP(960DN$H\\](?.-F!@8&DK0\=.J26 4K097QH:"B4 M?_OMMYQR2*!0OF/'#O+UUU]_)8,!2WM MF4!Z]MEG?_SQ1ZF6*VP3<>7B*)R0,CLW .KKZ^&R"M6[=.D"'_KV[7OFS!F1 MU^C2V$,IP_#WO_\=#B$_/Q]JP84?+OEPL8<.![/T(XU;4KHN!Q4UF]P 7;P1 M=:EUFZ1+EW]?^TG&A%3L1_E0)?(-[@MEEJVX=NC[XOR;E1I-[;ESY2#0TC;! MUB'Q].D'G.KMG9-!@XO;\:W;&WJ9.3D5-O:)Y(ZM>R4U[ZVY,>WUG!6KKM^^ M8\;OVJNIJ=FT:1-Y0Q"A7[]^AP\?IM<0$Q-C(713M]X 8:J3O7?HT.&SSSZ# MDI]__KEERY:;-V_6-C[5OWKUZJE3IRY;MNSV[=N*#U<%I"8?78ENYLR9%HUO ML?'V]L[.;G@^% 8SY(D)N ;ITJ:KM<41S&R4$2K#0RB[3PI3!"(..BHZ*L(& M(P(CHOF!HR'3CH:T1IB0TOXQ6^;DY!09&3EOWCSRD"1Y!1L$K5H&*$&7\9,F M38+R P<.<,JG3Y\.Y;MV[2)?/_GD$_B:DI*B%4*D940J/GSX$#*RR#R%N&9Q M#'>\=75UD+MOWKP9%Q?GYN9F967%O)F"TG*%;2*N7!R%$U)FYP8$N$RN6K6J M1X\>S+6V4Z=.L;&Q@HF8QA[*TR0"65EPPH0)Y"N-6U*Z+@<5-9O< $$2DTI; MV"2L?O\&4R)C0NKI 6E0Y52:_L6>YOZMX4U\_SOQ/*>\KJZ^I*3FT:/?%R\/ M&I7EXY\!7S6:VAZ]3KIV29DZ+:=K]Q-=NJ68Z3U3$"RC1X^&TQ$6%I:1D0'] MB:-'C_KX^$")KKM$^3SUU%,@GYJ:JE>2$R ,D'Y+2DJ8R(4P'#QX,'R%SDVW M;MVPA-]TE)BC!K8 AQY''*RLH$"Q7N"!T5'=68U-[N+LERA6TBKEQY11F6RZYH:#?@ %=93T_/N7/GMFO7#A1&1T?+ ML(?^-(D O1.+QA^7R%<:MZ1T70XJ:C:Y 7S@@NW9)[7WDZFW;E<7WZLA?^]_ M<*.%3<(["Z_ Y_)R_>^4.)5V'^3[>^MY6RWA/%2PXWW^3WM#^=6K5^'S_?OW MK:VM15:-U:5<5T5HG''CQEDTWI)*%JF5JEDO!CU>-A!%4/'>O7N4!BAO$Q'E M>E$R(66.;L"!>6KZEU]^<71T='!P8.^7QAY)ITF$!P\>@)+6K5N3KS1N22/# M1T7-)C> #_^"S?GC/X7'!V1 \L,-^7HEM0TGK@Z$'9_X29> 1E/;N6O*&U&_ M[W?,7\X.>B:=V3IB]!G?H9DZJC9IR((1Y.$X-F3M59HGTR%D0#(V-I9F=YP MX:/1:#IUZA09&4F^CAHU:L" 5 .0P+^[B2UME9?9J.)4.4>(M)]DITBS!TX%_L>!SH;@H5J[1$=5:\-Z*C* M@5.W_T 1^^]>28U@H:DMQ8C B# XQ@\'' TIT2S;JXTZ(<7PQ1=?@/#4J5/5 MVKM"=!E_^O1I*&?>GTVX>_=NBQ8MW-S67(,-98I9&N6!%R%SD[0S0 M.'IO05)]YD65XV6 %&QC8P/"$%&4!BAO$Q'EJE249+GLBL9Q P[L9?S !T#G MPXV1>II$.'[\..CIU:L7^4KCEC0R?%34;'(#^#QZ5#]O?A[G+W!D5@N; M!+]AF?!Y[U=Z5EBLJ*AKZ_23K4-BT5VJU9U23I2!\K[]3ND2@)TZNQYG^@V# M?3-&C/[O;?D37C[?JZ^$^_";#N07H8\^^HA33GHD_&?I.5145$"/Q]K:NJBH MB&9WG #A\_;;;SLY.3'C\($#!P8&!C);0T)">O3H0;,CHR&2?!AT);J"@@)+ M2\O.G3MSRH.#@RV$5M:4VMIZ,QM-A"KT$#;\[I/L%(%(!1V5QA(".NJ? 8P( M&DL(&!'F HZ&E&B6[=7&F)#BW 9U[=HU5U?75JU:-9'G];2BQI/5R!(3$YF2 M!0L6L"?_)DV:9&=G]]MOOTE5SJ]84U/STDLO@3!LHKEWS! S+_*.]^;-FQ"! M'%7+EBV#BD.&#*$W0'F;B!^=\HKTELNN:#0W ,Z<.0.Y@WQF4O"5*U=:MV[= MNW=O>GOH;?[ZZZ]7KUZ=E95%OD*/A.,Y&HUF\.#!%H\_=*W7+2EE.'M743.E MV#_^\0\PX-:M6X8P@ ;!-:0V_[/@O34W;MWFAO".?]T"X="_$ @H*JZJK M'[O0:C2U/OX9Y)UZ@KL^?[Z\5>M$LJXY 31[]#S)7)Z\!J6-&BN\;$039_OV M[7 Z!@X<"(' %.;EY4$<08?[UU]_)27\LT_X_///H?KX\>/YFBD#A$UV=C9< M^,FZY@30[.[NSO0#P)U&C!@A_2A5AB;YL!%)=&/'CH5-7W[Y)5-R\>+%EBU; M0FHM+B[F"(NTMI:7(B@SF]X(E>TAE-TG%5,$P@$=%1T588,1@1'1_,#1D,E' M0THGI/;NW3NQD>'#A\/.NG;M2K[.GCV;D0D*"GKMM=?6K5OWSW_^$\H='1U! M$CXKW+5R:(R'!H7DV+9MV_7KU\?'QY-5XCT\/$I+2[6-G@>;@H.#I2H7K+AF MS1J+QA7^0D-#)S[.!Q]\(,EL(Q\OF->Q8\<9,V; !SBSRY/7N6E)0PM<3=DEZ& MLW<5-5.*P7%!(?O]:"H:0(/@A%3O)U.AD/-V/&!XX&DH__ZPP ,OL1_EN[@= MCWSCT@?K?OET2\&"Z"NN75) &%25"-TX75^O#0C*\A^6R?YUY,#7=Z'*_WU\ MLZ:F/N[?#9-?\%_J$34%'CY\2):*&#!@ +CQ@0,'WGOO/7!L*&&>F],*G7T" M='TL=-S\3QD@#/7U]<.&#?/U]67_#+5__WZHLG'C1D@X.W;LL&@:K^^A23Y: MND0'77Q2$3H]^_;M@\Z&DY,3"*]=NY:_7Y'6UO)2!&5FTQNALCV$LOND8HI M.*"CHJ,B;# B,"*:'S@:,OEH2.F$U-*E2RV$Z-:M&R/SRBNO6%E9,9OZ].DC MZ2Y'PT%C/'#PX,$N7;HP6Z&[SSP#^<,//T#)]NW;I2H7K!@='2U8!1@[=JQ4 MLXUYO!"N_?KU8^NTM+0<,6($9^AEN#8Q=+/(L-S0ARS[>-D\>/ @+B[NI9=> M\O3TM+6UA3B%\ P/#\_-S95D#_UI J^ PN3D9/(5KN[N[NYL>1L;F["P,/Y; MP$3X>)^KJ!.ZP_3K^KD?/D^P5J5JW M20J/N*CK-7EQ_[YE;9>8E<6=\YKUUF6H"YO@?UAX#O,F/K.CH*!@_/CQ["L= M=&46+U[,_EE5\.R312O=W-P$?TRC#Q#"CAT[P ;FASX&TB$@YDV9,D7A;>2J M0)-\M-2)+B,CP\O+B]G:OGW[39LV\7A]!WG]1*$0@' M=%1T5(0-1@1&1/,#1T-J::844W]"BI+2TM+T]/3$Q,2\/+-\B1)TW\^=.Y>4 ME'3]^G5V^9MOO@E>2_D\LRH5C8.\XX6P@8'0L6/'TM+2[M_7_Y)X#DV\341H M'FZ0DI+"/#5M(*JKJ^WL[$:.',DI+RPLA$X)> [X3V5EI:[JNMR24D;7WI5K MEB%F. .,2>&MJLQ,34)B:5;6@\I*L3F.C S-J33AG)!_LS(QJ?3J->["$^9( M65E9:FHJ>/*9,V?X3S'+AC) +C.ZGH?=GY^?D)"0M/LZ:J5?*"# <<(K<0> M*M CDB)HH(E0&1Y"WWUJ@BFBF8&.*@(ZZI\0C @1,"+,%!P-F60T9*0)J>9* M8&#@A D3C%G1M!C4;#-M$VUS<8.3)T\:.@4G)R=;6%CH&C ;&M/N'4$071@A M^=" *0(1!QT50=A@1"#-#QP-F02.((@NC)!\:, 4@8B#CHH@;# BD.8'CH9, DY((0B"( B"( B"( B"($8% M)Z00!$$0!$$0!$$0!$$0HX(34@B"( B"( B"( B"((A1P0DI!$$0!$$0!$$0 M!$$0Q*C@A!2"( B"( B"( B"( AB5'!""D$0!$$0!$$0!$$0!#$J."&%( B" M( B"( B"( B"&!6K5)4#HA=?[\^14K5H2$A P<.-#7UW?&C!D9&1E\ ML8GI")E>U)J-MKQUM?70Y6Y<^>.&3-F8".AH:&[=NUZ].@1IQ:E M)\AH$WK+952DM\$LW$"04Z=.#1TZ5' 3C3WT3<1A]>K5LW@L7KR8(T;C.?+R MC(J:36Z .'>+:^;,S7WK[=Q#WQ>+B&5F:D!&U]^C1_5$[+TU-_A;E[Y[E:,M M/4,3$IH]8$CZRY/.7[A0SMD*@XW_&9ZYZKWK,@ZGJ7'V[-FHJ"@_/[_^_?L' M!05!.!07B[4S! C?\QF8Y$D9(&EI:> 87EY>D'LA&#E;H8,%AJU2CI4YTA86%RY8M(S$R:M2HA0L77KAP09XJ#C1G5J]FRO/(1V_L4SH2HAQT M5!$,Y*AIZ9KA@:?YY>I>IQKM?[0^]I<1H\\,]$F':]:!K^_J/63*6FK)R*XE M3SD-XA$!5R+H"OKX^ P:-.BUUUY+3D[FRU"Z.D8$8C04CH:TLMQ5W0ZAR0?-FBT8<'!SZ]NW;KET[^&QI:;EFS1JVF$:C&3!@ &QR=WLU&.][*RDHB M#R>W3Y\^G3IU(E]'CAP)FY@J])X@M4T,VBST-FC-P0UTH2L%T]@CJ8DX@,-8 M\'!Q<6'+T'B.O#RCHF:3&Z"7B:]>:&&3 '_O+K\F(K9S]VTBQO]S5=^LV^;-#3@=.Q'^8.>26_7X:>"PBJVP.*E5]L[)]\IJI9Z M+$V-N+BX%BU:P'GIW;LWQ*:SLS-QXTN7+NFJ\L477_ ]G_'_^C\:FB9 \O+R M;&UM_?W]8V)BP%7 0PH*"M@"T='1;=NVO7/GCB&.73DB_3_*1'?X\.$V;=J M "0?2$%PL/!YZ=*E,E1QH#FS-)IISB,?FMBG="1$.>BHNC"4'#QX4,G>E1,: M&OKRRR^O6[=N^?+ENIR&1H;P]MMO@U_>NG5+=D7*]J37;+3CK:VMW;IUZ_7K M_[W-(3L[NU>O7J!A[=JU3"&])TAM$X,V"[T-6G-P SY'CQZ%ZMV[=V_9LB6< MM;%CQZY:M>K^_?OTAR^IB3A >K6QL2E^G)*2$K8,C>?(RS,J:C:Y >+$?W,7 MNJ$!05EZ)Z2JJAX5WZOA_$'_%2HN6O+?'Y:AH]^Z31)'K*2DAJTJ(O)B>^?D M\O(&K[A35 WR\^;G,5LO7?[-SC'IXW_\2G\431.X^MK;VT/\[MV[EY145U?# M^8)S-&;,&%VUJJJJBGG -1MJ+5RXD!&C"9#P\' 8V9:7-]R =N?.'9"'?,)L MA?XW# 8V;=JD\F&K@7CRT=(EN@L7+L APSA_W[Y]S ^)4'CRY$FVF(R<27EF M:333G$<^-+%/Z4B($M!1Q0TPA*/^YX>25R;_[-DGU<8^L6^_4W]YX>SJ]V_< MOU_[AS;5KE/ &U&7H.+,-R^16ZM 9L"0ADF<[PZ)W>5*4TLM&7E[EZU<+^(1 M <,!FT:.'#E"2O+R\D 87#0S,Y-10NGJ&!&(<5 ^&M+*'9VIV"$T^6!$G@&* M)J284\(&^L&PUP4+%I"O]^[=@_/JY.3$OE/F^/'C(#-\^' E>U>1[[[[3J_3 MZ)7Q\/#P]?554I&F/:6:+8A!CY=A__[]%HTW29&ODCQ!=IO06*X+714EV6!& M;D"8,V<.5(?,"QK&:>)@:17$0$:SY&79U34;'(# MQ"DMK>W<-24D-'OCIIMZ)Z3XU-75NWN<@(KLM3Q(1U^\XF#?#!A%,%]]AV8& MCLQBOHX>U_ $ 2B79$P3A-S>R/E)#3K$$$?BOLT!XLC-S0U4L=[?&J:6^O8[]9VZ5U)C8Y_H['J\LO*_#TFEG"@#5<^.R%)22RT9V3;+4ZX7O1'Q M[KOO@@"(L6OMV[I_YHA #(TJHR$V"D=G\CJ$)A^,R'9^]1AF/'CH%,<' P^4KO"4K:1*_E(DBJ*&B#>;D!D)N;"W7] M_?UK:FK8-ZE>O7J5_=NO)'LDR6@ITBN-Y\C+,RIJ-KD!XH2%YSS1,;F@L$K> MA-3WA^]!+:2&AV#=#55=7PU6Y??OV]'H.'3K$[T/3](:??/)))M-J&^\8?^:99\CG/7OV0(^* MH*1-]%HN@J2* M@C:8EQL \?'Q4'?%BA5:?8M3TMLC24;;F%ZMK:W??__]UU]_??;LV5NW;N4D M+!K/D9=G5-1L<@-$.'*TH9O^Z9:&187D34B%_O4\U-KQKUOL0NCHVSHDKEE[ M8_J,BW/FYF[[O)#?NPT)S?;LDTH>?J^N?N3L>GSJM!SX7%Y>U[7[B8A(G0YO M7D WU\/# _K9,.9D"L&3X01-GSZ=7L_X\>.A"F<)3+T! @0'!W?OWIVL,@#& M.#DY39X\6=O0SN6=.W<.#P^7?VP&0VKRT97HMFW;9M'X4WQ)2,!\Y>J&52!T MK2'%1_9U:O'2JU 1+HZ<\G'/GX5R7;^:T-122T;>WF4K%XN93?2>H*1-*(].845=-IB7&VC_N#/+W]^_ MLK*2/@7K/064,@3^$GUMV[;]YIMO& $:SY&79U34;'(#=*'1U';K<2(@*(O, M"LF8D"JZ6PT=^K9./U54//:K)G^QV/;.R=\>?&Q9BJ/_:9@+6[CH2E;6 [*2 M17J&!LH71%_IT"GY;C%W(0_SY>S9LSU[]G1T=(0$N&3)DN#@8$M+RQ=>> &Z MX)0:BHJ*H)\!(5-1\=@S*7H#!#ARY B4O_/..Z=/GR9/[Y,5#>;/G__$$T_< MO:O:.Y541&KRT97H2.\G*BK*U=45/MC:VI)6\O+R*BPLE*1*$$EG5GQ4H_<\ MY>M7!R:B("Q ,C L)E=F)*20CPJ*2F)(Z_ZA)2V>44$8F@, M,1I2,CJ3W2$T^6!$]IA%S0DI"/+^_?O#_K9MV\84AH:&0LFWWW[+$8:K,I3O MV+%#10-DHW""YM=??R6# 74K"K:G5+-E5Y1GMKV]/1,DSS[[[(\__LALHO0$ MA6U">71**NJRP>S< *BOKX?+,U3OTJ4+?.C;M^^9,V?$WS5+_ MPR'DY^=#+>A 0-45&SR0W0Q1M1EUJW2;IT^?^+\V]6:C2UY\Z5@T!+VP08$IP^_8!3'08 H,'% M[?C6[0WCKIR<"AO[1'+'UKV2FO?6W)CV>LZ*5==OWS'C=^W5U-1LVK2)O#.+ MT*]?O\.'#]-KB(F)L1"Z\5MO@##5R=X[=.CPV6>?0O74J5.7+5MV^_9MQ8>K E*3CZY$-W/F3(O&-]UX>WMG9S<\'PK#>_+ M"%R#)*D21-*9%=%,>1[9R(M]78Z$R ,=U?B.6E^O#1Z?#5>-;CU.P(=^7J?. MGGU UN36A9+KU,N3&FZM.O@==Y'O66]=AO*X?]_2"D%32RT9>7N7K5P49W9=71U< V[>O!D7%^?FYF9E9<6\X8+2$Q2V">71 MR:XH8H/9N0$!>@FK5JWJT:,'<\WNU*E3;&RL8"*FL8?R-(E 5A:<,&$"^4KC M.?+RC(J:36Z ((E)I=#I7/W^#:9$QH34TP/2H,JI-/WW]I-E:/]WXGE.>5U= M?4E)#3.<"!J5Y>.? 5]AA-"CUTG7+BE3I^5T[7ZB2[<4,[UG"H)E].C1<#K" MPL(R,C*@KW#TZ%$?'Q\H8=\E*LY33ST%\JFIJ7HE.0'" .FWI*2$B5P(P\&# M!\-7Z+ATZ];-V=EY\N3)G3MW=G5U;2+W3$E*/KH2'7D-38L6+=@+?T(6(JN! M0I^27A4?J6=64C;6=1X9Y,4^O2.9.S"$./(X965E@H4*=X2.:GQ'K:Q\!%>N M7GU3F3N;.G=-^7!#OJYI*277J5>G_ PE7\=SL^*,F0UW]>[^4O@N;YI::LG( MV[MLY7JAB0ARHX23DU-D9.2\>?/(VC?D[=L)"0DX0FGPP(GO,HLZ$%)Q%$OE145&<3>1'(?[T(9E" MD_0#LN%0.$$#Q]ZQ8T==,ZDR*HJTIU2S95>4?;P,F9F9H,'=W9U\I?0$A6TB M;KG"BN(VF)T;<("KM:>GY]RY<]NU:P<*HZ.C9=A#?YI$@/ZZ1>-O:^0KC>?( MRS,J:C:Y 7S@@NW9)[7WDZFW;EKO^U:]"_!_G^ MWFEZ)8'+N0TKT;JY"\_)$G;MOMW2-B&C\<&]E:NO6]LE7KS4<$-R_LU*.\>D M^0NX2TN8!601Q^>>>XY=6%I:"G$-77":.Y*@VV%!O> Q)T $V;ESIZ6E97IZ M.GQ>OGRYE9456:(.^N6M6K6"X0'-CHR&WN2CU9WHR.N<^O7KQRF?.G4JE&_9 MLH5>%1^I9U92-M9['F7$OB1',G=J:VLM'B M2OW;.WE.+@UWVBY>>I4OH_ Z]>;LAMN%MN_@/CA);B\ZH!Z:6FK)R-N[ M;.7TB$0$]&D__/!#,@,%%Z!APX;!2??S\X.O.3DY'#VJ3T@UXXCXLU%;6\]Y MZO;$R3+!0K7VJ,IH2*M@=*:D0VCRP8CL,8L*$U)5557CQHVS:+RUC"RJRF;# MA@VP:=&B19QR;V]O*+]Z5>#28GR43-# M-A AH.3>O89K'HTG*&\3RJ.345'[\T]D@Z M32(\>/ E+1NW9I\I?$<>7E&1,_W< '9$#RPPWY>B6U#2>N M#H0=G_A)EX!&4]NY:\H;4;_O=\Q?S@YZ)IW9.F+T&=^A.N^!;\J0]3+(PW%L MR)J4_,<3^$#(@&1L;"S-[C@!PD>CT73JU"DR,I)\'35JU( ! YBM@8&!/CX^ M-#OZ?_;. ZR**WO@H"(@HD8,*HIB-]%%41&,0L"^)8AAW6AL(:BQQ;*N8DGL M&@VF_,W&Q#4J6:.&H)*H43>K("!($10; J+! *$(^!"!1_T?G.QDG/;NE%? M\_OX^-Z[<\ZY=^Z<>VYY,W<,AGCPH1 *=-3$P]/3DY6^?/ER2(<9$3<[\I@I M]W,'!0C4Q9E934P^K=J'9Y?0+2[4_2E$C#>?\!E(0'(U+YS%#UN&.J6 M,'K<[P^JO#[E>I_^C?)F=>H7H8\__IB53HU:N,_2LR@K*X,1CX6%17X^T1:S MK ;"9>G2I79V=O0\W,7%Q;FYEVZ M=&&E^_CXF/'MK"EBBHO4*RLI&NN\CE+;OE1'0J2"CLJ+7AV5N:DY]%S0Q927 M/S/ 4-Y/)2654MWB,^4OK&K9*MS1Z9)0'TNBI9:,O-QE&R>'I$70'#ITB!HB M<@^IOB#5A%L$HF\4SH9HY,W.% X(C3X9D3UG4;0@5555-6G2),AXZM2IW 5O M&FK3K_#P<#IEY/(!6 MRI)7G(RWSBQ(DM6[8D)2517V&,SO("L-_?V'M" =DYE5KM M,YVQ1E/M.B*!>J<>;];7KS^&03"UKSD%6';J%4-W3\Y#XL9.X-E(Q?39OW\_ M7 X7%Q=H"'1B>GHZM".8@O[RRR]4"O?J4QPX< #4)T^>S+5,V$"8I*2D0,=/ M[6M. 98='1WI<0"XT^C1HZ6?I?&!1L21$-F@HQK>4:]>+4U*^FW3<7I!*N-N MN>T+%U\:R/[!0Y5^"GH?2(RX6$RG!*[)8-U;%/9] 724RS3Z^?F]\2P??/ !+09E@AZW;=NV'W[X85A8&+71NI.3 M4W%QL8AQ Q 2$D*5UL/# XK4K5LWZNOBQ8L)9< [X;Q\?'RD&N=5)*Q/DF(; M^'RA>"^^^.*\>?/@PY=??KEAPP9J[T K*ROF]@WBGJ"D3O1:+3K+T+C<@ EU M?Y:[N_O:M6LAG/7HT6/^_/FVMK86%A;T+W!X%>O7H5%1716B0QA$2&E;N*E@G%X+P@D?ER%A4+ M0 +O@E3?EQHVCF6]'0^ :0"D_WB&YX&771]G=72(FOM.Z@<[?_YB;_;*P(S. M7:-!&$P5\=TX75=7[^F=-&)4(O/7D>,G"D#E_SY[4%55%_SO7-DO_3$ZY>7E MU$X9@P.'0.53S_]% +.P8,'S4SC_;8DP:>>+-#!#(=2A$%/:&CHSIT[[>SL M0'C'CAW,'$E,L4($X975:9GP.LJ+#S0BCH3(!AW5\([Z;4@>= >O>"2^MSYS MU>J,WOUB%RZ^TZY#PVU0W/Y(E7XJXF*QI4UX>_O(H(^ROO^A@'H)7:^^,<7% MO^^4/&U&PP;A7_XK6Y*66C+<;II$BUR,',(6X>WM/7WZ='!RF!2 @X$ :,%G MIBG"<2RV"$3?J#4;JB?V:NY\A$+Y@+"1SH84+4@%!@::"3!AP@2FY,F3)[MV M[4H?A1&S*>P>M6[=.M["=^_>G5#FIY]^@L_[]^^7:IQ7D; ^28IMX/.%EC-@ MP "FO+FY^>C1H[E3+Q%/4%(G>JT6G65H7&[ I+2T-#@X>-*D2;U[][:RLFK6 MK%F_?OW\_?W3TM(DE8?\,H%70&)D9"3U%48)CHZ.3'E+2\O9LV=SWP)&$D-T MRK!R5]$RH1CODH2*!= )^8(4M?.KH].EFAJ>.VQ/A!4X]8IA[DC5JDV$?\!M MH=?D!?\[U\(ZG/[1FX8:',,A^#_;_Y;XB[U-F>SL[,F3)T,+HJ\1#&76K%G# M_'F6]^I3&U(Z.#CP_N!&WD H#AX\"&6@?^BCH08$5/%FSIRI\*%:52 )/O7$ M@2XA(<'9V9D^VKY]^]V[=[-R)#'%#1$D5U:G9<+K*#L^U.MR)$0VZ*B&=]32 MTIJO#^5._FM*OY=C;=I&0 ?Q\A\N!\R]G9;.O@E=Q7[JU.G"[CTOT9*>WDFL M+9;&3DB&]*CH$DE::LGP=M,DELG%""%L$=.F36-Z(\AP'Y0C;#78(A!]H]9L MJ)[8JWGG(VH-"!OC;$B=M^R1 "/@:]>N141$W+MWSV"9ZIN%"Q>"U\IXZ%>V MHG$1+S8T"9@(G3]_/BXN[M$CP9?O"GE"(ZV3^J;B!M'1T?13TWI"J]5:6UN/ M&3.&E9Z3DP/#=/ <\)^*B@HA=9(8(B(CE+MRRS+$]%< 0Y*36YF8J+D07IR4 M5%I1(;;&D9"@$7HA=]:#BO"(8N6[JYH")24EL;&QX,G)R*'W!&=E95VX<,$4?@KBHE;P24]/AW.$6F)..<@1"1&J7%GRZ\C"!-O^\PDZ MJCCZ<-1+,27T'E+R(.^G:FOK4E(>7XPLOG>?W1]IM;6MVT6,F\CS4+F(ENHR MLK7D&=>)>(LH+BZ&+BD\/!P<7L5,N3Q7+0+1-T:<#9&@?,9DFK,APRU(-4F\ MO+Q>?_UU0RH:%[T6NY'627U3<8.8F!A]A^#(R$@S,S.A";.^,6[N"(((88#@ M0P*&"$0<=%3#$WOYD<(%*56(BF[8"EWH9Y7G%FP12-,#9T-& 1>D$ 1I("$A M8>+$B7K-(C,S\\R9,WK-PF1S1Q!$" ,$'Q(P1"#BH*,:GL1$S9]>NV;L4M1G MWBL_>XYGFZKG'&P12-,#9T-& 1>D$ 1!$ 1!$ 1!$ 1!$(.""U((@B (@B ( M@B (@B"(0<$%*01!$ 1!$ 1!$ 1!$,2@X((4@B (@B (@B (@B (8E!P00I! M$ 1!$ 1!$ 1!$ 0Q*+@@A2 (@B (@B (@B (@A@47)!"$ 1!$ 1!$ 1!$ 1! M# HN2"$(@B (@B (@B (@B &!1>D$ 1!$ 1!$ 1!$ 1!$(.""U((@B (@B ( M@B (@B"(0<$%*01!&B@K*[MSYXZQ2X$@R','!A^D48".:GC*RFKNI#TQ=BD0 M?K!%($T/]&JCH'1!ZOKUZQLW;O3U]75Q<7%SLF1)<' PN7&NHK[K4T_G6U=7!V:7+5LV M?OQXEZ?X^?D=/GRXMK967LEEU FY<:G(*+.DPD@]6?(*D<3ERY='CAS)>TA_ M;@EV%@E#^\^6+5NX1]>L6<.R5EY>OG/G3B\OKT&#!OGX^!P[=HRD#"1:A):- M7@!Q"@JKEBQ+>W=IVND?"T7$$A,U("/T5UM;1XEMW7Z?>W3=^W=9UN(3-+Y^ M*8.'Q4^9>OW&C<>LHS#9>,4CS).Q]2X>O7J@@4+W-W=!PX.7;5JU8T;-^29DF2?JF_H9&L_W/7SZ'')+J[QT&<=/U$@?LKD6FK)R-:29YP$\18!7@&>X.KJ M.F3(D.G3IT=&1G)E"%T=6P1B,(PR&Z)0:SI@],F(C (H6I#:LV>/V5-:MV[= MOW__=NW:P6=S<_/MV[BHH)2M+6U[=>O7Z=.G:BO8\:,@4,R2BZU3I14BS@RRBRU,)). M5M(UDH10"-:K6QXZ=,A,@(X=.\)P@1(#I^(58)K2:#2#!P^&=$='1T]/3W!% M^+QX\6+Q I!H$5HV>@%T\L:;-YI;7H"_]S=DBHA]<^172HS[Y^ 8_;]K4O_R M'R[S"C!-I6<\L6D;,=+SRJZ/LX8,CV_7X6)V3B538,VZN^WM(_/RM5+/Q=0( M#@YNWKPY7)>^??M"6["WMZ=<-#4U54A%1>=/3T^WLK(:,6)$4% 0N IX2'9V M-E,@,#"P;=NV>7EY^CAWY8B,_P@#RYDS9]JT:0,"$* @3,')PN=UZ];),"75 M.&'W1W(=61#&7D)'0I2#CLJ+7AU5:$%*Q7ZJOJ&3K88>"@XY]8KQ&I,$715\ M7K(L3;S"2;34DI&7NVSCA(BTB&^^^<;"P@+< %QBV+!A+5NVA,^[=NUBRA"Z M.K8(Q) 89394K]YTP.B3$7D%4+0@]=EGG[WYYIN1D9$U-354"A6 (..XN#A: MS,_/;\J4*3MW[MRP88.D:Z-O=!:,\ 0IEBY="GZ9FYM+:)RKJ._ZU-_Y5E=7 M[]NW[]Z]WV]S2$E)Z=.G#RCNV+%#1LFEUHF2:A%'1IFE%D;2R4JZ1H2<.W<. M2MBC1X\6+5K 59LP8<+FS9L?/7HD*4=Y]5]965G( <(66%BU:A4M!@,"2TM+ MEEA141'3U-RY%"D B1:A9:,70)RP[PM@&.KI MG:1S0:JRLK;P817K#\:OH+AZ[>\_+,- OU6;")9845$5TU3 W-OM[2,?/V[P MG+Q\+<@O7Y%.'TV]\\3:-N*SSW\A/PO3!'I?&QL;:,4A(2%4BE:KA>L%UVC\ M^/%"6BHZO[^_/PRU'S]NN $M+R\/Y"&JT$=34U-A,K![]VZ53UL-Q(-//5E@ MN7'C!IPR3#Q"0T/I7Y4A,28FABDF+T;I-$[8_9%<1Q:$L9?0D1 EH*.*9*TG M1_W/3T739MSLW2_6TB:\_X#+?_S+U2W;[C]Z5/T_:ZKU4\ ["U)!?4:;&[7$FTU)*1E[MLXSH1;Q'@9I9/.7OV+)62GIX.PM!+)B8F MTD8(71U;!&(8C#@;JE=O.F#TR8B\ BA:D*(O"1,8!T.N*U>NY!XZ=>J422U( MT0@53-().CDYN;FYD1OG*AJL/O5ZOC3'CATS>_I3 WD!N,:EU@F)<7F0EUEJ M822=K(P*$6?)DB6@"Y$7"NGHZ @1Q-W='08-]%W-!F[FD)V#@P-88#["30T( M1+0>/GP(_8>=G1WS=ZVHJ"BPX^'AH42+T++1"R!.<7%UEV[1OGXIG^Y^H'-! MBDM-39VCTR509.[E00WTQ16'NB7 +(+^ZC8RT6M,$OUUW,2&)PC N*3"F"#4 M38ZLG]0T&@VT(W&_92'/^0$7%Q<8.=%?75U=/3T]Z:\0A <-&L3;D(V+SN## M1"2P>'M[PZ&PL##"?"7%**G&*;C='\EU9"$[VO,Z$B(;=%1Q].&HR_[>L+34 M?\#E:3-N.O6*F;\P]16/Q!96%V[>+!.V)K.?>EA496D3;M\YJJ+B]X>DHB^5 M@*E71RN02+O8U/BQD44 M1;*346S9BE+/E^;\^?,@X^/C([4 2NI$IW'9R"NSSL(H/%ER&5[2TM) <<2( M$5555O'#AT'KK;?>8J5W[-BQ6;-F M)24ELK4(+1N] .+,]K_UPHN1V3F5\A:D?CSS$+18STV0#/0'#HKS]4NAO\(( MV'W4;[^.AGR7![.+V,MB;M98B(^/Y]X,I=5JH5=NW[X]N1UYS@^\]-)+S$@+ MO?[PX<.IS]]^^RV,J%BW8)@"4H./4&#)R,B =*@!\JS)8Y0,XQ3<[D_&K(87 MDFC/ZTB(/-!1Y:'$4=/2GT"/,]+S2E55'?.1O;N9Y?0=4EQD]U-'CN:!XMMS M;K/2'1RC+:S#2TKX'I$7X^OJ"3&AH*%,Q/S\?$FUL;+@3 M>]47I)I8BT#TC=%G0VI-!XP^&9$]9U%_0>K==]^%H@0%!7$/-8T%*=X3W+1I M$R3>OLT.^CJ-BRB*9">CV+(5I9XO165EY6NOO08R1XX_'BQ?OV[6,%M<# 0-#ZY)-/6-;&CQ\/Z4*S<1(M0LM&+X (9\\U#-._V-NP MJ9"\!2F_OUT'K8-?YS(38:!OU3I\^X[[<^;=7K(L[:L#.=S1K:]?2N]^L=1. M"%IMK7WGJ%EOW8+/CQ_7=.MQ*6"NH-LW+K1:K9.3$XRS81!,)X*7P@6:,V<. MN1UYS@_ Z+E'CQ[4EA-0&#L[NQDS9M0WU//C+EVZ^/O[RS\WO2$U^ @%EJ^^ M^LKLZ4_Q145%GW[Z*50X1*=OO_VVNEIPKD4>HV08KQ?H_DBN(PDDT9[7D1!Y MH*,:WE&__Z'A ?--6QJ>I1+:0XJ+['YJS;J[H B=(RM]XI^O0KK0KR8D6FK) MR,M=MG%Q2%K$G__\9S/.$SH:C<;L*>GIZ2QYU1>DFEB+0/2-T6=#:DT'C#X9 MD3UG47E!"J*,M;5UZ]:M>3=/;0(+4D(G.&3(D-Z]>\LP+J(HDIW48LM6E'J^ MBQ8M"@@(@)#:L6/'-FW:?/CAAS(*H*1.=!J7C;PRZRR,PI,EE!&"NC]KQ(@1 M%145Y"%8?\T\/S\?.GZP7%;VS&WYW$TEV[9M^_WWW],",V?.A$08;; ,SIX] M&]*_^^X[WNQ(M @M&[T 0F@TU=U[7O+T3J)6A60L2.47:&% W];N8EG9,[]J M+;6\?^?AK6P5:LSDI)*J9TLXA,TD+XR,*-#I\B"0O9&'HV7 MJU>O]NK5R];6%@+@VK5K?7Q\S,W-__*7O\ 0G-"";.<'SIX]"^G_^,<_KERY M0CV]3^UHL&+%BA=>>*&@0+5W*JF(U. C%%BHT<^"!0LZ=^X,'ZRLK*A:[;./BD+0(\#&0V;9M&S,Q.CJ:\JB( MB B6O.H+4DVL12#ZQNBS(;6F T:?C,B>LZBY( 4C[X$#!T)^7WWU%:] 8U^0 M$CK!7W[YA9H,2#4NKJB_^M3?^=K8V- A^]577_WO?_\KM0 *ZT3^^]!V:S MLK(@=YCY@P#,]J'GIG?']//S \4??OB!I0C#$4@_>/ @;W8D6H26C5X (=Y9 MD-JJ343JG=_VU)"Q(+7KXRQ0F?M.*BM]_<;,TS\69CVHT&BJKUU[# (MK"[ ME.#*E5*6.DP P$)'AZA]^QL&@K=NE5G:A%-W;#TLJMJZ_?Y;;]_:N/G>KWF- M^%U[5555NW?OIE[B0S%@P( S9\Z06Y#M_+0ZE7N'#AW^]:]_0^J=/]6_9LF76K%GKUZ__]==?%9^N"D@-/D*!9?[\^69/WW0S:-"@E)2& MYT-AOD$], )]D"137"09%^_^"*^C"(317LB1$'F@HQK>4>OJZGTFIT"OT;WG M)?@PP/GRU:NEU)[<0BCIIZ9,;;BUZN0I]B;?B]Z] ^G!_\ZMYX-$2RT9>;G+ M-BX.28NX<.&"V=-7Q='O>X5YOI>7%^5UIT^?9ME4?4&JB;4(1-\8?3:DUG3 MZ),1V7,6U1:DRLO+H1F+S*[K&_F"E,@)_O.?_X3TZ&CV>V1U&A=1U&M]ZN]\ M:VIJ8&+VX,&#X.!@!P>'9LV:T:^=(BR PCHA/#L9R"NS>&$4GBQAA8@#HX3- MFS?W[-F3[H\[=>JT:]DU-75%157T=,)[;)+KB 3X"C.$GGUB.G>-GO76K6X]+G7M M'MU([YF"QC)NW#BX'+-GSTY(2("1Z[ESYUQ=72%%Z"Y1+K*=GP;";U%1$=UR MH:D.'3H4OL*PJ7OW[O;V]C-FS.C2I4OGSIU-Y)XI2<%'*+!0[R1JWKPYA)038>RH.&]^PUV]1X[RW])" MHJ66C+S<91O7"4F+H&Z4L+.SFSMW[O+ERZF=F*AWV%VX<(%E4/4%J:;7(IY; MZNH:[K5G_I645/,F*LS(N+,AM:8#1I^,R)ZSJ+,@!5>1&HXO6+! 1*SQ+DB) MGR <>O'%%X564D6,"RGJNS[U>KXTB8F)8,'1T5%2 136B;AQ)<@HL\["*#E9 M\@HA!*;0O7OW7K9L6;MV[]OU%?JUS#N MSQ344KW0C2HD6H26C5X +M!A]^X7V_>EV-Q?M?3KKK=]A77X[=2& MN].S'E18VT:L6,G>6J)10&WB^*<__8F96%Q<#*T;AN D=R0I<7Y>OOGF&W-S M\_CX>/B\8<,&&&%3&]5E966U;-D2I@LN\N54=A/+5S<<+O0_H/L)[FHVXO.GGO(:X=$ M2RT9>;G+-DZ.2(N D>U''WU$K4!!!S1JU"BXZ.[N[O#UUJU;+#NJ+T@UX1;Q MO%%=7<=ZZO923 EOHEHY&F4VI-9TP.B3$=ES%A46I"HK*R=.G&CV]#Y#:E-5 M(1KI@I3X"3YZ],C"PD)DUU@AXT**!JA/O9XO$XC78.?A0W:?I[\Z$3&N$*EE MUED8)2O9HD-&C0(TN_>Y1G"$FH16C9Z ;AP.VS6'_?I!BX@ Y(??9*E M4[*^X:+4@+#M"Q>%!#2:ZB[=HM]9\%N^X_]X=/KHZ'');B-)[X$W*:C] M,JB'XYA0&Y1R'T_@HL3YN6@TFDZ=.LV=.Y?Z.G;LV,&#!]-'O;R\7%U=23(R M&.+!AT(HL%"K@9Z>GJSTY'I$5HM5IJ*W'P$&MK:\.\9:\)MXCG#:BY8\?S MF7\/BZIX$]7*T2BS(;6F T:?C,B>LRA=D() 0[U,8=:L63IOF6F,"U(Z3_#H MT:-P5&1_.R'CO(J&J4^]GB\-]$"6EI8@#+&;L #*ZT3$N$(DE9FD,+)/5FJ% M$,+0:!%:-GH!N-36UBU?D<[Z\QJ3!,-0]U&)\)F[ MT2F+LK(:&/U;M0[/+R#:W2GZ4@D8[S_@LI 9&K?.8H>-PQU2Q@][O<[YU^? M]%%? M7]^>/7N29&0P1((/C5!@R<[.-C)R+&%4)>9L+"R#M9&14B0G)R,L0.ZC,= M@C,R,EJU:M6W;U]Y.8K7_XD3)[9LV9*4E,1*/W#@ &A-GCR9JP(#"Y9W:32: MH4.'FCW[\#:UN6!X>#B=LG+E2M8Z/3=W$BT2&4*QSS__' J0FYLK28NP "3P M[B&UY\OLK=OOY_[*;L('O\X%8;^_L?>$ K)S*K7:9SICC:;:=40"]4X]WJRO M7W\,@V!J7W,*L.S4*X;NGIR'Q(V=P+.1BNFS?_]^N!PN+B[06.C$]/1T:$